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Abstract 
Background 
Pressure ulcers, a form of chronic wound, represent a significant health and resource burden in 
elderly and immobilised patient populations. Pressure ulcers have been shown to exhibit high 
matrix metalloproteinase (MMP) activity which prevents normal wound healing and 
doxycycline, as an MMP inhibitor, offers a potential novel treatment. Intradermal delivery of 
doxycycline could help treat the earliest stages of wound development and prevent further 
wound progression. The skin, however, has a natural barrier function which prevents the 
diffusion of large exogenous molecules. Microneedle rollers offer a minimally invasive 
technique to transiently permeabilise the skin, creating microscopic pores that act as conduits 
for doxycycline diffusion. 
Methods 
The research described in this thesis focusses on the repurposing of existing microneedle rollers 
for the intradermal delivery of doxycycline as a pressure ulcer treatment. Firstly, the effect of 
microneedle length and application method on micropore formation and rate of drug permeation 
was investigated using the recently-launched artificial membrane Strat-MTM and compared with 
excised biological tissue. Next, the biological effects of doxycycline and its transmembrane 
delivery were modelled in a dermal tissue equivalent (DTE) model, formed from collagen and 
dermal fibroblasts, by assessing changes DTE contractile behaviour and matrix 
metalloproteinase (MMP) activity. This simplified in vitro model was further developed to better 
emulate the pressure ulcer microenvironment by introducing: (i) mechanical loading using a 
bespoke metal weight, (ii) glucose deprivation through the use of glucose-free media, and (iii) 
inflammatory cells, specifically macrophages, through co-culture. Investigations progressed to 
a preliminary in vivo surgical wound model using compression by magnets to determine the 
biological effects of pressure in a whole organism. This pre-existing model was established in 
our lab for future investigations of microneedle-mediated doxycycline delivery. Finally, the 
repurposing of the existing non-invasive imaging technology optical coherence tomography 
(OCT) for pressure ulcer evaluation was explored in an observational clinical audit. 
Results 
The results demonstrate that microneedle rollers significantly enhance the transmembrane 
delivery of doxycycline with significant effect on tissue-equivalent contraction and MMP 
activity. Results from the pressure ulcer models corroborate previous findings that the pressure 
ulcer microenvironment augments MMP activity. Lastly, OCT is shown to detect subsurface 
biomarkers of skin in the earliest stages of pressure ulcer development, most suitable for 
treatment with doxycycline.
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Thesis Overview 
Interdisciplinary nature of the thesis 
This thesis was completed as part of the newly formed London Interdisciplinary Doctoral 
(LIDo) training programme and was funded by the Biotechnology and Biological Sciences 
Research Council (BBSRC). An integral part of the LIDo Ph.D. programme is to demonstrate 
interdisciplinarity throughout the body of research undertaken, especially with regards to the 
methods and approaches used in answering research questions. To achieve this, several national 
and international collaborations were undertaken to combine the expertise of different specialist 
research groups and institutions with a common aim of developing novel biotechnologies for 
medical and clinical applications. As a result, a range of scientific disciplines (including protein 
chemistry, pharmaceutics, clinical imaging and cell biology) were introduced, in an integrated 
way, to the research which was primarily based at the Applied Biomedical Engineering Group 
(UCL). The BBSRC itself puts emphasis on “New Ways of Working” and encourages the union 
of traditionally disparate research fields for the rapid development of cutting edge technologies. 
Thesis chapter outline 
The overall direction of the research was to explore novel bioengineering technologies in the 
prevention, treatment and evaluation of pressure ulcers which could supersede the current 
conventional therapies and nursing care practices. The thesis is sub-divided into five 
experimental chapters encompassing four major areas: (i) the development and investigation of 
biotechnologies that could deliver suitable drugs locally, (ii) investigation of an active 
pharmaceutical ingredient (API) efficacious as a treatment for pressure ulcers, (iii) the 
development of a simple yet informative non-human in vivo model of the pressure ulcer that 
could help bridge the gap between in vitro models and clinical studies, and (iv) the repurposing 
of existing imaging tools to improve upon current pressure ulcer evaluation. A summary of the 
thesis chapters are as follows: 
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General Introduction — The literature review provides an overview of pressure ulcers in the 
clinical setting, discussing their aetiology, presentation, complications and traditional clinical 
care (including current prevention methods and treatments).  Fundamental aspects of human 
skin are detailed to provide a background on healthy skin structure and architecture. The 
pathophysiological mechanisms behind pressure ulcer development are also detailed and 
doxycycline is introduced as a potential therapeutic. Intradermal drug delivery methods are also 
discussed. Finally, the review assesses the current research models of the human pressure ulcer, 
detailing their advantages and limitations. 
Chapter 2 — Assessment of a Microneedle Roller System to Enhance Transmembrane 
Delivery of Doxycycline. This chapter introduces the microneedle roller system used 
throughout the research. The ability of the microneedles to enhance the transmembrane delivery 
of doxycycline are investigated using Franz diffusion cell permeation studies. 
Chapter 3 — Microneedle-Enhanced Transmembrane Delivery of Doxycycline to a 
Dermal Tissue Equivalent. In this chapter, doxycycline is delivered to a cell-based in vitro 
model of the human dermis. This was carried out so that the permeability of the membrane to 
doxycycline could be monitored through doxycycline’s biological effects. The effect of 
microneedling on cell viability is also explored. 
Chapter 4 — Modelling the Pressure Ulcer Microenvironment in an In Vitro FPCL 
System. In direct continuation of Chapter 3, the in vitro human dermis model is developed to 
better reflect the environmental conditions that result in pressure development. 
Chapter 5 — An In Vivo Preclinical Surgical Model of Early Stage Pressure Ulcers. This 
chapter details experimental pressure ulcer formation in a preclinical model using surgical 
implantation of magnets for compression in which the effects of microneedling and doxycycline 
can be explored. 
Chapter 6 — Optical Coherence Tomography for the Non-invasive Evaluation of 
Pressure Ulcers. This chapter focusses on repurposing a non-destructive in vivo imaging tool 
to identify changes in the skin that could be linked to pressure ulcer development and validates 
the technical feasibility of this approach in humans. 
Overall Discussion — This chapter unites the entire body of research and discusses the thesis’ 
contribution to knowledge. It also discusses how the work as a whole could be used to develop 
new technologies for clinical applications.  
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Research hypothesis 
The overall research hypothesis is: 
 “Intradermal delivery of doxycycline by microneedles is a promising tool for treating 
and preventing the development of early stage pressure ulcers.” 
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Chapter 1   General Introduction 
1.1   An introductory clinical background to pressure ulcers 
1.1.1   What are pressure ulcers and who do they affect? 
Pressure ulcers, also known as decubitus ulcers, pressure sores, bed sores and more recently 
pressure injury, constitute one of the three major groups of chronic wounds alongside diabetic 
ulcers and venous leg ulcers1. Pressure ulcers are most commonly seen in two patient 
populations, the bed-ridden elderly in long-term care and immobilised patients with spinal cord 
injuries (SCI) in the acute care setting. Pressure ulcers are pathophysiologically different to 
other skin disorders and wounds that may display similar physical characteristics such as 
incontinence-associated dermatitis, intertriginous dermatitis, medical adhesive-related skin 
injury and traumatic wounds. Despite current treatments and management protocols, the 
prevalence/incidence of pressure ulcers remains high2. This suggests that either the true 
etiology has yet to be ascertained, hindering development of effective treatments at the research 
level, or the current preventative measures are being insufficiently implemented at the clinical 
level.  
1.1.2   Prevalence, incidence and cost of pressure ulcers 
Pressure ulcers occur across many healthcare settings including in the hospital and at long-term 
care facilities such as nursing homes. Worldwide, the highest incidence (the number of 
individuals with new pressure ulcers divided by the number of individuals at risk) is in the 
hospital, while the highest prevalence (the number of individuals with a pressure ulcer divided 
by the number of individuals at risk) is in long-term care facilities3. The prevalence rates of 
pressure ulcers in UK ranges from 5‒32% in hospital settings and up to 22% in long-term care 
facilities4. Though a lot of the literature on pressure ulcers reports on ulcer development in 
elderly populations under long-term medical care, pressure ulcers also occur in the acute health 
setting in both adults and children5,6. Critically ill patients in intensive care units are often 
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confined to beds for long periods of time due to sedation or ventilation and are susceptible to 
developing pressure ulcers7.  
About 60% of pressure ulcers have been reported to occur in hospitals8,9. The wards which are 
at greatest risk of pressure ulcer development occurring in newly admitted patients are the 
orthopedics wards and intensive care units3. Pressure ulcers that arise in hospital will typically 
occur within the first two weeks of patient hospitalisation. For example, about 75% of new 
pressure ulcers occur in this time period in orthopedic patient populations10. This suggests that 
initial injury on ward admission is more crucial to pressure ulcer development than the length 
of time spent in the hospital3. Understanding when and where the pressure ulcer developed is 
important in determining where the deficit in care may lie since pressure ulcers are often 
deemed preventable adverse events, with their emergence representing a potential failure of 
care11. A new pressure ulcer may be categorised as community-acquired if it develops within 
three days of ward admission, and hospital-acquired (a HAPU) if it develops from three days 
after ward admission. In the UK, pressure ulcers represent a leading resource burden on the 
National Health Service (NHS) with annual costs having being estimated between £1.4‒£2.5 
billion in 2004, approximately 4% of the total NHS expenditure12. Much of this cost has been 
attributed to nurse time3. Importantly, the worse a pressure ulcer becomes the more costly it 
becomes to treat and manage12.  
1.1.3   Clinical pressure ulcer aetiology and pathogenesis 
In the clinical setting, pressure ulcers are understood to be caused by prolonged periods of 
immobility where the body weight is concentrated at a few points. In normal situations of 
immobility, such as during sleep, the body responds to the increase in pressure at these points 
through neurological feedback, causing periodic changes in position13. In several situations, 
such as in heavily anesthetised or immobilised patients, or in patients with neurological 
pathologies (such as a spinal cord injury [SCI]), where sensation is decreased or absent, these 
feedback mechanisms are either not in place or not functioning properly leading to impaired 
and delayed responses to increased pressure. The localised and sustained mechanical loading 
to the skin and underlying tissues then results in soft tissue breakdown, worsening with 
increasing duration and resulting in a more severe wound14.  
The anatomic sites most susceptible to consistent unrelieved pressure are weight bearing points 
that come into contact with surfaces over bony prominences, and these are the regions where 
the vast majority of pressure ulcers develop (Figure 1.1)15. Approximately 95% of all pressure 
ulcers occur in the lower parts of the body, most commonly the sacrum (lowermost part of the 
back), coccyx (tail bone), calcaneus (heel), ischial tuberosities (sitting bones), greater 
Chapter 1: General Introduction 
- 38 -
trochanters (lateral aspect of the upper thighs), buttocks, and hips3. Pressure ulcers can also 
develop on the elbows, occiput (back of the head), ears, and hallux (big toe)16. The most 
common site for pressure ulcer occurrence is the sacrum (36% of ulcers) followed by the heel 
(30% of ulcers)17. The anatomic site where a pressure ulcer is most likely to develop is 
dependent on the resting position that the immobilised patient is placed in. Supine positons, 
where patients are placed on their backs, typically have pressure ulcers develop on the heel, 
sacrum and buttocks. In lateral positions, where patients are laid on their sides, vulnerable sites 
to pressure ulcer development are the trochanteric regions. In prone positions, where the patient 
is rested on their front, the hips are the most vulnerable sites. Wheelchair users and patients 
seated upright have a different distribution of pressure than those laid horizontally18. Vulnerable 
sites in this seated positions are the ischial tuberosities and sacrum. Hospitalised patients will 
be typically placed in a supine resting position but may be repositioned during long surgical 
procedures19. 
1.1.4   Intrinsic and extrinsic risk factors 
The etiology behind pressure ulcer development is multifactorial. A combination of extrinsic 
and intrinsic factors results in pressure ulcer formation13. Extrinsic factors are the 
environmental conditions that the patient exists in which increase the risk of pressure ulcer 
development. Such factors include pressure (the leading contributing factor) in combination 
with prolonged immobility, friction, shearing and moisture at susceptible regions. Intrinsic 
factors are the risk factors which make the individual particularly susceptible to developing a 
pressure ulcer. These include old age, neuropathy (decreased or absent sensations), particular 
medications, nutritional factors, incontinence and the presence of acute illness. It is evident that 
the greatest intrinsic risk factor for developing pressure ulcers is old age. People aged 70 years 
and older are most vulnerable to developing pressure ulcers due to several age-related factors 
including a reduced blood supply, aging of the skin and a higher rate of immobility compared 
with the general population20. This is reflected in the statistic that two out of every three 
pressure ulcers develops in this demographic21,22. 
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Figure 1.1 — Pressure points and pressure distribution in four different resting 
positions. Adapted from “Pressure ulcers: Back to basics,” by K. Agrawal and N. 
Chauhan, 2012, Indian Journal of Plastic Surgery, 45, pp. 249.  
Figure 1.2 — The most common anatomic sites for pressure ulcer occurrence: (A) 
Back (posterior aspect) of the heel. (B) Sole (plantar aspect) of the heel. (C) Sacral region 
(lower back). (D) Buttocks. Pressure ulcers are also known to occur at the hips, 
trochanteric and coccygeal regions, and elbows. Adapted from “Morphological 
characteristics of the human skin over posterior aspect of heel in the context of pressure 
ulcer development,” H. Arao et al., 2013, Journal of Tissue Viability, 22, p. 43. 
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1.1.5   Risk assessment scales 
On admittance into hospital care, several risk assessment scales are available to help medical 
staff determine the likelihood of the admitted patient developing a pressure ulcer. The first risk 
assessment scale for pressure ulcers was the Norton scale, developed in 1962, followed by the 
Waterlow scale (1985) and Braden scale (1987)23. Of the three, the Braden and Waterlow scales 
have been the two most commonly used to date – Braden more so in the USA, and Waterlow 
more so in the UK24. The Waterlow scale assesses eight factors: build/weight, height, skin 
type/visual risk areas, gender/age, continence, mobility, appetite, medication, and special risk 
factors (tissue malnutrition, neurological deficit, major surgery/ trauma)25. The scale identifies 
three ‘at risk’ categories based on how high the patient scores (‘at risk’, ‘high risk’ and ‘very 
high risk’). Higher scores indicate a higher risk. The Braden scale assesses six factors: sensory 
perception, activity, mobility, moisture, nutrition, and friction/shear26. The scale identifies four 
‘at risk’ categories based on how high the patient scores (‘at risk’, ‘moderate risk’, ‘high risk’ 
and ‘very high risk’) with lower scores indicating a higher risk23. The intention of these scales 
is to serve as a tool to be used alongside clinical judgement in predicting pressure ulcer risk in 
hospitalised patients. Any indication of risk from these scales should be followed with the 
appropriate action by the clinical staff. Despite their utility, these scales have been met with 
much criticism in recent years including poor inter-rater reliability and limited validity in 
predicting pressure ulcer risk24,27.  
1.1.6   Clinical presentation and traditional pressure ulcer staging 
Traditionally, there are four clinical stages of pressure ulcer progression in order of increasing 
severity, with stage 1 being the least severe and stage 4 being the most severe (Figure 1.3). 
Staging is based on qualitative aspects of the wound that can be observed by clinical staff and 
has been outlined in guidelines made by bodies such as the National Pressure Ulcer Advisory 
Panel (NPUAP), the European Pressure Ulcer Advisory Panel (EPUAP) and the Pan Pacific 
Pressure Injury Alliance (PPPIA). With reference to the NPUAP staging system, stage 1 is the 
pre-ulcerous stage where the wound presents as a unblanchable erythema at susceptible regions 
with the skin remaining intact. This may appear differently in more darkly pigmented skin. 
Changes in temperature, sensation or firmness may also precede these visual changes. By stage 
2, the skin surface has been breached, with partial thickness skin loss. The epidermis is 
compromised and the underlying dermis exposed. At this stage the ulcer is often described as 
‘superficial’ as there is no visible involvement of subcutaneous tissue. The ulcer presents as an 
abrasion, blister or shallow cavity with no presence of granulation tissue, eschar (black scab-
like tissue) or slough (yellow pus). 
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Stage 3 refers to full-thickness skin loss, with subcutaneous tissue necrosis or damage, which 
may extend down to, but not through, the underlying fascia. By stage 4 the pressure ulcer has 
progressed deep into the tissue, so much so that muscle and bones and sometimes even tendons 
and joints may be exposed or destroyed. Pressure ulcers may be classified as unstageable if full-
thickness tissue and skin loss cannot be confirmed due to obscuration of the wound bed by 
slough or eschar. Debridement of this material may reveal a stage 3 or 4 pressure ulcer. The 
final category, deep tissue [pressure] injury (DTI), describes suspected deep tissue damage of 
unknown depth observable only as purple, deep red or maroon localised area of discolored 
intact skin. DTI can remain undetected for days or weeks until the discoloration is visible and 
in darkly pigmented skin may not be visible at all28. Notably, the NPUAP recently announced 
a change in terminology in their staging system, updating the term ‘pressure ulcer’ to ‘pressure-
related injury’. The rationale behind this change was that the term ‘pressure-related injury’ 
more accurately describes tissue injury of both intact skin and ulcerated skin, while the term 
‘pressure ulcer’ described open ulcers and was not clearly inclusive of injured intact skin.  
Table 1 — Description of pressure related-injury stage from the most recent guidelines 
published by the NPUAP (2016).  
Pressure related-
injury stage 
Stage description 
1 
Unblanchable erythema of intact skin with tactile changes in 
skin temperature, tissue condition and/or sensation.  
2 Partial thickness skin loss with exposed dermis. 
3 Full-thickness skin loss (with subcutaneous tissue necrosis or 
damage). 
4 Full thickness skin loss – muscle, bones, tendons and joints may 
be exposed and/or destroyed. 
Unstageable Obscured full-thickness skin and tissue loss. 
Deep tissue pressure 
injury 
Persistent unblanchable deep red, maroon, or purple 
discoloration. 
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Figure 1.3 — Schematic representation of the NPUAP’s updated scoring system of pressure-related injury: 
(A) Healthy, lightly-pigmented skin. (B) The four stages of pressure ulcer development. Stage 1 represents tissue
injury of intact skin while stages 2, 3 and 4 represent open ulcers of increasing severity. (C) Two additional
pressure-related categories - unstageable pressure ulcers where eschar and/or slough is obscuring the wound bed 
and deep tissue [pressure] injury (DTI) where the skin is intact but there is tissue breakdown in the underlying
layers. From “Pressure Injury Staging Illustrations,” NPUAP Free Resource Staging Illustrations, 2016, (http://
www.npuap.org/resources/educational-and-clinical-resources/pressure-injury-staging-illustrations).
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1.1.7   Medical complications of pressure ulcers 
The morbidity and mortality associated with pressure ulcers mainly occur in the later pressure 
ulcer stages and are attributed to serious medical complications including cellulitis, blood 
poisoning, bone and joint infections, and gas gangrene (Figure 1.4)29. The occurrence of 
pressure ulcers increases mortality in patients in both acute and long-term care settings3. In 
some cases, the pressure ulcer itself does not cause death since it occurs in critically ill patients 
who are already more likely to die. The presence of pre-existing or co-existing illness is also 
likely to worsen the effect of pressure ulcers, especially in the critically ill and frail patient. 
Sepsis is one of the more serious consequences of pressure ulcers since it frequently results in 
death. Osteomyelitis, infection of bone, is a common complication of pressure ulcers and has 
been reported in 38% of patients with infected pressure ulcers30. A consequence of such an 
infection may be amputation, to prevent further spread of infection throughout the body and to 
salvage as much of the remaining uninfected limb as possible. In fact, amputation is a serious 
complication of other chronic wounds as well, especially the diabetic foot ulcer.   
1.1.8   Traditional clinical care: preventative measures, intervention methods and 
treatments 
Traditional approaches to pressure ulcer prevention include strategies to prevent the effect of 
external risk factors that cause pressure, shear, moisture and friction on vulnerable regions of 
skin. These include specialised pressure-redistributing mattresses, removal and replacement of 
wet bedding, especially for incontinent patients, and periodic turning of patients every one to 
two hours to relieve pressure, by nursing staff3. Once developed, treatment of the pressure ulcer 
varies depending on wound severity. It is important to debride unstable necrotic tissue and 
slough within an ulcer to prevent bacterial colonisation and to allow healing to occur3. Surgical 
intervention is indicated in the case of large, open and cavitied pressure ulcers. The procedure 
involves debriding the ulcer and suturing together the perimeter of healthy skin. Occlusive 
dressings supplemented with antimicrobial agents and wound healing promoters are also 
available. These techniques are explored further in this section.  
Pressure ulcer prevention 
Pressure ulcer prevention begins with identifying patients that are at risk of developing a 
pressure ulcer and understanding which factors are most likely to promote pressure ulcer 
development in that individual. Preventing pressure ulcer development in these at-risk patient 
populations is the next step. There are several ways this is accomplished – through adapting the 
patient’s external environment and through improving the patient’s health. Decreasing the 
moisture, friction, shear, and pressure that the patient experiences is deemed fundamental in 
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pressure ulcer prevention. The most traditional method of relieving pressure is through patient 
repositioning. Though there is no defined time interval for patient repositioning, it is reported 
that patients are typically turned once every one to two hours31. This repositioning helps relieve 
the pressure on weight-bearing anatomic sites in particular resting positions (Figure 1.2).  
Between patient repositioning intervals, a common pressure ulcer prevention method is the use 
of specialised mattresses that redistribute, relieve or reduce pressure. The market is brimming 
with many types of mattresses made from a variety of materials and foams. Conventional 
mattresses are static but there are also dynamic-powered devices, such as alternating air 
mattresses, that use an electric air pump to promote the uniform distribution of pressure over 
the body surfaces32. These more dynamic and electricity-powered mattresses are generally more 
expensive options. Additionally, bony prominences can be directly point-protected from high 
pressures using foams, pillows, wedges or elevation devices over the region, for example 
through the use of a heel protection device16,33.  
In combination with pressure, moisture can macerate and injure the skin. In patients, moisture 
comes from three major sources: sweat, wound drainage and incontinence (both urinary and 
fecal)3,34. The effects of moisture can be managed in patients through removal and prevention 
of excessive moisture build-up at vulnerable sites such as around the buttocks and especially 
within the gluteal folds. This includes regular changing of incontinence pads and devices, and 
wiping down of areas that have accumulated moisture. The patient’s nutritional status is also 
deemed important as poor nutritional status may impair wound healing35. Therefore, improving 
the patient’s health through nutritional and vitamin supplements may help prevent the 
development of new ulcers and prevent existing ones from worsening36.  
Pressure ulcer management and treatment 
Treatment of pressure ulcers is multi-fold. Many treatment options are aimed at late stage 
pressure ulcers (stages 3 and 4) where there is a high risk of mortality and life-threatening 
complications such as infection. One of the most important treatments is the removal of necrotic 
debris from the wound. By this stage of pressure ulcer development, phagocytosis by the host’s 
immune cells is insufficient to remove the dead tissue. Therefore, debridement is essential to 
prevent establishment of bacterial colonies and biofilms, and to promote wound healing. There 
are several methods used to debride pressure ulcers including mechanical and surgical 
debridement. Of the two, surgical debridement is the most rapid method of removing necrotic 
tissue, though both methods can cause damage to healthy tissue or may insufficiently clean the 
wound3. During surgical debridement dead tissue is cut away from the wound. This procedure 
can be performed at the bedside or may need to be carried out in an operating theatre. During 
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mechanical debridement, fluid force is used to remove necrotic tissue from the wound. This 
includes wound irrigation systems using pulsed lavage where a handheld device delivers normal 
saline at safe pressures to force out the debris1.  
Ultrasound-assisted wound therapy uses a combination of surgical and mechanical 
debridement37. During this type of treatment, ultrasonic waves are passed over the surface of 
the wound via a saline filled pressure wave to separate the necrotic tissue from the healthy skin 
in the wound bed16. Autolytic debridement, using occlusive dressings38, enzymatic 
debridement, using exogenous enzymes35, and biological debridement, using maggot 
therapy39,40, are viable longer term treatments options. Once an ulcer has been debrided, the 
remaining cavity may need to be surgically closed. This is done either by suturing the perimeter 
of healthy tissue or though flap surgery36. Alternatively, the pressure ulcer may be left to heal 
by secondary intention and managed with the use of dressings. A multitude of dressings are 
available and are chosen depending on the characteristics of the wound such as its depth and 
drainage. Transparent polymer films may be used on uninfected wounds that have little to no 
drainage, hydrocolloid dressings for shallow wounds with moderate drainage and  foams or 
alginates for deeper wounds with heavier drainage16. The wound may also be packed with 
gauze16. 
Management of bacterial colonisation with the use of antibiotics is an important protocol in 
pressure ulcer treatment. Infection control is crucial to aid wound healing and prevent life-
threatening complications such as bacteremia. Though it may be difficult to determine if a 
pressure ulcer is infected, a foul odour is usually indicative of the presence of anaerobic 
organisms3. Patients may also present with systemic symptoms of infection such as fever or 
organ failure16. Presence of bacteria in the wound has been shown to worsen pressure ulcers 
and topical antibiotics may be required if a pressure ulcer fails to progress toward healing. 
Notably, quantitative microbiology has been shown to be a poor predictor of clinical infection 
in chronic wounds41, and the species of colonising bacteria is likely to be more significant to 
the severity of the infection42,43.  
Limitations of current pressure ulcer care 
Despite the multitude of current pressure ulcer prevention methods, there is some doubt 
surrounding their efficacy. Furthermore, many of the prevention and treatment options that have 
been outlined here are outdated or contraindicated in many patients. For example, practical 
issues have been encountered with current treatment methods; whilst surgical repair of 
developed ulcers results in rapid resolution, there is an inability of frail patients to tolerate the 
procedure as well as the procedure being costly and resulting in frequent recurrence35. There is 
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also no consensus in the literature or amongst researchers on the efficacy of patient turning and 
repositioning in preventing pressure ulcers44. In some situations, such as is with certain SCIs, 
immobilisation precludes the need to reposition the patient. The efficacy of pressure-
redistributing mattresses in order to prevent pressure ulcers is also debatable3. There are data 
to suggest that the use of specialised mattresses does not reduce the incidence of pressure ulcers 
and that there is no considerable difference in pressure ulcer occurrence between dynamic and 
static mattresses45. Several studies have also concluded that there does not seem to be a benefit 
of one over the other46–48. There is also limited evidence to suggest that improvement in 
nutritional status (another prevention method) has a significant impact in preventing pressure 
ulcers. Despite an epidemiological association between poor nutritional status and pressure 
ulcers, nutritional supplementation has proved disappointing with several observational studies 
reporting that it did not have an effect on the development of pressure ulcers49,50. In one study 
there was shown to be no statistically significant difference in prevalence, incidence or 
mortality of pressure ulcers between critically ill patients given oral supplements and those who 
had not49,50.  
Alternative approaches to pressure ulcer resolution 
A potential approach to pressure ulcer resolution involves targeting pressure ulcers at a 
molecular level, that is, to interfere with the pathways that are involved in its etiopathogenesis 
and which promote wound development. Adjunctive therapies can be used alongside primary 
treatment in pressure ulcer management. Hyperbaric oxygen therapy, for example, involves the 
delivery of oxygen to improve tissue oxygenation and promote wound healing through 
stimulation of fibroblasts and epithelisation51. Electrical stimulation, though not widely used in 
clinical practice, is a method used to stimulate the cellular processes involved in wound healing 
through the use of electrical currents37,52. Growth factors required in the wound healing process 
such as platelet-derived growth factor (PDGF), endothelial growth factor (EGF) and vascular 
endothelial growth factor (VEGF), have been shown to be degraded in the presence of increased 
levels of elastases in chronic wound fluid53 and bacterial proteases54. Increasing local levels of 
growth factors by delivering them to the wound, or through the use of protease inhibitors, has 
proved promising in chronic wound treatment55. Wound chemotherapy is a fast-growing area 
of adjunctive therapy and is explored further in section: 1.4 Pharmacological treatment of 
pressure ulcers,  p. 59.  
Chapter 1: General Introduction 
- 47 -
Fi
gu
re
 1
.4
 —
 C
lin
ic
al
 o
ve
rv
ie
w
 o
f t
he
 p
re
ss
ur
e 
ul
ce
r.
 
Chapter 1: General Introduction 
- 48 -
1.1.9   Are pressure ulcers avoidable? 
A reasonable assumption that could be made is that ‘if pressure ulcers develop in immobilised 
patients, mobilising them along with meticulous clinical care would prevent pressure ulcer 
development?’. The answer has not been that simple. Despite current protocols, pressure ulcer 
incidence remains high and whether or not pressure ulcers are completely preventable remains 
controversial56. The question then becomes ‘where does the blame lie?’ — is it due to a deficit 
in nursing care or the inability of the current risk assessment scales and prevention methods to 
actually prevent pressure ulcers? Once again the answers have not been so clear. Pressure ulcers 
are often believed to be an indicator of poor patient care that are costly to the individual as well 
as the public healthcare system35.  
Penalties for poorly managed pressure ulcers are adverse outcomes and high treatment costs, 
and, increasingly, financial institution-wide penalties specifically for HAPUs. As the old adage 
goes, prevention is better than cure and this holds true for pressure ulcer care both in terms of 
cost and patient’s quality of life3,35,37,57–60. In the UK, the cost of treating a stage 4 pressure 
ulcer was placed at £10,554 in 2000, compared with an average of £1,064 to treat a stage 1 
ulcer12. Nonetheless, it has been shown that with conscientious medical management many 
pressure ulcers that have developed will heal completely without the need for treatment or 
surgical intervention. At annual consortiums and sandpit events, including the recently formed 
Medical Device and Vulnerable Skin Network (MDVSN), there is growing interest in emerging 
biotechnologies that can help evaluate pressure ulcers and that can provide more detailed 
subsurface information on a developing ulcer as well as in novel biotechnologies that can 
prevent the first stages of ulcer development before skin deterioration accelerates. 
1.2   Fundamental aspects of human skin architecture and structure 
1.2.1   The skin —  a resilient but breachable barrier 
Skin is the largest organ of the human body and is essential for terrestrial life since it carries 
out a multitude of vital functions. Skin primarily acts as a dynamic barrier that allows us to 
safely exist within and interact with a harsh external environment. To a great extent, skin 
protects our internal organs from direct exposure to many external threats including pathogens, 
parasites, sunlight, toxins and exogenous chemicals. Not only does it help limit entry of these 
unwanted substances it also prevents what would otherwise be rapid and devastating water loss 
from our body’s interface to the surrounding environment. Skin is also important as a sensory 
organ and allows the body to respond to changes in heat, cold, touch, pressure and pain through 
a network of nerves connected to the central nervous system. Temperature control is further 
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aided through a rich blood supply, fine hair, and sweat glands. It is important to remember, 
however, that though skin is resilient, it is also vulnerable to injury and its surface can be 
breached with certain perturbations. Wounds, disturbances to the skin’s structural continuity, 
leave the body vulnerable to infection. Furthermore, deviation from normal skin function and 
behavior due to acquired or genetic diseases are known to have debilitating consequences, from 
the relatively common inflammatory skin disorders such as eczema and psoriasis61 to the rarer 
skin diseases such as ichthyosis62.  
1.2.2   Function and structure of the skin layers 
At its simplest, human skin can be divided into three main ‘zones’ or layers: the epidermis, the 
dermis and the subcutis. The epidermis is the thin, avascular outermost layer of skin. The 
principle cell type here is the keratinocyte which accounts for 95% of all epidermal cells63. The 
epidermis is further sub-divided into five distinct layers: (i) the stratum corneum or SC, (ii) the 
stratum granulosum, (iii) the stratum lucidum, (iv) the stratum spinosum, and (v) the stratum 
basale (Figure 1.5). The SC is the outermost epidermal layer and is the most important for 
imparting the barrier properties of the skin which makes it incredibly important when 
considering the physiological obstacles to transcutaneous delivery64. The SC is composed of 
dead keratinocytes, known as corneocytes, and has a high resistance to changes in temperature 
and pH65. These dead skin cells are constantly being lost from the surface of the SC in a process 
known as desquamation66. Beneath the SC are the remaining layers of the epidermis, 
Figure 1.5 — Schematic representation of the epidermal layers and the basement 
membrane zone [BMZ] that separates the stratum basale from the underlying 
dermis. Adapted from “Structure and function of the epidermal barrier,” by R. R. 
Wickett l and M. O. Visscher, 2006, American Journal of Infection Control, 34, p. S99. 
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collectively known as the viable epidermis. This loss of cells from the SC is constantly being 
balanced by the self-renewing viable epidermis through mitosis and cell growth originating in 
the stratum basale. Upon leaving the stratum basale, keratinocytes begin to differentiate and 
migrate through the stratum spinosum and granulosum66. During their maturation, keratinocytes 
undergo a series of changes in their structure and composition synthesising different structural 
proteins and lipids as they differentiate. 
The epidermis is separated from the underlying dermis by the cutaneous basement membrane 
zone (BMZ) which contains proteins and glycoproteins that ensure adhesion of the two layers63. 
The dermis is a layer of connective tissue that sits below the BMZ and contacts both the 
epidermis and the subcutis. Unlike the epidermis, the dermis is richly supplied by blood vessels 
and sensory nerve endings. It also contains lymphatic vessels, sweat glands and hair follicles. 
Structurally, the dermis is composed of interstitial components including collagen fibres, elastic 
tissue and ground substance, and cellular components including fibroblasts, mast cells, plasma 
cells, dermal dendritic cells and histiocytes63. Most dermal cells are fibroblasts which are 
responsible for synthesising and maintaining the tissue’s extracellular matrix (ECM)18.  They 
secrete collagens, elastic fibres and ground substance, a gelatinous substance composed of 
proteoglycans and glycoproteins. The dermis is often sub-divided into two sections, the 
papillary or upper dermis and the reticular or lower dermis63. 
Roughly 70% of the dry weight of the dermis is made up of collagens67, of which the 
predominant types are type I and type III. Collagens are proteinaceous structural molecules 
found throughout the body with at least sixteen different types found in humans68. Collagens 
impart tensile stiffness and strength to the skin. Elastic fibres, on the other hand, form about 
5% of the dry weight of the dermis and are responsible for the skin’s elasticity. Elastic fibres 
consist of elastin and elastic microfibrils such as fibrillin. The collagen and elastic fibres are 
bathed in the ground substance which is important in maintaining the spatial structure of the 
collagen-elastin network and in supporting the skin’s capacity to carry compressive loading18. 
Beneath this network is the subcutis which is composed of lipocytes arranged into fat lobules. 
Bundles of fibres originating from the dermis percolate into the subcutis, strengthening the 
connection between the two compartments63.  
1.2.3   Skin vasculature and innervation 
While the epidermis is avascular, the dermis has a rich blood supply. The vasculature of the 
dermis is comprised of two interconnected systems — the superior vascular plexus and the deep 
vascular plexus. The superficial vascular plexus is located in the papillary dermis and consists 
of terminal arterioles, arterial and venous capillaries and post capillary venules69. Capillaries 
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arising from the arterioles extend upward into the papillary dermis and then loop back into 
ventrioles. These structures are known as capillary loops (Figure 1.6). The deep vascular plexus 
is connected to this system by paired ascending arterioles and descending venules. 
Thermoregulation is, in part, regulated by blood flow through the skin’s vasculature by 
processes known as vasodilation (widening of blood vessels) and vasoconstriction (narrowing 
of blood vessels). In a stable thermal environment of ambient temperature, skin surface 
temperature of the torso ranges from 33‒37oC  while that of the extremities tends to be slightly 
lower70. As well as a role in thermoregulation, the dermis is also well innervated and has an 
important sensory function. Several branches of the spinal and cranial nerves pass through the 
subcutaneous space into the dermis and form three plexuses — the papillary, dermal and 
subcutaneous plexuses71. Free nerve endings, sensitive to pain, lie in the dermis with a few 
extending to the cells of the epidermis. The dermis also contains several additional receptors 
with larger receptive fields. Important roles include mechanoreception, thermoception and 
nociception.  
1.2.4   Variation of epidermal skin layer thickness 
Skin layer thickness varies between different body regions and between individuals based on 
factors such as age. Epidermal layer thickness typically ranges from 50 to 200 µm while dermal 
thickness is substantially larger and ranges from 1 to 3 mm. Viable epidermal thickness has 
been shown to significantly decrease with age72. This is in conjunction with a substantial loss 
in function of aging skin and a dramatic reduction in turnover rate. This is a consequence of 
cell proliferations rates dropping in the dermis as the skin cells biologically age with the 
individual. The SC thickness varies considerably with anatomic site and ranges from 5‒600 µm 
thick, though is typically around 20 µm73. It has been well documented that the SC is much 
thicker on the palms and soles of the feet (up to 50 cells thick) compared with the skin on more 
delicate regions such as the face (around nine cells thick). Considering the frequent interaction 
with the environment — tactile grasping and gripping with the hands and movement and weight 
bearing of the feet — these surfaces inevitably require a tough and more resilient SC layer. The 
SC has also been shown to thicken significantly with hydration74,75.  
1.2.5   Skin barrier function and permeation pathways of molecules 
As previously described, the barrier function of the skin is imparted by the epidermis, 
specifically the SC. The ‘bricks and mortar’ analogy is commonly used to explain how the SC 
functions as this barrier. The ‘bricks’ are the resident corneocytes — elongated, flat cells filled 
with keratin filaments which have densely cross-linked lipoprotein-containing envelopes, 
These are surrounded by the ‘mortar’ — lipid bilayers with hydrophilic regions inbetween64,76. 
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The main mechanism of transport of substances into the skin is by passive diffusion. Molecules 
can pass directly through the lipophilic SC, through either intercellular or transcellular diffusion 
routes, or indirectly through transappendageal routes, via hair follicles, sebaceous glands or 
sweat ducts (Figure 1.6)77. The total surface area afforded by the skin appendage openings 
constitutes only 0.1% of the total skin area however, so their contribution to steady state flux 
of molecules is considered minimal77. Furthermore, permeation is hindered in these routes by 
natural structures such as hairs78. The intercellular route is the most common permeation 
pathway of drug molecules and involves diffusion of the substance through the lipid matrix 
occupying the intercellular spaces of the keratinocytes. Due to its hydrophobicity, lipid-soluble 
molecules will penetrate more readily through the SC than water-soluble molecules.  
As the primary skin barrier, the SC is the rate-limiting step to molecular penetration. Diffusion 
of compounds through the skin is governed by Fick’s first and second laws of diffusion77. Small 
lipophilic molecules with lower melting points are of an optimal chemical composition to 
readily permeate through the SC79. A study was carried out by Meinardi and Bos (2000) to 
define the term ‘small’ in this context, who proposed the 500 Da rule for the skin penetration 
of chemical compounds and drugs76. The authors reviewed the most commonly used topical 
drugs in dermotherapy and found, with the exception of two, that they all had a molecular 
weight of less than 500 Da. They also noted that topical application of an immunosuppressant 
treatment for inflammatory skin conditions that had a molecular weight of just over 1200 Da 
was ineffective80 when compared with its administration by intralesional injections81. Though 
their proposal has been met with several arguments, there is a general consensus amongst 
researchers that for particularly high molecular weight and hydrophilic molecules disruption of 
the skin barrier is necessary to allow the compound to efficiently permeate through the SC 
barrier. 
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1.3   Pathophysiological mechanisms behind pressure ulcer development 
1.3.1   The normal acute wound healing paradigm 
Wound healing is an important homeostatic process which restores the integrity of the skin and 
its barrier function after it has been breached. Several biological events are involved in the 
process of wound healing in an orderly and predictable manner. These are hemostasis, 
inflammation, cell proliferation and skin remodelling and re-epithelisation collectively known 
as HIPR82. These processes are themselves governed by a plethora of coordinated signals 
between the diverse cell types involved in wound healing including dermal cells, inflammatory 
cells, enzymes and cytokines83,84. The body’s hemostatic mechanism is important in preventing 
Figure 1.6 — Schematic representation of the human skin and penetration 
pathways of molecules through the stratum corneum. The three penetration pathways 
are: (i) the transcellular route, (ii) the intercellular route and, (iii) the transappendageal 
route. Adapted from “Modelling the human skin barrier — Towards a better 
understanding of dermal absorption,” O.G. Jepps et al., 2013, Advanced Drug Delivery 
Reviews, 2, p. 154. 
Third p
arty co
pyrigh
t mate
rial rem
oved
Chapter 1: General Introduction 
- 54 -
excessive blood loss and in initiating the healing process. Collagen that is exposed during a 
skin injury activates a clotting cascade pathway which results in platelet aggregation and blood 
coagulation forming a clot made from collagen, platelets, thrombin, and fibronectin. This fibrin 
clot acts as temporary wound plug and as a foundation for the laying down of new ECM85. The 
clot also contains a milieu of cytokines and growth factors that initiate wound closure through 
chemoattractant signals. Prostaglandins cause vasodilation of local blood vessels to increase 
cellular traffic to the site86.  
Neutrophils are recruited to the wound site within minutes of injury by chemoattractant signals: 
interleukin-1 (IL-1), tumour necrosis factor-alpha (TNF-α), transforming growth factor-beta 
(TGF-ß) and platelet factor-4 (PF4)57. Neutrophils play an important role in removing bacteria 
and tissue debris by releasing proteolytic enzymes and through phagocytosis. Next, circulating 
monocytes are recruited to the wound site where they are stimulated to become activated 
macrophages. They are responsible for phagocytosing remaining pathogenic material. They 
also release growth factors and cytokines including collagenases to debride the wound and 
interleukins and TNF-α to stimulate fibroblasts.  
Towards the end of the inflammatory phase, the proliferative phase of wound healing begins. 
This phase involves re-epithelisation to restore the barrier function of the skin, angiogenesis to 
supply the growing tissue with the required oxygen and nutrients and granulation tissue 
formation. Keratinocytes at the wound edge migrate and proliferate to re-epithelise the breach 
in the skin. This is stimulated by keratinocyte growth factors (KGFs) whose expression, 
synthesis and secretion are upregulated in fibroblasts in response to IL-1 and TNF-α57,87. 
Angiogenesis involves the development of new blood vessels; endothelial cells release 
proteolytic enzymes which degrade the basement membrane and allow the formation of primary 
vessels85. 
Around seven days after the initial injury, the wound site undergoes remodelling85. Fibroblasts 
that have migrated into the wound synthesise collagen types I and III82. This occurs at a greater 
rate than collagen degradation, resulting in net collagen accumulation. Wound contraction 
begins around the start of collagen synthesis and helps reduce wound size. During scar 
formation, collagen fibrils become tightly packed. The entire remodelling phase can persist for 
years after the initial injury. As a normal wound heals, the final process is resolution of the scar. 
Macrophages, fibroblasts and endothelial cells release collagenases to degrade wound collagen 
and other matrix proteins, degrading the scar tissue and ultimately healing the wound85. 
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1.3.2   Chronic and delayed healing wounds 
Chronic wounds do not proceed through the phases of normal wound healing in an orderly or 
timely manner3. There are three major types of chronic wound – pressure ulcers, diabetic ulcers 
and venous leg ulcers — that develop by different pathophysiological mechanisms but have 
several similar characteristics. These wounds do not resolve easily, are an immense health and 
resource burden and reduce the patient’s quality of life as they can be painful and debilitating. 
There is a multitude of factors that contribute to the non-healing characteristic of chronic 
wounds. These include a combination of environmental factors and certain patient risk factors 
such as an underlying disease. Chronic wounds exhibit a persistent inflammatory phase and a 
prolonged influx of inflammatory cells compared with acute wounds. There is excessive 
expression of certain enzymes and cytokines that leads to cell necrosis and apoptosis. In many 
cases there is colonisation of the wound by infectious bacteria and, most noticeably, a lack of 
advancement to the remodelling stage of wound healing.  
1.3.3   Effect of pressure on human skin 
It is theorised that pressure on the skin can cause damage in multiple ways, especially to the 
dermis, which constitutes a large structural and functional part of cutaneous tissue. Underlying 
muscle is also susceptible to pressure-induced injury. The critical threshold for injurious 
pressure on the body tissues is often referenced as 32 mmHg35. This is the capillary closing 
pressure – the interface pressure at which the capillaries collapse and close completely, thus 
occluding local blood flow. Prolonged pressure of greater than 32 mmHg for more than two 
hours at focused regions of the skin is believed to: (i) interrupt the intricate structure of the 
ECM network causing changes in ECM turnover and potentially leading to ECM degradation37, 
(ii) result in compromised lymphatic transport leading to an accumulation of toxic substances
in the tissues18, (iii) lead to direct mechanical insults to cells that cause cellular necrosis88 and
(iv) cause cyclical microvasculature occlusion (if the pressure is intermittently relieved) known
as ischemia-reperfusion (IR) injury, ultimately leading to cellular necrosis and apoptosis89,90.
1.3.4   The role of ischemia-reperfusion injury in pressure ulcer development 
Ischemia-reperfusion (IR) injury is a major complication for many clinical conditions including 
myocardial infarction, stroke and organ transplantation91. It is also one of the most widely 
acknowledged pathophysiological mechanisms behind pressure ulcer development. This has 
not always been the case, however. Preliminary studies into pressure ulcer formation focused 
on tissue ischemia as the sole etiological factor92. Many of these first studies believed it was 
ischemia leading to tissue necrosis which drove pressure ulcer development and this was 
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reflected in the experimental groups and in vivo research models used. Over the years, however, 
many in vivo studies have shown a discrepancy between the effect of ischemia alone and the 
effect of cycles of IR injury89,93. In fact, IR injury is believed to be more injurious than ischemia 
alone, as ischemia alone is unable to account for all the effects seen in pressure ulcers. 
IR injury describes the damage to a tissue by not only the initial period of ischemia but also the 
subsequent reperfusion of blood to that region94. When prolonged pressure is applied to the 
body, the microvasculature in the skin becomes occluded resulting in tissue anoxia and glucose 
deprivation. If this goes unrelieved for two to six hours, it will lead to local ischemic injury19. 
This total arrest in circulation affects the metabolism of the skin and subcutaneous tissues and 
will result in cell death and tissue necrosis after six hours of unrelieved pressure18. Hyperemic 
reperfusion represents the reintroduction of blood to the previously ischemic tissue and is 
believed to play a key role in pressure ulcer development95. This is because it not only 
introduces critically needed oxygen and nutrients back into the tissue, but harmful oxygen 
radicals as well, including reactive oxygen species (ROS) such as superoxide radicals and 
hydrogen peroxide18. These ROS can lead to oxidative damage and inflammation through the 
recruitment of leukocytes (macrophages and neutrophils) ultimately resulting in cell apoptosis 
and further necrosis51,96. In addition, toxins are circulated to the area which further contribute 
to inflammatory damage during reperfusion90,97,98. 
Though IR injury is the most widely supported pathophysiological mechanism behind pressure 
ulcer development, there have been suggestions of other factors in play. Other mechanisms that 
are believed to contribute to pressure ulcer development include compromised lymphatic 
transport leading to an accumulation of toxic substances in the tissues18 and direct mechanical 
insults to cells that cause cellular necrosis88. For the time being however, IR injury remains at 
the forefront of pressure ulcer research. For this reason there is speculation about whether the 
current prevention protocol of intermittently relieving pressure in ‘at risk’ patients every few 
hours is contributing to, rather than ameliorating, pressure ulcer development99,100. If this is the 
case current nursing practice may need to be re-assessed. However, it is likely that such 
intermittent mobilisation is essential in the prevention of life-threatening nosocomial conditions 
such as thrombosis or chest infection33. Furthermore, patients who must remain unmoved due 
to particular spinal cord injuries also develop pressure ulcers.  
1.3.5   The role of matrix metalloproteinases in pressure ulcer chronicity 
Among the pathophysiological mechanisms believed to be responsible for pressure ulcer 
development and other chronic wounds, unregulated degradation of the extracellular matrix 
(ECM) has been proposed to be key in ulcer chronicity and wound non-healing88,101–111. In a 
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non-healing chronic wound, the wound environment is such that there is prolonged 
inflammation, unregulated enzymatic activity and a lack of re-epithelialisation resulting in an 
open wound that is highly susceptible to infection and which reduces a patient’s quality of 
life112. It is believed that defective activity in the enzymes responsible for ECM degradation, 
the matrix metalloproteinase (MMPs), and their inhibitors, tissue inhibitors of 
metalloproteinases (TIMPS), is a major contributor in potentiating the chronic wound 
environment113.  
MMPs are a family of zinc-dependent proteases that degrade several components of the skin’s 
ECM including collagen, gelatin, fibrillin and elastin. Twenty-three different MMPs have been 
identified in humans and include the collagenases, gelatinases, stromelysins and membrane-
type MMPs amongst the major types114. Importantly, MMPs are required for normal 
physiological processes such as cell migration, angiogenesis and scar remodeling110. However 
aberrant MMP expression and altered regulation can result in too much or too little MMP 
activity leading to ulcer formation or other maladies such as tumour metastases or fibrosis115.  
Over the years, observational clinical studies have investigated which MMPs could be 
responsible for wound development and chronicity by examining the content of tissue exudate 
and granulation tissue from chronic wounds102,104–107.  
Clinical observational studies combined with evidence from experimental models suggest that 
elevated MMP levels and aberrant regulation are responsible for the inflammatory component 
and chronicity of several diseases, pressure ulcers included102,106,110,113,116. Despite their 
deleterious behaviour in these diseases, MMPs have an integral physiological role in 
maintaining and remodelling extracellular spaces for tasks such as tissue growth and scar 
repair114. What tips the balance in favour of damage has been extensively studied and is 
believed to result from either MMP overexpression, inadequate MMP inhibition or a 
combination of both. There is currently no consensus on which MMP or MMPs are responsible 
for wound severity but patterns in chronic would fluids indicate an increase in several MMP 
levels, MMPs 2, 8 and 9 and a concurrent increase in the MMP/TIMP ratio114. Simultaneously 
levels of the endogenous MMP inhibitors, TIMPs and alpha2-macroglobulin (α2M) have been 
shown to be decreased in would fluid contributing to the imbalance that results in ECM 
degradation111,117–119. 
MMP 9, or gelatinase B, has been suggested as a major protease responsible for ECM 
degradation in chronic wound fluid. Its persistently elevated state has been observed in pressure 
ulcers, venous leg ulcers and non-healed burns, with levels dropping as wounds heal113. The 
role of MMP 9 In normal wound healing is to promote inflammation and facilitate migration of 
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neutrophils. In their murine wound model using 6 mm punch biopsies, Reiss et al. (2009) 
observed that wounds treated with exogenous MMP 9 were significantly larger than control 
wounds up to twelve days after the initial injury120. Their results suggested that MMP 9 could 
directly delay wound healing through interference with re-epithelialisation and keratinocyte 
migration. MMP 2, or gelatinase A, has been shown to have increased expression in chronic 
wounds despite its anti-inflammatory role and role in keratinocyte migration. In one preclinical 
wound model, MMP 2 was shown not to be essential for wound healing121 and was shown to 
be at elevated levels in the wound fluid of chronic leg ulcers122. Both MMP 2 and 9 were also 
shown to be increased in a preclinical model of ischemic stroke123. MMP 8, collagenase 2 or 
neutrophil elastase, has been strongly implicated in the tissue destruction of the inflammatory 
condition periodontitis, and inhibition of its action has resulted in improvements in wound 
healing124,125. 
Table 2 — Summary of MMPs that have been implicated in pressure ulcer chronicity in 
the literature. 
However, it should be noted that, firstly, the composition of chronic wound fluid does not 
represent the composition of the wound bed. It has in fact been shown that the concentration of 
MMPs is higher in the fluid than the bed itself113. Secondly, MMPs play a crucial role in wound 
healing and so physiological wound healing would be impaired if their action were fully 
inhibited. Nonetheless, if administered carefully MMP inhibitors provide a potential treatment 
for pressure ulcers and other chronic wounds. Thus targeting such MMPs in a precise and 
controlled way to improve cutaneous wound healing is of great interest. By reducing the time 
to heal or by preventing ulcer development, this could substantially decrease the healthcare 
costs as well as alleviate the physical burden on the patient111. MMP inhibitors, also known as 
MMPIs, pose a potential solution to the problem by mimicking endogenous TIMPs. They have 
gathered great interest in the treatment of late stage cancers as drugs to prevent tumour 
metastases126. Their action could be translated to the prevention and/or treatment of pressure 
MMP Sub-Family Alternative name Principal Substrates 
MMP 2 Gelatinase Gelatinase A Non-fibrillar collagens, 
types IV and V 
MMP 8 Collagenase Neutrophil 
collagenase / 
Collagenase 2 
Fibrillar collagens, types 
I, II, III 
MMP 9 Gelatinase Gelatinase B Non-fibrillar collagens, 
types I and IV 
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ulcers116. Their role is discussed in the section: Targeting MMPs to treat pressure ulcers, p. 
60. 
1.3.6   The effect of pressure on muscle: superficial versus deep tissue injury 
Though degeneration of the skin is the most evident stigmata of pressure ulcer damage the 
underlying subcutis, especially muscle, is also highly susceptible to the effects of sustained 
compression14. In fact, evidence suggests that this underlying muscle is more susceptible to 
pressure-induced injury than skin for a given mechanical load127,128. Thus, it is believed that 
superficial ulcers develop in the skin and involve maceration and detachment of the superficial 
skin layers, while deep ulcers arise in the deeper muscle layers, especially in the skeletal muscle 
that covers bony prominences susceptible to sustained compression14. Hence it should be noted 
that what is seen clinically may be just the ‘tip of the iceberg’13. This is to say that the extent of 
damage to the skin may not reflect the extent of damage to the underlying muscle and 
subcutaneous tissue which is more susceptible to ulceration37. This is important when 
considering that clinical ulcer staging is achieved through visual inspection and that deep tissue 
injury of the skin is often not visible for weeks, if at all. 
1.3.7   Bacterial colonisation and wound bioburden 
In addition to MMP dysregulation, bacterial colonisation of an exposed chronic wound can 
cause complications114. Not only do the bacteria illicit further inflammatory responses, if they 
are in excess they will firstly delay wound healing and eventually lead to infection. Chronic 
wounds with a high bacterial load will not heal38. Bacteria can form biofilms in the wound 
which are highly resistant to antibiotics, host antibodies, inflammatory cells and 
disinfectants129. These persistent biofilms can serve as a long-term inflammatory source. As an 
important co-factor, the proteinaceous exudate from the wound and nonviable tissue acts as a 
nutrient source, aiding bacterial growth and survival130. Additionally, the host immune response 
to biofilms is deleterious to wound healing. Inflammatory cells secrete ROS and MMPs to 
counteract the biofilm bacteria which inadvertently destroy the ECM and pro-healing factors in 
the wound bed, further delaying the wound healing process114. 
1.4   Pharmacological treatment of pressure ulcers 
1.4.1   The need for new treatments and improved understanding of pressure ulcer 
development 
Pressure ulcers are not currently at the forefront of medical research and mainly present in an 
age group that suffers from a range of primary diseases that demand more immediate attention. 
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However, global shifts in demographics, especially in more economically developed countries, 
have resulted in aging populations and a corresponding rise in age-related disease and pressure 
ulcers. With this increasing incidence, there is a need for innovation in pressure ulcer care. 
Pressure ulcers are important and merit such innovation. Advisory panels and sandpit events 
such as the Medical Device and Vulnerable Skin Network (MDVSN) have made efforts to unite 
researchers and clinicians, with the aim of creating devices to efficiently eliminate pressure 
ulcers and reduce related medical costs.  
1.4.2   Targeting MMPs to treat pressure ulcers  
Elevated MMP levels can be counteracted in a number of ways including the physical removal 
of the MMPs or through the use of MMP inhibitors. Promogran, the first MMP-modulating 
wound dressing, absorbs MMPs from the wound exudate and bed83,131, and has been shown to 
improve healing rates of diabetic foot wounds132 and venous leg ulcers133. A large group of 
MMP inhibitors, which have also been investigated as anti-cancer drugs and which include 
BB94 (batimastat), GM6001 (ilomastat/galardin) and  BB 2516 (marimastat), could also 
provide effective treatment126. These drugs function as potent inhibitors of the MMPs that are 
responsible for detaching cells from the basement membrane to ultimately prevent cancer 
spreading throughout the body i.e. inhibiting tumour metastases (though clinical trials for this 
application were unsuccessful)134. However, delivering these drugs in a controlled manner to 
prevent perturbation of normal physiological function is an important consideration. 
Doxycycline, an antibiotic and MMP inhibitor used in the treatment of aphthous ulcers (a form 
of mouth ulcer), has been suggested as a suitable and effective treatment for chronic 
wounds116,135, and this suggestion further supports the destructive role the MMPs are believed 
to play. 
The rationale behind choosing doxycycline as the experimental API in this research was based 
on several factors. Firstly, doxycycline is desirable as it has confirmed MMP inhibitory activity 
independent of its other pharmacological activity and is already FDA-approved for the 
treatment of aphthous ulcers based on this attribute136,137. For these reasons it also has an 
established safety and adverse effects profile138. Doxycycline has numerous pharmacokinetic 
advantages over its tetracycline counterparts such as oxytetracycline and tetracycline HCL 
including improved bioavailability and better penetration into body tissues and fluids139. In 
terms of administration, there are multiple pre-existing formulations of doxycycline (which 
typically comes in powder form) and this allows for a wide scope of drug delivery methods. 
Notably, doxycycline had not been experimentally investigated in the treatment of pressure 
ulcers, or in chronic wounds in general, at the time of its choosing making the concept behind 
this research novel.   
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1.4.3   Doxycycline as chronic wound chemotherapy 
Doxycycline hyclate is a tetracycline compound that is used as a broad-spectrum antibiotic in 
the treatment of a wide variety of bacterial infections including Chlamydia and gonorrhea140138. 
At sub-antimicrobial doses doxycycline is also a broad-spectrum inhibitor of MMP141. MMPs, 
produced and secreted by a number of dermal cells including fibroblasts, are responsible for 
the digestion of the structural ECM components, gelatin and collagen. It follows that aberrant 
or uncontrolled regulation of MMPs resulting in high MMP activity is associated with the 
chronicity of non-healing wounds due to excessive and unabated tissue degradation142. Thus 
doxycycline, as a matrix metalloproteinase (MMP) inhibitor, is a potential treatment for chronic 
wounds116. 
Doxycycline comes in three crystal forms: doxycycline hyclate, doxycycline hydrochloride and 
doxycycline monohydrate140. Doxycycline hydrochloride and doxycycline monohydrate can be 
derived from doxycycline hyclate through several chemical reactions (Figure 1.7). 
Doxycycline hyclate, chemical formula (C22H24N2O8.HCl)2·C2H6O·H2O, is a large hydrophilic 
molecule with a molecular weight of 1025.89 g/mol (1.03 kDa) and presents as a hygroscopic 
yellow crystalline powder140. It can be readily dissolved in water to form an aqueous solution 
with a solubility limit of 50 mg/ml143. Doxycycline can be delivered orally or intravenously 
with bioavailability being marginally greater for the latter. It is transported in the bloodstream 
mostly bound to plasma proteins and is widely distributed in tissue and fluid, with a half-life of 
12‒24 hours140. Clinically, it’s the choice treatment over other tetracyclines due to its better 
absorption and longer half-life. 
Doxycycline is sold as a medicament in several formulations including solutions, gels and 
tablets. Its Periostat® formulation, used to treat aphthous ulcers, is delivered as a mouthwash 
containing 20 mg doxycycline hyclate for a single oral dose (20 mg twice per day is considered 
a sub-antimicrobial dose)144. Vibromycin® comes as an oral tablet formulation and contains 
doxycycline powder while Doryx® is an enteric-coated slow release doxycycline-containing 
pellet138. Both are used as antibiotics against multiple types of bacterial infection. Atridox® is 
a biodegradable in situ-forming drug delivery system comprising Atrigel® (the delivery 
system) and 10% doxycycline145. It is used as a locally applied antibiotic as a treatment for 
periodontitis. The two components are combined together using a dual syringe system 
immediately prior to application and are injected onto the affected area. 
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As with all drugs, even those previously approved for other applications, there are safety 
concerns surrounding doxycycline-based treatment of pressure ulcers. At antimicrobial doses, 
common allergic reactions with oral doxycycline include hives, shortness of breath and 
swelling of the face while common systemic reactions include headaches, dizziness, nausea, 
diarrhea, vomiting, thrush and vaginitis138. Oral doxycycline treatment has also been reported 
to elicit effects on the skin including photosensitivity — sensitivity to UV light — which 
requires patients to protect their skin from sunlight during the course of the treatment. Skin 
reactions are rare but include erythema, swelling and blistering rash. These side effects may not 
be the case with local sub-antimicrobial doses as desired in pressure ulcer treatment but it is 
important to be aware of potential complications. 
As a potential prophylactic treatment for chronic wounds, doxycycline could be delivered 
intradermally to susceptible skin at the earliest stages of wound development. Later stages of 
wound development may also benefit from the effects of MMP inhibition but are more likely 
to require surgical intervention as ultimate treatment. The etiopathogenesis of chronic wounds 
often begins with MMP-mediated damage occurring below the intact skin. This makes 
Figure 1.7 — (A) Skeletal and chemical structure of doxycycline (hyclate form). (B) 
Chemical derivation of doxycycline monohydrate and hydrochloride from doxycycline 
hyclate; from “Doxycycline hyclate: a review of properties, applications and analytical 
methods,” by A.C. Kogawa and H.R.N Salgado, 2012, International Journal of Life 
Science and Pharma Research, 2, p. 13. 
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therapeutic access to the early stages of chronic wounds challenging and requires the skin 
barrier to be transiently permeabilised to allow for the absorption of larger molecules, like 
doxycycline, into the dermis to reach the deeper tissue injury. 
1.5   Intradermal and transdermal delivery of large drug molecules 
1.5.1   Negotiating the epidermal barrier 
Transdermal drug delivery (TDD) and intradermal drug delivery (IDD) are indicated when 
other administrative routes, such as oral administration, are not as effective as desired. TDD 
describes drug delivery that has a target beyond the dermis (either the underlying tissue or 
systemic circulation), while IDD typically describes drug delivery where the target is the 
dermis. There are three major groups of drug that involve skin application: (i) epidermal 
formulations which are designed to remain active on the surface of the skin such as dermal 
insect repellents, (ii) endodermal or diadermal formulations which are designed to function in 
the viable epidermis and dermis but not the systemic circulation, and (iii) formulations that, 
even though are applied topically, have systemic action146. Most proteinaceous drugs are of a 
large size and are hydrophilic so they cannot permeate passively across the skin due to the 
stratum corneum which selectively allows the trans- and inter-cellular transport of small 
lipophilic molecules147,148. Tight junctions in the skin epithelium, known as zonae occludentes, 
may also contribute to the barrier function of the epidermis by inhibiting drug diffusion. To get 
these larger drugs across the skin the barrier must be temporarily disrupted. 
1.5.2   Percutaneous penetration enhancers 
Topically treating the skin is often prevented by the skin’s natural barrier function and can be 
especially troublesome if the target lies just beneath the skin’s surface. However, delivering 
drugs through the skin rather than orally provides a range of advantages, mainly by bypassing 
first-pass metabolism and by increasing local bioavailability. There are many different ways to 
circumvent the skin barrier, namely percutaneous penetration enhancers, which fall into the two 
major categories: (i) chemical enhancers and (ii) physical enhancers. Chemical enhancers are 
compounds, often added with or prior to drug application, that increase drug permeation 
through biochemical changes to the skin. Examples include alcohol, sulphoxides, surfactants, 
glycols and pyrrolidines146,149,150. Physical enhancers are devices or techniques that 
mechanically alter the skin to provide channels for drug transit. Common examples include 
iontophoresis, electroporation and sonophoresis. There are several desirable properties for 
percutaneous penetration enhancers: the enhancer should not be irritating, allergenic or toxic, 
its effect should be both predictable and reproducible, it should have no pharmacological effect 
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within the body, it should have an acceptable sensation or tolerable pain and, once removed, 
the skin barrier properties should return rapidly and fully149.   
Physical enhancers make use of ultrasound, electric fields, heat and ballistic methods to increase 
the permeability of the skin151. Ultrasound devices have been shown to help deliver high 
molecular weight medicaments, including proteins, percutaneously152. Paliwal et al. (2006) 
showed that the acoustic waves emitted by ultrasound devices made ultrastructural defects in 
the SC, increasing its permeability153. During iontophoretic delivery, low amplitude electrical 
currents are applied to the skin154. This has been shown to enhance percutaneous delivery of 
drugs, especially charged molecules, by several mechanisms including direct electrophoresis155. 
Iontophoresis has been clinically approved for several drug delivery applications including 
delivery of lidocaine for local anesthesia156. Electroporation utilises electrical fields in a similar 
manner to iontophoresis. Short, high-voltage pulses (tens to hundreds of volts) are applied to 
the skin using electric fields for microseconds or milliseconds157. This technique is not 
commercially used in transdermal delivery but has been successful in drug delivery for the 
treatment of several tumours158.  
High-pressure devices, such as jet injectors, use fluid impact to force drug solutions at high 
velocities into the skin151. Jet injectors have been successfully used in mass immunisation 
programmes and in the delivery of insulin159. Laser heating involves thermal ablation of the SC 
barrier – it selectively removes the SC without damaging underlying tissues through rapid 
heating of the skin for a short period of time151. Most of the devices and techniques that have 
been used have a long history in drug delivery across the skin. An emerging technology 
indicated in an increasing number of TDD and IDD applications are microneedles, another form 
of physical percutaneous penetration enhancer. These micron-sized needles are able to 
penetrate through the tough outer layers of skin to deliver a defined amount of drug to a target 
skin region. Their micron dimensions mean trans-epidermal delivery can be painless, 
improving patient compliance especially in skin which may already be sensitive and sore. 
1.6   Microneedles for intradermal and transdermal drug delivery 
applications 
Microneedles sit at the interface between hypodermic needles and transdermal patches160. They 
are microfabricated arrays filled with micron-sized needles typically ranging from 100–1000 
µm in length. Microneedles are considered as an attractive minimally invasive method of 
delivering drugs across the epidermis and function to increase skin permeability by forming 
channels that act as conduits for drugs161,162. By bypassing oral administration, this approach 
can avoid degradation of the drug in the gastrointestinal tract and first-pass metabolism by the 
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liver162,163. Microneedles are able to penetrate through the tough outer layers of skin (the SC) 
to deliver a defined amount of drug to a target skin region. Since they are able to deliver drugs 
locally, they can avoid distribution to the whole body via systemic circulation, decreasing 
toxicity and reducing side effects146. Conversely, they may be used to deliver drugs, such as 
insulin, and vaccines to the microcapillary system with deep enough penetration if systemic 
circulation is desired. Microneedles are relatively low-cost and self-application by patients is 
possible in comparison to other mechanical enhancer techniques, as demonstrated by 
microneedle rollers that are already commercially available for personal cosmetic applications. 
Microneedles have improved patient compliance when compared with hypodermic needles and 
have been shown to deliver drugs painlessly and blood-free164–166. 
Microneedles come in a variety of designs and delivery mechanisms depending on the desired 
application. They can differ in shaft geometry, tip shape and needle material162. These physical 
parameters govern depth of penetration, rigidity and reusability amongst other factors. Drug 
formulation, required drug dose and molecular drug size must also be considered when 
choosing a suitable microneedle array for an application167. When choosing the material that 
the arrays will be made from, several parameters need to be carefully considered including the 
material’s rigidity, hydrophobicity, biocompatibility and toxicity, and costs (both for 
acquisition and manufacture). Materials currently explored in microneedle manufacture include 
a range of synthetic and natural polymers, metals, ceramics and biomaterials. For single or 
smaller dosage amounts, such as with vaccines168,169 or insulin170,171, a spot application with a 
microneedle patch or single microneedle may be sufficient for drug delivery172. However, to 
deliver a drug over a larger surface area, such as a region of skin at risk of chronic wound 
development, more efficient microneedling techniques for permeabilising skin are required 
(Figure 1.8). Microneedle rollers offer a method for achieving barrier disruption over a large 
surface area. 
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1.6.1   Mechanisms of microneedle-mediated drug delivery 
There are several ways that microneedles can be used to deliver a drug through the skin. To 
date, there have been five different microneedle-mediated drug delivery modalities reported in 
the literature. These are: (i) the ‘poke and patch’ method using solid microneedles, (ii) the ‘poke 
and flow’ method — a controlled release method of infusion using hollow microneedles, (iii) 
the ‘coat and poke’ method using coated microneedles, (iv) dissolvable or degradable 
microneedles, and (v) hydrogel-forming microneedles173,174 (Figure 1.9). Solid microneedles 
are microneedles that do not have an annulus (internal channel) while hollow microneedles 
have an annulus running their entire length to allow for substance delivery by infusion. Solid 
microneedles are the most commonly reported microneedles in the literature175,176. In the ‘poke 
and patch’ approach the solid microneedles are applied to the skin, removed and the drug added 
on top of the microchannels created in the skin in a two-step process. The drug then enters the 
skin through these microchannels by passive diffusion. The drug may be stored in a patch acting 
as a reservoir which is applied onto the skin, or added directly as a solution, gel or nanoparticle 
formulation. In the ‘poke and flow’ approach, hollow microneedles are inserted into the skin. 
The drug (or vaccine) may be stored in a reservoir, such as a cartridge, and is infused through 
Figure 1.8 — Types of microneedle array design: (A) A single hollow microneedle 
drug infusion unit. Adapted from “Faster pharmacokinetics and increased patient 
acceptance of intradermal insulin delivery using a single hollow microneedle in children 
and adolescents with type 1 diabetes,” by J.J. Norman et al., 2013, Paediatric Diabetes, 
14, p. 461. (B) A microneedle patch with multiple needles combined with a drug delivery 
unit that can store liquids.  Adapted from “Painless drug delivery through microneedle-
based transdermal patches featuring active infusion,” by N. Roxhed et al., 2008, IEEE 
Transactions on Biomedical Engineering, 55, p. 1066. (C) A set of microneedle rollers 
of various microneedle lengths. Adapted from “Transdermal delivery of insulin using 
microneedle rollers in vivo,” by C. Zhou et al., 2010, International Journal of 
Pharmaceutics, 392, p. 128. 
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the microneedles’ annuli directly into the skin. The microneedles are removed once the drug 
has been delivered. This technique is also referred to as ‘microinfusion’ or ‘microinjection’. 
In the ‘coat and poke’ approach, solid microneedles are pre-coated with the active drug on their 
outer surface. They are then inserted into the skin and the coated drug transferred into the 
microchannels created during application. The microneedles are then removed from the skin. 
Dissolvable microneedles are made from soluble or biodegradable material which includes the 
active drug. Such materials include silk177, maltose178, sodium hyaluronate or hyaluronic 
acid179,180. Once inserted into the skin the microneedles either dissolve or degrade into the 
microchannel spaces they created, releasing their load into the skin. The applicator used to 
deliver the microneedles may be removed after initial insertion or until the microneedles have 
sufficiently dissolved. Hydrogel-swelling microneedle arrays are formed from polymeric 
microneedles combined with a drug reservoir. Once the microneedles are inserted into the skin, 
the hydrogels expand quickly by absorbing water from the interstitial fluid174. The drug diffuses 
from the reservoir along the swollen microneedles into the skin181. Due to the nature of the 
swelling process, hydrogel-swelling microneedles can be left on the skin securely. 
Unpublished data presented during conference proceedings at Microneedles 2016 – The 4th 
International Conference on Microneedles (London, UK) by A.R Tadros and M.R. Prausnitz 
(Georgia Institute of Technology, Georgia, USA) introduced a potential sixth microneedle-
mediated drug delivery modality. “STAR” particles are single four-pointed (i.e. star-shaped) 
microneedle units suspended together in an aloe vera gel topical formulation. The microneedles 
are applied to the skin by gentle rubbing, as would be done with a lotion. They permeabilise 
the skin in a similar manner to the ‘poke and patch’ approach, except that the active drug is 
incorporated into the topical formulation so there is only a single step to the application. One 
of the major advantages of the “STAR”-microneedle particles approach is that it enables 
treatment over a large surface area of skin and of anatomic sites that are not so easily accessible 
with microneedle patches.  
1.6.2   Commercially available microneedle systems 
Many authors have explored the use of novel and bespoke microneedle arrays, designs and 
delivery modalities. However, there are already several commercially available 
Chapter 1: General Introduction 
- 68 -
 Figure 1.9 — Mechanisms of drug delivery by solid, hollow, coated, 
dissolvable/degradable and hydrogel-forming microneedles: (A) ‘Poke and patch’ 
approach using solid microneedles — the microneedles are used to create micropores and are 
then removed.  The drug to be delivered is immediately applied to the permeabilised region of 
skin. (B) ‘Poke and flow’ approach using hollow microneedles. (C) ‘Coat and poke’ approach 
using solid microneedles — the microneedle surfaces are coated with drug. On insertion into 
the skin, the drug is transferred from the microneedle surface into the skins. (D) 
Dissolvable/degradable microneedles are transferred into the skin during application, with just 
the array removed. The microneedles degrade over time releasing the drug into the skin. (E) 
Hydrogel-swelling microneedles absorb water from interstitial fluid on insertion into the skin. 
The drug from the attached drug reservoir diffuses through the swollen microneedles into the 
skin. Adapted from “Microneedles: A New frontier in Nanomedicine Delivery,” by E. 
Lerraneta, 2016, Pharmaceutical Research, 33, p. 1060.   
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microneedle systems on the market. These CE-marked devices allow for standardised, reliable 
and consistent microneedle application, requiring only drug loading and positioning of the 
device by the operator. Some also have integrated display screens that can offer feedback to the 
operator. The pharmaceutical company, 3M, currently offers two such microneedle devices, 
their ‘Solid Microstructured Transdermal System’ and their ‘Solid Microstructured 
Transdermal System’ (Figure 1.10 – A). The solid microneedle device functions as a ‘coat and 
poke’ delivery system for fast bolus delivery of vaccines into the skin. The device inserts the 
microneedles into the skin, which are delivered as a removable patch. The hollow microneedle 
device allows for the microinjection delivery of medicaments with a wide range of viscosities 
and doses from 0.5 – 2 ml into the skin. The solid microneedles are available in various lengths 
(250, 500 and 700 µm) while the hollow microneedles are available only at a length of 1500 
µm. 
Several independent or smaller companies have also developed their own microneedle devices, 
including DebioJectTM, DermoPen, DermaJet, DermaFrac and Derma-stamp182. These drug 
delivery systems are typically more expensive than conventional methods since the entire 
device is not disposable due to integration of digital components. They also typically need to 
be electrically powered. The DermoPen is a modular microneedling device with an electric 
handle and disposable needle tip containing twelve microneedles (Figure 1.10 – B). The device 
is also motorised allowing the microneedles tips to oscillate which is claimed to minimise 
dermal tearing on insertion. DermaJect is a digitalised injection system that allows the operator 
to set and regulate the exact quantity before injecting (Figure 1.10 – C). Detachable and 
disposable single and multiple microneedle heads are available. DebioJectTM by DermoTech 
(Lausanne, Switzerland) offer syringe compatible microneedle attachments for microinfusion 
which come with single or multiple microneedles (Figure 1.10 – D). 
1.6.3   Microneedle biocompatibility and safety 
Material cytotoxicity is an important parameter to consider in microneedle design because the 
array is to come into contact, at least transiently, with the skin162. Skin irritation and exposure 
to harmful and toxic substances is a valid concern, especially if the area to be treated is already 
sensitive. Sources of such substances include leachables eluted from the microneedle material 
when liquid is passed through it or when the microneedles contact with fluids present in the 
tissue. It is thus important to assess the microneedle material for leachables released on fluid 
exposure and to be aware of short- and long-term bio-effects of these leachables (i.e. material 
biocompatibility). Safety of microneedles is discussed further in Chapter 3: 3.5.3 Microneedle 
application on injured skin and its effect on cell viability, p.139.  
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1.6.4   Medical and cosmeceutical applications of microneedles 
Although microneedles have been shown to improve permeation of various dyes and stains, 
such as methylene blue, trypan blue, bovine serum albumin and calcein-AM183, across the SC 
in ‘proof-of-concept’ studies, they have also been explored successfully in a multitude of 
medical and cosmeceutical applications173,184. These include intradermal and transdermal 
delivery of drugs and vaccines as well as the use of microneedles in cosmetic purposes to 
improve the skin appearance. The interest in delivering vaccines using microneedles surrounds 
the current need to solve current practical issues such as cold chain elimination and reducing 
sharps waste, as well as a desire to illicit cutaneous immune responses by exposing antigens to 
the antigen-presenting cells (APCs) in the skin184,185.  Vrdoljak et al. (2012) reported a 
successful immune response in mice injected with live virus vaccines using coated 
microneedles, comparable to what had been achieved with traditional needle-and-syringe 
intradermal immunisation186. In their research models, Kommareddy et al. (2011) reported 
immunogenicity against influenza antigens using dissolvable microneedle patches168 and Edens 
et al. (2013) showed that microneedles coated with measles vaccine resulted in neutralising 
antibody levels equivalent to those achieved with subcutaneous immunisation at the same dose. 
Similar success has been observed with microneedle-mediated insulin delivery170,171,187. 
Current delivery is achieved by daily insulin injection through the abdomen, thigh, arm or 
buttock using hypodermic needles and syringes or with sub-cutaneous insulin pump catheters. 
Delivery by microneedles could improve patient compliance and accelerate insulin 
pharmacokinetics170. Delivery of nanoparticles has also been successful188–190 and has opened 
up new avenues for microneedle-assisted drug delivery in the field of nanomedicine174. There 
is also much interest in facial administration of microneedles for cosmetic purposes such as 
facial rejuvenation to reduce the appearance of wrinkles and as a post-acne treatment for skin 
resurfacing and improvement of the appearance of scarred skin191. In recent years there has 
been development of novel technologies where microneedles are used In combination with 
other devices192. Sonophoresis-enhanced microneedle arrays (SEMA) which use the additive 
effect of the two established physical enhancers, acoustic waves and microneedles, have been 
shown to improve upon their individual effects on molecular diffusion rate193,194. In the future, 
microneedles may also be used for fluid removal as well as drug delivery, such as for blood 
sampling and extraction195 and as biosensors, especially for glucose196–199. 
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Figure 1.10 — A range of commercially available microneedle devices: (A) Hollow and solid 
structure microneedle systems from 3M. (B) DermaPenTM consisting of an electrically-powered adaptor 
and disposable 12-microneedle head attachment. (C) DermaJet consisting of a digital precision injection 
device adaptable with various microneedles. (D) DebioJectTM by Debiotech for single and multiple 
microneedle microinjections. 
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1.7   Preclinical research models of the human pressure ulcer 
1.7.1   Animal skin models of human skin disease and pressure ulcers 
From mice to non-human primates, a range of animals has been used to model human skin 
disease. The use of non-living (ex vivo) animal tissue and other skin substitutes are also widely 
used. These include skin mimetics such as silicone membranes200, biosynthetic skin 
substitutes201, in vitro cellular models of skin and ex vivo skin202, especially human and porcine. 
However, these models represent the skin in isolation from a fully functioning biological system 
and this must be taken into account before extrapolating results to living organisms. Animal 
models provide an excellent alternative and can be used to study wound development and 
healing in a whole organism. Good ethical research practice should follow the framework of 
the 3Rs of animal research: replacement, reduction and refinement. 
Traditionally the most commonly used animals for in vivo skin studies are rodents especially 
mice, rats and guinea pigs203. The advantages of using such small animals are their small size, 
ease of housing and handling, and relatively low cost. However, larger animals including the 
pig and non-human primates are believed to make better human skin models due to their 
similarities to human skin including epithelial architecture, nerve density, vascularity and 
matrix components204. Since the use of primates is highly restricted, the next relevant animal 
model for human skin is porcine. Pigs have the advantage of anatomic and vascular similarities 
to humans; the red Duroc pig, in particular, has been extensively validated as a model for human 
skin pathology and is believed to be the ideal large animal model to study human cutaneous 
disease204,205. However, pigs are large, difficult to house and are expensive, thus the practical 
use of rodent models cannot be overlooked. As the most recent non-human surgical models of 
pressure ulcers concentrate on the use of rodents they are the focus of this research. 
1.7.2   Fundamental differences between human and rodent skin 
Though there are structural and functional similarities between human and rodent skin, there 
are evident and important discrepancies which need to be considered when using rodents to 
model a human disease. One of the most evident differences is the hair coverage for the majority 
of rodents as compared with humans. Rodent skin is typically covered in thick dense hair 
craniocaudally whilst human hair is much thinner with an androgen-sensitive distribution206. 
This extremely high density of hair follicles is believed to affect percutaneous absorption of 
molecules so hairy rodent skin is not desirable203. Thus, to mimic the hairless nature of human 
skin, many in vivo models remove the dorsal hair of the subject via shaving/clipping, hair 
removal (depilatory) creams or a combination of the two. However, these techniques are 
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believed to cause cutaneous injury due to abrasion (either mechanical or chemical) to the skin 
surface. To circumvent the need for hair removal pre-treatment, groups have employed hairless 
rats or nude mice in their studies, which genetically lack a hair coat and are believed to better 
mimic human skin than hairy skin207. 
As with human skin, rodent skin is divided into three main layers, the epidermis, the dermis 
and the subcutis. However, the anatomy and physiology of these layers vary greatly. The 
thickness of each layer differs with species, with murine skin being much thinner and rat and 
human skin having more comparable dimensions203. Rodent skin lacks rete ridges, epidermal 
thickenings which extend down through dermal papillae, as well as apocrine sweat glands 
responsible for secreting several components of sweat208. Conversely, rodents contain a 
subcutaneous muscle layer known as the panniculus carnosus which humans lack86. 
Biomechanically, rodent skin is relatively thin, loose and compliant while human skin is thick, 
relatively stiff and adherent to underlying tissues86. For mice, there also exists a gender 
difference in skin anatomy and physiology204. Females have a thicker epidermis and 
hypodermis while males have a much thicker dermis that imparts greater strength209. This 
gender discrepancy should be taken into consideration when designing experiments with mixed 
gender subjects. 
As rodent skin is fairly loose and compliant, open wounds can heal by skin contraction whereby 
normal unwounded skin stretches over the injured area1. This process is relatively rapid and 
sufficient for wound healing and is aided by the presence of the panniculus carnosus. Human 
wounds, in contrast, do not heal by contraction, which is slow and incomplete, but mainly 
through the process of re-epithelisation204. Humans are also susceptible to chronic wounds 
whilst most animals do not suffer from them naturally. This is attributed to the lack of truly 
aged animals as well as the absence of combined hemostatic dysfunction, such as venous 
insufficiency, neuropathy and chronic debility in animals1. Furthermore, chronic wounds in 
humans tend to occur in regions where skin contraction is relatively poor compared with other 
sites, such as in the lower leg and feet. 
1.7.3   The history of modelling pressure ulcers in vivo 
To briefly touch on the history of the surgical approaches to modelling in vivo pressure ulcers, 
the very earliest models used large mechanical compression devices on the femoral trochanters 
in swine or canine models. These devices were cumbersome and required anesthetised subjects. 
Importantly, from these pioneering studies, it was found that: (i) there existed an inverse 
relationship between the amount and duration of pressure required to render pathological 
changes in tissue and (ii) prolonged ischemia alone was insufficient to invoke skin necrosis, 
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suggesting other critical factors in pressure ulcer aetiopathogenesis92. Henceforth, the 
phenomenon of IR injury has been at the forefront of pressure ulcer modeling and is believed 
to be an inciting event in pressure ulceration. 
The unifying theme amongst the most recent pressure ulcer models is the use of a compact 
device to generate a compressive force that is able to simulate IR injury. The system generally 
uses a reversible mechanism whereby mechanical loading by the device causes ischemia which 
can then be easily and repeatedly unloaded to simulate reperfusion. Due to the simplicity of 
most of these models the animals are often non-anesthetised during the experiment and do not 
require long-term immobilisation. Some groups have devised their own novel devices89,99,100,210,
 
while others have employed previously developed techniques to their particular area of 
research59,210. One of the major challenges these groups face is replicating the pressure 
exhibited in the human pressure ulcer. The device must be able to provide pressure of a 
clinically relevant magnitude and for a sufficient duration. Furthermore, to truly mimic the 
human pressure ulcer, the wound must progress through all clinical stages of ulcer development 
in order. Two commonly used devices are magnets59,89,99,100,211,212and compression chambers93. 
1.7.4   Modelling pressure ulcers using magnetic compression 
The use of magnets to create a compressive force appears to be a popular technique and has 
been utilised by various academic groups throughout the past decade or so. The techniques 
themselves vary in the procedure (invasive or non-invasive), the properties of the magnet(s) 
being used, the respective lengths of the compression and release cycles, the location of the 
magnet(s) as well as the strain of animal being employed, amongst other parameters. Each of 
these parameters impacts on the severity and stage of the ulcer produced, the types of controls 
that the experiment requires to validate it and ultimately how well the model reflects the human 
pressure ulcer. 
Surgical procedure 
One popular method of mechanically modeling IR injury using magnets is magnet implantation 
which involves creating an incision in the dorsal tissue and implanting a magnet into the body. 
This intracorporeal magnet may be placed either beneath the fascia (subcutaneous) or into a 
muscle layer (sub-muscular). The incision is then sutured and an extracorporeal magnet 
is placed on top of the implanted magnet (Figure 1.11 – A, B and D). In place of an 
internal magnet, a steel plate may also be used89,99. Another surgical method employed 
by several groups59,211,212provides a non-invasive alternative to the implantation procedure. 
Two magnets are externally loaded onto the skin, pinching the skin between them and leaving 
a small bridge 
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of normal tissue ( .  -). For either method, contralateral skin can act as an intra-individual 
control. 
One of the major and notable disadvantages of the method of magnet implantation is the 
systemic effect the surgical procedure may have on the animal. Disrupting the skin and 
implanting a relatively large foreign object into such a small animal may result in inflammatory 
responses that could affect the interpretation, and thus the validity, of the results. One way to 
account for the effects of the surgery is to use sham and control animals, which undergo the 
surgical procedure but which do not form part of the experimental groups. This way differences 
between the sham and experimental groups can be attributed to the experimental injury. 
Another way studies have accounted for the effects of the surgical procedure is to allow the 
animals to recover post-surgery for periods ranging from 18 hours to two weeks. However, the 
length of time sufficient to completely remove the effects of surgery has not yet been defined. 
Furthermore, a foreign body (the intracorporeal magnet or plate) will still remain within the 
body and could continue to provoke responses despite a respite period from surgery. This 
problem is circumvented by the noninvasive technique of using two external magnets. Removal 
of the external magnet(s) in either magnet protocol to begin the reperfusion period may cause 
some local trauma however, as substantial force is required to prise off the magnet. 
The location of magnet placement determines the type of wound created; a magnet implanted 
subcutaneously will develop a different wound from a magnet placed within a muscle. 
Wassermann et al. (2009) suggest their technique of implanting the internal magnet sub-
muscularly better represents pressure ulcer pathogenesis as it involves all the relevant tissue 
layers99. This contrasts with the cutaneous pressure ulcer models that target the injurious IR 
cycles solely at the cutaneous region of the skin. Arguably the Wassermann model of deep 
tissue injury is the superior technique as it allows pressure ulcer development up to clinical 
stage 4, resulting in a full-thickness wound whilst the cutaneous models cannot develop past a 
stage 3 pressure ulcer in a way that could be considered analogous to humans because 
compression is not being delivered to the subcutaneous tissues.  
Anesthesia is an important consideration in surgical models. Anesthesia is required in situations 
where the surgical procedure is likely to cause significant distress or pain in the subject or 
subject immobilisation is required for a significant period of time to allow the procedure to take 
place successfully and safely. Earlier studies that involved large compression devices required 
anesthesia and subject immobilisation for the entirety of the compression periods92. However, 
the physiological consequences of anesthesia are likely to have confounded the true effects of 
pressure in the non-anesthetised animal89. Due to the simplicity and speed of the procedures, 
Chapter 1: General Introduction 
- 76 -
the recent models do not require anesthesia or prolonged immobilisation. Animals appear to 
tolerate the procedures well and have been documented to move freely and naturally, despite 
the extra weight of the magnets
Magnet properties 
Magnets can be tailored according to their shape, size and strength. A variety of magnets has 
been used in pressure ulcer models making direct comparisons between different studies 
difficult. Circular magnets are the most common, creating wounds of similar shape to pressure 
ulcers. Several studies have used circular disc magnets in their model whilst others have 
employed ring magnets100. Magnet geometry determines the magnetic field and this, in turn, 
affects the compressive forces experienced by objects placed between its two magnetic poles. 
For example, one consideration of using a disc magnet model is that the compression occurs 
over the entire surface area of skin in contact with the magnetic faces. A ring magnet, in 
comparison, applies most of its compressive force to the circumferential edge of skin that is in 
contact with it. 
The extent of tissue damage caused by magnets is related to their strength. This is typically 
measured in Gauss, a measurement of magnetic flux density or magnetic induction. The higher 
the Gauss value the greater the strength of the magnetic field. Gauss values can be converted 
to clinically meaningful measurements of pressure, measured in ‘mmHg’. Normal human 
capillary pressure ranges from 16 to 32 mmHg depending on body region13. It is believed that 
external pressures of greater than 32 mmHg are sufficient to cause capillary occlusion, reduce 
capillary inflow and begin the process of tissue necrosis13. Most groups, in fact, use a 50 mmHg 
pressure to initiate ischemia, enough to cause capillary occlusion in a rodent. A consideration 
here is whether the compressive pressure is in fact too high for a rodent to be truly analogous 
to typical injurious pressures seen in the relatively larger human. 
The magnet itself must be inert if it is to be implanted in the body or if is to come into contact 
with tissue for prolonged periods of time. This minimises the risk of (i) magnet corrosion and 
(ii) the leeching of chemicals into the body which may invoke inflammatory responses. Inert
magnet coatings can either be ceramic or gold-plated. The material of surgical tools should also
be taken into consideration when choosing equipment which, preferably, should be non-
magnetic to minimise interference by the magnets. Housing of animals post-surgery must also
be considered carefully. Subjects should be housed singly, if possible, to prevent the magnet
from becoming dislodged or wounds being tampered with by other subjects. Caging should be
non-magnetic to prevent animals from getting stuck; in this respect the use of stainless steel
implants becomes more attractive.
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Figure 1.11 — Schematic representation of the recent in vivo murine models of 
pressure ulcers using magnets: (A) Sub-muscular implantation of disc magnets into 
gluteal muscle. (B) Cutaneous implantation of ring magnets. (C) External placement of 
disc magnets to skin. (D) Cutaneous implantation of steel magnetic plate and external 
magnet. 
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Length and number of compression/release cycles 
Studies have altered either (i) the length of the compression and release periods, (ii) the total 
number of compression-release cycles, or (iii) both. There are no standardised protocols for the 
length and number of compression-release cycles in order to generate a model pressure ulcer 
amongst the studies. However, it has been suggested that the current practice of relieving 
pressure every two hours in afflicted patients contributes to, rather than ameliorates, pressure 
ulcer progression99,100. Therefore several studies have included an experimental group that 
undergoes a compression period of two hours and a release period of one hour to mimic clinical 
practice93,99,100. Several studies59,89,100
 
have also included an ‘ischemia alone’ experimental 
group to compare with the ‘IR injury’ experimental groups, with the aim to assess any 
additional injurious effect reperfusion may have on top of tissue ischemia. 
Modelling pressure ulcers using compression devices 
Tsuji et al. (2005) forwent the popular magnet model and established a novel cutaneous IR 
model using a skinfold chamber coupled with an intravital microscope93. Their method allows 
visualization of the in vivo microcirculatory response to IR injury which has not been well 
studied before. Their original chamber is constructed from two aluminum frames held together 
by four plastic tubes along with several attachments. During the application procedure, an area 
of dorsal skin on the subject is pulled up and fixed to form a skinfold. A square of skin is then 
cut away from one of the layers and a coverslip, which is incorporated into one of the frames, 
covers the underside of the other skin layer. The authors then allow for a 48-hour recovery 
period post-surgery. 
In contrast to the magnet models, compression is provided mechanically via the chamber at 500 
mmHg using a tension gauge, an articulated manipulator and a compression tip held in place 
by three holding screws. A fluorophore-conjugated molecule, FITC-dextran, is then injected 
via the tail vein for contrast enhancement while epi-illumination of the compressed tissue is 
provided by a lamp with a green filter. Images are recorded on video. As previous groups have 
done, Tsuji et al. (2005) divided their subjects into compression only and compression-and-
release groups to simulate ischemia only and IR injury respectively93. Both groups had a total 
of eight hours compression: the compression-only group received this in one sitting while the 
compression-release groups had four cycles of two hours of compression and one-hour release. 
This once again mimics the time frames reported in clinical practice31. Like the magnet models, 
the skinfold chamber model does not require subject immobilization throughout the entirety of 
the compression treatments. However, the technique is quite involved and requires specialist 
equipment that is relatively cumbersome. The procedure is also highly invasive as it requires 
surgical removal of the skin. However, one of the main advantages of the model is its ability to 
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visualise the changes in the microcirculation whilst compression is taking place. This has 
allowed assessment of changes in blood flow associated with IR injury.  
Currently, most studies of pressure ulcers in humans are limited to those in patients with pre-
existing ulcers. This, in turn, limits the assessment of pressure ulcer development, progression 
and healing from beginning to end. Animal models represent an alternative avenue to 
investigate the full pressure ulcer paradigm in vivo, bridging the gap between in vitro and 
human studies. However, one must bear in mind inter-species differences as well as the 
difficulty of fully mimicking pressure ulcer pathogenesis. As described in this review of the 
literature, there is a spectrum of contributing factors which cannot all be adequately addressed 
in a single model. Thus the aim of surgical and mechanical animal models is to improve our 
basic understanding of how pressure ulcers develop and progress. These models have become 
invaluable tools and, while bearing in mind their limitations, can inform on the biomolecular 
mechanisms and histological detail of pressure ulcer development in a whole organism. 
Preclinical surgical models of the human pressure ulcer are further explored in Chapter 5.
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Chapter 2   Assessment of Solid 
Microneedle Rollers to Enhance 
Transmembrane Delivery of 
Doxycycline  
2.1   Introduction 
2.1.1   Doxycycline for the treatment of pressure ulcers 
Doxycycline, as a matrix metalloproteinase (MMP) inhibitor, is a potential treatment for 
chronic wounds116. High levels of MMP activity have been widely documented in studies of 
the chronic wound microenvironment106,111,113,117,142 and the effect of doxycycline, and other 
members of the tetracycline family, has been extensively investigated in human diseases that 
exhibit high MMP activity such as osteoarthritis, rheumatoid arthritis and periodontitis. 
Doxycycline has also been shown experimentally to reduce tissue degradation31,58–60. The 
MMP inhibitory action of doxycycline is independent of its antimicrobial properties and thus 
unrelated to its inhibitory effect on bacterial protein synthesis; though the full mechanism has 
yet to be elucidated, it is believed to inhibit enzymatic MMP activity through the chelation of 
the zinc molecule
213
. This makes it an attractive treatment for chronic wound care as its 
antibiotic effects can be clearly distinguished from its MMP inhibitor activity.  
Doxycycline’s inhibitory activity extends to TNFα-converting enzyme (TACE)116, a molecule 
that causes the release of tumour necrosis factor-alpha (TNFα)   which is an important 
inflammatory mediator known to impair wound healing. In all, doxycycline has multiple 
attributes which make it desirable as a treatment for pressure ulcers; not only does it exhibit 
MMP inhibitory activity it also is a hydrophilic compound that can be administered as a powder, 
an aqueous solution or formed into a gel. Furthermore, it is already FDA-approved and has 
shown pharmacokinetic advantages over its tetracycline counterparts. Thus there has been some 
interest in doxycycline as a potential treatment for chronic wounds116. 
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2.1.2   Microneedle rollers for intradermal doxycycline delivery 
The primary barrier to intradermal and transdermal drug delivery (IDD and TDD) is the stratum 
corneum (SC) which forms the outermost layer of the epidermis214. Many drugs, especially 
proteinaceous drugs, are large and hydrophilic so cannot passively diffuse across the skin due 
to the SC which selectively allows the intercellular transport of smaller lipophilic molecules, 
typically up to 500 Da76,147,148. Tight junctions in the skin epithelium known as zonulae 
occludentes also contribute to the barrier function of the epidermis by inhibiting drug 
diffusion215–217. To get larger molecules across the skin, the SC barrier must be temporarily 
disrupted. There are different ways to achieve this using penetration enhancers which 
chemically or physically alter the skin to transiently increase its permeability150. Microneedles 
offer a minimally invasive way to achieve this, however patches and arrays only deliver to a 
relatively small area of skin. To cover larger regions of skin microneedle systems, known as 
microneedle rollers, can be employed. 
Microneedle rollers are solid microneedle systems composed of two main parts – a handle for 
manual rolling (usually plastic) and a head attachment (sometimes detachable) containing 
multiple microneedles. The concept behind the use of microneedle rollers is to roll the system 
against the region of skin where permeabilisation to the active drug is desired. This technique 
can reach much larger areas much more quickly than repeated applications of microneedle 
patches. Microneedle rollers come in a multitude of different microneedle lengths while the 
microneedles themselves are typically made of metal. These systems are commercially 
available in the public domain and are advertised for personal as well as clinical use. They have 
become particularly popular in cosmeceutical applications where they can be used alone to 
stimulate collagen remodelling84 or to deliver cosmeceuticals such as antioxidant-infused 
creams and collagen218,219. Both approaches have been used to improve the skin appearance 
after scarring191,220,221 and as techniques for facial rejuvenation222–224. One of the most well-
known microneedle roller devices is the Dermoroller® produced by Dermaroller S.a.r.l. 
(Friesenheim, France) that has been successfully used in the TDD of several drugs182,225.  The 
device is composed of 192 metal microneedles (eight circular arrays of 24 microneedles each). 
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2.1.3   Strat-MTM membrane as a skin substitute for modelling human skin 
The use of excised biological tissue (either human or animal in origin) is widely used to model 
human skin in the investigation of microneedles. However there are multiple disadvantages of 
these models including high inter-sample heterogeneity, instability of the skin ex vivo and 
significant dissimilarities between human and animal skin when animals are used as a human 
skin model203. Furthermore, bioengineered skin equivalents are costly and have been shown to 
have higher diffusion rates when compared with human skin226. As an alternative, there are a 
range of synthetic skin substitutes on the market with differing claims on their likeness to 
human skin permeation properties227. Artificial skin membranes hold several advantages over 
excised skin, including high reproducibility, high stability and being easier to obtain. Strat-MTM
(Merck Millipore, Massachusetts, USA), a synthetic non-animal derived human skin mimetic, 
is marketed as a modified ultrafiltration membrane with human skin-like permeation 
properties226. Structurally it is composed of polyethersulfone and has a pore size of less than 
0.1 microns226. It has been designed for the screening of active pharmaceutical ingredients 
Figure 2.1 — Photographs of different commercially available microneedle roller 
systems: (A) A microneedle roller with smaller head attachment for application on 
smaller regions of skin such as the eyelid. (B) Microneedle roller system with 540 
titanium microneedles. (C) The Dermaroller® with 192 metal microneedles. From 
“Microneedling: Advances and widening horizons,” by A. Singh and S. Yada, 2016, 
Indian Dermatology Online Journal, 7, p. 245. 
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(API) amongst other groups of chemicals such as cosmetics. The manufacturers claim that 
Strat-MTM is predictive of diffusion of drugs through human skin and that it is also sensitive to 
enhancers. 
2.2   Research outline 
This chapter introduces the microneedle roller system used throughout the body of research and 
investigates the effect of microneedling on Strat-MTM membrane using this roller system and 
the feasibility of delivering doxycycline hyclate across the skin using this model. Firstly, the 
materials are analysed in detail. The ultrastructure of the recently marketed Strat-MTM 
membrane is analysed and compared with the upper layers of human skin. The geometry of the 
microneedle tips on the roller system is also explored. Micropore entry area is evaluated in 
detail using high-resolution scanning electron microscopy and the difference between 
application modes of the roller systems on micropore area is also assessed. In situ membrane 
depth penetration is compared between increasing microneedle lengths (250, 500 and 750 µm) 
using optical coherence tomography (OCT). To determine the pharmacokinetic diffusion 
properties, a Franz cell permeation study was used to evaluate the permeability of Strat-MTM to 
doxycycline hyclate and the effect of microneedle application on drug permeation under infinite 
dose conditions. Finally, comparison of Strat-MTM and human skin is made by observing the 
micropores created in each type of surface. Any significant differences may have implications 
for the suitability of Strat-MTM as a model of the uppermost layers of human skin. 
Methods and materials 
2.2.1   Microneedle rollers 
Commercially available CE-marked microneedle rollers were supplied by SodacodaTM 
(Delmenhorst, Germany) in three microneedle lengths: 250, 500 and 750 µm. Rollers were 
composed of two parts, a detachable head containing the microneedles and a handle for holding 
and manual insertion (Figure 2.2 – A). Each roller head had 540 titanium microneedles 
arranged as nine discs with 60 microneedles each (Figure 2.2 – B). 
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Figure 2.2 — Photographs of the microneedle roller system: (A) The device is made up of 
two parts, a handle for gripping and rolling and a head containing the microneedle discs. (B) 
Each roller head is made up of nine discs of 60 microneedles (540 microneedles in total). 
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2.2.2   Franz diffusion cells 
Transmembrane drug diffusion was studied quantitatively in synthetic membranes mounted in 
vertical static Franz diffusion cells (Soham Scientific, Ely, UK). Cells were of modular design 
and consisted of an upper donor compartment and a lower receptor compartment (Figure 2.3). 
Both chambers had a bore size of 12 mm and could each hold up to 3 ml of fluid.  The area of 
permeation afforded by the cells was 113 mm2. 
Figure 2.3 — Vertical static Franz cell apparatus: (A) Schematic  representation 
of the apparatus set-up. (B) Photograph of the apparatus set-up. 
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2.2.3   Perforation of Strat-MTM with microneedle rollers 
Strat-MTM synthetic membrane was obtained from Merck Millipore (USA). Membranes were 
cut into circular discs, 23 mm in diameter, and transferred onto a cutting board with tweezers. 
The discs were mounted onto a support made of silicone elastomer to mimic the compressibility 
and rigidity of human skin over bony protuberances (Figure 2.5). The microneedle roller head 
(Figure 2.4 – A). was placed onto the membrane, secured at the holder base with tack and a 
500 g mass added onto the head for 30 seconds (Figure 2.4 – C). This provided a downward 
force on the microneedles of 3.8N. The mass and roller were then removed. In a separate 
experiment, the rollers were applied to the membranes by manual insertion. The roller was 
placed onto the membrane and rolled five times bi-directionally along a single axis (Figure 2.4 
– B; Figure 2.5 – B).
Figure 2.4 — Digital photographs of the microneedle roller system: (A) 
Microneedle roller head. (B) The x and y planes of the microneedle roller head. 
During manual rolling, the microneedle is rolled along the y plane. (C) Application 
of 500 g mass onto microneedle head providing a vertical force of 3.8N, 
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Figure 2.5 — Schematic representation of the two methods of microneedle 
application onto the Strat-MTM membrane: (A) Static impact insertion of the 
microneedle roller using a standardised downward force of 3.8N. (B) Manual rolling 
of the microneedle system. 
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2.2.4   Scanning electron microscopy of Strat-MTM and microneedles (SEM) 
Membranes, micropores and microneedles were imaged by scanning electron microscopy 
(SEM). Strat-MTM membranes were air dried and coated with gold-palladium (SEM coating 
unit E5000; Polaron Equipment Ltd., Hertfordshire, UK). Microneedle roller heads were 
dismantled before imaging. Samples were mounted onto metal blocks and placed under vacuum 
in a scanning electron microscope (XL-30 FEG SEM; Philips Electron Optics, Eindhoven, The 
Netherlands,). Images were analysed with the Java-based imaging software ImageJ® (National 
Institutes of Health [NIH], Maryland, USA). Micropore area was calculated using the ‘polygon 
selections’ tool to outline the perimeter of the pore and measure the internal area. For each 
microneedle length, six micropore areas were calculated. Micropores were also visualised by 
micro-computerised tomography. 
2.2.5   Optical coherence tomography (OCT) of Strat-MTM 
Microneedles inserted into Strat-MTM membrane by applying a mass of 500 g (i.e. a downward 
force of 3.8N) were imaged using the Michelson Diagnostics EX1301 OCT (Michelson 
Diagnostics, Kent, UK). The 2D images were analysed in ImageJ®. 
2.2.6   Permeation study using Franz diffusion cells 
Strat-MTM membranes were cut into discs that overlapped with the edges of the Franz cell 
compartments to prevent leakage. Membranes were not pre-wetted as per manufacturer’s 
instructions. Membranes were mounted between donor and receptor chambers of individual 
Franz cells using a horseshoe clamp. High vacuum silicone grease (VWR International, 
Lutterworth, UK) was applied between the compartments as a water-tight sealant. Temperature 
equilibrated receptor fluid, 0.01M PBS (NaCl 8 mg/ml, Na2HPO4 1.15 mg/ml, KH2PO4 0. 2 
mg/ml, KCl 0.2 mg/ml; pH 7.4), was sonicated to remove air bubbles that could reduce the 
surface area of permeation.  
Receptor fluid (3 ml) was added to the receptor compartment via the sampling arm using a 5 
ml syringe and long hypodermic needle (120 mm FineJect® needle, VWR International) 
ensuring no bubbles were introduced into the chamber; bubbles underneath the membrane 
would reduce the total area of permeation. A Teflon-coated magnetic stirrer (VWR 
International) was then added into the receptor compartment. Cells were placed in a 
temperature-regulated water bath on top of a water-resistant magnetic stirring plate (Thermo 
Fisher Scientific, Loughborough, UK) and stirred at 400 rpm to maintain receptor solution 
homogeneity. Distilled water was added to submerge the receptor chamber below the level of 
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the membrane. The water bath was maintained at 32oC, human skin surface temperature, and 
an electronic thermometer used to monitor the temperature.  
There are two main methods used to investigate drug permeation through membranes: infinite 
and finite dosing. Infinite dose conditions are achieved when the applied dose of the donor drug 
formulation is so large that it is essentially unlimited. In this way, drug permeation through the 
membrane is not restricted by its concentration. This method is used to determine absolute 
pharmacokinetic parameters and was used in this study for this very reason. This is in 
comparison to finite dose conditions where a set dosage (i.e. a limited amount of donor 
formulation) would be applied to the membrane. This is done to mimic the dosages that would 
be used during real-world in vivo application and to monitor the resultant drug permeation 
properties at that dose228.  
Conditions for infinite dose permeation were met by using a concentration of doxycycline 
hyclate at 10% of its solubility limit (50 mg/ml) deliverable to the receptor compartment. 
Doxycycline hyclate solution (10 mg/ml) was made by dissolving 30 mg of doxycycline hyclate 
powder (Alfa Aesar, Massachusetts, USA) in 3 ml of PBS (pH 7.4) and was pipetted into the 
donor compartment. Donor and receptor cell compartments were covered with ParafilmTM 
(Sigma-Aldrich, Poole, UK) to prevent water loss through transpiration. Samples of receptor 
fluid (200 µl) were taken at pre-determined time intervals — every 10 minutes for the first hour 
then every hour for the first five hours, and at 24 hours — via the sampling arm using a 1 ml 
syringe and a long needle (120 mm FineJect® Needle; VWR International). Samples were 
transferred to 1 ml ChromacolTM vials (Thermo Fisher Scientific), wrapped in foil to protect 
the solutions from light and stored at 4oC for later high-performance liquid chromatography 
(HPLC) analysis. Temperature-equilibrated PBS was immediately added back into the receptor 
compartment to replace the volume removed with the sample. This was carried out to maintain 
thermodynamic equilibrium by keeping the total volume of fluid in the receptor compartment 
constant. 
2.2.7   High-performance liquid chromatography (HPLC) method 
An isocratic method for detecting doxycycline hyclate dissolved in aqueous solutions was 
developed on a modular HPLC system (Agilent HPLC 1200 series; Agilent Technologies, 
Chesire, UK) using a 15 cm x 4.6 nm, 5 µm, RP-amide column (Sulpeco Analytical, Poole, 
UK). The mobile phase consisted of 75% (v/v) di-iodinated water (with 0.1% [v/v] 
trifluoroacetic acid) and 25% (v/v) HPLC-grade acetonitrile (Sigma-Aldrich). System 
parameters were set with a pump flow-rate of 1.0 ml/min, a sample injection volume of 10 ml, 
a method stop-time of 10 minutes and a detection wavelength of 273 nm. This method produced 
Chapter 2: Assessment of Solid Microneedle Rollers to Enhance Transmembrane Delivery of Doxycycline 
- 90 -
a chromatogram with a major analyte peak corresponding to doxycycline at 6 minutes. A 
calibration curve was created from serial dilutions of doxycycline solution. This was used to 
calculate doxycycline concentration from solutions of unknown concentration using the area 
under the chromatogram peak. 
2.2.8   Ex vivo human skin 
Surgically excised human abdominal skin was obtained from Biopedric International (Saint 
Grégoire, France). The skin provided contained no stretch marks and had had the adipose tissue 
removed. Skin was stored at -80oC and used within three months of receipt. Prior to 
experiments, the skin was thawed for 15 minutes at room temperature in aluminium foil (to 
prevent dehydration) until soft and flexible. Skin samples measuring approximately 1 cm2 in 
area were cut using a surgical scalpel. The skin surface was carefully wiped with cotton buds 
that had been wetted in sterile PBS buffer.   
2.2.9   Perforation of human skin with microneedle rollers 
A skin section of 1 cm x 1 cm was transferred onto a cork support where it was fixed into place 
using hypodermic needles in each corner. Full thickness skin has a strong tendency to shrink 
once cut, so the needles were placed in such a way that the skin was stretched back to its original 
size with great care taken to avoid over-stretching. The section was then transferred into 2% 
glutaraldehyde and fixed for 3 hours at 4oC. The skin was then washed with sterile PBS buffer 
using a Pasteur pipette to remove the fixative. It was then placed onto a cutting mat and the 
microneedle roller was placed on top. The microneedle handle was secured with tack and a 
500g weight added onto the roller head for 30 seconds. The weight and roller were then 
removed and the skin transferred back into fresh 2% glutaraldehyde solution for a further 3 
hours.  
2.2.10   Skin sample preparation for SEM imaging 
Samples were dehydrated in graded ethanol solutions of 20, 50, 70 and 90% for 10 minutes 
each and then 100% ethanol three times for 10 minutes. They were then critically point dried 
with ≥99% hexmethyldisiazine (HMDS; Sigma-Aldrich) for 5 minutes and sputter-coated with 
gold-palladium (SEM coating unit E500; Polaron Equipment Ltd.). Samples were mounted 
onto metal stubs and imaged by SEM (XL-30 FEG SEM; Philips Electron Optics).  
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2.2.11   Statistical analyses 
For each condition there were four replicates (unless otherwise stated) to allow for experimental 
variation. Where appropriate, data were analysed using a one-way or two-way analysis of 
variance (ANOVA) with Tukey correction for multiple comparisons. For averages, results are 
presented as mean ± standard error of the mean. In all instances, p < 0.05 denotes a statistically 
significant difference. 
2.3   Results  
2.3.1   Strat-MTM membrane structure  
Strat-MTM membrane thickness was measured as 300 (± 2.7) µm by SEM analysis. Cross-
sectional SEM images showed that Strat-MTM had two main architectural layers — a lipophilic 
smooth top-most layer that became increasingly porous and had a layer thickness of 108 (± 2.8) 
µm and a large highly porous bottom layer made up of bundles of thick synthetic fibres with a 
layer thickness of 192 (± 5.8) µm (Figure 2.8 – A). 
2.3.2   Microneedle ultrastructure 
The ultrastructure of the microneedle tips and shafts of the roller systems were visualised using 
SEM (Figure 2.6 – A‒E). Two ridges were observed down both sides of the microneedle shafts 
which joined adjacent needles (Figure 2.6 – B). The tips were of an atypical shape for 
microneedle systems, with two sharp points at the edges and a peak in the centre creating a 
diamond (Figure 2.6 – E). This was reflected in the shape of the micropores.  
2.3.3   Micropore area in Strat-MTM 
Micropores created with all three microneedle lengths were visible by light microscopy. 
Maximum contact area with the membrane was nine microneedles per row along the 𝑥 axis, 
four microneedles per row along the 𝑦 axis when force was applied perpendicularly and infinite 
microneedles along the 𝑦 axis when rolled. SEM allowed the morphology of the micropores 
created in the Strat-MTM to be examined in greater detail. Due to the tip shape of the 
microneedles the pores had an atypical modified diamond shape (Figure 2.7). Average 
micropore areas for static impact insertion with standardised force were 11200 (± 1400) µm2, 
14600 (± 2700) µm2 and 17100 (± 3000) µm2 for 250, 500 and 750 µm microneedle lengths, 
respectively (Figure 2.9 – C). Though pore size increased with increasing microneedle length, 
a statistically significant difference in micropore area was only observed between the 250 and 
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750 µm microneedles (p < 0.001) and not between the 250 and 500 µm or 500 and 750 µm 
microneedles.   
Figure 2.6 — Scanning electron micrographs showing the ultrastructure of the  tip 
and shaft of the 500 µm microneedles, imaged from different angles. The shafts of 
the microneedles had two ridges on the sides joining adjacent microneedles. 
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Figure 2.7 — Scanning electron micrograph showing the micropore created in the 
Strat-MTM apical surface after rolling with a microneedle roller with a microneedle 
length of 500 µm.  
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Table 3 — Effect of microneedle length of the roller systems on micropore area, depth of 
penetration and drug diffusion in Strat-MTM. 
Microneedle shaft length 
250 µm 500 µm 750 µm 
Micropore area in Strat-MTM
    500g mass (µm2) 11190 ± 1358 14580  ± 2685 17100  ± 3012 
     Manual rolling (µm2) 26768  ± 1432 29627  ± 1502 36146  ± 1502 
 Depth penetration in Strat-MTM 
     Needle tip protrusion (µm) – 80 170 
     Unpenetrated needle length (µm) – 120 280 
Drug diffusion parameters 
     Mean cumulative drug conc. after 
1 h (mgml-1) 
0.8 1.6 2.2 
     Mean rate of drug permeation 
(mgml-1min-1) 
0.88 1.53 2.3 
Results are presented as mean ± standard error of the mean. 
Figure 2.8 — Cross-sectional scanning electron micrographs of Strat-MTM membrane: (A) 
Untreated Strat-MTM showing its three major architectural layer, which mimic the human epidermis 
(i-ii) and dermis (iii), respectively. (B) Strat-MTM membrane after application with a 500 µm 
microneedle roller which had created a micropore [MP]. The membrane structure was disrupted 
by this process. 
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Figure 2.9 — Comparison of 250, 500 and 750 µm microneedle lengths: (A) 
Digital photographs of the head portion of the roller system containing the 
microneedles. (B) Light microscopy images of the microneedle tips. (C) SEM images 
of micropores in Strat-MTM membrane after application of a 500 g mass onto 
microneedle rollers providing a downward force of 3.8N. (D) SEM images of 
micropores in Strat-MTM membrane after the bidirectional rolling application method 
with the microneedle rollers. 
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Figure 2.10 — Micro-CT images of a micropore created by manual rolling of the 
microneedle roller system (500 µm) against the apical surface of Strat-MTM membrane. 
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Figure 2.11 — OCT images of the depth penetration of microneedle rollers [MN] 
in the Strat-MTM membrane [SM].  The 500 µm and 750 µm microneedle rollers 
penetrate the full-thickness Strat-MTM membrane and protrude from the membrane’s 
basal surface. The 250 µm microneedles did not penetrate the basal surface of the 
membrane. Artefacts are caused by the light casting shadows beyond the microneedle 
tips. 
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Figure 2.12 — Schematic representation of micropore insertion into the apical surface of 
the Strat-MTM membrane: (A) Microneedle depth penetration while inserted, as determined 
from the OCT images. (B)  Micropores created within the Strat-MTM membrane. 
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2.3.4   Depth penetration of inserted microneedles in Strat-MTM 
Depth penetration of the roller tips was investigated using OCT and was used to assess which 
skin layer the microneedles could theoretically reach. The tomographic images show that the 
500 and 750 µm length microneedles completely penetrated the 300 µm-thick Strat-MTM 
(Figure 2.9). The 750 µm microneedles protruded further than the 500 µm microneedles with 
170 µm tip protrusion compared with 80 µm, suggesting that 750 µm rollers would reach deeper 
in full-thickness skin. The 250 µm microneedles were shown to enter the Strat-MTM but to not 
fully penetrate the membrane. 
2.3.5   Manual rolling versus standardised force application 
Force was applied to the microneedle rollers in two ways, through manual rolling in a single 
plane and through application of a 500g mass onto the roller handle. Application of a constant 
mass is a more standardised way of delivering force to the microneedles in order to penetrate 
the membrane. However, a more realistic clinical application of the microneedles is to roll them 
onto the skin by hand. The range of force applied by manual rolling by a single operator was 
measured as being 2.8-7.8N, while the standardised force was 3.8N. Manual rolling was shown 
to disrupt the membrane significantly more than a single weighted application demonstrated by 
greater average micropore areas which were 26800 (± 1400), 29600 (± 1500) and 36100 
(±2700) µm2 corresponding to an average increase in area of 141, 103 and 110% for the 250, 
500 and 750 µm microneedle lengths respectively (Figure 2.9 – D). Additionally, it was 
observed under SEM that the manual rolling caused greater damage to the microneedle tip than 
the standardised force application. Though not all tips were damaged by the application process,  
those that were more blunted by the rolling than the weighted application (Figure 2.13).  
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2.3.6   Transmembrane delivery of doxycycline hyclate 
In order to assess the ability of microneedle rollers to enhance intradermal doxycycline 
delivery, the permeation of doxycycline through untreated and microneedle-treated Strat-MTM 
was investigated. Disruption of the skin barrier normally results in an increased permeation of 
small molecules that are already able to traverse the epidermis and allows the transit of larger 
molecules whose permeation would otherwise be prevented. Microneedles achieve barrier 
disruption by creating micropores that act as aqueous conduits for drugs to permeate through. 
Cumulative doxycycline concentration was monitored in the receptor fluid over 24 hours. No 
doxycycline was detectable in the receptor fluid of untreated membranes, indicating that Strat-
MTM alone inhibited doxycycline permeation ( . – A). Conversely, doxycycline was detectable 
in the receptor fluid in membranes treated with all microneedle lengths after 10 minutes. Lag 
time, the time taken for the doxycycline to achieve steady state flux through the membrane, 
was one hour across all microneedle lengths. Differences in cumulative permeated drug 
concentration were statistically significant between all microneedle lengths, with 750 µm 
treated membranes having the greatest rate of drug permeation and 250 µm treated membranes 
the least. Total doxycycline permeation at steady state flux was 0.8, 1.6 and 2.2 mg/ml and rate 
of doxycycline permeation during lag time was 0.88, 1.53 and 2.30 mg/ml/min for 250, 500 
and 750 µm microneedle lengths respectively ( . – B). Dose depletion of doxycycline was 
exhibited up to 24 hours. 
Figure 2.13 — Scanning electron micrographs of the 500 µm microneedles after 
application onto the Strat-MTM membrane: (A) Microneedle tip after standardised 
force application of 3.8N.  (B) Microneedle tip after manual rolling in a single plane 
five times in each direction.  
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Figure 2.14 — Effect of microneedle application on doxycycline permeation 
through Strat-MTM membrane (n = 4): (A) Cumulative concentration of doxycycline 
in receptor compartment fluid after treatment with 250, 500 and 750 µm microneedle 
lengths. (B) Rate of drug permeation from linear regression of cumulative doxycycline 
concentration during the 1 hour lag period. ‘Control’ represents the membrane samples 
which had not been treated with the rollers. Error bars represent the standard error of 
the mean.  
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2.3.7   Doxycycline retention in and on the Strat-MTM membrane 
SEM images and membrane mass measurements indicate that doxycycline was retained within 
and on the Strat-MTM membrane. Doxycycline crystals were observed partially and completely 
occluding micropores as well as on the membrane surface (Figure 2.16 – A). Mass 
measurements show that even after desiccation, to account for post-experimental wet mass, 
there was a statistically significant increase in membrane mass for both treated and untreated 
membranes (Figure 2.17). Doxycycline crystals on the membrane surface were also observable 
by eye. The total theoretical doxycycline concentration deliverable to the receptor fluid was 5 
mg/ml (half of that in the donor fluid), but the maximum concentration reached was 2.2 mg/ml 
which was through Strat-MTM treated with the 750 µm rollers ( . – A), indicating drug retention.  
. 
Figure 2.15 — Photograph of yellow crystals that precipitated on the apical surface 
of the Strat-MTM membrane during the permeation study. Crystals were present on 
the hydrated tissues and were not a result of drying processes. 
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Figure 2.16 — Scanning electron micrographs of doxycycline crystals retained 
in and on the Strat-MTM membrane: (A) Doxycycline crystals [DC] partially and 
completely occluding micropores [MP] in Strat-MTM membrane treated with 500 µm 
rollers. (B) Cross-sectional view of micropore occlusion with doxycycline and crystal 
formation on the membrane surface. 
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2.3.8   Microneedling on human skin compared with Strat-MTM 
Micropores were created on the apical surface of the excised human skin using the microneedle 
roller systems applied with a standardised static force of 3.8N. The micropores were then 
visualised by SEM. It was immediately evident that the skin surface greatly differed from that 
of the synthetic Strat-MTM membrane (Figure 2.18). The human skin was covered in striations, 
pits and grooves with evidence of dead skin sloughing off. There were also several vellus hairs 
and hair follicles. None of these natural structures were mimicked in the Strat-MTM which had 
a much smoother, more uniform apical surface. Furthermore, in comparison with micropores 
created in the Strat-MTM, there were fewer micropores distinguishable on the excised human 
tissue especially since they were less easily demarcated from other structures on the skin 
surface. When comparing micropore entry area created in the human skin with the those created 
in the Strat-M, those in the human skin were significantly smaller (p < 0.001) across all 
microneedle lengths (Figure 2.19). The 250, 500 and 750 µm microneedles created micropores 
of 3350 (± 335) µm2, 5531 (± 695) µm2 and 8282 (± 1002) µm2 respectively in the human skin. 
Consistent with what was observed in the micropores created in the Strat-MTM, there was a 
statistically significant difference in micropore area between the 250 and 750 µm microneedles, 
but not between the 250 and 500 µm or 500 and 750 µm microneedles. 
Figure 2.17 — Box and whisker plot comparing the dry mass of the Strat-MTM membrane 
before the permeation study [‘before’] with the mass of the same membrane after the 
permeation study and post-desiccation [‘after’] (n = 4). ‘Control’ represents the membrane 
samples which had not been treated with microneedles. The statistical significance shown 
compares the mass of the same membrane before and after the permeation study. Error bars 
represent the standard error of the mean; **** = p < 0.0001. 
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Figure 2.18 — Scanning electron micrographs of micropores created in the apical 
surface of excised human skin by the microneedle roller systems: (A) Micropore 
created by a 250 µm microneedle. (B) Photograph of a critically point dried and 
sputtered-coated skin section with micropores created by 500 µm microneedles. (C) 
Micropore created by a 500 µm microneedles. (D) A hair follicle containing a hair — a 
structure which was distinguishable from the micropores (E) Micropore created by a 750 
µm microneedles. (F) A series of micropores created in the skin from a row of 500 µm 
microneedles. 
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2.4   Discussion 
Doxycycline has multiple attributes which make it a potentially effective treatment for chronic 
wounds. It not only exhibits MMP inhibitory activity independent of its antibiotic action, but is 
already FDA-approved for the treatment of ulcers and has several pharmacokinetic advantages 
over its tetracycline counterparts138. The skin offers a large surface area for precise localised 
drug delivery. However, for intradermal delivery, doxycycline is too large and hydrophilic to 
passively diffuse across the skin since the acellular keratinised SC is such an efficient barrier 
against absorption of large exogenous molecules. In this study an in vitro model of the skin 
barrier was investigated using the synthetic membrane Strat-MTM, to determine the feasibility 
of delivering doxycycline intradermally using commercially available microneedle rollers.  
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Figure 2.19 — Comparison between micropore areas created in the Strat-MTM and 
excised human skin by the microneedle roller systems (250, 500 and 750 µm 
microneedle lengths) (n = 6). A statistically significant difference in micropore area 
created by the 250, 500 and 750 µm was observed between Strat-MTM membrane and 
excised human skin. Error bars represent the standard error of the mean; *** = p < 
0.001, **** = p < 0.0001.  
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2.4.1   Microneedle and micropore ultrastructure 
The solid microneedle roller systems used in this study were formed of multiple discs 
containing microneedles made of titanium. Solid microneedles are typically made of metals 
including stainless steel, titanium and nickel-iron160, but are also known to be synthesised from 
natural polymers229, plastics and ceramics230. This would undoubtedly influence the 
microneedle’s rigidity, durability and minimum impact insertion force. The microneedles used 
in these experiments had a different geometry to those typically investigated elsewhere in the 
literature. Firstly the shaft, which had two lateral ridges up to the tip, resulted in an atypical 
micropore shape ( .). Microneedles are typically cone-shaped, pyramidal or polygonal and 
create more circular micropores than what was observed with the SodaCodaTM system (Figure 
2.21). Though it has yet to be thoroughly investigated here, or in the published literature, the 
significance of micropore shape is that it may influence fluid flow, drug crystallisation and 
precipitation, and pore closure (especially in dynamic tissue). This would impact on several 
pharmacokinetic parameters including drug delivery rates, however further studies would need 
to be carried out to assess this. 
2.4.2   Strat-MTM as an acellular synthetic epidermal mimetic 
Excised animal tissue and other skin substitutes have been widely used to model human skin. 
No skin model is without its limitations, however, and all models represent the skin in isolation 
from a fully functioning biological system which must be taken into account before 
extrapolating results to living organisms. Inevitably human skin provides the best model, but 
alternative membranes can be used to provide useful data while still being cognisant of their 
limitations.  An important criticism of the Strat-MTM membrane as a skin mimetic is the lack of 
a dynamic response to mechanical penetration enhancement which is a behaviour exhibited in 
human skin. It has been widely documented that pore closure is observed in excised human 
skin that has been treated with microneedles231. This process is aided by elastic recoil in the 
collagenised dermis231. This is an important physiological mechanic in vivo and is a necessary 
response of the skin to reduce the risk of infection and prevent water loss by reinstating the skin 
barrier. Strat-MTM fails to respond to these stimuli which would otherwise have a huge impact 
on skin permeability as resealing kinetics ultimately reduces drug permeation over time. 
Furthermore, drying methods (dehydration and desiccation) during sample preparation did not 
have an effect on the micropores in Strat-MTM but had a huge effect on the excised skin causing 
tissue shrinkage, collapsing of surface structures and pore closure. 
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Figure 2.21 — Micropores (above) created by cone and polygonal-shaped metal 
microneedles (below):  (A) Adapted from “Microneedle-mediated intradermal delivery of 5-
aminolevulinic acid: Potential for enhanced topical photodynamic therapy,” by R. Donnelly et 
al., 2008, Journal of Controlled Resease, 129, pp. 156-157. (B) Adapted from “Transdermal 
delivery of insulin using microneedle rollers in vivo,” by C. Zhou et al., 2010, International 
Journal of Pharmaceutics, 392, pp. 128, 130. (C) Adapted from “Skin penetration 
enhancement by a microneedle device (Dermaroller®) in vitro: Dependency on needle size 
and applied formulation” by M.M. Badrana, J. Kuntschea and A. Fahr, 2009, European Journal 
of Pharmaceutical Sciences, 36, pp. 513, 516. 
Figure 2.20 — Schematic representation of a cross-section through the shafts of 
microneedles with different geometries: (A) The suppliers of the microneedle rollers 
used in this study claimed that the microneedles had a diamond-shaped shaft. This was 
corroborated by SEM image analysis. (B) Microneedle rollers typically have a circular 
shaft forming a cylindrical needle. Square pyramidal geometries are also commonly 
used. 
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The permeation properties of Strat-MTM in comparison to human skin have been previously 
investigated by Uchida et al. (2015 )232. Their study concluded that the diffusion and partition 
parameters of chemicals between 152–289 Da in Strat-MTM were in good concordance with 
those seen in excised human skin. However, the molecules investigated were well below the 
theorised 500 Da molecular weight threshold for passive drug diffusion through healthy human 
skin and the authors did not explore penetration enhancement of the membrane. Similar studies 
have compared Strat-MTM to other membranes233,234, but none have looked at the effect of 
microneedling on Strat-MTM. Doxycycline hyclate has a molecular weight of 1028.56 kDa and 
will theoretically not naturally diffuse across the human skin. It was observed in this study that 
native Strat-MTM was also impermeable to doxycycline hyclate solution. Permeabilistion of the 
apical surface of the Strat-MTM by microneedle application resulted in the creation of 
micropores that greatly increased drug permeation through the membrane, identifying it as the 
rate-limiting step of transmembrane diffusion. However, these micropores had a significantly 
greater entry area than those created in the human skin with microneedles of the same length. 
This may be an effect of the harsh drying process on the human skin which causes the skin to 
shrivel and collapse as water is eliminated but may also be a result of the contractile behaviour 
of the elastic dermis which tends to recoil if the skin is not sufficiently stretched.  
Structurally comparing Strat-MTM to human skin, the two membrane layers defined in this study 
could be considered analogous to two of the major skin layers, the epidermis (including the SC) 
and the upper portion of the dermis, in terms of layer thickness and porosity. Human skin begins 
as a tough thin keratinised layer which is highly lipophilic and becomes increasingly porous, 
fibrous and hydrophilic. This is mirrored in the Strat-MTM. However, the surface topology of 
the Strat-MTM differs greatly from that of human skin. Strat-MTM exhibits a much smoother, 
more uniform surface while the human skin surface is filled with ridges, pits and hair follicles. 
These natural structures inevitably affect drug delivery since processes such as drug pooling 
and retention in the skin’s natural contours will impact on its permeation. They also make it 
much more difficult to distinguish the micropores from other features on the skin. Additionally, 
resealing of the micropores and contraction of the skin in vivo is a biological behaviour that 
cannot be mimicked by the Strat-MTM. In all, Strat-MTM bears many of the advantages and 
limitations of pre-existing synthetic membranes.  
2.4.3   Microneedle application enhances transmembrane drug delivery in a length-
dependent manner 
The results presented here show that micropore area and depth of penetration into Strat-MTM 
membrane is determined by microneedle length. The longest microneedles investigated (750 
µm) gave the largest micropore entry area and penetrated the Strat-MTM the deepest, followed 
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by the next longest (500 µm) and then the shortest (250 µm). Since Strat-MTM membrane is 
impermeable to doxycycline, micropore area afforded by the microneedles act as the sole 
conduits for its permeation. It follows that the longer the microneedles the larger the 
micropores, the greater the rate of doxycycline diffusion and the higher the cumulative 
concentration of doxycycline is in the receptor fluid. Though there were was an increase in 
micropore area between 250 and 500 µm, and 500 and 750 µm microneedle lengths, these 
differences were not statistically significant. Thus the significant difference in permeation 
between these microneedles lengths is most likely accounted for by the increase in depth 
penetration in addition to the greater micropore area. Studies comparing the effect of differing 
microneedle roller lengths have also shown a positive correlation between increasing 
microneedle length and increased drug permeation, Badran et al. (2009) between 150, 500 and 
1500 µm needle lengths in their excised human skin model235, and Hyeong et al. (2012) 
between 150, 250 and 500 µm needle lengths in their in vivo rat model of Rhodamine B 
permeation236.  
It is notable that the full lengths of the 500 and 750 µm microneedles did not penetrate the 
membrane since there was a residual portion of the shaft that never made contact with the 
membrane. There are several plausible explanations for this, including the inhibitory effect on 
penetration that neighbouring needles have on one another which prevents maximum depth 
penetration. This is referred to as the ‘bed of nails’ effect and confounds the effect of 
microneedle length on microneedle penetration173,237,238. Additionally, the rigid supporting 
surface underneath the Strat-MTM may interrupt full penetration in a situation where the 
microneedles are longer than the membrane. A greater force applied to the microneedles may 
be able to overcome these factors or may simply cause damage to the needle tips. To investigate 
the confounding effect of needle proximity on maximum needle penetration, a model using a 
single microneedle would be ideal to look at the effect of shaft length alone239. 
The most desirable microneedle length is the shortest that can deliver doxycycline to the dermal 
layer with optimal results. However, there is a fine balance between risk of pain and bleeding 
with the most efficient delivery. Microneedles up to 500 µm in height have been inserted 
painlessly in some human subjects while lengths up to 1000 µm have shown reduced pain 
sensation and intensity compared with hypodermic needles9. It appears that as well as with 
length there is a correlation between pain perception and needle diameter240. It is important to 
note that pain sensation and pain perception is highly subjective and may be confounded by 
those who are nervous of needles in general. Additionally, actual depth penetration is not easily 
determined by microneedle length, that is to say, a microneedle length of 750 µm does not equal 
a depth penetration of 750 µm due to the resistance of the material to needle insertion and the 
inhibitory effect on penetration by the neighbouring microneedles. Furthermore, whether there 
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is sufficient penetration of needles into dermis will depend on the target body region since SC 
thickness differs from body site to body site.  For example, the heel, a site where several chronic 
wounds commonly develop, has a notably thicker SC than most body regions and microneedles 
evaluated on abdominal skin may not be of sufficient to length deliver drugs through heel skin. 
2.4.4   Application method of the roller system influences micropore area 
Rolling of the microneedles resulted in larger micropores compared with a single application 
of perpendicular force. Rolling involves shearing forces that disrupt the membrane along the 𝑦 
axis which perpendicular application of force does not. The extent of membrane disruption by 
manual rolling may be dependent on the number of rolls and the number of planes in which the 
microneedles are rolled in. In this study the microneedles were rolled bilaterally without 
removal of the microneedle from the membrane but other studies have used multilateral rolling 
which creates overlapping micropores225,241. Sung-Kyun et al. (2010) investigated the effect of 
the number of rolls in differing numbers of planes on drug permeation and concluded that 
increasing the number of rolls (from one to nine) increased the drug flux of L-ascorbic acid in 
their rat model242. This suggests that for ‘poke and patch’ TDD, rolling is a more efficient way 
of permeabilising skin than impact insertion of an array and that repeated rolls increases drug 
diffusion rates235. However, the force applied with manual rolling is inconsistent and will differ 
slightly with each application and between individuals, making valid comparisons across and 
within studies difficult. Furthermore, repeated rolling is likely to reduce the shelf-life of a 
microneedle roller making it less efficient or more painful by blunting the needle tips and 
increasing their diameter. It should be noted that, in general, direct comparisons between the 
work presented here and studies from the published literature are not possible due to substantial 
differences in: (i) the microneedles and membranes used, (ii) the application methods employed 
(including both application force and number and direction of rolls),  and (iii) the drug being 
investigated, as a result of a current lack of standardised protocols amongst researchers. 
2.4.5   Doxycycline solution is retained in the Stat-MTM membrane in crystal form 
A portion of the doxycycline solution was retained within and on the Strat-MTM membrane. 
Unexpectedly doxycycline formed crystals on the membrane surface of untreated Strat-MTM 
and also within micropores of microneedle-treated Strat-MTM. These yellow crystals were 
visible in hydrated membranes immediately after the permeation study, confirming that the 
presence of crystals was not a result of the drying process. These crystals were also not seen 
when PBS only was applied onto the membrane. The reason for the crystallisation of 
doxycycline and its deposition on the membrane is unclear. The donor fluid concentration was 
a fifth of its solubility limit, so the solution was theoretically unsaturated.  Molecules in solution 
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will crystallise when a nucleation point is reached and it is more energetically favourable to 
form and deposit crystals than remain dissolved243.  
It is possible that there is an interaction between the Strat-MTM surface and dissolved 
doxycycline molecules that stimulates this process. The presence of these crystals explains why 
the theoretical concentration of doxycycline in the receptor fluid is not reached; crystallisation 
of doxycycline inside micropores would limit further drug permeation and also reduces the 
available drug to diffuse. A solvent, such as methanol, could be used to improve doxycycline 
solubility. However, this is likely to interfere with the Strat-MTM structure and integrity, 
confounding its true permeation properties as it is structurally sensitive to such chemicals. In 
in vivo human skin, drug crystallisation may be overcome through the addition of solubilising 
agents to the drug. Moreover, concentrations of doxycycline hyclate administered by 
intradermal delivery would, in reality, be much lower than 10 mg/ml which was used to satisfy 
infinite dose conditions.  
2.4.6   Durability of microneedle roller systems 
The microneedle roller systems are commercially available in the public domain. The 
manufacturers state that they are suitable for repeated individual use. However, it was observed 
in this study that application of the rollers onto the Strat-MTM membrane resulted in blunting of 
some of the microneedle tips, most likely the microneedles that made initial contact with the 
membrane. Moreover, manual rolling caused more damage than application of a vertical 
standardised force. This suggests that, with repeated use, the microneedles’ tips would become 
more blunted, reducing their efficacy. Further investigations would be needed to determine this 
however. Furthermore, though disinfection of the roller system is possible, given the nature of 
the disease that the target patient population typically have, single use would be best clinical 
practice for hygiene purposes.  
2.5   Future work 
2.5.1   Drug permeation and micropore resealing kinetics in excised human skin 
Further comparisons between the Strat-MTM and membrane excised human skin should be 
made. For example, differences in microneedle depth penetration observable by OCT and 
diffusion rates measured by Franz cell permeation studies could be explored. Penetration 
studies using fluorescently-labelled drugs or dyes with a similar molecular weight to 
doxycycline could be carried out followed by histological analysis of the micropores created in 
human skin. Side-by-side comparisons of these sections could then be made with OCT images. 
The effect of solubilising agents on crystal formation and membrane/skin integrity would be 
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useful in determining the feasibility of delivering doxycycline in vivo, as crystal formation 
would be undesirable.  
The resealing kinetics of micropores created in human skin could be investigated by imaging 
them at regular time intervals after initial needle application. This would give an indication of 
the time frame within which doxycycline could be delivered intradermally without the use of 
drugs to delay micropore closure. The rate of pore closure will be dependent on the elasticity 
of the skin (age, body site, hydration etc.) and the size of the initial pore created so these factors 
could also be explored. The effect of the number of microneedle applications and the effect of 
microneedle application in an increasing number of planes could be investigated along with the 
effect of different standardised forces on both micropore entry area and depth penetration, and 
on microneedle blunting.  
2.5.2   Controlled-release and gel-based vehicular IDD of doxycycline 
One of the next set of experiments of great interest is to investigate the delivery of doxycycline 
in different formulations. Preliminary experiments have already been carried out to assess 
controlled-release mechanisms of delivering doxycycline in place of simply adding 
doxycycline as an aqueous solution onto micropores. To date, these experiments have included: 
(i) application of a patch impregnated with doxycycline, (Appendix B — Impregnating various
wound dressings with doxycycline solution, p.242), (ii) doxycycline delivery in a Granugel
vehicle and Atrigel vehicle (Atridox) of varying viscosities, and (iii) development of an in situ
forming smart gel to be applied into the micropores (Appendix C — Development of an MMP-
cleavable protein-based smart gel, p.243).
2.6   Conclusion 
The body of work carried out in this chapter has shown, for the first time, how microneedle 
roller systems are able to enhance the transmembrane delivery of doxycycline hyclate through 
Strat-MTM membrane. Strat-MTM acts as an effective barrier against the permeation of large 
molecules like doxycycline, making it a suitable skin mimetic to investigate mechanical 
penetration enhancement. However, several limitations should be kept in mind when making 
direct comparisons to human skin including the lack of a dynamic response to mechanical 
stimuli, specifically micropore closure. In this in vitro model increasing microneedle length 
increased micropore area, depth penetration and ultimately doxycycline permeation through the 
Strat-MTM. Furthermore, manual rolling disrupted the membrane more than the downward 
application of a standardised force alone. Evidence of doxycycline retention in the membrane 
was attributed to interactions with the drug and the membrane surface. It can be concluded that 
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repurposed microneedle rollers are a promising tool in the treatment of early stage pressure 
ulcers and the next step is to monitor the biological effects of microneedle-mediated IDD of 
doxycycline.
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Chapter 3   Microneedle-Enhanced 
Transmembrane Delivery of Doxycycline 
to a Dermal Tissue Equivalent  
3.1   Introduction 
Transmembrane delivery of doxycycline in an acellular static system, as outlined in Chapter 2, 
has provided fundamental permeation data under infinite dose conditions. However, its delivery 
through the Strat-MTM membrane can also be monitored in cell-based models by directly 
measuring changes in MMP activity and expression, and indirectly through observing its effects 
on cell behaviour such as contraction.  
3.1.1   Role of dermal fibroblasts in tissue contraction 
Dermal fibroblasts are the major cell type found in the human dermis and are integral to tissue 
remodelling, tissue development and wound repair244. Alongside mast, dendritic and plasma 
cells, they form the cellular component of the skin’s extracellular matrix (ECM), while 
collagens and other proteinaceous molecules form the structural component. The ECM acts as 
a dynamic structural scaffold for the dermal cells to populate and also functions as a transmitter 
of mechanical forces originating in their cytoskeleton. Fibroblasts play a fundamental role in 
the synthesis of the ECM through production of collagens – mainly types I and III in the skin. 
They are also responsible for secreting and responding to cytokines, chemokines and growth 
factors for ECM maintenance and remodelling244.  
Forces originating in and transmitted across a population of dermal cells via the ECM contribute 
to tissue contraction, an integral step of several biological processes245. When activated, 
fibroblasts undergo a variety of changes including establishment of a smooth muscle-like 
contractile apparatus which allows them to generate these transmissible contractile forces246. 
Rapid myosin adenosine triphosphatase (ATPase) directs the arrangement of collagen fibrils 
into thicker, longer fibres through elimination of water247. As a result, the ECM undergoes 
compaction, becoming a denser matrix with a reduction in volume. Additionally, by a separate 
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mechanism, physical locomotion of fibroblasts functions to contract collagen248. This 
contractile behaviour can be modelled in vitro by emulating the three-dimensional architecture 
of dermal tissue and its resident cells, allowing factors that may accelerate or inhibit tissue 
contraction to be investigated.  
3.1.2   Tissue equivalent models of the human skin and dermis 
Tissue equivalents have been developed to reproduce key structural and functional aspects of 
human skin. They were originally developed as artificial skin to be used as skin grafts in burns 
patients, but are now more commonly used as bioengineered research alternatives to excised 
biological tissue248. Tissue equivalents are able to emulate several behaviours exhibited in the 
in vivo tissue by replicating the interaction of the tissues three-dimensional structural 
environment using its cellular and molecular components. Tissue equivalents provide improved 
culture systems compared with two-dimensional monolayer cultures since functional studies, 
such as those based on contraction, can be performed. Collagen substrata for studies on cell 
behaviour were first described by Elsdale and Bard in 1972249. The classic free-floating 
fibroblast-populated collagen lattice (FPCL) contraction model was first introduced by Bell et 
al. in 1979 and has been replicated and modified ever since250. Though their model 
unfortunately did not translate to successful skin grafts in humans it did provide a robust 
research model to investigate factors influencing fibroblast-mediated tissue equivalent 
contraction. 
The typical dermal tissue equivalent is composed of collagen gel lattices exclusively populated 
with dermal fibroblasts. These soft collagen-cell gels are created from three major components: 
(i) a moderate density of fibroblasts cultured in (ii) serum-enriched culture medium in the
presence of  (iii) solubilised rat tail type I collagen247. In vitro, the native collagen spontaneously
polymerises into a gel under physiological conditions and the fibroblasts interact with this
newly polymerised collagen matrix247. Once set, the gel can be detached and become free-
floating though gentle agitation or remain attached to the base of the culture plate. Compaction
of the collagen fibrils by the resident fibroblasts results in reduction in lattice volume, also
referred to as lattice or gel contraction. The FPCL model can be modified to include higher
densities of fibroblasts, cell co-cultures or external stressors, each having an effect on the rate
and mechanics of gel contraction.
3.1.3   Effect of doxycycline and other MMP inhibitors on FPCL contraction 
Upregulation of MMP activity has been linked to fibroblast activation which, in turn, has been 
linked to augmented tissue contraction. In numerous studies, inhibition of MMPs in FPCL 
models has resulted in reduced gel contraction, though the exact mechanisms have yet to be 
Chapter 3: Microneedle-Enhanced Transmembrane Delivery of Doxycycline to a Dermal Tissue Equivalent 
- 117 -
fully elucidated213. The effect of MMP expression and activity on gel contraction can be 
investigated in several ways including culturing fibroblasts lacking expression of particular 
MMPs251, transfection of fibroblasts with MMP-specific small interfering RNA (siRNA)251 or 
treatment of the FPCLs with MMP inhibitors213,252. These methods provide insights into the 
pathophysiological molecular pathways and thus potential treatments for MMP-mediated 
disease states. 
 Of particular interest are non-specific MMP inhibitors which have been shown to reduce gel 
contraction in FPCLs. The anti-cancer drug and MMP inhibitor GM6001 (also known as 
ilomastat) initially investigated in the prevention of tumour metastasis, was shown to 
significantly reduce gel contraction in collagen gels populated with dermal rat fibroblasts252. 
Sub-antimicrobial doses of doxycycline were also reported to reduce gel contraction and inhibit 
MMP activity in an ocular fibroblast model of human trichiasis containing fibroblasts harvested 
from affected conjuctiva213. Thus, doxycycline is reportedly able to reduce the gel contraction 
associated with activated fibroblasts and more importantly this acts as an indirect biomarker for 
its direct inhibition on MMP activity.  
3.1.4   Safety of microneedling on injured tissue 
The issue of safety of microneedling on skin has been raised166 and could be especially 
problematic  on injured skin. Though there are no details in the literature of microneedling onto 
early stage chronic wounds per se, there is evidence to suggest that ischemic tissue more easily 
propagates apoptotic death signals to neighbouring cells due to an upregulated gap junction 
function253–256. This process may be potentiated by application of microneedles which could 
further stress tissue. If microneedling does indeed have a deleterious effect on cell viability 
(which may be length dependent) then a trade-off may need to be made between the initial 
stress signalling it causes and the effect that delivering the drug has on promoting wound 
healing and resolution. Additionally, the pain sensation associated with longer microneedles (> 
500 µm)257, may not pose an issue for target patient populations since many of these individuals 
are paraplegic. Even in these situations, microneedles are advantageous over hypodermic 
injection as they allow for much more precise dermal delivery.  
3.2   Research outline 
This chapter outlines a series of experiments that ultimately investigated the delivery of 
doxycycline to FPCLs through microneedle-treated Strat-MTM. The dermal tissue equivalent 
model used was based on the free-floating FPCL originally described by Bell et al. (1979)250, 
though human instead of rat fibroblasts were used. Firstly, the effect of doxycycline treatment 
on the FPCLs was established. Then, in direct continuation of the investigations outlined in 
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Chapter 2, doxycycline was delivered to the FPCLs through Strat-MTM treated with increasing 
microneedle lengths on the roller systems. This was carried out to assess the effect of 
microneedling on enhancing transmembrane doxycycline delivery in a cell-based in vitro 
system. The Strat-MTM was mounted into wells using a cell crown, compartmentalising the 
upper surface from the FPCL beneath. Doxycycline solutions were then added onto the Strat-
MTM surface and gel contraction and MMP activity measured. This group of experiments used 
fibroblast-mediated gel contraction to produce functional and quantitative data related to 
doxycycline activity. Gel contraction indirectly reflected the amount of doxycycline that 
reached the FPCLs — since the more doxycycline that could reach the FPCLs, the greater the 
reduction in gel contraction mediated by inhibition of MMP activity. MMP activity was also 
directly assessed by sampling the culture medium that the gels were immersed in. 
This chapter aims to corroborate the effect of non-specific MMP inhibitors, specifically the 
drug of interest, doxycycline, on inhibition of MMP activity and gel contraction (reported in 
previous studies) in combination with its delivery through microneedle-treated Strat-MTM. The 
set of experiments demonstrated the effect of microneedle application and length on drug 
permeation through Strat-MTM using established biological markers. Novel aspects of the 
experiments include: (i) treatment of three-dimensional collagen gels populated with dermal 
fibroblasts using doxycycline in combination with the assessment of its delivery through 
microneedled-treated Strat-MTM, (ii) monitored through the extent of gel contraction and MMP 
activity. Additionally, a potentially negative effect of microneedling on cell viability was 
explored as further physical injury to already wounded tissues raises valid concerns. 
3.3   Methods and materials 
3.3.1   Human adult dermal fibroblasts 
Isolation of fibroblasts 
Human adult dermal fibroblasts (also referred to as HDFa cells or fibroblasts) were kindly 
provided by Dr Maryse Bailly (Institute of Ophthalmology [UCL], London). A 5 mm punch 
biopsy was harvested from the presternal dermis of a healthy adult donor undergoing 
blepharoplasty surgery. The biopsy was mechanically dispersed, outgrown from the explant 
and established as a primary in vitro culture258. 
Cell culture 
Monolayer cultures of fibroblasts were grown in T75 cm2 vented flasks in x1 DMEM (D6546; 
Sigma-Aldrich, Poole, UK) supplemented with 10% (v/v) FBS (Gibco, Paisley, UK), 1% (v/v) 
L-Glutamine (Sigma-Aldrich) and 1% (v/v) penicillin-streptomycin-amphotericin B (Sigma-
Chapter 3: Microneedle-Enhanced Transmembrane Delivery of Doxycycline to a Dermal Tissue Equivalent 
- 119 -
Aldrich). Their environment was maintained at 37oC and 5% CO2 in a fully-humidified 
incubator. Cells were used between passages five and 15 and were grown to approximately 
80% confluence before passaging. Prior to formation of dermal equivalents in the form of 
cellularised collagen gels, the cell monolayers were washed once with PBS and detached with 
trypsin-EDTA (Sigma-Aldrich). The cell-trypsin suspension was neutralised with complete 
DMEM and cells were pelleted of solution by centrifugation at 1500 rpm for 5 minutes at room 
temperature. Pellets were then resuspended in complete DMEM and viable cell counts 
determined using trypan blue staining. For maintenance of cultures, cells were transferred to 
T75 cm2 flasks and resuspended in DMEM at a density of 2.5 x 105 cells per ml. Cell media 
was aspirated and replenished 24 hours after passaging and then every three days until cells 
became confluent. 
3.3.2   FPCL contraction assay 
Collagen gel synthesis 
Concentrated media was made by adding (v/v/v) 73.7% x10 DMEM (Sigma-Aldrich), 7.4 % 
L-glutamine (Sigma-Aldrich) and 18.9% sodium bicarbonate (Gibco). Concentrated media was
added drop wise to 1 ml of Type I Rat Tail Collagen (First Link UK Ltd., Birmingham, UK)
and the solution neutralised with 80 µl of 1M sodium hydroxide (Sigma-Aldrich). 100 µl of 1
x105 cells resuspended in FBS was added to the collagen solution. The cell-enriched collagen
gel solution was cast quickly into the 10 mm microwells of uncoated glass bottomed 24-well
plates (P24G-1.5-10-F; MatTek Corp., Massachusetts, USA). The plates were gently tapped to
ensure the gels made contact with the microwell edge and to remove any large air bubbles that
could affect gel ultrastructure. Gels were allowed to solidify at 37oC for 15–20 minutes to form
the FPCLs. FPCLs were monitored under a light microscope. This was useful to assess cell
viability when FPCLs were not contracting. Small rounded cells suggested cell death possibly
due to on overly acidic environment caused by insufficient neutralization of the concentrated
media during FPCL formation.
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Preparation of doxycycline test solutions 
Doxycycline hyclate powder (Alfa Aesar, Massachusetts, USA) was dissolved in sterile water 
and vortexed to create a 48.7 mM stock solution. A range of sub-antimicrobial concentrations 
of doxycycline were created (104, 208, 416, and 832 µM) through serial dilutions in complete 
DMEM. The comparative effect of an alternative doxycycline hyclate powder (Sigma-Aldrich) 
was also investigated. Once set, gels were gently detached from the edges of the microwell to 
become free-floating using a sterile pipette tip. DMEM or doxycycline test treatments (1 ml) 
were added to the gels and plates incubated at 37oC.  
Gel contraction analysis 
Gel contraction is a qualitative observable effect that occurs when fibroblastic activity causes 
the surrounding interconnected ECM to contract. The effect can be quantitatively monitored by 
periodically measuring the size of the gel and comparing it to its original size (Figure 3.2 – A). 
The data can then be used to examine how gel contraction changes over time and the effect of 
that any treatments added to the gel have. Digital photographs of the FPCLs were taken on days 
1, 3, 6 and 7 with a 20MP camera, against a black surface for contrast. Gel areas were measured 
using the ‘elliptical’ measuring tool in ImageJ®. Contraction was plotted as a percentage of gel 
area normalised to the original gel area when cast on day 0 (also equivalent to microwell area). 
Figure 3.1 — Photographs of modified cell culture plates supplied by MatTek 
Corp. containing glass-bottomed microwells [MW] into which cellularised 
collagen gels were cast: (A) A 24-well glass-bottomed plate (MatTek Corp.) (B) A 
35 mm glass bottomed dish.  
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Gel thickness was not measured by this method, and contraction in the vertical dimension was 
not assessed. Starting gel thickness was 1.5 mm with a convex meniscus (Figure 3.2 – B). 
3.3.3   Assessing MMP activity 
Sample collection 
Samples of supernatant (75 µl) were collected 1 hour after initial incubation on day 0 and then 
on days 3 and 7. Samples were stored at –20oC. 
MMP activity assay 
The MMP activity assay is a method used to assess and quantify the activity of MMPs in a 
solution using changes in fluorescent activity. The assay utilises a fluorescence resonance 
energy transfer (FRET) peptide as an MMP substrate. When this peptide is intact, the 
fluorescence of the donor portion of the peptide is quenched by another portion known as the 
‘quencher’. When the FRET peptide is cleaved by MMP activity the two fragments are 
separated and the fluorescence is recovered. This fluorescence can be detected and measured. 
The assay broadly distinguishes between MMPs depending on the length of incubation with 
Figure 3.2 — Schematic representation of gel contraction analysis of FPCLs: (A) 
FPCLs were cast into the 10 mm diameter glass-bottomed microwells of modified tissue 
culture plates. FPCLs were allowed to set for 20 minutes at 37oC and were gently 
detached from the microwell to become free-floating by tapping. Percentage gel 
contraction was calculated by measuring the area of the FPCL compared with that of the 
microwell from digital photographs. (B) Once set, FPCLs had a convex meniscus. Gel 
contraction was only assessed in the horizontal dimension by this method. Starting gel 
thickness was approximately 1.5 mm. 
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substrate solution, for which 3 hours detects the activity of MMPs 1, 2, 7, 8, 9, 11, 12, 13 and 
14, inclusive of the MMPs (MMPs 2, 8 and 9) of interest to pressure ulcer pathophysiology.  
Total MMP activity was determined using the Abcam FRET-based MMP activity assay kit 
according to manufacturer’s protocol (ab112147; Abcam, Cambridge, UK). Supernatant (25 
µl) collected from collagen gel contraction cultures was transferred to 96-well plates (Appleton 
Woods, Birmingham, UK) and 25 µl of the provided 2 mM p-aminophenylmercuric acetate 
(AMPA) solution added. Plates were incubated at 37oC for 3 hours. MMP red substrate working 
solution (50 µl) was added to the samples and the plate incubated at room temperature for 1 
hour, protected from light. Fluorescence was measured at Ex/Em 540/590 nm using the 
FLUOstar Optima plate reader (BMG Labtech, Ortenberg, Germany).  
Normalising MMP activity 
The fluorescent output readings from the MMP activity assays are relative values that could be 
affected by signals from background substances and materials. To correct for this effect, the 
readings for each treatment group were normalised to a background control that contained just 
the treatments, for each day. This was done by subtracting the background reading from the 
reading of the sample. This also allowed for meaningful and direct comparisons between 
treatment groups.  
3.3.4   Strat-MTM membrane 
Perforation of Strat-MTM by microneedle rollers 
Strat-MTM membranes (Merck Millipore, USA) were cut into circular discs, 23 mm in diameter, 
and transferred onto a cutting board support. Microneedle rollers (Sodacoda, Delmenhorst, 
Germany) 250, 500 and 750 µm in shaft length were placed onto the membrane and rolled five 
times bi-directionally along the 𝑦 axis as previously described (Method 0, p. 85).  
3.3.5   Mounting Strat-MTM membrane into cell crown inserts 
Strat-MTM membranes were mounted into cell crowns (Scaffdex, Tampere, Finland). Cell 
crowns were then inserted into individual wells of the 24-well MatTek plate so that the basal 
surface of the membrane was in contact with the medium (750 µl) bathing the collagen gels 
(Figure 3.3 – A). Treatment solutions (250 µl) were pipetted onto the apical surface of the 
Strat-MTM membrane. Supernatant was sampled from around the collagen gel on days 0, 3 and 
7 using a fine needle and syringe (Figure 3.3 – B) for subsequent MMP activity measurements 
(Method 3.3.3, p. 121).  
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3.3.6   Effect of microneedle application on cell viability 
Scratch assay 
In addition to Strat-MTM perforation, microneedle rollers were applied onto (i) fibroblast 
monolayers grown on polystyrene tissue culture substrate and (ii) onto the FPCLs. This was 
investigated to assess the effect of microneedling on cell viability. The volume of collagen gels 
was scaled up to fit a 35mm diameter glass bottomed MatTek dish (P35G-1.5-14-C; MatTek 
Corp) — large enough to accommodate the microneedle roller. For the monolayer cultures, 
fibroblasts were seeded at a density of 1 x 106 cells per ml in 6-well plates (Appleton Woods, 
Birmingham, UK) and incubated for 3 days at 37oC to allow for adhesion and proliferation and 
for cell density to reach 80% confluence. Microneedles, 250, 500 and 750 µm in length, were 
applied onto the monolayers and FPCLs by applying a 500 g calibration mass onto the rollers 
producing a downward force of 3.8N. Cell viability was assessed at 0, 1 and 24 hours. A 
horizontal scratch wound was applied using a p200 pipette tip and served as a positive control. 
Figure 3.3 — Set-up of the cell crown inserts and Strat-MTM membrane mounted in 
24-well plates: (A) Schematic representation of Strat-MTM membrane inserted into a cell
crown and mounted into an individual well of a 24-well glass-bottomed plate. The basal
surface of the membrane contacted with the DMEM immersing the FPCL. Doxycycline
solution was pipetted onto the apical surface of the membrane. (B) Photographs of cell
crowns with Strat-MTM membrane inserts mounted into individual wells. Supernatant was
sampled from around the cell crown and membrane using a very long, thin needle which
could reach the underlying medium without disturbing the experimental apparatus.
DMEM (750 µl)
MatTek well
Strat-MTM membrane
doxycycline solution (250 µl)
collagen gel (FPCL)
cell crown
A B doxycycline solution (250 µl)
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Apoptosis/necrosis staining kit 
Apoptotic and necrotic activity in the cell monolayers and FPCLs was determined using an 
apoptosis/necrosis detection kit, a fluorescence-based assay designed to simultaneously 
monitor apoptotic, necrotic and healthy cells (ab176749; Abcam, Cambridge, UK). The kit 
contains three different sensors, the Apopxin Deep Red Indicator, DNA Nuclear Green DCS1 
Dye and CytoCalcein Violet 450 which distinguish between cells that have undergone apoptosis 
– active, programmed cell death, necrosis – passive, accidental cell death and healthy live cells,
respectively. The Apopxin Deep Red indicator distinguishes apoptotic cells by binding to
phosphatidyl serine presented on the cell membranes and producing a red fluorescence. Nuclear
Green DCS1 Dye is a membrane-impermeable stain that is able to label the cell nucleus when
there is loss of membrane integrity producing a green fluorescence. It stains for late apoptotic
and necrotic cells. CytoCalcein Violet 450 is a live cell cytoplasm labelling dye which stains
viable cells by producing a blue fluorescence.
For the apoptosis/necrosis assay, media was aspirated from the samples and cells were washed 
with 100 µl of Assay Buffer. A staining mix consisting of Assay Buffer with 1% (v/v) Apopxin 
Deep Red Indicator 200x, 0.5% (v/v) Nuclear Green DCS1 Dye 200x and 0.5% (v/v) 
CytoCalcein Violet 200x was added to the samples. Samples were incubated at room 
temperature for 1 hour. Cells were washed twice more with Assay Buffer. Samples were imaged 
under the Leica DM16000 B fluorescent microscope (Leica Microsystems, Wetzlar, Germany) 
with an N PLAN 10.0 x 0.25 dry objective. Apopxin Deep Red indicator, Nuclear Green DCS1 
Dye and CytoCalcein Violet 450 were excited by the 647, 488 and 405 nm wavelength lasers 
respectively. Bright-field imaging was used to assess physical damage made by the 
microneedles onto the plate substrates when they were applied to the fibroblast monolayers and 
FPCLs. 
3.3.7   Statistical analyses 
For each condition there were six replicates (unless otherwise stated) to allow for experimental 
variation. A two-way ANOVA with Tukey correction for multiple comparisons was carried out 
to determine statistical significance of percentage gel contraction and MMP activity between 
treatment groups for each day. Where appropriate, results are expressed as mean ± standard 
error of the mean (SEM) and in all instances, p < 0.05 denotes a statistically significant 
difference.  
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3.4   Results 
3.4.1   Effect of doxycycline on collagen gel contraction and MMP activity 
Collagen gels cellularised with human dermal fibroblasts (FPCLs) and cultured in FBS-
supplemented DMEM exhibited contraction at a decreasing rate over a seven-day period. 
Collagen gels showed percentage contraction of 59.9 ± 2.2%, 82.3 ± 1.1%, 94.6 ± 0.7%, and 
95.7 ± 0.3% on days 1, 3, 6 and 7 respectively. In follow-up studies it was confirmed that 
percentage gel contraction never reached 100% and would plateau at approximately 98% when 
allowed to contract over an extended period of time. The presence of sub-antimicrobial 
concentrations of doxycycline within the culture medium was shown to significantly reduce 
percentage gel contraction compared with control groups at equivalent time points (p < 
0.0001), but not to prevent it (Figure 3.4).  
A doxycycline concentration of 416 µM was used, as this is a validated concentration in the 
literature, shown to significantly reduce gel contraction213,259. For gels treated with 416 µM 
doxycycline solution, percentage gel contraction was 29.5 ± 2.4%, 52.6 ± 0.9%, 60.8 ± 2.2% 
and 63.2 ± 1.9% on days 1, 3, 6 and 7 respectively (Figure 3.5). The extent of gel contraction 
inhibition was shown to be dose dependent between doxycycline concentrations of 104 and 832 
µM (Figure 3.6). Increasing doxycycline concentration had a statistically significant effect on 
increasing inhibition of gel contraction compared with control  104 µM (p < 0.001), 208 µM (p 
< 0.0001), 416 µM (p < 0.0001) and 832 µM (p < 0.0001)  by day 7). As with the control 
FPCLs, the rate of gel contraction in all doxycycline-treated FPCLs progressed rapidly up until 
day 3 then gradually decreased for the remainder the experiment. A dose dependent effect of 
doxycycline within this concentration range has been also reported in previous studies259. 
MMP activity assays were used to assess the activity of MMPs in the FPCL supernatant 
throughout the experiment. In control gels, the normalised activity of MMPs was shown to 
sharply increase over the seven day experiment and effectively doubled between days 0 and 7. 
Treatment of the FPCLs with 416 µM doxycycline significantly inhibited MMP activity in the 
gel supernatant compared with control by days 3 and 7, maintaining them at day 0 activity 
levels (p < 0.0001).  Inhibition of MMP activity was dose dependent in a range of 104 to 832 
µM doxycycline concentrations. The presence of 104 µM doxycycline resulted in statistically 
significant inhibition of MMP activity. The lower concentrations of 104 and 208 µM reduced 
the MMP activity compared with control but 416 µM kept them at day 0 levels. The highest 
concentration assessed of 832 µM resulted in a reduction of MMP activity on days 3 and 7 
compared with day 0, consistent with this concentration having the greatest effect on inhibiting 
gel contraction.   
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Figure 3.4 — Photographs of gel contraction in FPCLs treated with 416 µM 
doxycycline and control FPCLs. The collagen gels [CG] were cast into the plate’s 
microwells [MW] on day 0 and photographed on days 1, 3, 6 and 7. Percentage gel 
contraction was calculated by measuring the area of the collagen gel relative to the 
microwell. Control gels that were cultured in only complete DMEM, showed rapid 
contraction between days 1 and 3. Treatment of gels with 416 µM doxycycline 
significantly reduced total percentage contraction by day 7 (p < 0.0001).  
` 
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Figure 3.5 — Effect of 416 µM doxycycline concentration on FPCL  gel contraction 
and MMP activity (n = 6): (A) Gel contraction compared between control FPCLs and 
doxycycline-treated FPCLs. For control gel contraction increased significantly over a 
seven-day period. A concentration of 416 µM doxycycline significantly reduced gel 
contraction compared with control on days 1, 3 6 and 7, though gel contraction continued 
to increase.  (B) MMP activity compared between control FPCLs and doxycycline-treated 
FPCLs.  For control groups, MMP activity increased over the 7-day experimental period, 
significantly so between days 0 and 3. For doxycycline-treated FPCLs this increase in 
MMP activity was significantly inhibited on days 3 and 7.  Error bars represent the 
standard error of the mean; *** = p < 0.001, **** = p < 0.0001. 
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Figure 3.6 — Effect of a range of doxycycline concentrations on FPCL gel contraction 
and MMP activity (n = 6): (A) The effect of doxycycline concentration on collagen gel 
contraction. Increasing doxycycline concentration between 104 µM and 832 µM, increased 
its effect on reducing gel contraction in a dose dependent manner. (B)  The effect of 
doxycycline concentration on MMP activity. For a doxycycline concentration range 
between 104 and 832 µM, MMP activity was significantly reduced compared with control. 
Error bars represent the standard error of the mean; * = p < 0.05, ** = p < 0.01, *** = 
p < 0.001, **** = p < 0.0001 and represent a statistically significant difference compared 
with the day-matched ‘Control’ value;. 
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 Figure 3.7 — Effect of fibroblast seeding density on FPCL gel contraction and MMP 
activity (n = 6): (A) Effect of fibroblast seeding density on gel contraction. The rate and 
extent of gel contraction over the seven-day experimental period was correlated with the 
initial fibroblast seeding density. FPCLs initially cellularised with 2.0 x106 fibroblasts 
showed a statistically significant increase in percentage gel contraction on days 1, 4 and 6 
compared with FPCLs cellularised with 0.5 x 106 and 1.0 x 106. In the absence of 
fibroblasts, no FPCL gel contraction was observed. (B) MMP activity compared between 
different FPCL fibroblast seeding densities. Increasing the FPCL seeding density resulted 
in significantly increased MMP activity between 0.5 x106 and 1.0 x106 and 1.0 x106 and 
2.0 x106 by days 3 and 7. No increase in basal MMP activity levels was observed in the 
absence of cells in the collagen gels. Error bars represent the standard error of the mean; 
** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.  
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Figure 3.8 — Evaluating the delivery of doxycycline through untreated Strat-MTM
membrane (n = 6): (A) The effect of untreated Strat-MTM on gel contraction in 
comparison with control FPCLs and 416 µM doxycycline treated FPCLs was 
investigated. Strat-MTM was able to significantly inhibit the delivery of doxycycline to 
the FPCLs by compartmentalising the doxycycline. There was no significant difference 
between gel contraction exhibited in control and Strat-MTM groups (B) Comparison of 
MMP activity between control FPCLs, FPCLs compartmentalised from 416 µM 
doxycycline by the Strat-MTM control and FPCLs treated directly with 416 µM 
doxycycline. As seen with the gel contraction results, Strat-MTM compartmentalisation 
of doxycycline did not result in statistically significant difference in MMP activity 
compared to control, but was statistically different from ‘Dox’ groups on days 3 and 7. 
Error bars represent the standard error of the mean; *** = p < 0.001 **** = p < 0.0001. 
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Figure 3.9 — Evaluating the delivery of doxycycline through  microneedle-
treated Strat-MTM membrane (n = 6): (A) Percentage gel contraction was 
correlated with the length of the microneedles used to permeabilise the Strat-MTM 
membrane to the 416 µM doxycycline solution. Permeabilistion of the membrane to 
doxycycline using the microneedles resulted in reduced gel contraction compared   to 
control, significantly so for 250 µm on days 1 and 3, 500 µm on all days and 750 µm on 
all days assessed of the seven-day experiment. The magnitude of effect was related to 
needle length; the 750 µm microneedle-treated membrane resulted in the greatest 
reduction in gel contraction while the 250 µm resulted in the least. (B) A statistically 
significant difference in gel contraction was observed between both the 500 and 750 µm 
microneedle groups and control group by day 7. (C) Correlation of MMP activity 
between and Strat-MTM treated with increasing microneedle lengths. A statistically 
significant difference was only observed between untreated Strat-MTM and 750 µm 
microneedle-treated Strat-MTM on day 7. Error bars represent the standard error of the 
mean; ** p < 0.01, *** = p < 0.001 **** = p < 0.0001.  
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3.4.2   Effect of fibroblast number on gel contraction and MMP activity 
The presence of fibroblasts in the collagen gels was essential for gel contraction as acellular 
gels did not exhibit any gel contraction ( Figure 3.7). The results showed that the rate and extent 
of gel contraction after 24 hours was dependent on the number of fibroblasts originally seeded 
into the collagen mix. FPCLs seeded with 2 x 105 cells contracted at a significantly greater rate 
than FPCLs seeded with 1 x 105 or 0.5 x 105 (p < 0.0001) after 24 hours. By day 3, however, 
the difference in total gel contraction became less marked as the rate of contraction began to 
plateau across all groups. A limiting effect of cell number on gel contraction was not observed 
with an initial seeding density of up to 2 x 105 cells per ml of gel mix.  
3.4.3   Delivery of doxycycline through microneedle-treated Strat-MTM 
The addition of the Strat-MTM membrane into the cell crown insert compartmentalised the 
doxycycline solution from the FPCLs. This prevented the doxycycline from reaching the 
FPCLs and inhibiting gel contraction and MMP activity unlike gels directly treated with 
doxycycline (Figure 3.8). The results suggest that the permeation of doxycycline was 
significantly inhibited by the Strat-MTM membrane for two reasons – (i) there was no statistical 
difference in gel contraction or MMP activity between control and Strat-MTM values on any 
day, and (ii) there was a statistically significant difference in both gel contraction and MMP 
activity between groups treated with doxycycline and those treated with doxycycline 
compartmentalised by Strat-MTM on days 1, 3, 6 and 7 (p < 0.0001).  
To assess the effect of microneedle treatment on enhancing transmembrane diffusion of 
doxycycline solution, the Strat-MTM membrane was firstly treated with microneedles of 250, 
500 or 750 µm in shaft length.  Doxycycline solution was then pipetted onto the membrane’s 
apical surface. Since Strat-MTM had been determined to be impermeable to the doxycycline 
solution, any doxycycline reaching the FPCLs could be attributed to the microneedles 
permeabilising the membrane. Changes in percentage gel contraction and MMP activity acted 
as quantitative biomarkers of this effect (Figure 3.9). Treatment of the Strat-MTM with the 250 
µm microneedles resulted in a statistically significant difference in gel contraction compared 
with untreated (control) Strat-MTM on days 1 and 3 (p < 0.0001), but not on days 6 and 7. 
However, increasing microneedle length beyond this corresponded to a significantly reduced 
total gel contraction for 500 µm (p < 0.001) and 750 µm (p < 0.0001) microneedles compared 
with control on days 1, 3, 6 and 7. There was also a significant difference in percentage gel 
contraction between 250 and 750 µm groups by day 7 (p < 0.0001).  
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3.4.4   Effect of an alternative doxycycline hyclate powder on collagen gel contraction 
To confirm that the effect of doxycycline on the FPCLs was consistent across powders from 
different sources, doxycycline powder from a different supplier (Sigma-Aldrich, Poole, UK) 
was compared with the originally used powder (Alfa Aesar, Massachusetts, USA). No 
significant difference in effect on collagen gel contraction or MMP activity was observed 
between these doxycycline powders from alternative suppliers at varying sub-antimicrobial 
concentrations over a period of seven days (Figure 3.10).  
3.4.5   Effect of microneedling on cell viability 
A concern with the use of microneedling on wounded skin is the possibility of direct injury to 
cells at the site of application that may trigger and propagate apoptotic death signals to 
neighbouring cells. The effect of microneedle application on cell viability (without doxycycline 
application) was investigated firstly in a cell monolayer of fibroblasts cultured on a rigid 
polystyrene substrate and then in the FPCLs. A scratch created by a p200 pipette tip acted as a 
control. In the p200 scratch created in the fibroblast monolayer, cells were found to have been 
removed and displaced from the site of application (Figure 3.11). By 24 hours there was 
evidence of cell migration into the scratch, alongside an increased number of red fluorescent 
(apoptotic) signals in the cells neighbouring the scratch margins. Application of the 
microneedle rollers onto the fibroblast monolayers did not displace the cells as the p200 pipette 
scratch had done, but instead caused punctures in the polystyrene substrate’s surface (Figure 
3.13 – A).  
These punctures matched the tip shape of the microneedle rollers as was observed by the 
micropores created in Strat-MTM membrane in Chapter 2. Expression of apoptotic and necrotic 
signals were observed in the centre of the microneedle punctures, but not at the margins or 
neighbouring cells. (Figure 3.11). In the FPCLs, the p200 pipette tip created a different shaped 
scratch to that made on the fibroblast monolayer (Figure 3.12). There was evidence that the gel 
structure had been displaced but with resistance from the collagen matrix. There was also a 
significant increase in green fluorescent (necrotic) signals around the margins of the scratch. In 
contrast, microneedle application on the FPCLs did not create a puncture but most likely 
transiently displaced the gels due to the elastic recoil of the collagen (Figure 3.13 – B). No 
apoptotic or necrotic signals were observed in microneedle-treated FPCLs 0, 1 or 24 hours after 
initial microneedle application. 
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Figure 3.10 — Comparison of FPCL gel contraction between two different commercially 
available doxycycline powders over a range of sub-antimicrobial concentrations on day 7 
(n = 6). No statistically significant difference in gel contraction was observed between the two 
powders provided by different suppliers (Alfa Aesar and Sigma-Aldrich). Error bars represent 
the standard error of the mean.  
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Figure 3.11 — Cell viability staining using the apoptosis/necrosis detection kit on 
microneedle-treated fibroblast monolayers at 0, 1 and 24 hours. Fibroblast 
monolayers were grown on a polystyrene substrate for 3 days. After 3 days of culturing, 
the microneedle rollers (250, 500 or 750 µm) were applied to the monolayers using a 
standardised vertical force of 3.8N. Monolayers were imaged immediately after 
microneedle application (left)  and then at 1 (centre) and 24 (right) hours after. A scratch 
wound created by a p200 pipette tip acted as a standard control. Red signals indicate 
apoptotic cells, green signals indicate necrotic cells and blue signals indicate healthy 
viable cells. The site of the puncture (physical injury) is outlined in each image.  
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Figure 3.12 — The effect of microneedle application on cell viability on FPCLs. Cell 
viability staining using an apoptosis/necrosis stain on microneedle-treated FPCLs (left). 
Bright field microscopy of microneedle-treated FPCLs immediately after application 
(centre). Bright field microscopy of microneedle-treated fibroblast monolayers 
immediately after application (right). A p200 pipette tip scratch acted as a standard 
positive control. Red fluorescence indicates apoptotic cells, green — necrotic cells, and 
blue — healthy, viable cells.    
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Figure 3.13 — Schematic representation of microneedle application during the  cell 
viability experiments: (A) Microneedles were applied with a downward force of 3.8N 
using a calibrated 500 g mass onto the dermal fibroblast monolayer that had been 
cultured on polystyrene substrate until confluent. This created microscopic punctures on 
the apical surface of the plate. (B) The same process was carried out on the FPCLs. No 
punctures or disturbance to the cells in the FPCLs were microscopically visible. 
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3.5   Discussion 
A three-dimensional cell-enriched collagen matrix, the FPCL, was used as a model of the 
human dermis to investigate the delivery of doxycycline across Strat-MTM membrane using 
microneedle roller systems. FPCL contraction was used an as indirect marker of MMP activity 
and doxycycline-mediated inhibition of MMP activity acted as an indirect marker of the 
doxycycline concentration in the FPCL supernatant. 
3.5.1   Inhibition of MMP-mediated gel contraction and MMP activity in FPCL 
supernatant by doxycycline 
The effect of MMP inhibitors on modulating FPCL contraction is well documented213,252,260,261. 
These include compounds being trialled as anti-cancer drugs such as BMS-275291260, BB94 
(batimastat)261, GM6001 (ilomastat/galardin)252,261 and the antibiotic doxcycline213,261,120. In 
agreement with previous findings, doxycycline was shown to reduce gel contraction of the 
FPCLs in a dose-dependent manner over a period of seven days. A concentration of 416 µM 
doxycycline was chosen based on the work carried out by Franco et al. (2006) and Li et al. 
(2014) wherein the authors showed that this sub-antimicrobial concentration significantly 
reduced contraction in cell-enriched collagen gels by 72 hours and 7 days respectively258,259. It 
has also been reported in numerous studies that removal of the MMP inhibitor from the FPCL 
supernatant resulted in reversal of its effect with FPCLs continuing to contract. To confirm that 
the effect of doxycycline on inhibiting gel contraction was correlated with its inhibition of 
MMP activity, MMP activity was assessed in samples that had been collected from FPCL 
supernatant. As with its effect on gel contraction, doxycycline inhibited MMP activity in the 
FPCL culture medium in a dose-dependent manner over a period of seven days. 
3.5.2   Microneedle-assisted Strat-MTM membrane permeabilisation monitored by 
biomarkers in the FPCL model 
Initially the FPCL model represented the structural and cellular components of the human 
dermis by containing fibroblasts, serum and the fundamental ECM component, type I collagen. 
However, there was no component that mimicked the skin barrier to intradermal drug delivery. 
Strat-MTM membrane, a non-animal derived synthetic membrane, was selected to act as an 
epidermal mimetic due to its reported human-like permeability properties and limited 
evaluations in the literature. From SEM analyses, the Strat-MTM can be structurally subdivided 
into two major layers — a lipophilic upper layer which replicates the structure and biochemical 
behaviour of the SC and a hydrophilic underlying layer that replicates the porosity of the upper 
dermis. When the Strat-MTM membrane was used to compartmentalise the FPCL from the 
doxycycline treatment, it was able to effectively prevent permeation of doxycycline to the 
underlying FPCL. This was determined since gel contraction was not inhibited and there was 
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no statistically significant inhibition of MMP activity compared with control. This corroborated 
the results reported in Chapter 2, wherein the Franz permeation cell study showed no presence 
of doxycycline in the receptor fluid when untreated Strat-MTM was placed into the Franz cell.  
Once the inhibition of Strat-MTM on DOX permeation to the FPCLs had been ascertained, the 
effect of microneedle application on permeabilising the membrane was then investigated. 
Microneedles of 250, 500 and 750 µm in length were applied to the membrane’s apical surface 
using a standardised vertical force of 3.8N. Microneedle application was able to sufficiently 
permeabilise the membrane, providing conduits for the doxycycline solution to diffuse through. 
Instead of directly measuring the amount of doxycycline that permeated to the FPCL, this was 
quantified through doxycycline’s biological effect on reducing gel contraction and inhibiting 
MMP activity. The greater the inhibitory effect, the greater the volume of doxycycline that had 
reached the FPCL. It followed that for a fixed volume of 416 µM doxycycline solution the 750 
µm microneedles permeabilised the Strat-MTM the most to doxycycline over a seven-day 
period, followed by the 500 µm and then 250 µm microneedles. This is in good concordance 
with the previous findings which showed that increasing microneedle length correlated with 
increased total cumulative doxycycline concentration in receptor compartments and an 
increased rate of drug permeation. The reason for this is likely to be two-fold. Longer 
microneedles create micropores with a greater entry area on the membranes apical surface. 
They also are able to penetrate through the entire 300 µm thick Strat-MTM membrane to a 
greater depth, creating a greater micropore annulus than shorter microneedles that may not fully 
penetrate the membrane, or do so to a lesser extent.   
3.5.3   Microneedle application on injured skin and its effect on cell viability 
Undesirable effects such as skin irritation and redness caused by microneedle application are 
difficult to gauge in in vitro systems due to their simplicity compared with the tissues they 
model such as a lack of blood supply. Safety of microneedle application on in vivo human skin 
has been widely investigated. Studies have reported on the pain sensation associated with 
microneedling on human subjects especially in comparison to hypodermic needles166,257. 
Localised irritation, redness, bleeding, crusting, oozing and infection and have also been 
investigated166,262. However, there is little reported in the published literature on the effect that 
microneedle application has on cell viability in in vitro systems. The effect of microneedle 
application on cell viability, especially on injured skin, is indeed an important consideration. 
Early stage pressure ulcers are at high risk of progression and disturbance of the upper layers 
may be enough to initiate that transition.  
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Apoptotic death signals can be propagated to neighbouring cells through connexin gap 
junctions. Gap junction proteins have an implicated role in various chronic ulcers including 
human venous leg ulcers and diabetic foot ulcers253,263. Gap junctions form hemichannels 
believed to be important in potentiating the effects of IR injury. IR injury has been hypothesised 
to cause (i) an up-regulation in the number of hemichannels and (ii) uncontrolled opening of 
these channels254. Through the combination of these effects, cell death can be initiated through 
cell lysis, metabolite loss, ATP leakage and excessive Na+ and Ca2+ influx and the resultant 
stress and apoptotic death signals can be propagated to neighbouring cells via docked 
hemichannels264. Emerging evidence has suggested novel roles of hemichannels in IR injury. 
When these cells are communicating strongly in a stressed state these propagating signals will 
contribute to cell death in that area. If microneedle application stresses the cells and initiates a 
cascade of apoptotic death signal transduction it could possibly potentiate ulcer development. 
The effect of microneedle application on fibroblast viability when applied against different 
surfaces was investigated in this study. Scratch assays are typically used to monitor cell 
migration of confluent layer of cells265, for example, in response to small molecules in search 
for therapeutics266. The first substrate assessed was a confluent fibroblast monolayer grown on 
a polystyrene tissue culture plate. This acted as a hard rigid surface against which to apply the 
microneedles. A control scratch, made by scraping a p200 pipette across the monolayer, did not 
cause a significant loss in cell viability but rather displaced the cells creating a gap within the 
monolayer. Surrounding viable cells were observed to migrate into the gap within in 24 hours. 
This migratory behaviour is a standard response of healthy and proliferating cells, as been 
reported in the literature265.  
With microneedle application against the hard surface, there was very little depth penetration 
and, instead of displacing cells, a puncture was created in the substrate killing the cells directly 
contacted. After 24 hours there was no evidence of apoptosis or necrosis beyond the initial 
injury site. On the soft FPCL surface the control scratch, by the p200 pipette tip, disrupted the 
collagen matrix, creating a hole with necrotising cells observed around its perimeter. The 
microneedles, however, did not cause any microscopically observable disruption to the collagen 
matrix or cells, nor to the underlying polystyrene substrate. It is plausible that during 
application, the microneedle tips did not pierce through the FPCL meniscus, but rather 
compressed it. This is most likely due to the compressibility of the FPCL that mimics the 
structural integrity of the collagen-filled dermis. The results from the scratch wound models 
suggest that microneedle application in this in vitro system does not cause significant cellular 
damage in the FPCL after 24 hours with a vertical application force of 3.8N and that puncture 
injury is surface-dependent. 
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Despite valid concerns surrounding safety, microneedling has been reported to have desirable 
responses on cell behaviour and ECM structure in sensitive skin191,262,267. Positive results with 
facial skin resurfacing in acne scar treatment have been observed and microneedling has been 
shown to improve skin appearance and encourage proliferation in previously or persistently 
inflamed skin, both alone and in conjunction with other therapies. Authors have also reported 
minimal irritation and redness that subsides165,166, though bleeding, crusting and oozing after 
microneedle application on certain skin has been observed (Figure 3.14)262. This is likely to be 
highly dependent on microneedle length. Direct comparison between studies is difficult due to 
differences in the microneedles used, the anatomic site of application and the force of device 
insertion. One of the major attributes of a good penetration enhancer is that it should be non-
irritant, as well as non-toxic and non-allergenic. Though much of the literature suggests that 
microneedling achieves this, more experiments involving its effect on chronic wounds need to 
be carried out. 
3.5.4   Potential side effects of cutaneous doxycycline treatment 
Doxycycline has well-documented side effects which includes skin sensitivity to UV light. As 
the intended application is cutaneous it is responsible to explore the potential problems this may 
create. A large proportion of the target patient population for doxycycline-based pressure ulcer 
Figure 3.14 — Blood spotting after facial application with a microneedle roller 
system. From “Microneedling: Advances and widening horizons,” by A. Singh and S. 
Yada, 2016, Indian Dermatology Online Journal, 7, p. 246. 
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chemotherapy are hospitalised and immobilised so are generally protected from sunlight. 
Additionally, pressure ulcer sites are typically covered with hospital garments and wound 
dressings protecting them from the effects of indoor lighting. Notably, local and not systemic 
doxycycline delivery may prevent generalised photosensitivity. However, side effects can only 
be speculated and not ascertained at this stage without the appropriate clinical trials.  
3.6   Future work 
3.6.1   Improving the FPCL model and scratch wound assay 
Future work should involve improvements to the FPCL model. The current FPCL model 
presented here has several limitations. One of its major criticisms is that it represents fibroblasts 
in a healthy, proliferative state with no external stressors on the cells.  Ischemic cells are likely 
to respond very differently to healthy cells.  Thus, the model should better replicate the pressure 
ulcer microenvironment with the appropriate cells and stimuli. This could be achieved through 
harvesting dermal fibroblasts from the wound beds or exudate of late stage pressure ulcers, or, 
through obtaining excision biopsies of tissue from early stage ulcers and out-growing them 
from the explant. This sort of FPCL model would better reflect the behaviour and secretion 
profiles exhibited in the chronic wound state. 
The scratch wound assay for assessing the effect of microneedling on cell viability also has 
several limitations. The microneedles are only being applied to the dermal equivalent portion 
of skin since there is no epidermal component included in the model (i.e. no keratinocytes). 
Though the Strat-MTM membrane is being used as model for the human epidermis, it itself is 
acellular. Bi-layered epidermal-dermal equivalents, compatible with the FPCL do exist 
however, where keratinocytes are seeded at the air interface between the FPCL and the culture 
medium surface268. This could be used to better investigate the effect of microneedling on the 
epidermal portion of cells. 
3.6.2   Creating MMP-specific expression and activity profiles and using MMP-specific 
inhibitors 
The use of MMP and/or TIMP multiplex profiling could be used to determine the exact activity 
profile and concentration ranges of MMPs already present in the FPCL supernatant and to what 
extent they are inhibited by doxycycline treatment (though this technique would be best suited 
in a model that better reflects the ulcer environment). A major assumption of the current model 
is that all MMPs behave the same, but the activity and/or expression of MMPs may not increase 
at the same amount and doxycycline has also been shown to inhibit different MMPs to different 
extents269. Preliminary work has been carried out to assess the profile of specific MMPs in the 
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FPCL model using a technique known as zymography (Appendix D — MMP zymography of 
FPCL supernatant, p. 261). 
Though doxycycline appears to be a suitable active drug in the treatment of pressure ulcers, the 
fact that it acts as a broad-spectrum MMP inhibitor may prove problematic if only specific 
MMPs need to be inhibited. One way to achieve this is through the use of MMP-specific 
inhibitors, especially against the MMPs of most interest in chronic wounds — MMPs 2, 8 and 
9. The effect of inhibiting each MMP on different aspects of FPCL behaviour can then be
investigated individually.
3.7   Conclusion 
This chapter has outlined the development of an in vitro model of human dermis, the FPCL, in 
combination with the Strat-MTM membrane acting as an epidermal barrier to drug permeation. 
The FPCL is a simple, economical and reproducible model of the human dermis. This is the 
first study to report enhanced delivery of doxycycline through microneedled Strat-MTM
membrane to FPCLs. While Chapter 2 focussed on an absolute permeation profile under infinite 
dose conditions, this body of work aimed to explore how the permeability of Strat-MTM to 
doxycycline could be assessed by biological markers of its activity in an in vitro system. This 
should give better indication of how doxycycline treatment may translate into in vivo 
experiments using clinically realistic concentrations and observing a biological response. In all, 
the current model is suitable as a preliminary in vitro drug assay but requires further 
development to better replicate the pressure ulcer microenvironment. 
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Chapter 4   Modelling the Pressure 
Ulcer Microenvironment in an In 
Vitro FPCL system 
4.1   Introduction 
There are several pathophysiological molecular mechanisms which together drive the onset, 
development and chronicity of pressure ulcers. These include the molecular effects of ischemia-
reperfusion (IR) injury (induced by cycles of blood occlusion), local recruitment of 
inflammatory cells and the direct mechanical effects of intermittent loading on the skin tissue 
over prolonged periods of time. These features can be factored into in vitro dermal tissue 
equivalent models to better replicate the pressure ulcer microenvironment and the conditions 
leading up to their development.  
4.1.1   Application of external pressure onto the FPCLs 
Intermittent pressure on the skin over prolonged periods of time is a key risk factor in the 
development of pressure ulcers. The pressure associated with ulcer development is not 
traumatic — it is not great enough to crush muscle or bones — but it is sufficient to occlude 
blood flow and cause mechanically-induced damage to the tissue18. The pressure required to 
instigate pressure ulcer development has not been clearly defined but is often linked to the 
human capillary critical closing pressure (CCP) of 32 mmHg35. Application of pressures greater 
than or equal to 32 mmHg for two hours has been shown to cause local ischemia, with periods 
of more than six hours leading to tissue necrosis270. Capillary CCP is the minimum pressure 
required to occlude blood flow within the capillaries that supply regional body tissues including 
the skin. However, the exact pressure exerted at sites where pressure ulcers eventually develop 
in patients will vary from individual to individual and is also likely to be greater than the 
capillary CCP threshold. The pressure exerted on the skin is dependent on several factors:- the 
mass of patient and its distribution, for example whether the mass is concentrated on a single 
point like over a bony prominence such as the heel or sacrum, and the rigidity of the external 
support surface such as the mattress or wheelchair271. Moreover, the pressure required to 
potentiate pressure ulcer development may be less than the CCP threshold in particularly 
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vulnerable patients who have other major risk factors such as very fragile aged skin and co-
morbidities such as vascular disease272.  
The effect of mechanical loading on fibroblasts in skin can be simulated by applying external 
pressure onto the collagen gels. In an in vitro fibroblast-populated collagen lattice (FPCL) 
model using ocular fibroblasts, the pathological pressure associated with Grave’s orbitopathy, 
a disfiguring eye disease, was simulated on collagen gels using a metal insert273. This insert had 
been designed to deliver a pressure onto the gels equivalent to the injurious pressure reported 
in Grave’s orbitopathy of 28 mmHg. The authors reported that this pressure had an effect on 
the contractile and protein expression profiles of the cellularised collagen gels. Since a pressure 
of 32 mmHg is enough to incite blood occlusion in human skin it is reasonable to introduce this 
into the FPCL model to replicate the effect of ulcer-inducing pressure.  
4.1.2    Recruitment of inflammatory cells at the wound site 
Another component deemed integral in pressure ulcer etiopathogenesis and chronicity is the 
recruitment and presence of inflammatory cells in the injured tissue109. Inflammation is a 
fundamental step in normal wound healing and the crosstalk between fibroblasts and 
inflammatory cells including macrophages and neutrophils drives several important processes 
before the proliferative stage of healing can take place244. Neutrophils release proteolytic 
enzymes responsible for digesting invading bacteria and removing non-viable cellular debris274. 
Macrophages are cytokine-producing immune cells that affect surrounding cells at injured sites, 
including the resident fibroblasts. Monocytes circulating in the bloodstream are stimulated to 
differentiate into macrophages by stress signals released from the wound site. Macrophages 
then migrate into the injured tissue where they release cytokines and enzymes to mediate 
inflammatory processes. Activated macrophages increase local matrix metalloproteinase 
(MMP) levels through secretion of collagenases, that help debride the wound, and activation of 
fibroblasts83,109,275,276. They also stimulate fibroplasia and fibroblast-mediated collagen 
production through secretion of tumour necrosis factor (TNF), interleukins, and synthesis of 
nitric oxide57. 
Even though inflammation is essential to wound healing, prolonged unabated inflammation 
with no progression to the proliferative stage is not conducive to healing and, in fact, results in 
tissue damage. Studies investigating chronic wound fluid composition have reported 
significantly higher levels of proteolytic and collagenolytic activity compared with healing 
dermal wounds102,104,111. This indicates that high levels of MMP activity are linked to the non-
healing characteristic of chronic wounds. In the original FPCL model outlined by Bell et al. 
(1979), the collagen gels were exclusively populated with fibroblasts250. However, in isolation 
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from immune and inflammatory cells, fibroblast behaviour is far from what would be exhibited 
as a pressure ulcer develops. Macrophages can be introduced into collagen gels in co-cultures 
with fibroblasts to produce fibroblast and macrophage-populated lattices (FMPCLs). The 
interaction and response of fibroblasts to the presence of macrophages should better simulate 
the cell behaviour that would be exhibited within a site where a pressure ulcer develops. 
4.1.3   Effect of glucose deprivation on pressure ulcer development 
Under raised tissue pressure, ischemia induces hypoxia and glucose deprivation leading to 
compromised cellular function since vital nutrients cannot reach the cells and cellular waste 
cannot be transported away90. The result is cell starvation, necrosis — unprogrammed cell death 
— and tissue loss65. Furthermore, wound healing is an energy-dependent process which 
requires an adequate supply of adenosine triphosphate (ATP)57. The proliferative phase of 
wound healing in particular requires increased metabolism and protein synthesis for tissue 
repair. This, in turn, requires a rich blood supply of oxygen and glucose. In the absence of a 
continual supply of these nutrients, wound healing is impaired57. Glucose deprivation can be 
simulated in the FPCL model by culturing the collagen gels in glucose-free culture medium. 
The effect on protein expression, collagen biosynthesis, gel contraction and matrix degradation 
can then be monitored under these conditions277,278. 
4.2   Research outline 
In Chapter 3, it was shown how sub-antimicrobial concentrations of doxycycline were able to 
reduce MMP-mediated gel contraction in the FPCL model. However, the model was comprised 
of a normal population of fibroblasts that were not exposed to the same external and internal 
stressors responsible for pressure ulcer etiopathogenesis. To better replicate the pressure ulcer 
microenvironment these stressors can be introduced to the FPCLs, individually and in 
combination. This chapter outlines a series of experiments wherein macrophages, glucose 
deprivation and external pressure were introduced into the model (Figure 4.1). It was 
anticipated that these three processes would have a significant impact on the gel’s contractile 
profile by augmenting MMP activity and by potentially affecting other processes. The ability 
of doxycycline to counteract any changes was also explored. 
Firstly, macrophages were resuspended with fibroblasts to form a fibroblast-macrophage co-
culture which was then used to cellularise the gels. The macrophages were derived from 
monocytes by phorbol myristate acetate (PMA) stimulation. The effect of macrophages on gel 
contraction and MMP activity was assessed. It was also important to assess the effect of 
macrophages alone on gel contraction to rule out any contractile behaviour they may have. 
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Secondly, external pressure was applied to FPCLs  using a custom-made metal insert based on 
the work carried out by Li et al. (2014) in their model of Grave’s orbitopathy273. A pressure of 
32 mmHg was applied for 1.5 hours before being removed, equivalent to the period of time 
reported between patient turning in the hospital setting3. The effect of compression on FPCL 
contraction, MMP activity and cell viability was explored. Finally, FPCLs underwent glucose 
deprivation by culturing them in glucose-free medium. The effect of pre-conditioning the 
FPCLs to glucose deprivation was also assessed. In all, the results in this modified FPCL model 
provided indications on which mechanisms implicated in pressure ulcer development result in 
significant changes in gel contraction and MMP activity making them most treatable by 
doxycycline. 
External stressors
FPCLs v. FMPCLs
FPCLs and compression
FPCLs and glucose 
deprivation
EXP 
1.
EXP
2.
EXP
3.
Figure 4.1 — Schematic summarising the three arms of experiments carried out in 
Chapter 4 which investigate the effect of external stressors on FPCL contractile 
behaviour and local MMP activity: (i) the effect of introducing macrophages on the 
FPCLs, (ii) the effect of 1.5 hours of external pressure on the FPCLs, and (iii) the effect of 
glucose deprivation on the FPCLs. 
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4.3   Methods and materials 
4.3.1   Human dermal fibroblasts 
Please refer to Method 3.3.1, p.118. 
4.3.2   U937 monocytes 
Cell culture 
U937 monocytes are human monocytes that were originally harvested from the lymphoma of a 
cancer patient and are routinely used to study the differentiation and behaviour of monocytes. 
Under specific conditions, U937 monocytes can be stimulated to differentiate into activated 
macrophages which exhibit a different morphology, cytokine secretion profiles and adherence 
properties compared with their precursor279,280. U937 monocytes (American Type Culture 
Collection, Vancouver, USA) were grown in suspension in complete Rosswell Park Medical 
Institute (RPMI)-1640 medium (Sigma-Aldrich, Poole, UK) supplemented with 10% (v/v) FBS 
(Gibco, Paisley, UK) in vented T75 cm2 flasks (Thermo Fisher Scientific, Loughborough, UK). 
Their environment was maintained at 37oC and 5% CO2 in a fully-humidified incubator. Cell 
suspension density was maintained between 1 x 105 and 2 x 106 cells per ml by regular counting 
with trypan blue every three days. Excess cells were aspirated and the culture replenished with 
fresh medium.  
Stimulating U937 monocyte differentiation using phorbol myristate acetate (PMA) 
Phorbol myristate acetate (PMA) is a compound that can stimulate monocyte differentiation to 
macrophages by mimicking an activator of protein kinase C (PKC). Activation of PKC initiates 
a signal transduction pathway which induces adherence, cell cycle arrest and differentiation281. 
PMA powder (Sigma-Aldrich) was dissolved in an aqueous solution to create a 5 mM PMA 
stock. PMA stock was diluted at 1% (w/v) in RPMI medium to create a 5 µM PMA solution. 
A final concentration of 150 nM PMA was made by adding the 5 µM PMA solution to RPMI 
medium containing 2 x 106 of monocytes and making up the remaining volume with RMPI 
medium. Cells were cultured in vented T75 cm2 flasks (Thermo Fisher Scientific) for 72 hours 
at 37oC and 5% CO2 in a fully-humidified incubator. After 72 hours of differentiation, cell 
media and floating undifferentiated cells were aseptically aspirated and replenished with fresh 
medium. Cells were left to differentiate for a further 48 hours. Differentiated cells adhered to 
the flask and appeared as grape-like clumps. They were detached by washing once with PBS 
and treatment with trypsin-EDTA solution [0.02 mM trypsin-0.48 mM EDTA 4Na 2H2O 
solution (Sigma-Aldrich)], followed by removal of remaining cells from the bottom of the flask 
using a sterile cell scraper (Sigma-Aldrich). The cell-trypsin suspension was neutralised with 
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complete RPMI medium and viable cell count determined by trypan blue exclusion staining 
using a hemocytometer. 
4.3.3   Co-culture of differentiated monocytes with dermal fibroblasts 
Volumes of medium containing 1 x 105 human dermal fibroblasts and 1.5 x 105 differentiated 
U937 monocytes were added together in a 30 ml Universal tube. The cells were pelleted by 
centrifugation at 1500 rpm for 5 minutes at room temperature. The cell pellets were resuspended 
in 100 µl of FBS or in 100 µl of serum-free DMEM for non-FBS treated groups. Collagen gels 
were synthesised as previously described (Method 3.3.2, p. 119) using 100 µl of the re-
suspended fibroblast-macrophage co-culture in place of 100 µl of fibroblasts. Fibroblast to 
macrophage ratios of 1:2 and 1:4 were also used. 
4.3.4   Mechanical loading of FPCLs using a bespoke metal insert 
Collagen gels, populated exclusively with fibroblasts (FPCLs) were allowed to polymerise 
within the microwells of MatTek plates (MatTek Corp., Massachusetts, USA) for 1 hour. 
External pressure, equivalent to the capillary closing pressure of 32 mmHg, was applied to the 
gel using a custom-made brass rod as a metal insert.  The rod was designed with a 10mm 
diameter — to match the diameter of the MatTek plate’s microwell — and had a mass of 32.4 
g to deliver the target pressure based on the rod’s density and height. 
Figure 4.2 — Schematic representation of the two types of collagen gels. Collagen 
gels populated exclusively with fibroblasts (FPCLs) (right) and cellularised with a 
fibroblast-macrophage co-culture (FMPCLs) at a ratio of 1:1.5 (left). 
FPCL FMPCL
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The rod was applied to the FPCL by firstly laying a fine sterile fabric mesh and a 10 mm 
diameter coverslip on top of the gel’s apical surface, followed by careful placement of the rod 
on top (Figure 4.3). The coverslip and the mesh prevented the gel from sticking to the coverslip. 
The rod was secured in place by a custom holder to prevent it from moving. One ml of complete 
DMEM (for untreated FPCLs) or 416 µM doxycycline solution (for treated FPCLs) was 
pipetted into the well. Wells without FPCLs had the experimental solution and the compression 
apparatus added to serve as background controls for MMP activity. Due to the height of the rod 
and the presence of a holder, the experimental apparatus needed to be placed into a vented 
container to maintain sterility whilst in the incubator. The container with the apparatus inside 
was incubated at 37oC with 5% CO2. After 1.5 hours the rods, along with the coverslips and net 
mesh, were carefully removed from the gels and the plates returned to the incubator for the 
remainder of the experiment.  
4.3.5   Assessing the effect of mechanical loading on cell viability in FPCLs 
Cell death in FPCLs that experienced mechanical loading was quantified using the ‘Live/Dead 
Viability and Cytotoxicity’ assay (Molecular ProbesTM, Oregon, USA) for mammalian cells, a 
fluorescence-based kit designed to differentiate between live (viable) and dead (non-viable) 
cells. Calcein-AM is used to distinguish live cells while ethidium homodimer-1 (Ethd-1) is used 
to distinguish dead cells. The non-fluorescent calcein-AM is enzymatically converted to the 
highly fluorescent calcein by intracellular esterase activity and is retained within the live cells. 
Ethd-1 enters dead cells with damaged membranes becoming fluorescently enhanced by 
Figure 4.3 — Schematic representation of the compression apparatus used to apply 
external pressure onto the collagen gel. The custom-made brass rod had a 10 mm 
diameter to match that of the microwell.  
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binding to their nucleic acids but is excluded by the intact plasma membranes of live cells. 
Together these stains are able to provide superimposable fluorescence signals that identify 
specific regions of cell death amongst healthy cells. 
For the assay, medium was aspirated from the FPCLs, which were then gently washed with 
sterile phosphate-buffered saline (PBS). A staining mixture consisting of x1 Dulbecco's PBS 
[10 mM PO43−, 137 mM NaCl, 2.7 mM KCl] (Sigma-Aldrich) with 0.2% (v/v) Ethd-1 [2 mM 
in DMSO/H2O 1:4 (v/v)] and 0.1% (v/v) Calcein-AM [4 mM in anhydrous DMSO] was added 
onto the gels and allowed to stain for 1 hour at room temperature protected from light. The 
staining mixture was then aspirated from the FPCLs and the FPCLs gently washed again with 
PBS. Stained gels were imaged under a fluorescent microscope (Leica DMI6000 B; Leica 
Microsystems) with an N PLAN 10.0 x 0.25 dry objective. The fluorescence from these dyes 
was observed separately. Calcein-AM was excited by a 488 nm (L5 cube) wavelength laser 
producing a green fluorescent signal in the cell cytoplasm and Ethd-1 by a 647 nm (Y3 cube) 
wavelength laser producing a red fluorescent signal. Images of the two fluorescent signals were 
overlaid to determine regions of cell death in the gels and relative proportions of live to dead 
cells. Six regions of interest (ROIs) of 250 µm x 250 µm were randomly selected from six 
different composite images of control gels and gels that had been exposed to an external 
pressure of 32 mmHg. The number of live and dead cells was measured using ImageJ® 
(National Institutes of Health [NIH], Maryland, USA). The ‘colour threshold’ and ‘analyse 
particles’ tools outlined and counted the cells with thresholds based on fluorescence intensity, 
size and circularity. The proportion of live and dead cells was then calculated as a percentage 
of total cells.  
4.3.6   Depriving FPCLs of glucose 
Glucose deprivation is a consequence of occlusion of blood flow through the capillary networks 
that supply the skin and can be brought about when high enough pressure is exerted onto the 
blood vessels. FPCLs were exposed to glucose deprivation by culturing them in glucose-free 
medium (Gibco). FPCLs were cultured in the usual high-glucose DMEM (4.5mg/ml [25 mM] 
glucose). All DMEM was supplemented with (v/v) 10% FBS (Gibco) and (v/v) 1% of PSA [10, 
00 units/ml penicillin, 10 mg/ml streptomycin, 25 µg amphotericin B] (Sigma-Aldrich) and 
contained 584 mg/ml [4 mM] L-glutamine. FBS was included in the culture medium since it 
had already been determined in FPCL models that there was no fibroblast-mediated gel 
contraction in the absence of FBS282 and this was corroborated by preliminary results reported 
here.  A separate set of fibroblasts were pre-conditioned to glucose deprivation by sub-culturing 
them in the absence of glucose for four days prior to the experiment.  
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4.3.7   Gel contraction analysis 
Digital photographs of the gels were taken on days 1, 3, 6 and 7 and analysed for percentage 
gel contraction as previously described (Method 3.3.2, p. 119). 
4.3.8   MMP activity assay analysis 
Supernatant (75 µl) collected from the samples on days  0, 3 and 7 were analysed by the MMP 
activity assay as previously described (Method 3.3.3, p. 121). 
4.3.9   Statistical analyses 
For each condition there were six replicates (unless otherwise stated) to allow for experimental 
variation. Data were analysed using a two-way ANOVA with Tukey correction for multiple 
comparisons. Averages are represented by the mean ± standard error of the mean (SEM). In all 
instances, p < 0.05 denotes a statistically significant difference. 
4.4    Results 
4.4.1   Effect of fibroblast-macrophage co-culture on collagen gel behaviour 
Monocytes were stimulated to differentiate into activated macrophages using PMA and were 
then introduced into the collagen gels in co-culture with dermal fibroblasts (Figure 4.4). The 
results show that the presence of macrophages in the co-culture (FMPCLs)  significantly 
increased gel contraction compared with gels populated with fibroblasts alone (FPCLs) (p < 
0.0001) (Figure 4.5 – A). Additionally, macrophages were able to induce gel contraction even 
in the absence of FBS (the component of culture medium required for gel contraction in the 
original FPCL model) (Figure 4.5 – B). However total gel contraction was significantly 
reduced compared with serum-treated FMPCLs. In the absence of FBS, FPCLs experienced 
negligible contraction by day 1 and did not show their typical contractile profile over the seven-
day experiment remaining at around 5% gel contraction throughout. A range of fibroblast to 
macrophage co-culture ratios was used to investigate whether increasing the number of 
macrophages to fibroblasts augmented gel contraction and MMP activity (Figure 4.6 – A and 
B). This was shown not to be the case and maximum contraction was observed with a ratio of 
1:1.5 fibroblasts to macrophages.  
Doxycycline solution (416 µM) was added to the FPCLs and FMPCLs to compare its inhibitory 
effect on gel contraction between the two gel types. A macrophage to fibroblast ratio of 1:1.5 
was chosen for the FMPCLs since it had had the greatest effect on augmenting gel contraction 
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observed in the FPCLs compared with other ratios. In the FMPCLs, doxycycline significantly 
inhibited gel contraction over the seven-day experiment (p < 0.0001) (Figure 4.7 – A). Gel 
contraction of doxycycline-treated FPCLs was significantly less than doxycycline-treated 
FMPCLs on days 1, 3 6 and 7 (p < 0.0001) (Figure 4.7 – B). For MMP activity, doxycycline 
treatment significantly inhibited the increase in MMP activity observed in the FMPCLs on days 
3 and 7 (p < 0.0001). 
FPCL FMPCL
Figure 4.4 — FPCLs and FMPCLs were stained for viable cells with calcein-AM 
(green fluorescent signal) after 72 hours of incubation: (A) FPCLs are seen with 
fibroblast of spindle-shaped morphology. (B) Collagen gels populated with a co-culture 
of dermal fibroblasts and macrophages (FMPCLs) at 1:1.5 ratio. Macrophages have a 
more rounded morphology and are found in grape-like clumps. Due to the co-culture 
there are considerably more cells in the FMPCLs than the FPCLs. Background signals 
are caused by auto-fluorescence from the collagen gel. 
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Figure 4.5 — Effect of co-culturing dermal fibroblasts [FB] with macrophages [Mφ] 
on FPCL gel contraction (n = 6): (A) Co-cultures of fibroblasts and macrophage as 
FMPCLs at a ratio of 1:1.5, 1:2 and 1:4 incubated in FBS-enriched DMEM resulted in 
significantly increased gel contraction on days 1, 3, 6 and 7 compared with fibroblast-
only gels (FPCLs). Macrophage-only gels did not show any contractile behaviour. (B) 
FMPCLs grown in FBS-free DMEM resulted in significantly reduced contraction 
compared with those grown in FBS-enriched medium. FPCLs and macrophage-only gels 
exhibited negligible contraction under serum-free conditions. Error bars represent the 
standard error of the mean; ** p < 0.01, *** = p < 0.001 **** = p < 0.0001.  
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Figure 4.6 — Effect of co-culturing dermal fibroblasts [FB] with macrophages 
[Mφ] on MMP activity (n = 6): (A) MMP activity profiles of FMPCLs were 
significantly greater than that of FPCLs. Macrophage-only gels did not show an increase 
in MMP activity levels. (B) For gels grown in FBS-free medium, MMP activity was 
dramatically reduced for FMPCLs while FPCLs and macrophage-only gels did not show 
any increase in MMP activity. Error bars represent the standard error of the mean; ** 
= p < 0.01, **** = p < 0.0001 and denotes statistically significance in comparison to 
fibroblast-only gels (FPCLs). 
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Figure 4.7 — Effect of doxycycline treatment (416 µM) on gel contraction and 
MMP activity in FPCLs compared with FMPCLs (n = 6): (A) Treatment with 416 
µM doxycycline significantly reduced gel contraction in both FPCLs and FMPCLs to  a 
similar extent over the seven-day experiment. (B) Doxycycline  treatment significantly 
inhibited the increase in MMP activity measured in the FMPCL supernatant, which was 
greater compared with the FPCL on days 3 and 7. Error bars represent the standard 
error of the mean; * = p <0.05, ** p < 0.01, **** = p < 0.0001. 
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4.4.2   Effect of mechanical loading on FPCLs 
FPCLs were subjected to external pressure through the application of a custom-made rod onto 
their apical surface. The rod was designed to deliver a pressure of 32 mmHg onto the FPCLs 
equivalent to human capillary CCP. The pressure was applied for 1.5 hours, in concordance 
with the time period between patient turning reported in the literature. Control FPCLs and 
FPCLs treated with 416 µM doxycycline solution were observed to contract as previously 
reported (3.4.1 Results, p. 125). However, FPCLs treated with an external pressure of 32 
mmHg for 1.5 hours exhibited significantly reduced gel contraction compared with control (p 
< 0.05) with 12.7 ± 1.1%, 22.8 ± 1.4%, 23.0 ± 1.6% and 24.4 ± 0.4% gel contraction on days 
1, 3, 6 and 7 respectively (Figure 4.7) (Figure 4.9 – A). Treatment with 416 µM doxycycline 
solution on these gels did not significantly inhibit gel contraction, with 8.48 ± 1.1%, 18.6 ± 
1.4%, 18.3 ± 1.6% and 18.6 ± 2.4% gel contraction observed on days 1, 3, 6 and 7 respectively. 
As with the gel contraction profiles, the control FPCLs and FPCLs treated with 416 µM 
doxycycline solution exhibited the expected pattern of MMP activity (as previously reported in 
Figure 3.6 – B). Control gels showed an increase in MMP activity from days 0 to 7 while gels 
treated with doxycycline had MMP activity levels maintained at levels similar to day 0 (Figure 
4.9 – B). Gels that underwent mechanical loading exhibited a continual reduction in MMP 
activity between days 0 and 7.  
Figure 4.8 — Digital photographs mapping the gel contraction of FPCLs and 
FPCLS that experienced mechanical loading on days 1, 3 and 7. FPCLs were seeded 
into microwells [MW] on day 0. Control FPCLs [CTRL] that were not exposed to 
pressure followed the normal contractile pattern over the seven-day experiment. 
Compressed FPCLs that were exposed to an external pressure of 32 mmHg for 1.5 hours 
(EP [1½h]) contracted slightly by day 3 but did not contract any further by day 7.  
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Figure 4.9 — Effect of mechanical loading through application of external pressure 
[EP] on FPCLs (n = 6): (A) Control FPCLs and FPCLs treated with 416 µM 
doxycycline solution followed the previously reported contractile pattern. Application 
of EP (32 mmHg for 1.5 hours) on the FPCLs resulted in significantly reduced gel 
contraction (p < 0.0001) on all days compared with control FPCLs, with no further 
contraction beyond day 3. FPCLs which experienced mechanical loading and that were 
then treated with 416 µM doxycycline did not exhibit significantly inhibited gel 
contraction compared with those that did not receive any doxycycline treatment. (B) 
Treatment with 416 µM doxycycline inhibited the increase of MMP activity in FPCLs 
on days 3 and 7. FPCLs that had experienced mechanical loading showed a significant 
drop in MMP activity levels that was not affected by treatment with doxycycline. Error 
bars represent the standard error of the mean; **** = p < 0.0001  and represents 
statistical significance compared with control FPCLs [CTRL] . 
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Figure 4.11 — Proportions of the cell population that stained as live or dead in 
FPCLs after mechanic loading (n = 6). The bar graph shows the comparison between 
FPCLs that did not experience external pressure (EP) and FPCLs that had experienced 
an EP of 32 mmHg for 1.5 hours. Mechanical loading resulted in a significantly increased 
proportion of cells that stained as dead. Error bars indicate the standard error of the 
mean; *** = p <0.001 and represents a statistical difference compared with control 
FPCLs.  
Figure 4.10 — Effect of mechanical loading on cell viability in FPCLs using 
the live/dead detection staining. An external pressure of 32 mmHg was applied onto 
the FPCLs for 1.5h followed by a 24-hour incubation period at 37oC. FPCLs were 
then stained with Ethd-1 and calcein-AM. Green fluorescence signals indicate live 
cells and red fluorescence signals indicate dead cells. 
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The effect of mechanical loading on cell viability in control gels was assessed 
using fluorescence staining that distinguished between live and dead cells (Figure 4.10). 
Gels that underwent mechanical loading for 1.5 hours at 32 mmHg had a significantly greater 
proportion of dead to live cells compared with control gels (Figure 4.11). The gels were 
also notably thinner and flatter compared with control gels when observed microscopically 
under the same field of view and had a reduced number of planes from the top-most to 
bottom-most planes at consistent increments.  
4.4.3   Effect of glucose deprivation on FPCL contractile behaviour 
In the glucose deprivation experiments, FPCLs containing unconditioned or pre-conditioned 
fibroblasts were cultured in glucose-free medium. No statistical difference was observed 
between the contraction profiles of high-glucose and glucose-free groups during the seven-day 
experiment (Figure 4.12). There was also no significant difference between the gels containing 
pre-conditioned and unconditioned cells over this same period.  
Figure 4.12 — Comparison of gel contraction between FPCLs cultured in glucose-
enriched medium (Control), glucose-free medium with unconditioned fibroblasts 
(GF) and with pre-conditioned fibroblasts [GF(PC)] on days 1, 3 and 7 (n = 6): (A) 
In untreated FPCLs, no statistically significant difference in gel contraction was 
observed between the three groups. (B) For FPCLs treated with 416 µM doxycycline 
solution, no statistically significant difference in gel contraction was observed between 
the three groups. Error bars indicate the standard error of the mean. 
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4.5   Discussion 
Pressure ulcers are chronic non-healing wounds characterised in their later stages by large open 
sores filled with proteolytic exudate. In the earliest stages, pressure ulcer development is 
instigated by: (i) external stressors, (ii) several normal physiological mechanisms that become 
aberrant under stress, (iii) in combination with the appropriate patient risk factors. IR injury, 
which is caused by on-going cyclic mechanical loading on the skin at pressures greater than or 
equal to capillary CCP, is currently believed to be the main cause of pressure ulcer 
development95. IR injury results in tissue breakdown and prolongs the inflammatory stage of 
wound healing. Additionally, the mechanical loading responsible for the IR injury is itself 
reported to cause direct physical damage to cells and tissues18. These stressors can be included 
in tissue equivalent models to better predict the effect that potential therapeutic drugs would 
have in inhibiting, reversing or resolving the associated pathological mechanisms in vivo. In 
this chapter, mechanical loading, activated macrophages and glucose deprivation were 
introduced to the FPCLs through modifications to the original model by Bell and colleagues250. 
4.5.1   Macrophage co-culture and FMPCL contractile behaviour 
Macrophages significantly augmented the initial rate of contraction of FMPCLs compared with 
FPCLs. By adding activated macrophages in co-culture with fibroblasts, the rate of gel 
contraction between days 1 and 3 was greater than that seen with fibroblasts alone (p < 0.0001). 
Additionally, total gel contraction by day 7 was significantly greater in the FMPCLs than the 
FPCLs. This was as expected, since macrophages are known to bolster MMP levels85, including 
collagenases, and this was further corroborated by the MMP activity profiles which showed 
that the presence of macrophages caused a marked and significant rise in MMP activity (p < 
0.0001). Notably, macrophages on their own did not exhibit any contractile properties since 
they lack the contractile apparatus to do so. They also did not significantly increase MMP levels 
on their own. This suggested that their effects were mediated through their interactions and 
signalling with the fibroblasts. When a wound is created, macrophages are recruited to the site 
of tissue injury and communicate with the resident fibroblasts as part of an inflammatory 
response. Since pressure ulcers are known to be in a persistent inflammatory state, interaction 
and modulation of behaviour between the activated macrophages and fibroblasts are likely to 
be significant. 
FPCLs were cultured in serum-free media to assess the effect of macrophages on fibroblast 
behaviour and MMP activity in the absence of FBS. Removal of serum from the culture medium 
resulted in negligible contraction of FPCLs since FBS is a crucial component of the FPCL 
model268,282. Additionally, MMP activity levels did not significantly increase in FPCL 
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supernatant in the absence of FBS. For the FMPCLs, however, the macrophages were able to 
potentiate fibroblast-mediated gel contraction and were able to continuously increase MMP 
activity between days 0 and 7. Since gel contraction had not plateaued by day 7, a feature that 
normally occurs in FBS-treated FPCLs, it suggested that the FMPCLs would have continued to 
contract over an extended experimental time frame.  
Even though it was anticipated that a greater density of macrophages would significantly 
increase initial gel contraction, this was not the case and in serum-free groups the highest ratio 
of fibroblasts to macrophages, 1:4, significantly reduced gel contraction. This could be because 
at a 1:1.5 ratio of fibroblasts to macrophages, maximal effect of the macrophages on the 
fibroblasts has been reached (i.e. the number of fibroblasts is limiting). Additionally, as the 
number of macrophages increased, the total number of cells in the gel increased, resulting in 
competition for limited nutrients. This could then act as another limiting factor to the effect of 
macrophages in the model especially in the absence of FBS. When the effect of cell density in 
the FPCLs was first explored in Chapter 3, a seeding density of 2 x 105 did not have a negative 
impact on gel contraction and, in fact, greatly increased it. It had not been ascertained however 
whether a cell seeding density of 5 x 105 cells, or greater, would have a negative effect on 
resources or contraction. Higher fibroblast densities are known to more rapidly reduce FPCL 
and thickness, but the threshold of a limiting or deleterious effect is not clear268. 
Contrary to the results shown here, in their extended blood monocyte-lung fibroblast co-culture 
model of 21 days, Skold et al. (2000) reported that gel contraction was initially attenuated 
compared with fibroblast-only gels283. This was corroborated by Zhu et al. (2001), from the 
same research group, who carried out similar experiments284. Their models went on to show 
augmented tissue contraction from day 15 onwards with the gels being significantly smaller by 
day 21 than in the fibroblast-only groups. However, direct comparisons between the results 
reported here and those reported in these studies are confounded by the fact that lung and dermal 
fibroblasts are distinctly different, for example in terms of the MMPs they express, since they 
have different developmental origins285. Additionally, there was no mention of stimulation of 
the extracted blood monocytes to macrophages. Activated macrophages and monocytes have 
distinctly different protein expression profiles and may influence fibroblast-mediated 
contraction in different ways.  
4.5.2   Effect of external pressure and mechanical loading on the FPCLs 
Pressure is the main extrinsic risk factor in pressure ulcer etiopathogenesis and development 
since it leads to blood flow occlusion and acts as a mechanical stressor on cells. It is therefore 
an important component of any in vitro FPCL model attempting to replicate pressure ulcer 
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development. Since the FPCL model is static, compression on the gels would not be able to 
mimic the effect of blood occlusion and reperfusion due to the lack of nutrient flow. It would, 
however, be able to replicate several of the other effects of IR injury, including the effect on 
cell viability and several aspects of oxygen glucose deprivation (OGD). The results reported 
here show how an external pressure of 32 mmHg for 1.5 hours on FPCLs resulted in: (i) gel 
compression and flattening, (ii) prevention of normal contractile behaviour, and (iii) a 
significant loss of cell viability.  
Compression of the FPCL is likely to reduce gas exchange and glucose transport to the cells as 
well as cause physical damage to the resident fibroblasts, all resulting in cell death. The 
structural integrity of the collagen fibres is also likely to be compromised, resulting in the 
observable thinning and flattening of the FPCL. Several in vivo models of IR injury that 
involved compression of animal skin for 1-2 hours reported changes in collagen alignment. 
This has also been observed during compression of ex vivo skin and FPCL models273. In the 
FPCLs, contractile behaviour was slightly regained between days 1 and 3 but this may have 
been due to recoil of the collagen or locomotion of the remaining viable fibroblasts. 
Importantly, compression applied in this model could not replicate reperfusion of blood which 
would not only reintroduce critically needed glucose and oxygen but a milieu of harmful free 
radicals and toxins that are known to upregulate MMP activity276. 
4.5.3   Effect of glucose deprivation in the FPCL model 
Due to the limitations of what compression can replicate in the static FPCL model, several 
aspects of IR injury must be replicated by alternative means. The effect of glucose deprivation, 
for example, can be modelled by culturing the collagen gels in glucose-free medium277,278. 
Fibroblasts can also be pre-conditioned to glucose deprivation to minimise the effect of 
fibroblasts using alternative energy-generating mechanisms in the absence of glucose. This 
result showed that in the FPCL model, glucose deprivation through removal of glucose from 
the culture medium` did not have a significant effect on percentage gel contraction within the 
seven-day experimental period. Gel contraction, as with wound healing, is a highly energy-
dependent process requiring energy for fibroblast locomotion and collagen compaction. So it 
could be theorised that glucose deprivation would reduce gel contraction through the removal 
of the cell’s primary energy source. This was not observed. Alternatively, glucose deprivation 
could cause stress signals to be released that may bolster MMP activity and augment gel 
contraction. It is possible that these two opposing effects counteracted each other resulting in a 
gel contraction profile that was not statistically significant from control. 
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Several studies have reported that glucose deprivation significantly reduced collagen 
biosynthesis in their FPCL model277,278. However, collagen biosynthesis is not a reported 
process by which fibroblasts contract gels and is more a function/feature of matrix remodelling. 
Notably, glucose deprivation only constitutes one arm of the pathological mechanism of IR 
injury and the second arm, blood reperfusion, is likely to have significant effects. This is 
corroborated by differences observed between the effects of IR injury and ischemia alone by 
several authors in in vivo models98–100. Glucose re-introduction can be investigated by 
replenishing gels with glucose-enriched medium.  
4.6   Future work 
4.6.1   Combined effect of external stressors on the FPCLs 
The effect of macrophages and compression on FPCLs have been explored and defined in this 
study but their combined effect may, in fact, be synergistic. Each individual stressor can be 
combined together in the FPCL to investigate this combined effect. For example, pressure could 
be applied to the FMPCLs in the absence of glucose and in the presence of macrophages. As 
previously described, introduction of wound fluid and ischemic fibroblasts in place of complete 
medium and healthy fibroblasts is likely to improve the overall ability of the model to simulate 
the pressure ulcer environment. Alternatively, neutrophils along with inflammatory cytokines 
could be introduced into the model to better replicate the body’s inflammatory response. The 
effects of increasing magnitudes of external pressures applied for different lengths of time could 
also be explored. 
4.6.2   Hypoxic chamber for cyclic oxygen deprivation 
The effects of cyclical hypoxia and normoxia can be explored through the transient incubation 
of gels in a hypoxic chamber286. Glucose can also be added and removed from the FPCL 
supernatant to mimic nutrient depletion as seen in IR injury. Both these methods in combination 
with exposure of the gels to reactive oxygen species (ROS) and free radicals would better 
replicate the pressure ulcer microenvironment and may give different results to initially those 
reported here.  
4.7   Conclusion 
The pressure ulcer microenvironment is complex and dynamic and there are numerous 
challenges to fully replicating it in vitro. With certain limitations, several aspects of the pressure 
ulcer microenvironment can be introduced. The results here suggest that the increase in MMP 
activity levels mediated by macrophage-fibroblast interactions is a reasonable target for 
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doxycycline treatment. However, since relative cell populations and protein expression for each 
pressure ulcer stage have not been clearly defined it is difficult to ascertain at what stage 
doxycycline treatment would be most effective. There is a need for newer evaluative scales 
based on different, more informative biomarkers (this is explored in Chapter 6). The utility of 
in vivo models in replicating pressure ulcer development is explored next, in Chapter 5. 
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Chapter 5   An In Vivo Preclinical 
Surgical Model of Early Stage 
Pressure Ulcers  
 
 
5.1   Introduction  
The main aim of the body of work carried out in this chapter was to establish a pre-existing and 
peer-reviewed preclinical human pressure ulcer model in our lab that was entirely new (in both 
terms of materials and methods) to our research group. Once the model had been established 
the following aim would be to use this model in future explorative experiments to further 
investigate the effect of microneedle-mediated doxycycline delivery on pressure ulcer 
development in vivo.  
5.1.1   Bridging the gap between in vitro models and human studies  
Despite the utility of our current in vitro models, their simplicity means they are limited on 
what they can inform us. The challenge is to find a model that best mimics pressure ulcers in 
humans. The model must not only be clinically relevant but also simple, economical and 
reproducible and should aim to bridge the gap between these in vitro studies, which cannot 
emulate a fully functional biological system and human clinical studies, which are often limited 
to patients with pre-existing ulcers. Historically, in vivo models of pressure ulcers have used 
cumbersome compression equipment in large animals21,52, while more recently, compact 
reversible mechanisms with the ability to mimic IR injury have been employed13,22,23,28,29,97,98. 
These devices are more suitable for small animals such as rodents and do not require subject 
immobilisation or anesthetisation in most instances. By far the most popular technique of the 
past decade has been the use of magnets to generate the injurious IR cycles. Rodents are popular 
choices for preclinical research due to their perceived lower sentience, ease of handling and 
relatively low cost that makes large scale studies possible99.  
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5.1.2   Mechanical loading of pressure ulcers using magnetic compression 
The in vivo murine model was developed primarily based on the work carried out by Mustoe 
and colleagues (2004)29. The concept was based on mechanically modeling IR injury using 
magnets that periodically compress the skin to mimic the injurious pressure-release cycles. The 
aim of the model was to replicate the pressure exhibited in the human pressure ulcer by 
providing a pressure of a clinically relevant magnitude for a sufficient duration. Furthermore, 
to truly mimic the human pressure ulcer the wound must progress through all clinical stages of 
ulcer development, in order. The procedure requires magnet implantation which involves 
creating an incision in the dorsal tissue of the subject and implanting a magnet into the body. 
This intracorporeal magnet is placed subcutaneously (beneath the fascia) and the incision is 
then sutured and an extracorporeal magnet placed on top. The extracorporeal magnet can then 
be removed and replaced at predetermined intervals and the effects of the cycles monitored by 
tissue harvesting.  
5.2   Research outline 
This chapter describes an in vivo preclinical surgical model using magnetic compression and 
release to mimic several of the morphological, histological, cellular and biomolecular changes 
exhibited in the human pressure ulcer. The main aim was to develop an in vivo pressure ulcer 
model using magnet-based compression-release cycles and to investigate the histological and 
molecular effects in the dermis. This was carried out using a single ischemia-reperfusion cycle. 
Injured and non-injured tissue were harvested and assessed for inflammatory, structural and 
vascular changes in the dermis, in order to have a model to then assess the effect of treatment 
with doxycycline on. 
5.3   Methods and materials 
5.3.1   Magnets and magnetic compression 
Gold-plated neodymium disc magnets (12 mm x 2 mm, N42 Gold Plated) supplied by Magnet 
Expert Ltd. (Tuxford, UK) were used to create the compressive force to occlude blood flow in 
the skin of a pressure ulcer. The magnets provided a pressure of 50 mmHg — greater than the 
conditions required to develop an ulcer but comparable to surface-tissue interface pressure in 
at risk patients and enough to effectively occlude blood flow through skin placed between 
them29.  
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5.3.2   Experimental groups 
The experiment was split into two groups based on the length of reperfusion. Group A had a 
1.5-hour period of ischemia followed by a 4-hour period of reperfusion while group B had a 
1.5-hour period of ischemia followed by a 24-hour period of reperfusion (Table 4). A 1.5-hour 
period of ischemia was chosen to replicate the approximate time between patient turning 
commonly reported in the literature. 
Table 4  — Experimental group designation and respective lengths of ischemia and 
reperfusion. 
Group 
designation 
No. of subjects Ischemia 
(hours) 
Reperfusion 
(hours) 
Total no. of 
IR cycles 
A 5 1.5 4 1 
B 5 1.5 24 1 
Figure 5.1 — Schematic representation of the magnetic compression apparatus and 
IR injury procedure: (A) Gold-plated neodymium north and south pole magnets each 
12 mm in diameter and 2 mm in height were used to create a compressive force. (B) The 
attraction between the intracorporeal and extracorporeal magnets created a compressive 
force of 50 mmHg on the skin (shown here in cross-section). 
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5.3.3   Murine subjects 
Six-week old male ICR mice (Harlan Laboratories, Oxon, UK) were used with UK Home 
Office approval and according to their regulations (PPL number: 70/6778). All subjects were 
housed singly in non-metal cages during experimental procedures. Immediately prior to the 
experimental procedure each subject was subcutaneously injected with 0.03 mg/kg 
buprenorphine (Vetergesic; Recknitt Benckiser Healthcare, Hull, UK). Analgesia lasted for a 
maximum of 12 hours and the analgesic was reapplied if an animal showed signs of pain or 
distress. Anesthesia was induced via an induction chamber using 4% isoflurane, 2 l/min oxygen 
and 1 l/min nitrous oxide and was maintained via nose cone using 1.5% isoflurane. All subjects 
were humanely euthanised by cervical dislocation at the end of the experiment.
5.3.4   Implantation procedure 
Whilst under anesthesia, subject dorsum was carefully shaved with a razor and the fur removed 
from a suitably sized area. The subject was transferred to a heating pad and the exposed skin 
cleaned and sterilised with a sterile gauze and 70% ethanol. A single intracorporeal magnet was 
inserted sub-dermally into each mouse via a single 1-2 cm incision made in the mid-line of the 
dorsal skin using a scalpel ( .). The skin was separated from the underlying fascia using blunt 
dissection with surgical scissors. The magnet was moved 3–4 cm away from the incision to 
prevent disruption of stitching with the metal needle and was held in place using a small 
external rod of metal. Once in place, the extracorporeal magnet was added onto the skin, on top 
of the implanted magnet. The incision was sutured with interrupted stitches. The area 
compressed by the magnets was demarcated with a permanent marker. 
5.3.5   Cyclic magnetic compression protocol 
The period of ischemia was measured from the moment the extracorporeal magnet was added 
until the moment it was removed. The period of reperfusion was measured from the moment 
the extracorporeal magnet was removed from the skin until the moment the animal was 
euthanised. The magnet was removed by hand using a swift sliding motion. For ease, the 
intracorporeal magnet was left under the skin for the entire experiment and not removed until 
after euthanisation. After the magnets were applied, subjects were recovered from anesthesia 
in specially prepared chambers and were returned to individual cages once they were able to 
move without showing signs of pain or distress.   
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5.3.6   Tail vein injections of FITC-BSA 
Fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) is a fluorophore-
conjugated plasma protein which can be used to measure vascular permeability; the FITC 
fluorophore is bound to BSA protein which accumulates where plasma leaks from blood vessels 
into the surrounding tissue. The FITC-BSA was formulated as a 1.5% injectable solution using 
Pluronic gel (Pluronic® F-127; Sigma-Aldrich, Poole, UK). All subjects had tail vein injections 
of FITC-BSA 20 minutes before their experimental endpoints. Subjects were transferred to heat 
boxes for 15 minutes to dilate their tail vein to aid the injection process. For the injection, 
subjects were transferred to tubes to hold them still and prevent needle-stick injuries. FITC-
BSA (200 µl) was injected directly into the tail vein of the mouse using a 29G diabetic needle 
and 1 ml syringe (Becton, Dickinson and Company, New Jersey, USA). 
5.3.7   Tissue harvesting 
Tissue was harvested on site. An approximately 2 cm x 3 cm section of injury tissue was taken 
from the right dorsum and an identical section was taken from the contralateral side to act as 
control tissue. Injury tissue was bisected through the wound. Tissue samples were fixed and 
stored in 4% (w/v) paraformaldehyde (PFA)-0.1M PBS solution. 
Figure 5.2 — Intracorporeal magnet implantation procedure in murine 
dorsum: (A) Schematic  representation of the IR injury procedure showing the 
mid-line incision and placement of the magnet to its right. (B) Photograph of the 
IR injury procedure as carried out in vivo with the subject under anesthesia. The 
midline incision was sutured with interrupted stitches.
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5.3.8   Cryosectioning 
Tissue samples were washed in 4% PFA-PBS solution (2 x 4 hour washes) and PBS (1 x 24 
hour wash) before being transferred to a 20% sucrose (w/v) 0.1M PBS solution containing 0.1% 
(w/v) sodium azide and left overnight. This was done to prevent ice crystal formation that could 
damage the tissue during the freezing process. For embedding, large cryomolds (Sakura 
Finetek, Thatcham, UK) were half-filled with TissueTek ‘Optimum Cutting Temperature’ 
(O.C.T.) medium (Sakura Finetek) and the tissue samples added. The remainder of the mold 
was then filled with O.C.T ensuring that no bubbles were in the medium or surrounding the 
tissue as this is known to affect sectioning. The cryomolds were placed on a cold stainless steel 
block on top of dry ice to rapidly freeze down the tissue. Tissue blocks were mounted into a 
cryostat (Leica CM3050 Cryostat; Leica Biosystems, Nussloch, Germany) and samples were 
cut into 14 nm sections. Sections were transferred to gelatin-coated glass slides and left to dry 
for 15 minutes to ensure the tissue had firmly adhered to the slide. Slides were stored at -20oC. 
5.3.9   Hemotoxylin and eosin (H&E) histological staining 
Hemotoxylin and eosin (H&E) staining was used to stain the structural and cellular components 
of the skin. The frozen sections were carefully washed in PBS buffer for 5 minutes. They were 
then stained with 0.1% Mayer’s hemotoxylin (MS16, Sigma-Aldrich) for 10 minutes then 
rinsed with cool running double distilled water (ddH20) for 5 minutes until the water ran clear. 
Slides were dipped in 0.5% Eosin (EMD Millipore, Darmstadt, Germany) for 10 minutes and 
rinsed with ddH20 by dipping (30 dips). The sections were dipped in graded concentrations of 
ethanol:  50% (15 dips), 70% (15 dips), 95% (30 seconds) and 100% (60 seconds). The slides 
were then dipped (15 times) in xylene (Sigma-Aldrich), and a coverslip mounted and fixed with 
clear nail polish. 
5.3.10   Counterstaining for cell nuclei 
Frozen slides were thawed for 5 minutes and bathed in PBS for 10 minutes. Slides were placed 
in cold acetone for 5 minutes to permeabilise the tissue. Slides were removed and 
counterstained for 5 minutes using Hoechst solution (Hoechst 33258 and Hoechst 33342 dyes 
each diluted to 1:50,000 in PBS; Sigma-Aldrich). Tissue sections were washed for 2 x 5 minutes 
in PBS and then mounted and cover-slipped using Citifluor AF1 antifade mountant (Citifluor 
Ltd., London, UK). Slides were viewed under light and confocal microscopes. Hoechst was 
excited by the 405 nm wavelength laser. 
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5.3.11   Histological dermal analysis and leukocyte counts 
The dermis in the (i) injury site, (ii) tissue directly surrounding the injury site, and (iii) control 
tissue in all samples was analysed and imaged under a light microscope. Polymorphonuclear 
leukoctyes were identified through high power imaging at the injury and control sites in the 
dermis of each sample. These leukocytes were counted from the histological images in 
ImageJ® (National Institutes of Health [NIH], Maryland, USA) and the results averaged 
amongst the subjects (n = 5) for both the 4-hour and 24-hour groups.  
5.3.12   Immunohistochemical dermal analysis using fluorescence confocal microscopy 
Immunostained specimens underwent sequential scanning using a Leica SP8 (Leica 
Biosystems) with a 40x 1.2 numerical aperture (NA) oil objective. Sequential scanning was 
used to prevent bleed-through of signals. Hoechst was excited by the 405 nm wavelength laser 
and FITC-BSA by the 488 nm wavelength laser. Images were captured through the Z plane as 
Figure 5.3 — Schematic diagram of regions of interest (ROIs) imaged in the 
excised dorsal tissue: (A) Top down depiction of injury tissue on the right created 
by the disc-shaped magnets and contralateral skin on the left. (B) During confocal 
microscopy, Z series images were taken through: (i) the injury site (ii) tissue directly 
surrounding the demarcated injury site i.e. marginal to the injury tissue, and (iii) 
control tissue collected from contralateral dorsum.
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a Z series of 1.51 µm slice thickness. For each sample a Z series was taken at the following 
regions of interest (ROIs): (i) injury site (ii) tissue directly surrounding the injury site, and (iii) 
control tissue (Figure 5.3). Image acquisition settings remained identical between images in 
order to allow comparisons in image analysis. Images were overlaid and given a maximum 
projection for visual purposes.  
5.3.13   Calculating vascular permeability using image thresholding 
Vascular permeability in control tissue, tissue surrounding the injury site and injury tissue was 
measured using ImageJ®. The Z series for each site were split into the three colour channels 
(red, blue and green) with the green channel being used to measure vascular permeability. The 
three middle slices of the Z series acted as triplicates. These were thresholded between 80 and 
150. The upper threshold of 150 eliminates the blood vessels and the lower limit of 80 captures
the leakage from the blood vessel. The total area covered by the pixels within these two
thresholds was calculated using an ImageJ® plug-in. The mean vascular permeability for: (i)
IR injury tissue (ii) tissue directly surrounding the injury site (transition tissue), and (iii) control
tissue was calculated per group. As there was most likely a discrepancy between the exact
amount of FITC-BSA injected into each animal, each animal was normalised to its own control
and the vascular permeability for the transition and injury tissue expressed as a fold-change.
The results were analysed by a two-way ANOVA with Tukey correction for multiple
comparisons and were represented as a column graph.
5.3.14   OCT of magnetic compression in ex vivo murine skin 
A skin section of 3 cm x 2 cm was excised from the dorsum of a young male ICR mouse. The 
skin was shaven and treated with a depilatory cream to remove as much fur as possible. The 
gold-plated N42 neodymium magnets (Method 1.1.1, p. 167) were applied to the apical and 
basal surfaces of the skin. The magnets were applied to the skin at room temperature for five 
minutes. Optical coherence tomography (OCT) was used to examine the effect of compression 
on the skin’s subsurface structure up to a depth of 1mm. Images were taken of the skin before 
and after magnet application at the centre and boundary using the EX1301 OCT scanner 
(Michelson Diagnostics, Kent, UK).  
5.3.15   Statistical analyses 
For each condition there were five subject replicates (unless otherwise stated) to allow for 
experimental variation. Where appropriate results were analysed by a two-way ANOVA with 
Tukey correction for multiple comparisons and were represented as a column graph. Averages 
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are represented by the mean ± standard error of the mean. In all instances p < 0.05 denotes a 
statistically significant difference. 
5.4   Results 
5.4.1   Macroscopic images of the magnet loading site 
Photographs taken of the injury sites during harvesting show how magnetic compression 
affected the skin macroscopically. After a reperfusion period of 24 hours, the skin showed 
evidence of erythema and localised damage, with the area compressed by the magnet being 
raised above surrounding tissue. This corresponds to the NPUAP description of a stage 1 
pressure ulcer (Figure 5.4). No deep tissue injury was observable since, in this model, 
compression was only provided to the cutaneous tissue. 
5.4.2   Histological analyses 
Qualitative histological observations in the dermis 
H&E stained specimens were analysed under a light microscope to observe structural and 
cellular changes in the dermis. Injured tissue demonstrated changes in cellularity, leukocyte 
count, the structure of the ECM and cell morphology when compared with the control tissue 
(Table 5). The eosin-staining of the proteinaceous components of the ECM such as collagen 
Figure 5.4 — Photographs of the primary injury site after a 1.5-hour period of 
ischemia induced by magnetic compression of cutaneous tissue: (A) The injury site 
immediately after the extracorporeal magnet was removed. (B) Injury site after a 24-hour 
period of reperfusion. 
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was much darker and more histologically ‘normal’ in control tissue than seen in injury tissue 
(Figure 5.5) where collagen fibrils were densely packed. In injury tissue the ECM appears to 
have lost its regular structure, with bundles of protein much more weakly stained (i.e. less pink) 
and less densely packed. Furthermore, there was a marked difference in cellular morphology in 
injured tissue when compared with control tissue, with fibroblasts appearing to have lost their 
stellate appearance in the injury tissue. Another clear feature of damaged tissue areas were 
blood vessels packed with erythrocytes and extravasating leukocytes — a feature not seen in 
control tissues (Figure 5.6 – A, B and C). In the 24-hour but not 4-hour injured tissues there is 
also evidence of dead cells and cellular debris scattered throughout the dermis (Figure 5.6 – 
D). Leukocyte recruitment was seen in all injured tissues; however, recruitment was greater in 
tissue after a 24-hour period of reperfusion than after a 4-hour period of reperfusion. 
Figure 5.5 — H&E stained histological sections of control and injury cutaneous 
tissue. Skin samples after a 4-hour period of reperfusion (A-B) and skin samples after a 
24-hour period of reperfusion . The figure compares control tissue (contralateral to the
IR injury site) to tissue from the injury site. Differences in the ECM staining are evident
between the two sites at both 4 and 24 hours, suggesting changes in the collagen and/or
elastin composition of the ECM as a result of the IR injury. Paired images were taken
with the same exposure and were white balance corrected where necessary.
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Figure 5.6 — H&E-stained dermis showing histological features of magnetic 
compression: (A) Injury tissue after 4 hours of reperfusion with extravasating 
leukocytes [LC] migrating from blood vessels [BV]. (B) Injury tissue after 24 hours of 
reperfusion with evidence of leukocyte recruitment. (C) injury tissue after 24 hours of 
reperfusion filled with recruited leukocytes in the lower dermis. (D) Injury tissue after 
24 hours of reperfusion shown to contain post-apoptotic cells, cellular debris and nuclear 
blebs.
Table 5 — Comparison of the histological features in control (non-injured) and injured 
tissue 
Histological Feature Control tissue Injury tissue 
4h 24h 4h 24h 
ECM structure Normal Normal Abnormal Abnormal 
Cell death None None No evidence of 
cell death 
Evidence of cell 
death 
Leukocyte recruitment None None Recruitment Recruitment 
Fibroblast morphology Stellate Stellate Rounded Rounded 
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Figure 5.7 — Maximum projections of FITC-BSA stained dermal tissue showing 
the effect of magnetic compression on blood vessel permeability in control tissue, 
tissue surrounding the injury site and injury tissue: (A-C) Vascular permeability in 
dermal tissue after 4 hours of reperfusion. Local vascular permeability was increased in 
injured dermis and tissue surrounding the injury site compared with control dermis. (D-
F) Vascular permeability in dermal tissue after 24 hours of reperfusion. Local vascular 
permeability was increased in injured dermis and tissue surrounding the injury site 
compared with control dermis. Green fluorescent signals indicate FITC-BSA staining. 
Image acquisition settings remained identical between images. 
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5.4.3   Vascular permeability 
Effect of magnetic compression on vascular permeability in dermal tissue 
FITC-BSA was used to assess the effect of IR injury on blood vessel permeability after a 4-
hour and 24-hour reperfusion period between injury, margin and control tissue. Of the five 
subjects in each group, only three were successfully intravenously injected with FITC-BSA due 
to the difficulty of the procedure. The FITC-BSA dye fluoresces green when excited by the 488 
nm laser. So when injected into the tail vein, the lumen of blood vessels become filled with dye 
and appear as bright green circumscribed bands. If a blood vessel becomes leaky, the FITC-
BSA can diffuse into the surrounding tissues. The greater the permeability of the blood vessel, 
the greater the amount of dye that leaks out leading to a more intense green staining. 
After a 4-hour period of reperfusion there was a statistically significant increase in blood 
vessel permeability at the injury site compared with control tissue (Figure 5.7 – A and C). In 
addition there was evidence that there was a spread vessel permeability  beyond the injury 
site into surrounding tissue, though this was not statistically significant (Figure 5.7 – B). 
There was a statistically significant difference in vascular permeability between the 
transition and injury tissue (p < 0.05), with a five-fold increase in leakiness at the injury 
site compared with the surrounding tissue (Figure 5.8 – A). After a 24-hour period of 
reperfusion, there continued to be a pattern of increasing vascular permeability from 
control to transition to injured tissue (Figure 5.7 – D, E and F). There also was  a highly 
significant increase in the fold change of vascular permeability between transition and injury 
tissue (p < 0.0001) (Figure 5.8 – B). No statistically significant difference between the 
control and transition tissue was observed. 
5.4.4   Leukocyte count 
Effect of magnetic compression on leukocyte recruitment to the dermis 
The leukocyte count in the dermis gives an indication of the inflammatory response within 
the skin after a particular insult. After a 4-hour period of reperfusion there was a significant 
increase in the average leukocyte count at the injury tissue compared with the control tissue (p 
< 0.001) (Figure 5.9). After a 24-hour period of reperfusion there was a significant 
increase in the average leukocyte counts in injury tissue when compared with control 
tissue with a much greater increase in fold change compared with what was observed after 
the hour reperfusion period (p < 0.001).  
- 178 -
Chapter 5: An In Vivo Preclinical Surgical Model of Early Stage Pressure Ulcers 
- 179 -
Figure 5.9 — Average leukocyte count in control and injury dermal tissue after 4 
and 24 hours of reperfusion (n = 5). Average leukocyte count was significantly 
increased in injury tissue compared with control tissue after both 4 and 24 hours of 
reperfusion. Error bars represent the standard error of the mean; *** = p < 0.001. 
Figure 5.8 — Fold change in vascular permeability in tissue after 4 and 24 hours of 
reperfusion (n = 3): Vascular permeability was significantly increased in injury tissue 
compared with transition [edge] and control tissue. No significant difference was 
observed between control and transition tissue, though fold change in vascular 
permeability in control tissue was numerically higher. Transition and injury tissue values 
were normalised to the corresponding control. Error bars represent the standard error of 
the mean; * = p < 0.05, **** = p < 0.0001. 
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5.4.5   OCT images 
OCT images of magnetic compression in excised murine dorsum 
Cross-sectional subsurface images were taken of excised murine dorsum using optical 
coherence tomography (OCT). This non-invasive, non-contact method of imaging provided 
subsurface details not visible by eye without causing morphological changes to the tissue. In 
control tissue, subsurface striations were observed (Figure 5.10 – A). In dorsal tissue that had 
been compressed on its apical and basal surface with the 12 m x 2 mm 2000 Gauss magnets, 
compression of the striations at the centre of the injury was observed (Figure 5.10 – B). At the 
boundary where the magnets were applied to the skin there was evidence that the tissue there 
had experienced greater pressure (Figure 5.10 – C).  
5.5   Discussion 
In vitro models, though useful, represent the skin in isolation from a fully functioning biological 
system and this must be taken into account before extrapolating results to living organisms. 
Figure 5.10 — OCT images demonstrating the effect of magnetic compression on 
excised murine dorsum: (A) Depilated control skin showing subsurface striations. (B) 
Skin after percutaneous application of magnets for five minutes. Striations are noticeably 
compressed. (C) Skin after the application of magnets at boundary (arrow). Skin has 
been significantly deformed at the boundary.  
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Animal models have provided an excellent alternative to in vitro systems to study wound 
development and healing in a whole organism. In the in vivo surgical model reported here, 
pressure-related injury was simulated by compressing the epidermal and dermal layers of the 
skin between two attracting magnets that provided a pressure of 50 mmHg. The effects on 
histological features, vascular permeability and leucocyte count were assessed after reperfusion 
periods of 4 and 24 hours. 
5.5.1   IR injury caused significant histological changes in the dermis 
IR injury that included a 1 hour period of ischemia followed by a 4-hour or 24-hour period of 
reperfusion was shown to cause significant histological changes in the dermis. The results 
showed that IR injury in this model invoked changes in cellularity, the acute inflammatory 
response, vascular permeability, ECM structure and fibroblast morphology in the dermis. The 
histological observations also corroborated the results of the FITC-BSA imaging of vascular 
permeability and leukocyte count analysis. Control tissue appeared histologically normal, with 
a well-structured densely-packed ECM, few or no leukocytes and normal cell morphology. 
Injury tissue, on the other hand, showed signs of a large degree of morphological damage which 
had spread into the surrounding transition tissue. 
The transition tissue found at the margins of the primary injury site showed intermediate traits 
of control and injury tissue. Injury tissue had lost the regular structure of the ECM and the 
normal cell morphology of fibroblasts; blood vessels were filled with erythrocytes, while 
neutrophils and other leukocytes could be seen being recruited into the area. It is important to 
note that significant differences between the 4-hour and 24-hour reperfusion periods could not 
be observed through the qualitative histological observations alone and called for more detailed 
and quantitative analyses through histological leukocyte counts and assessment of vascular 
permeability. OCT imaging of compressed murine skin provided indications that there were 
significant structural changes in the dermis and underlying fascia due to the compaction of 
striations. 
5.5.2   Acute inflammatory response to IR injury in the dermis 
There is evidence of an acute inflammatory response to IR injury in the dermis. The average 
leukocyte counts of polymorphonuclear cells were used to assess the acute inflammatory 
responses in the dermis to IR injury. During the initial phase of a normal inflammatory 
response, neutrophils are attracted and recruited to an injured area through the release of 
cytokines. A cascade of pro-inflammatory cytokines released from the neutrophils themselves 
then follows, resulting in the recruitment of more and more neutrophils and circulating 
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leukocytes including macrophages. The results presented here show that there is an initial influx 
of neutrophils into the dermis of injury tissue after 4 hours of reperfusion. As expected, the 
number of neutrophils greatly increased after a 24-period of reperfusion. 
These results corroborate the theory that IR injury causes an acute inflammatory response in 
cutaneous tissue. During reperfusion the production of reactive oxygen species (ROS) leads to 
oxidative stress in the tissue and encourages the recruitment of leukocytes ultimately leading 
to a pro-inflammatory response and damage to the region. The neutrophil is deemed to be the 
critical cellular mediator of this response. In their study, Mustoe et al. (2004) showed a 
significant increase in leukocytic infiltrates in groups that had been cyclically compressed for 
24 hours100, consistent with the results presented here. The authors also showed that infiltration 
of neutrophils was not only found in skin bearing necrosis but also in pre-necrotic skin, 
suggesting that the infiltration of neutrophils could be seen as a cause, and not an effect, of 
injury. Peirce and colleagues (2000), who were looking at average leukocyte extravasation in 
their rat model of IR injury89, showed a significant increase in leukocyte extravasation between 
control tissue (i.e. no IR injury) and tissue that had undergone 5 cycles of IR injury —  2 hours 
of ischemia and ½ hour reperfusion — in a 24-hour period. 
5.5.3   IR injury increased vascular permeability 
IR injury significantly increased vascular permeability at the primary injury site. The 
quantitative results from the vascular permeability studies are in good concordance with the 
initial histological observations. Together the results suggest that IR injury greatly increased 
vascular permeability at the site where the magnet was loaded 4 hours after the initial ischemic 
insult and continued to have this effect up to 24 hours later. Furthermore, this effect was not 
limited to the injury site alone, but appears to have spread to surrounding tissue according to 
the FITC-BSA images, though not significantly according to quantitative image analysis. 
Implications of this are that apoptotic death and stress signals could be more easily spread to 
neighbouring cells via connexin gap junctions —  a mechanism by which stress is known to 
spread during ischemic injury254,264,287–289. 
5.5.4   Discussion of the validity of recent surgical murine models of IR injury 
The seminal studies modeling pressure ulcers regarded ischemia to be the principal inciting 
factor in ulcer development92. In these experiments, single applications of high pressures 
(greater than 100 mmHg) were applied to the animal models92,127. Not only were the pressures 
too high to be of clinical relevance in humans, the single applications of pressure-induced 
ischemia were an inadequate explanation of pressure ulcer pathogenesis. This was still the case 
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even when lower pressures were applied92. The model needed to be advanced from the 
simplistic ischemic insult model to a more sophisticated model that incorporated the significant 
role of reperfusion. This has led to the current model designs of cyclical IR injury.  
IR injury versus ischemia alone
Though there are still no standardised in vivo models for pressure ulcers, studies in the 
published literature, though differing in protocol, appear to show similar trends. Firstly, as 
anticipated, ischemia alone is not as injurious as IR injury (with the same total compression 
time). This has been indicated amongst the range of studies. Peirce et al. (2004) showed a 
relative increase in the necrotic area and leukocyte extravasation in the IR-injury group (2 hours 
ischemia, ½ hour reperfusion, 5 cycles) when compared with the ischemia-alone group (10 
hours ischemia, 1 cycle) 89. Tsuji et al. (2005), using their compression chamber model, 
demonstrated that microcirculatory injury caused by compression-release cycles (2 hours 
ischemia, 1 hour reperfusion, 4 cycles) was significantly more severe compared with prolonged 
compression alone (8 hours ischemia, 1 cycle), indicated by analysis of the functional capillary 
density visualised through their compression chamber device93. 
Secondly, it appears that an increasing (total) number of IR cycles leads to a greater degree of 
tissue damage. Wassermann et al. (2009) demonstrated a strong association (r2 = 0.949) 
between the NPUAP stage of generated pressure ulcers and the number of applied compression 
cycle, and reported creating a stage 1, 2, 3 and 4 pressure ulcer after 4, 6, 8 and 10 cycles of 
compression-release respectively99. Reid et al.
 
(2004) reported in their study that the magnitude 
of necrosis appeared to be cycle responsive because a consistent daily progression was 
observed100. Similarly, Peirce et al. (2000)
 
showed significant differences in tissue damage 
between experimental groups that had received 5, 10 or 15 cycles of ischemia-reperfusion89. In 
groups that had received more IR cycles there was evidence of an increased area of tissue 
necrosis at the magnet application site and increased leukocyte extravasation, as determined by 
histological analysis. Furthermore, there was a significant reduction in both blood flow and 
tissue oxygen between groups that had received 5 and 10 cycles. 
Thirdly post-injury necrosis, which was used amongst studies as an indicator of the ability of 
the model to mimic a chronic wound, was observed in experimental groups that had undergone 
compression-release cycling. Post-injury necrosis describes continuing tissue death days after 
the experimental procedure has ended. This is key, as one major concern of a rodent model is 
its ability to successfully produce a wound that is considered analogous to a chronic wound in 
humans. Reid et al. (2004) observed the natural history of the compressed skin after the IR 
cycles were completed100. Their results indicated that necrosis was sustained over time with 
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lesions reaching their worst by day 10 (1 hour ischemia, ½ hour reperfusion, 5 cycles). 
Furthermore, for longer periods of ischemia (2 hours), the worse the post-ischemic skin survival 
exhibited. Similarly Stadler et al. (2004), reported that lesions reached their maximum extent 
10 days post-injury with continuing evidence of tissue necrosis and inflammatory exudate in 
the wound days after the end of the IR cycles212.  
Pressure exerted by magnetic compression 
The reported pressure generated in the magnet models has been fairly consistent across the 
recent studies, with most indicating a pressure of 50 mmHg being delivered by the 
magnets59,89,99,100, theoretically enough to occlude blood flow in a human and thus a rodent. All 
groups managed to achieve a substantial reduction in blood flow to the occluded area at this 
pressure, with Peirce et al. (2000) reporting an 80% reduction in flow89. The main disparities 
amongst the magnet studies have been (i) the location of the magnet and (ii) magnet geometry. 
The cutaneous models, which applied pressure to skin only, were able to emulate a stage 1 
pressure ulcer, with evidence of unblanchable erythema during macroscopic analysis, and 
production of a stage 2 pressure ulcer, evidenced by breakage of the skin and exposure of the 
dermis. However, these models were unable to mimic full pressure ulcer development as the 
wounds generated were ‘superficial’ (they did not develop from within the subcutaneous tissues 
such as muscle). This meant the ulcers failed to progress through to the most severe stage, stage 
4. In contrast, Wassermann and colleagues’ sub-muscular model was able to produce the full
range of pressure ulcers in progressive order and demonstrated the production of a stage 4 ulcer
after ten applications of compression-release cycling99. The wound showed evidence of
necrosis not only in the epidermis and dermis but in the subcutaneous tissue and muscle as well.
5.5.5   Compression versus crushing 
The aim of magnet application is to mimic the pressure conditions required to develop a 
pressure ulcer. However, the wound generated by the disc magnet model, like the one used in 
this chapter, could overlap with a closely related clinical condition known as crush syndrome 
due to the compression of the entire skin surface between the magnet faces. Clinically, crush 
syndrome results from direct pressure or crushing resulting in muscle cell damage with 
associated symptoms arising from the systemic manifestations of both IR injury and 
rhabdomyolysis290,291. It is possible that other physiological consequences of crushing, other 
than IR injury, are attributable to the tissue damage exhibited in the models using disc magnets. 
One study addresses this issue, reporting a lack of evidence of crush injury in their results, 
although without detailed explanation89. The use of ring magnets could circumvent this problem 
as, hypothetically, they should be able to induce tissue ischemia by occluding blood flow to the 
area without compressing tissue at the centre. 
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Thus, even though the use of disc magnets runs the risk of simulating crush syndrome, the use 
of ring magnets runs the risk of not sufficiently occluding the central area of tissue from blood, 
therefore not truly simulating ischemia. However, in their cutaneous ring magnet model, Reid 
et al. (2004) reported that necrosis occurred in the central portion of skin (in the middle of the 
ring) where no compression was occurring100. This suggests that ring magnets are sufficient to 
provide occlusion. However, without the appropriate technique to visualise the hemodynamic 
effect of the system, the distribution of pressure cannot be characterised. It is possible, however, 
that using two ring magnets provides sufficient magnet-magnet interactions that enhance 
uniformity of the pressure distribution100.  
Murine subjects 
The animal subjects employed differed amongst studies. Different rodent species and strains 
having particular strengths and weaknesses for modeling human skin. Rats have the advantage 
of having similar skin dimensions to humans as compared with mice203, while mice have a 
wider range of genetic variation allowing for a catalogue of knock-out studies292. For example, 
Saito et al. (2009) used a knock-out mouse model to investigate the role of 
monochemoattractant protein-1 (MCP-1) in their IR injury experiment59. Furthermore, rats tend 
to be more expensive to employ in studies due to their larger size, however they may tolerate 
surgical implantation and the extra weight of magnets better than mice. Both species come in 
hairless variations which eliminates the need for hair removal and the subsequent abrasion it 
causes to the skin. For this reason, Wassermann et al. (2009) employed a nude rat in their 
chronic pressure ulcer model99. 
In vivo modeling is limited by practicality and costs. Practical and budgetary considerations 
include the feasibility, ease and reproducibility of the surgical procedure, the costs of the animal 
subjects (purchasing, housing, maintenance etc.), the interference of magnets with surgical 
equipment and caging and the interference of co-housed animals with the wounds. In addition 
to this, there are confounding factors that may compromise the validity of the study. These 
include the trauma induced by the surgery, foreign body reactions of implanted materials, 
irritation to the skin by external magnets, induction of a different clinical syndrome and the 
systemic effects of anesthesia. Studies have accounted for many of these factors by using 
controls89,99,100. Peirce et al. (2000) included a control group that underwent their implantation 
procedure but which did not receive any IR cycles89. The sham group demonstrated significant 
differences in the area of tissue necrosis, leukocyte extravasation, tissue oxygen and skin blood 
flow compared with the group which received the minimum five compression-release cycles. 
Similarly, in the study by Reid et al. (2004), the authors noted that the histological features of 
tissue injury seen in the groups receiving IR injury, such as hyperchromatism, nuclear pyknosis, 
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vascular congestion and endothelial cell swelling were not present in the sham controls100. 
Furthermore, leukocyte counts were significantly lower in the control skin than skin taken from 
a group that had received IR injury.  
5.5.6   Towards better surgical preclinical models
Taking the culmination of work into consideration, it is evident that there is value of mechanical 
and surgical preclinical rodent models in pressure ulcer research. Based on these observations, 
an optimal model might consist of the following: (i) a nude rodent subject; (ii) compression 
provided sub-muscularly, (iii) an implanted intracorporeal steel plate; and (iv) an external ring 
magnet. The reasoning behind this is (i) to mimic human skin to the greatest possible extent, 
(ii) to deliver compression to subcutaneous tissues including muscle, (iii) to minimize implant
interference with surgical equipment and caging due to magnetism, and (iv) to circumvent the
simulation of crush syndrome. Any implanted materials would be coated with inert material,
such as gold plating, to minimise the possibility of invoking a foreign body reaction.
Furthermore, to prevent the stresses caused to the body by the surgical implantation procedure
clouding the interpretation and validity of the results and to prevent misleading conclusions,
there should be a long recovery period post-surgery along with the relevant controls (both sham
and intra-individual).
The evolution of the in vivo pressure ulcer model is on-going. No single in vivo model will ever 
be able to fully represent the complexity of pressure ulcer development in humans. The models 
addressed here focus mainly on IR injury but, as detailed, there are other factors that have 
contributing roles. Factors that have not been extensively studied in conjunction with pressure 
in these models include friction, moisture, and the effect of aged skin, though studies have 
looked at them in the past293. Despite this, the expected pattern of development of human 
pressure ulcers (i.e. progressive skin and subcutis degeneration) has been seen in these in vivo 
models. Even though the different protocols used by different groups makes direct comparisons 
difficult, the results from the studies are in good concordance and can inform on potential 
biomarkers of disease and on which preventative measures and treatments may be successful 
in humans. 
5.6   Future work 
Having gathered data from this preliminary experiment strongly implicating a role of IR injury 
in initial pressure ulcer development, the next step is to further develop the model to better 
represent the human pressure ulcer and to investigate, in more detail, other potentially important 
biomarkers of injury, in particular MMPs and their local levels of activity. The study presented 
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here shows how IR injury impacted several components of the skin up to 24 hours after the 
initial ischemic insult both at the primary tissue site and surrounding tissue. What has not been 
determined is whether the damage caused by the injury ameliorates or worsens beyond this time 
frame. Furthermore, a better representation of pressure ulcer development would be a model 
with repeated cycles of IR injury insult since some biomarkers of pressure-related injury may 
be cycle responsive. Future experiments would include assessing the treatment and prophylaxis 
of these model ulcers using doxycycline formulations and IDD/TDD with microneedles. 
5.6.1   MMP activity assays and zymography to assess the activity of MMPs in IR injury 
tissue after homogenisation 
As previously outlined, an up-regulation of MMP activity and/or expression is believed to be 
responsible for the ECM degradation seen in IR injury tissue. One method for assessing the 
effect of MMP on the ECM at an injury site is zymography, which is used for the detection of 
enzyme activity alongside the MMP activity. Excised tissue that has undergone IR injury can 
be liquefied and homogenised and the supernatant used to determine levels of MMPs present 
in the tissue. Data from these analyses could be used to determine how the activity and/or 
expression of MMPs correlates with ECM degradation. In this vein, other biomarkers of IR 
injury could be explored. For example, a validated marker of IR injury is inducible nitric oxide 
synthase (NOS)97. PCR analysis can be used to assess iNOS mRNA expression in IR injury 
tissue. If the model shows an up-regulation of iNOS at the injury site, it strengthens the 
argument that we are truly demonstrating IR injury in the model. 
5.6.2   Alternative methods to histology for determining ECM deformation and 
leukocyte counts 
It is evident that the ECM in IR injury tissue is being damaged and degraded, but exactly which 
component of the ECM is being affected is not quite clear. Elastin, collagen or both are potential 
contenders. One way of detecting collagen is second-harmonic generation imaging (SHG) 
which is a better method of collagen detections compared with the use collagen stains. SHG is 
a multi-photon technique that can be used on unstained tissue sections which contain non-
centrosymmetric structures such as collagens I and III. Elastin, on the other hand, can be stained 
for using the Verhoeff-Van Gieson (VVG) elastin stain. A less subjective way of assessing 
neutrophil counts than through counting cells under high power field is to use alpha-neutrophil 
elastase antibodies which can be used against murine neutrophils and can detect their 
recruitment as part of an acute inflammatory response. 
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5.6.3   Imaging techniques to monitor and confirm ischemia and reperfusion 
Ischemia and reperfusion can be visualised in situ using several techniques to confirm blood 
occlusion and reperfusion to the areas being compressed. This can achieved in real-time through 
several imaging modalities including laser Doppler imaging294, OCT microangiography295 or 
visualisation aided by a light compression chamber93. 
5.7   Conclusion 
This chapter has shown the role that IR injury plays in pressure ulcer formation using an 
established in vivo murine model. It was demonstrated that IR injury is a multifactorial process 
which involves many structural, functional and inflammatory changes in the dermis. The 
experimental outcomes of this were the successful development and implementation of the 
preclinical in vivo IR injury model using magnets, the demonstrated macroscopic effects of IR 
injury analogous to those seen in early stage human pressure ulcers and confirming the ability 
of IR injury in the model to increase local vascular permeability, stimulate leukocyte 
recruitment to injured tissue and alter the histological structure of the ECM.  
- 189 -
Chapter 6   Optical Coherence 
Tomography for the Non-Invasive 
Evaluation of Pressure Ulcers  
6.1   Introduction 
New methods of pressure ulcer evaluation are needed to complement the microneedle 
technology that this research has focussed on. The current methods are not able to inform on 
the subsurface changes that could be indicative of pressure ulcer development and this could 
be overcome by repurposing existing in vivo, in situ imaging modalities. Such modalities could 
also help precisely guide microneedles during intradermal drug delivery (IDD) and monitor the 
pharmacologic action of the administered active drug over time. Specifically, during my 
research, it was noted that insertion of microneedles into excised skin resulted in compression 
of the skin’s striations as visualised by OCT and implicated that OCT imaging, as an alternative 
imaging modality, may have diagnostic value in evaluating the pressure ulcer condition. For 
these reasons the use of OCT in subsurface imaging for microneedle-assisted drug delivery and 
pressure ulcer evaluation purposes was investigated. 
6.1.1   Traditional pressure ulcer evaluation systems 
Traditionally pressure ulcer evaluation at the bedside has been achieved through clinical scoring 
and classification systems such as the staging system outlined by the National Pressure Ulcer 
Advisory Panel (NPUAP). These systems categorise pressure ulcers on a scale of increasing 
severity, based on the presence of unblanchable erythema, extent of skin loss and exposure or 
damage to underlying tissues296. These scales, however, are heavily limited by the subjectivity 
associated with visual assessment of the skin that results in inter- and intra-observer variation. 
Importantly, miscategorisation at the clinical diagnosis level can result in incorrectly projecting 
patient prognosis thus impacting on preventative measures or treatments put in place for that 
patient. Furthermore, the assumption that the surface of the skin reflects the extent of internal 
damage has been widely disputed, with many studies suggesting that deep-tissue injury (DTI), 
not readily detectable at the skin surface, is responsible for rapid pressure ulcer development, 
leading to an ‘ice-berg’ effect14,37,297–299.  
Chapter 6: Optical Coherence Tomography for the Non-Invasive Evaluation of Pressure Ulcers 
This phenomena has also been referred to as the ‘bottom-up’ theory which theorises that a 
subset of pressure ulcers develop and worsen in subcutaneous fat and/or muscle tissue under 
intact skin with minimal surface indication of the underlying necrosis at first and without raising 
immediate medical concern300. Discussion amongst clinicians, researchers and educators on the 
issue of pressure-related DTI encouraged the introduction of a separate stage in the NPUAP 
classification system in 2007 known as the DTI stage296. As with the previous stages, this 
classification does not provide any information on the extent or severity of the underlying injury 
or whether or not the ulcer is likely to heal by secondary intention or if it requires surgical 
intervention methods. There is definitely a need for an improved standardised and universal 
method of evaluating pressure ulcers and this is corroborated by researchers repurposing 
existing medical devices or developing new tools for the evaluation of pressure ulcers and 
pressure-related injuries. 
6.1.2   Clinical applications of OCT imaging 
Optical coherence tomography (OCT) is a clinically-used imaging modality that can provide 
subsurface cross-sectional images of opaque structures such as the skin. Originally designed to 
image into the eye, OCT imaging has crossed over into the medical fields of cardiology, 
gastroenterology and dermatological diseases. This includes both cancerous and non-cancerous 
skins conditions such as skin melanomas, non-melanoma skin cancers, dermatitis and psoriasis. 
Even though OCT is not the standard technique for dermatological investigations, there has 
been much interest in recent years in repurposing this existing imaging modality for the 
diagnosis and monitoring of skin diseases. OCT imaging of skin diseases has shown correlation 
with the morphological changes observed in histopathological investigation of blistering 
disease, tumour tissue and inflammatory conditions including psoriasis and contact dermatitis 
as well as with markers of acute wound healing61,301,302. With this success, OCT devices have 
become better adapted for dermatological applications with development of light-weight and 
handheld scanners, such as the VivoSight scanner, which is marketed as the next generation 
imaging modality in the diagnosis of non-melanoma skin cancers by Michelson Diagnostics 
(Maidestone, USA). 
6.1.3   Technical aspects of OCT in dermatology 
OCT uses light to image into structures with micron resolution, employing a methodology 
analogous to ultrasound. However, unlike ultrasound which employs acoustic waves, OCT uses 
infra-red light with a wavelength of approximately 840 nm to provide depth-resolved tissue 
structure information303. This information is encoded in the magnitude and delay of the back-
scattered light and is based on the principle of Michelson interferometry304,305. Light from a 
single source is split into two paths — a sample path and a reference path. The light in the 
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sample path interacts with the tissue being imaged; some of this light is reflected while some is 
scattered. Meanwhile the light in the reference path is reflected back to recombine with the light 
returning from the sample path306. Optical interference only occurs when the distance travelled 
by the light in both paths matches with the coherence length of the source light307. At its 
simplest, the greater the backscattering of light from a region of tissue, the greater the intensity 
of the incoming signal. For grey-scale image acquisition this results in a brighter area on the 
generated image, while regions of low-back-scattering result in lower intensity signals leading 
to darker areas on the image. The back-scattering properties of tissues can thus be used to 
identify particular structures and demarcate different regions. 
The resulting ‘optical biopsy’ is achieved through non-invasive, non-contact, in situ and real-
time bedside imaging that rivals the gold standard, histology, in terms of ease and practicality. 
OCT imaging is able to provide information on discrete layers of skin including the stratum 
corneum, the viable epidermis and the upper (papillary) dermis due to a lateral resolution as 
low as 5-10 µm71,79,80. Furthermore OCT imaging offers different scans and image types. The 
simplest OCT scan is the A-scan, a one-dimensional scan that plots axial depth against 
scattering intensity at a particular point in a tissue305. When information from neighbouring A-
scans is collated a B-scan is generated — a two-dimensional grey-scale image with both width 
and depth308 (Figure 6.1). OCT B-scans across a tissue can be amalgamated to produce a three-
dimensional scan; this technique is known as 3D-OCT309. Depending on the scattering 
properties of the skin, which can vary from skin condition to skin condition and from site to 
site, depth penetration of cutaneous OCT imaging can reach up to 2 mm303.  
6.1.4   Non-invasive, in situ and in vivo imaging alternatives to visual-based assessment 
scales 
Though pressure ulcers are traditionally evaluated and scored by visual assessment scales, the 
gold standard for morphological investigations of the skin is excision biopsy and subsequent 
histological analysis308. Skin specimens are excised from the diseased tissue, then prepared, 
stained and analysed by microscopy. Histology has a very high resolution and provides a great 
amount of detail on the cellular and structural changes in tissues. This includes the presence of 
cell infiltrate as a result of inflammation, changes in extracellular matrix (ECM) density and 
collagen alignment and changes in cell morphology which is especially important in the grading 
of cancers. The skin layers are also well demarcated in histological sections and highly accurate 
measurements can be made. However, despite being an invaluable technique, histology presents 
a lot of disadvantages mainly surrounding its practicality. Specimen collection by excision 
biopsy is highly invasive and is injurious to damaged or diseased skin often creating a second 
iatrogenic wound72. The biopsy cannot be repeated at the same site and may alter the tissue’s 
original morphology301. Additionally, it takes time to prepare the samples so there is no real-
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time (immediate) feedback but rather a snapshot of the wound in time and analysis requires 
highly trained specialists.  
Due to the setbacks of visual-based scoring scales and the practicality issues surrounding 
histology, numerous studies have investigated the ability of a range of in vivo imaging 
modalities to image skin conditions. These modalities include ultrasound, scanning laser 
confocal microscopy, epiluminescence microscopy (also known as dermoscopy) and OCT. Of 
these techniques, ultrasound has the most in common with OCT. It is a widely used non-
invasive imaging modality that uses the reflectance of acoustic waves from internal structures 
to generate cross-sectional images through tissues. Due to its low associated health risk and 
deep tissue penetration, ultrasound is the most commonly used pre-natal imaging technique and 
has a range of other clinical applications. However, unlike OCT, ultrasound requires direct 
contact with the skin and the application of a gel at the site of contact to improve image 
Figure 6.1 — Different types of OCT scan: (A) The OCT A-scan gathers information 
on backscattering intensity relative to depth at a particular point in a tissue. (B) When a 
series of A-scans are collected from a tissue, an OCT B-scan is generated which provides 
a two-dimensional cross-sectional image through the tissue. (C) 3D OCT is an 
amalgamation of OCT scans across a tissue; adapted from “Optovue iSeries OCT 
Systems” by Optovue, Incorporated, 2016 (http://www.optovue.com/products/ivue-
ifusion/).   
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acquisition. This could pose a problem for assessing cavitied ulcers or broken skin when 
imaging pressure ulcers. Furthermore, even though high-frequency ultrasound has very good 
depth penetration and can image deep into structures, soft tissues and organs, it is at a cost to 
its resolution which is poorer than that of OCT (Table 6) .  
In vivo CSLM uses laser microscopy to image into the skin and provides high-resolution images 
approaching the level of cellular and sub-cellular detail seen with histology310. In contrast to 
ultrasound, CSLM offers excellent resolution in favour of depth penetration (Table 6). It has 
been used in the assessment of age-related effects in the skin311 and  pigmented skin lesions310. 
Epiluminescence microscopy, also known as dermoscopy, is essentially a magnification 
technique that enhances the morphological features of the skin that are not visible to the naked 
eye. This makes it particularly good for assessing pigmentation disorders and for accurately 
demarcating skin lesions. However, unlike the previous imaging methods, epiluminescence 
microscopy does not provide subsurface detail of intact skin. This makes it harder to make 
evaluations of skin lesions on darker, more heavily pigmented skin which poses a problem for 
all visual-based assessments. Overall, in comparison to other available techniques, OCT is 
arguably the superior imaging modality for this application since it provides a non-invasive 
alternative to histology, provides superior resolution of architectural components of the skin 
compared with ultrasound, allows for greater depth penetration than laser confocal microscopy 
and can provide subsurface images of intact skin unlike epiluminescence microscopy.  
Table 6 — Typical axial and lateral resolutions and depth penetration in soft tissues of different 
in vivo non-invasive imaging modalities. 
Imaging modality Resolution Tissue depth 
penetration 
Examples of traditional 
clinical/medical application(s) 
OCT ≥ 5 µm ≥ 2 mm Ophthalmology — retinal/corneal 
scans 
Ultrasound (high 
frequency 50 hz) 
≥ 20 µm 
TBC 
> 10 mm Pre-natal scanning 
CLSM ≥ 2 µm ≥ 500 µm Diagnoses of skin disorder 
Epiluminescence 
microscopy 
- - none Diagnosis of depigmentation 
disorders  
Demarcation of skin lesions 
OCT = optical coherence tomography, CLSM = confocal laser scanning microscopy. 
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Figure 6.2 — Images of various skin diseases, disorders and conditions using different imaging 
modalities: (A-B) From “Optical coherence tomography in contact dermatitis and psoriasis” by J. 
Wlezel et al., 2003, Arch Dermatol Res, 295, p. 52.  (C-D) From “In vivo confocal scanning laser 
microscopy in dermatology” by A. L. Branzan et al., 2007, Laser Med Sci, 22, pp. 76-77. (E) From 
“Dermatoscopy in the diagnosis of pigmented skin lesions: a new semiology for the dermatologist” 
by P. Carli et al., 2000, European Academy of Dermatology and Venereology, 14, p. 355. (F) From 
Ultrasound Assessment of Deep Tissue Injury in Pressure Ulcers: Possible Prediction of Pressure” by 
A. Noriyoki et al., 2009, American Society of Plastic Surgeons, 124, p. 546.
Third p
arty co
pyrigh
t mate
rial rem
oved
- 195 -
Chapter 6: Optical Coherence Tomography for the Non-Invasive Evaluation of Pressure Ulcers 
6.2   Research outline 
This chapter outlines an observational audit carried out by myself designed to investigate the 
potential application of OCT imaging in the assessment of pressure ulcer development and the 
evaluation of pre-and post-ulcerous skin. The ability of OCT to detect changes in skin layers 
that had undergone compression was demonstrated in Chapter 5, when magnets were applied 
to excised murine tissue. It was anticipated that these results could be extrapolated to human 
skin, whereby the effect of pressure on skins layers would be detectable in in vivo OCT scans. 
This chapter explores the ability of OCT to predict sites of pressure ulcer formation by imaging 
the skin before the ulcer is surface-detectable and to differentiate between ambiguous pressure 
ulcer stages based on internal subsurface biomarkers, such as changes in skin layer thickness 
and the presence/absence of particular structures. OCT can provide both standardised 
qualitative and quantitative data through B-scans and A-scans respectively and could 
potentially provide information on pressure-related injury on a continuous scale rather than in 
discrete categories. In this way, OCT scanning could help improve clinical diagnosis and help 
reduce the number of pressure ulcers that develop in hospital setting by providing information 
that is more indicative of the severity and nature of subsurface skin damage. Furthermore, its 
use could be combined with algorithms that could determine when and where the application 
microneedling should be applied to the greatest effect and could also be used to monitor the 
pharmacologic action of therapeutics delivered by microneedles. 
The main aims of the audit were to investigate whether OCT could improve the evaluation of 
early stage pressure ulcers at the bedside over traditional scoring scales. Secondary to this was 
whether OCT could predict if an existing pressure sore was likely to resolve or worsen (which 
could impact on treatment) and if it could identify where a pressure sore was likely to occur. 
The final aim was to investigate whether OCT could distinguish between early stage pressure 
ulcers and other skin diseases. To achieve these aims, the objectives of the observational audit 
were to acquire OCT images from subjects with: 
• pressure ulcers at differing NPUAP stages,
• resolved pressure ulcers (resolved either through secondary intention or surgical
intervention),
• areas predicted by the ward staff to be at risk of pressure ulcer development,
• any other existing skin conditions in the areas of the body at high risk of pressure ulcer
development.
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6.3   Methods and materials 
6.3.1   Subject selection 
The observational audit was carried out by myself in the Osborne 2 ward of the Spinal Cord 
Injuries and Neurorehabilitation Unit of the Northern General Hospital, Sheffield, UK. Osborne 
2 accommodates twenty-two subjects and admission into the ward is based on the primary 
criterion that the individual has a pressure ulcer that needs surgical intervention or close clinical 
care. Subject participation in this study was granted by verbal consent and a total of six 
volunteers consented to participate in the audit. Of the six participants four were male and two 
were female. There were no exclusion criteria based on age, gender, body mass index (BMI) or 
co-morbidities. To be included in the study the subject must either have a pressure ulcer of any 
stage or have previously had a pressure ulcer of any stage which resolved through surgical 
intervention or by secondary intention. Subjects with a dermatological condition at an 
anatomical site where pressure ulcers typically develop, such as the sacrum, were also included. 
6.3.2   Equipment 
This evaluative study used non-contact image acquisition of pressure ulcers, skin margins and 
healthy skin using a portable OCT scanning workstation. The workstation was supplied by 
Grafton Optics (Watford, UK) and was comprised of a central processing unit, a monitor and 
the lightweight and modular iVue® spectral-domain OCT ocular scanner (Optovue, California, 
USA). The iVue® scanner was originally designed for ophthalmological applications including 
retinal and corneal assessments of medical eye problems, but was employed in this study as the 
resolution was far superior to the available OCT skin-scanning alternative. The scanner had a 
special iCam® lens attachment required to take corneal scans. Corneal scans were chosen to 
image the skin instead of retinal scans since retinal scans modify image acquisition algorithms 
to account for the refraction of light as it passes through the eye’s viscous humour. The iVue® 
scanner produced 26,000 A-scans per second with a scan beam wavelength of 840 nm (± 10 
nm) and a subject interface working distance of approximately 2 cm. It offered a depth 
resolution of as low as 5 µm. 
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6.3.3   Image acquisition 
The OCT workstation was moved to the subject’s bedside on a portable table and was powered 
by mains electricity available by each bed. The skin was not cleaned prior to imaging but any 
wound dressings were removed. The working distance of the scanner was 2 cm, so the scanning 
head was held approximately this distance from the skin until the skin surface and a suitable 
portion of the subsurface were displayed. The images were displayed simultaneously on the 
computer monitor and on an in-built screen at the back of the OCT scanner. Image acquisition 
was manually controlled by the computer mouse and through foot pedals. Images were taken 
in grey-scale format and saved electronically for later analysis by imaging software. The 
scanning software provided immediate feedback on scan quality, prompting the operator to 
repeat the scan were the quality was below standard. A 5MP camera just below the lens also 
took digital images of the skin. 
 Figure 6.3 — Photographs of the OCT scanner and workstation supplied by 
Grafton Optics, Watford: (A) The OCT workstation consisted of the iVue® Optovue 
OCT scanner, a computer monitor and a central processing unit [CPU] on a portable 
table. (B) Side view of the OCT scanner. (C) Front view of the OCT scanner with the 
iCam® lens attachment. (D) Demonstration of non-contact imaging of wrist skin with a 
working distance of approximately 2 cm. 
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Each subject constituted an individual case study and data on their basic profile and medical 
history were collected with informed consent. Sites where images were taken depended on the 
location of the subjects’ pressure ulcer(s). Where possible, scans of contralateral or unaffected 
wrist skin were also taken. Subjects were asked to remain as still as possible during scans to aid 
the acquisition of high quality images. Multiple scans of the same region were achieved through 
stay-on modus replicates. Each set of subject scans took roughly ten to fifteen minutes including 
set-up of the OCT scanning equipment. The best quality scans were selected for analysis. To 
minimise cross-contamination between subjects the iCam® lens was cleaned and sterilised with 
antiseptic wipes and alcohol rub between different subjects. This was a precautionary measure 
advised by the nurses even though the OCT scan was a non-contact method. 
6.3.4   Image analysis 
The OCT images were saved during scanning and analysed afterwards using ImageJ® software 
by the operator (myself). Of the six subjects scanned, only one subject had insufficient scan 
quality as indicated by low quality scan score and their scans were excluded from the study. 
ImageJ® was used to make scaled measurements of the thickness of skin layers. Maximum 
subsurface penetration depth averaged around 600 µm across all scans. As the OCT images 
provided subsurface cross-sections through the skin, different architectural characteristics could 
be compared across different skin states and ulcer stages. OCT images were also taken from a 
healthy individual (who was not a patient in the ward) to act as a control. When analysing the 
images, the operator was not blinded to the patient or the NPUAP stage of the pressure ulcer 
due to the preliminary nature of the audit. Structures in the OCT images of the pressure ulcers 
were compared to the corresponding NPUAP description to help identify them. A ‘+’ score was 
assigned when a structure had been positively identified and ‘++’ when there was a strong 
presence of that structure. When a structure was not present in an image a score of ‘–’ was 
assigned. Quantitative data had also been collected for each image through the iVue® scanning 
system.
6.4   Cases studies 
Subject case studies are presented as a brief medical background of the subject followed by 
their pressure ulcer history and their OCT scans. For confidentiality, subjects are referred to by 
number. 
6.4.1   Subject 1 
Subject 1 was a 63 year-old Caucasian male with a normal BMI who had been paraplegic for 
30 years. The subject had a surgically debrided and sutured stage 4 sacral pressure ulcer that 
- 198 -
- 199 -
Chapter 6: Optical Coherence Tomography for the Non-Invasive Evaluation of Pressure Ulcers 
had been treated one week prior to the OCT scan and was the cause of ward admission (Figure 
6.4 – B). The subject also had a stage 1 pressure ulcer on the right ischium, previously stage 2, 
that had healed by secondary intention prior to ward admission (Figure 6.4 – C) and a stage 1 
pressure ulcer on their knee which was reported by the clinical staff to heal transiently (Figure 
6.4 – D-E). OCT scans where compared with healthy ipsilateral skin on the trochanter (Figure 
6.4 – A).  
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Figure 6.4 — OCT scans from subject 1: (A) Scan of the centre of normal ipsilateral trochanter. 
(B) Centre of a surgically treated and sutured stage 4 pressure ulcer on the right ischium. (C-D)
uneven layering and thickening of the upper skin layers observed in a stage 1 pressure ulcer on the
subject’s right ischium. (E) Thickening in upper epidermal layers observed in the OCT scans of a
stage 1 pressure ulcer on the subject’s knee; [PU = pressure ulcer; HF = hair follicle].
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6.4.2   Subject 2 
Subject 2 was a 75 year-old Caucasian female subject and T12 paraplegic The subject had a 
surgically debrided and cavitied stage 4 pressure ulcer on their right trochanter. 
Figure 6.5 — OCT scans and camera images from subject 2: (A) Scan taken from the centre of 
a stage 4 pressure ulcer on the subject’s right trochanter. Wound exudate and surface moisture can 
be seen in both the camera image (inset) and the scan. (B) Circular subsurface shadows observed 
in the centre of the same stage 4 pressure ulcer; [PU = pressure ulcer]. 
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6.4.3   Subject 3 
Subject 3 was an 80-year-old Caucasian male subject with a notably high BMI (> 25) and was 
a T10 paraplegic. The subject had a surgically debrided stage 4 sacral pressure ulcer treated one 
week prior to the OCT scan which had been the cause of admission to the ward.  
Figure 6.6 — OCT scans from subject 3: (A) Scan of non-ulcerous skin taken from the subject’s 
trochanter. (B) Circular subsurface regions observed at the centre of the subject’s stage 4 sacral 
pressure ulcer. (C) Scan of skin marginal to the stage 4 pressure ulcer; [PU = pressure ulcer]. 
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6.4.4   Subject 4 
Subject 4 was a 54-year-old Black-British male and a T10 paraplegic. The subject had a 
surgically debrided and sutured stage 4 pressure ulcer on their right ischium. New breakage of 
the skin (exposure of dermis) along the anterior portion of the suture line was observed. 
Figure 6.7 — OCT scans from subject 4: (A) Scan of non-ulcerous skin taken from the subject’s 
right wrist. (B) Scan from the suture line of a surgically debrided and sutured stage 4 pressure ulcer 
on the subject’s right ischium with evidence of thickening of the upper skin layers. (C) Scan of 
skin breakdown along the anterior aspect of the suture line layer showing evidence of layer 
thickening; [PU = pressure ulcer]. 
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6.4.5   Subject 5 
Subject 5 was a 74-year-old Caucasian female and a T6 paraplegic. The subject had no current 
detected pressure ulcers but had large areas of chronic dermatitis on their groin, genitalia, 
perianal region and buttocks. 
6.5   Results 
6.5.1   iVue® OCT scans 
The typical penetration depth of OCT scanning ranges from several hundred microns to several 
millimetres depending on the exact frequency of light being used and the scattering properties 
of the tissue being imaged. For the iVue® scanner, skin penetration depth in the observation 
audit was on average 600 µm (with up to 800 µm in some scans) and this provided enough 
depth to image into the upper dermis. The iVue® OCT scans were also able to differentiate 
between the discrete structural layers of the upper skin namely the stratum corneum, epidermis 
and papillary dermis as well as being able to resolve hair follicles. It is important to note that 
Figure 6.8 — OCT scan of subject 5 suffering from chronic dermatitis on their buttocks: (A) 
Non-ulcerous skin from the subject’s right wrist. (B) A region of dermatitis on the buttocks with 
evidence of subsurface texturisation and dilated area as indicated.  
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the relative thicknesses of these layers from the case studies were dependent on several factors 
including body region and the subject’s age. For example, the stratum corneum is thicker on 
the palms of the hands compared with the dorsal aspect of the forearm312. Additionally, older 
subjects may have thinner skin as the epidermis is known to thin with age72. Measurements 
from the OCT scans of healthy human skin from an individual with no prior history of pressure 
ulcers was in good concordance with previously reported values for the age-range and gender 
of the individual (Figure 6.9).  
Figure 6.9 — OCT scan of healthy forearm skin from an individual with no prior history of 
pressure ulcers. The OCT image is able to distinguish between three skin layers the stratum 
corneum [SC], epidermis [E] and dermis [D] which have been demarcated. A photograph taken on 
the the iVue® scanner’s in-built 5MP camera of the same region is inset.  
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6.5.2   Subject case studies 
Subjects had to be imaged lying down — all were paraplegic so body positions for imaging 
were highly limited or required assistance from a second person that needed to be a trained 
member of medical staff. Pressure ulcer distribution amongst the subjects indicated that the 
supine and lateral positions were the most common positions for bed-ridden subjects in the 
ward (Figure 6.10). Pressure ulcers were typically seen around the lower back, sacrum, ischium 
and trochanter. Despite current turning protocols reported in the literature, nurses commented 
that subjects in Osborne 2 were turned every 4–6 hours. All subjects in the study were 
paraplegic either due to congenital illness or paralysis acquired during their life-time. Of the 
five subjects included in the study, three presented with a surgically debrided stage 4 pressure 
ulcer, two with a surgically sutured stage 4 pressure ulcer, one with a stage 2 pressure ulcer and 
one without any pressure ulcers but with chronic dermatitis in a region vulnerable to ulcer 
development. Only one subject (subject 1) had two concurrent unresolved pressure ulcers. 
Figure 6.10 — Anatomical positions showing the distribution of exisiting or 
resolved pressure ulcers amongst all five subjects successfully scanned in Osborne 
2.
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Both subjects scanned with unsutured, surgically debrided stage 4 pressure ulcers (subjects 2 
and 3), showed circular subsurface shadowing indicative either of potential artefacts caused by 
surface moisture, deteriorated subsurface regions or subcutaneous fat. Two pressure ulcers on 
the same subject (subject 1), currently classed as stage 1, showed uneven thickening within the 
epidermal layer, not seen as prominently in healthy skin or ulcers at higher stages in other 
subjects. This uneven subsurface thickening was also observed at the breakage of a suture line 
of a surgically treated stage 4 ulcer (subject 4). Subsurface skin texturisation and very strong 
back-scattering signals could be indicative of underlying inflammation.	 What appears to be 
subsurface texturisation is present in the dermis of a subject suffering from chronic dermatitis 
of the buttocks (subject 5). Compared with healthy control skin, this area exhibited strong signal 
reflectance which is consistent over a series of images taken in that area.  
6.6   Discussion 
This first-of-its-kind observational audit was carried out to evaluate the ability of cutaneous 
OCT scanning to assess pre-ulcerous, ulcerous and post-ulcerous skin and to ascertain whether 
there was congruity between current clinical staging scales and the subsurface characteristics 
observed in the scans. OCT B-scans in cutaneous imaging have already been shown to be 
excellent for obtaining qualitative results on the subsurface skin architecture and quantitative 
measurements of individual skin layers59,71,98–100. Authors have reported accurate in vivo 
measurements of epidermal thickness across different genders, ages and body regions using 
OCT scanning72,312–314. OCT scanning has also been used to diagnose and evaluate a range of 
skin conditions and has been repurposed from its original clinical application of monitoring 
Table 7 — NPUAP staging and corresponding OCT findings for the five subjects with current 
or healed pressure ulcer injury or a dermatological condition at typical pressure ulcer 
development sites. 
OCT Finding 
Subject NPUAP stage 
or condition 
Location Uneven layer 
thickening 
Subsurface 
shadowing 
Subsurface 
texturisation 
1 1 
1 
4 healed 
(sutured) 
ischium 
knee 
sacrum 
++ 
+ 
– 
– 
– 
– 
– 
– 
– 
2 4 trochanter – ++ – 
3 4 sacrum – + – 
4 4 healed 
(sutured) 
ischium + – – 
5 dermatitis buttocks – – + 
NPUAP = National Pressure Ulcer Advisory Panel.   ++ strongly positive, + positive, – negative. 
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medical eye conditions, for example in the non-invasive diagnosis of non-melanoma skin 
cancer and monitoring of inflammation in inflammatory skin conditions. 
During the audit, there were four subsurface structures that were flagged as potentially 
representing abnormal tissue damage. These were uneven thickening of the uppermost skin 
layers, circular subsurface shadows, subsurface texturisation and dilated low back-scattering 
regions. Uneven thickening of the uppermost skin layers was seen in early stage ulcers of 
several subjects as well as at suture scars of surgically treated stage 4 ulcers. The epidermal 
layers appeared to thicken but without blistering and could be indicative of necrosis or 
inflammatory changes. This uneven thickening of subsurface layers in pre-ulcerous, early 
ulcerous and post-ulcerous skin could also be indicative of future skin deterioration. Circular 
subsurface shadows were present in all the open stage 4 pressure ulcers that were imaged and 
could be indicative of underlying necrotic damage, an artefact of wound exudate on the skin 
surface or the backscattering pattern of subcutaneous fat. Similar structures have been identified 
in OCT images of skin in the inflammatory phase of acute wound healing301. The authors 
identified honeycomb shadows caused by the presence of subcutaneous fat in a healthy subject 
that had been given a 5 mm punch biopsy (Figure 6.11 – B).  
Subsurface skin texturisation with very strong signalling could be indicative of underlying 
inflammation that may be a result of a dermatological condition other than pressure-related 
injury such as contact dermatitis. These structures have been previously identified as collagen 
misalignment in the dermis298. A participant in the audit with contact dermatitis and no current 
pressure ulcers exhibited these signals in the OCT scans of their buttocks. Dermatitis in this 
region is related to urinary and/or faecal incontinence, whereby moisture and changes in pH 
result in an inflammatory response due to prolonged excretory product contact with the skin. 
The OCT scans of this subject also contained regions of relatively low backscattering in the 
dermis. Similar structures have been reported in psoriatic skin and have been identified as 
dilated blood vessels61. This is in good concordance with tissue in a highly inflammatory state. 
Though dermal inflammation is not specific to dermatitis, presence of these markers may be 
able to differentiate between contact dermatitis and pressure-related injuries.  
OCT scanning could be also useful in scar assessment of subjects with surgically treated 
pressure ulcers. Skin scarred from surgical treatment of a severe pressure ulcer often has a very 
different physical appearance and texture to normal skin due to the remodelling of the ECM 
during post-wound closure. These scars should be closely monitored in subjects as they occur 
in places already identified as high risk for pressure ulcer development and are vulnerable to 
deterioration. OCT scans could be used to monitor such scars for signs of skin or suture line 
deterioration, especially in recurrently or consistently immobilised individuals. The scans may 
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be able to identify and differentiate between wounds that have healed successfully and those 
that are likely to worsen without the appropriate preventative measures.  From the OCT images 
on subject 4 it may be inferred that this subject is at risk of re-developing an ulcer at that site 
since the subsurface markers are similar to those seen with stage 1 ulcers, though a subject 
follow-up would be required to determine the exact outcome. For confirmation of what the 
observed structures represent, the OCT scans need to be compared with histological sections. 
Alternatively, to avoid highly invasive biopsies, a prospective aspect to the audit would assess 
whether predictions made from the subsurface biomarkers observed in the OCT scans were 
accurate. 
Table 8 — Summary of the possible relationship between OCT findings and the pressure ulcer 
stage or dermatological condition they were observed in; [PU = pressure ulcer]. 
OCT finding Possible biomarker of: PU stage or condition 
observed in 
Upper layer thickening Epidermal changes potentially indicative of 
skin deterioration 
• Stage 1 PU
• Suture line breakage
Circular subsurface 
shadows 
Exposed subcutaneous fat or 
Artefacts from surface moisture or 
Underlying necrotic damage 
Stage 4 PU 
Subsurface texturisation Collagen misallighnment in dermis Dermatitis (chronic 
inflammation) 
Dilated regions Dilated blood vessels in dermis Dermatitis (chronic 
inflammation) 
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Figure 6.11 — Images of different skin conditions using optical coherence tomography 
or ultrasound: (A) OCT scan of inflammation in psoriatic skin showing dilated blood 
vessels in the dermis. Adapted from “Optical coherence tomography in contact dermatitis 
and psoriasis,” by J. Wlezel et al., 2003, Arch Dermatol Res, 295, p. 52. (B) OCT scan of 
skin in the process of acute wound healing. Adapted from “Optical coherence tomography: 
a reliable alternative to invasive histological assessment of acute wound healing in human 
skin?” by N.S Greaves et al., 2014, The British Journal of Dermatology. 170, p. 846. (C) 
Ultrasound scans showing hypoechoic regions (left) and collagen misalignment (right). 
Adapted from “Ultrasound Assessment of Deep Tissue Injury in Pressure Ulcers: Possible 
Prediction of Pressure,” by A. Noriyoki et al., 2009, American Society of Plastic Surgeons, 
124, p. 546.  
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6.6.1   Limitations of the OCT scanning system 
During the observational audit there were several notable limitations of the OCT scanning 
system. Firstly, to acquire high quality scans the subject needed to remain completely still and 
the hand of the operator needed to be steady. Poor quality scans were typically a result of subject 
body movement (Figure 6.12 – A). With repeated measurements at the same site, scan quality 
typically became poorer as any unnatural positions the subject was placed in became more 
difficult to maintain. Secondly, undulating or jutting structures were difficult to image such as 
those around the knee or uneven wound surfaces (Figure 6.12 – B). Similarly, imaging into 
ulcerated cavities, such as the unsutured stage 4 pressure ulcers proved difficult since the 
scanning head had to be very carefully guided into the ulcer without any part of the lens or 
scanning head touching the sides of the wound bed. In these instances, imaging at the margins 
of the pressure ulcer was an easier option. Furthermore, artefacts in the images — namely the 
circular subsurface shadows seen in the stage 4 pressure ulcer scans — may have be caused by 
slough, debris and wound exudate on the skin which were not removed prior to scanning.  
Figure 6.12 — Examples of poor quality OCT scans and their corresponding digital 
photographs taking during the observational audit: (A) OCT scan taken across a stage 4 
pressure ulcer. (B)  An OCT scan taken during subject movement. 
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6.6.2   Novel pressure ulcer evaluation and early pressure ulcer detection techniques 
There have been two major approaches to the imaging of pressure ulcers that have emerged 
over the past twenty years. These are the repurposing of existing imaging tools and the 
development of new medical devices. Each approach has its own advantages and limitations. 
The rationale behind the repurposing of existing imaging modalities is to reduce costs 
associated with device development, extensive clinical trials and product manufacture. Well-
documented protocols and safety profiles already exist for the equipment, there are cohorts of 
staff already trained to operate the systems and the technology is often readily available in the 
clinic. The major disadvantage is that the technology is not specific to the disease in question. 
Furthermore, any biomarkers identified in one dermatological disease may in fact be seen in 
other diseases and thus not provide enough diagnostic detail. It is likely that the repurposed 
devices need adaptations to better suit their novel application, such as being made more portable 
or having adjustments made to image acquisition parameters. Examples of repurposed imaging 
modalities include magnetic resonance imaging (MRI), computerised tomography (CT), and 
ultrasound which have all been investigated in pressure ulcer evaluation210,298,315. Of particular 
interest, in comparison to OCT, is ultrasound due to its very low risk, highly portable, in vivo 
imaging capabilities. 
Ultrasonographic evaluation of pressure ulcers has identified potential bio-structural markers 
indicative of underlying DTI. In their clinical study, Aoi et al. (2009) investigated the ability 
of ultrasound assessment to predict pressure ulcer progression in pressure ulcers with DTI298. 
The authors noted four structures in their prospective study that were consistent with abnormal 
signs of DTI. These were unclear layered structures, discontinuous fascia, hypo-echoic lesions 
and heterogeneous hypo-echoic areas. Their results suggested that of the four structures 
observed only two, discontinuous fascia and a heterogeneous hypoechoic area, were reliable 
predictors of a negative outcome i.e. advancement of pressure ulcer staging, and were reported 
as being indicative of deep tissue necrotic changes. In comparison with OCT,  high-frequency 
ultrasound does not resolve structures or skin architecture as well as OCT but is able to image 
much deeper into the tissue. This can be clearly seen when comparing OCT and ultrasound 
scans of similar regions.  
As aforementioned, one of the major setbacks of repurposing existing imaging tools designed 
for a particular medical application is that the device is often not completely adapted or specific 
to the new purpose. In contrast, there have been several medical devices designed for use by 
healthcare providers for implementation as part of pressure ulcer prevention programmes. 
Objective biophysical markers such as tissue bioimpedance and sub-epidermal moisture have 
been identified as useful indicators of pressure ulcer-related subsurface injury316. Sub-
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epidermal moisture reflects changes in the interstitial fluid as a result of inflammatory and 
necrotic activity in the epidermal and dermal layers of the skin which also have an effect on the 
electrical properties — or bioimpedance — of the tissue316. The handheld SEM (sub-epidermal 
moisture) Scanner™ produced by Bruin Biometrics (California, USA) was designed as a 
biosensor for changes in pressure ulcer injury317. The developers suggest that sub-epidermal 
moisture representing localised oedema can differentiate between healthy skin and skin with 
current or imminent pressure-induced tissue damage which has been corroborated by numerous 
studies318–322. When pressed against the skin the SEM ScannerTM displays a digital reading 
which acts as a comparative measure of sub-epidermal moisture relative to adjacent tissues317. 
The device offers the operator simple feedback, providing an objective value with minimal 
interpretation needed. However, there is no visual feedback from the scanner of the regions 
being imaged. Pilot month-long trials have been undertaken to assess the predictive capacity 
and reliability of the SEM scannerTM in pressure ulcer assessment317. 
6.6.3   A role for OCT at the bedside? 
OCT for early stage pressure ulcer evaluation 
One of the main aims of pressure ulcer evaluation should be to reduce avoidable harm through 
early pressure ulcer detection. Pre-ulcerous skin or pressure ulcers at the earliest stages of 
development are most likely the best targets for OCT imaging evaluation since, at later stages, 
the extent of damage is already evident and the main intervention methods would be currently 
limited to surgical debridement and suturing. OCT may also be able to assess pressure ulcers 
marked as unstageable and provide insight to the extent of underlying non-visible damage to 
confirm clinical suspicion. A less subjective method of pressure ulcer categorisation could also 
improve consensus among medical staff. Despite its limitations, OCT offers a reasonable 
alternative to traditional bedside scoring systems and competitor devices. 
OCT for monitoring microneedle-assisted drug delivery 
In addition to its evaluative capacity, OCT could also be used to observe the effect of treatments 
at an injury site. OCT is able to image and guide microneedle-mediated drug delivery for 
example. Microneedle insertion has been successfully visualised by OCT scanning in 
vivo239,323, wherein microneedle dissolution177,323,324 and rate of micropore closure325,326 were 
observed. In Chapter 2, depth penetration of the microneedle was observed in the Strat-MTM 
synthetic membrane. In this vein, OCT could also be used to monitor the pharmacologic action 
of the delivered active pharmaceutical ingredient (API), such as doxycycline, and could help 
determine whether an intact ulcer is resolving or worsening through the observation of 
informative subsurface markers. OCT microangiography may also be useful in monitoring 
ischemia and reperfusion of tissue in response to external pressure at the bedside295,327. 
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Preliminary experiments have begun to explore the application of OCT in facilitating 
intradermal drug delivery (see 
Appendix E — OCT images of drug delivery through a hollow microneedle array, p.265). 
6.7   Future work 
Future studies would require a larger subject cohort, preferably with a broader range of skin 
pigmentation and pressure ulcer stages and a prospective aspect to the study to follow-up the 
pressure ulcers over time. In this way the predicative ability of OCT in evaluating pressure ulcer 
development can be assessed and can also be compared with existing risk assessment scales 
including the Norton, Waterlow and Braden scales. Furthermore, quantitative analysis of the 
OCT scans such as the mean grey value or peak values from A-scans could allow for an 
algorithm between scan and skin status to be developed. A high-resolution hand-held 
dermatological OCT scanner, rather than a portable ophthalmological OCT scanner could 
improve the scanning and image acquisition experience for the operator. Inclusion of two or 
more operators within the study would help determine whether inter-operator image acquisition 
and interpretation is in good concordance.  
6.8   Conclusion 
Here it has been demonstrated, with preliminary scans, a potential correlation between 
subsurface markers imaged by OCT and traditional clinical staging systems for pressure ulcer 
classification. It has been shown that OCT may offer additional useful information on top of 
these scales, such as prediction of normal skin areas likely to become ulcerous or predictions 
of that an existing sore will soon worsen, which could immensely improve clinical care and 
intervention strategies for the subject implicating a role for OCT at the bedside. Further still, 
scar assessment could be achieved through OCT scanning and allow for monitoring of high 
risk, previously deteriorated and ulcerous regions. A hypothesised congruity between current 
staging scales and architectural changes in OCT scans is outlined in Figure 6.14 .  
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Figure 6.13 — The use of OCT in the literature to visualise microneedle insertion and 
monitor dissolution: (A) OCT images over time of dissolving microneedles applied to rat 
skin. From “Influence of skin model on in vitro performance of drug-loaded soluble 
microneedle arrays”: by M. J. Gardland et al., 2012, International Journal of Pharmaceutics, 
434, p 86. (B) Dissolution of 2 mm silk microneedles in murine skin as visualised by OCT. 
From “In vivo and in situ imaging of controlled-release dissolving silk microneedles into the 
skin by optical coherence tomography,” by R. Lie, M. Zhang and C. Jin, 2016, Journal of 
Biophotonics, 8, p. 7. 
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Overall Discussion 
Research summary 
The research hypothesis outlined at the beginning of this thesis was as follows: 
 “Intradermal delivery of doxycycline by microneedles is a promising tool for treating 
and preventing the development of early stage pressure ulcers.”  
This hypothesis was tested by: (i) showing how doxycycline inhibits MMP activity in vitro, (ii) 
showing how doxycycline can be efficiently delivered across the skin barrier using an epidermal 
mimetic, (iii) refining  a preclinical model of pressure ulcer formation to simulate stage 1 ulcers, 
(iv) establishing a non-invasive in vivo imaging tool to identify changes in the skin in the in
vivo and preclinical models (and validating the technical feasibility of this approach in humans),
and (v) evaluating pressure ulcer formation in the preclinical model (MMP expression,
histological and vascular changes etc.) which could be used to assess the effect of treatment
with doxycycline delivered by microneedles. From the culmination of research reported in this
thesis, microneedles have been shown to enhance intradermal permeation of doxycycline and
doxycycline has several attributes of an active drug suitable for the treatment and prevention of
pressure ulcers. However, further confirmatory experiments and most likely clinical trials
would be required to test the latter portion of the hypothesis.
Contribution to knowledge 
This body of work has introduced several concepts that have not previously been published in 
the literature. Firstly, microneedles have been suggested specifically in the treatment of 
pressure ulcers and this research has provided a background to how and why this is feasible, 
which, to my knowledge, has not been done before. Secondly,  it has been shown for the first 
time how the newly launched synthetic epidermal mimetic Strat-MTM could be permeabilised 
to large, hydrophilic molecules through the application of microneedles. This offers a useful 
basis on which other similarly-sized drugs could also be tested. Thirdly, it was shown how the 
delivery of doxycycline through microneedle-treated Strat-MTM could be monitored through its 
effect on existing and validated tissue equivalent models.  
Overall Discussion
Furthermore, these existing in vitro models have been better adapted in this research to reflect 
the external stressors associated with the pressure ulcer microenvironment. This included 
introducing clinically relevant pressure (that results in tissue breakdown in vivo) by exposing 
the model to a pressure of 32 mmHg (equivalent to capillary closing pressure [CCP]). From 
this work, the effect of doxycycline and its microneedle-mediated delivery could be further 
explored in the preclinical model using magnetic compression to simulate CCP. Importantly, 
this research also began to explore a potentially negative effect of microneedling on cell 
viability in injured and stressed tissue, though further investigation is required to draw valid 
conclusions. Finally, the concluding research chapter detailed the first known evaluative study 
to use OCT to image into both intact and open pressure ulcers. This novel approach provided a 
basis for the repurposing of existing imaging tools in clinical pressure ulcer care and 
management.  
From bench to bedside — potential real world applications 
There is great potential for the clinical use of microneedle rollers in the chronic wound 
management of pressure ulcers, specifically to deliver an active drug in a timely manner to 
prevent pressure ulcer development and to treat existing tissue damage. There are several ways 
this can be achieved. The microneedle rollers could be used to permeabilise the skin surface of 
an intact stage 1 pressure ulcer, or DTI, using their high mobility and ability to cover large 
surface areas. A drug-infused patch or wound dressing could then be applied onto the skin to 
promote wound healing (Figure 7.1 – A). In the case of early stage open ulcers (i.e. stage 2 
pressure ulcers), the microneedle rollers can be used in a circumferential manner, by rolling the 
device around the perimeter of the wound. This process should itself promote re-
epithelisation84, but also permeabilises the surrounding skin to active drugs in order to help 
reduce the spread of damage into the surrounding tissue (Figure 7.1 —  B). 
For very large cavitied ulcers, the traditional treatment options are indicated. In these instances, 
doxycycline treatment could be used as an adjunctive chemotherapy to help reduce elevated 
MMP levels. This could be achieved through the administration of a doxycycline-containing 
gel into the wound cavity or lavage of the wound bed surface, essentially rinsing, 
with doxycycline solution (Figure 7.1 – C). Although doxycycline is the current drug of 
interest, it need not be the only drug delivered in pressure ulcer treatment — its role is 
interchangeable with other large hydrophilic drugs with a potential therapeutic effect in 
pressure ulcers. In a similar vein, microneedle-enhanced drug delivery could also be 
applied to other chronic wounds including diabetic ulcers and venous leg ulcers.  
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Hollow microneedles may be able to replace the solid microneedles in some instances, for 
example in the infusion of less viscous, fluid drug formulations. Sufficient dosaging by infusion 
may be problematic however. The development of a single hollow microneedle was explored 
during the research in collaboration with a materials scientist and is discussed further in: 
Appendix A — Development of a single custom-made hollow microneedle in combination with 
a Hamilton syringe,  p. 240.  A potential drug delivery vehicle that could be used in 
combination with the hollow microneedles is a specialised gel that was developed in 
collaboration with a protein chemist. This MMP-cleavable smart gel encapsulates doxycycline 
and only forms when the components are combined during dual microinjection. This novel 
smart gel is discussed in detail in: 
Appendix C — Development of an MMP-cleavable protein-based smart gel, p. 243. 
The maximum length of microneedles that were investigated in this research were 750 µm. 
However, microneedles, contrary to their name, can reach up to 3 mm. Due to the variety of 
different lengths, different microneedles could be used at different anatomic sites for 
intradermal drug delivery, seeing as skin layer thickness is not consistent throughout the body. 
Numbing cream may be applied if the patient is capable of pain sensation in the region of 
application (pressure ulcer patients are typically paralysed) and if the microneedles penetrate 
sufficiently deep as to stimulate dermal nerves. Clinically-used microneedle roller systems 
should be single-use devices for hygiene purposes and due to the likelihood of blunting of the 
needle tops which would reduce efficacy. The use of drug ‘delayers’ could help slow 
micropore-resealing kinetics to increase the length of time in which the drug can permeate328,329. 
Achieving the goals of the BBSRC LIDo programme 
The major goal of the LIDo programme is to answer research questions through inter-
disciplinary, multi-institution research. This has been demonstrated in this research through 
collaborations across several disparate, but complementary, fields. These have included 
pharmaceutics for the monitoring of microneedle-mediated drug delivery, cell and molecular 
biology for the development of a dermal tissue equivalent model, material sciences for the 
fabrication of microneedles, molecular biophysics and protein chemistry for the development 
of smart gels and clinical imaging, in a research and a hospital setting, for the evaluation of 
OCT in a novel application. 
- 219 -
- 220 -
Figure 7.1 — Potential approaches to microneedle-mediated doxycycline delivery to various 
pressure ulcer stages: (A) Microneedle-mediated permeabilisation of a stage 1 ulcer, followed by 
application of a wound dressing, gel or lotion containing doxycycline or another suitable API. (B) 
Circumferential application of the microneedles around the perimeter of the open ulcer, followed by direct 
application of a drug-infused gel or lotion. (C) Direct delivery of doxycycline into a cavitied late stage 
ulcer in the form of a gel (left) or lavage (right) with doxycycline solution. 
Overall Discussion
Bibliography 
- 221 -
Bibliography 
1. Mustoe, T. Understanding chronic wounds: a unifying hypothesis on their pathogenesis and
implications for therapy. Am. J. Surg. 187, 65S–70S (2004).
2. Coleman, S. et al. Patient risk factors for pressure ulcer development: Systematic review.
Int. J. Nurs. Stud. 50, 974–1003 (2013).
3. Thomas, D. R. Prevention and treatment of pressure ulcers: what works? what doesn’t?
Cleve. Clin. J. Med. 68, 704–7, 710–14, 717–22 (2001).
4. (2014a)., N. C. G. C. Pressure Ulcer Prevention: The Prevention and Management of
Pressure Ulcers in Primary and Secondary Care. CG179. (2014).
5. Schindler, C. A. et al. Under pressure: Preventing pressure ulcers in critically ill infants. J.
Spec. Pediatr. Nurs. 18, 329–341 (2013).
6. Shahin, E. S. M., Dassen, T. & Halfens, R. J. G. Incidence, prevention and treatment of
pressure ulcers in intensive care patients: a longitudinal study. Int. J. Nurs. Stud. 46, 413–
21 (2009).
7. Keller, B. P. J. A. & Ramshorst, B. Van. Pressure ulcers in intensive care patients  : a review
of risks and prevention. Intensive Care Med 28, 1379–1388 (2002).
8. Peterson, N. & Bittmann, S. The epidemiology of pressure sores. Scand. J. Plast. Reconstr.
Surg. 5, 62–66 (1970).
9. Barbenel, J., Jordan, M. & Nicol, S. Incidence of pressure sore in the greater Glasgow health
board area. Lancet 2, 548–550. (1977).
10. Versluysen, M. Pressure sores in elderly patients. The epidemiology related to hip
operations. J. Bone Jt. Surg. 67, 10–13 (1985).
11. Marsden, G. et al. A cost-effectiveness analysis of two different repositioning strategies for
the prevention of pressure ulcers. J. Adv. Nurs. 1–7 (2015). doi:10.1111/jan.12753
12. Bennett, G., Dealey, C. & Posnett, J. The cost of pressure ulcers in the UK. Age Ageing 33,
230–5 (2004).
13. Agrawal, K. & Chauhan, N. Pressure ulcers: Back to basics. Indian J. Plast. Surg. 45, 244–
254 (2012).
14. Bouten, C. V, Oomens, C. W., Baaijens, F. P. & Bader, D. L. The etiology of pressure ulcers:
skin deep or muscle bound? Arch. Phys. Med. Rehabil. 84, 616–9 (2003).
15. Bouton, V. C. B. Etiology and pathology of pressure sores: a literature review. WFW report
96.015 (1996).
16. Baranoski, S. Raising awareness of pressure ulcer prevention and treatment. Adv. Skin
Wound Care 19, 398-405–7 (2006).
17. Meehan, M. National pressure ulcer prevalence survey. Adv Wound Care 7, 27–37 (1994).
18. Mak, A. F. T., Zhang, M. & Tam, E. W. C. Biomechanics of pressure ulcer in body tissues
Bibliography 
- 222 -
interacting with external forces during locomotion. Annu. Rev. Biomed. Eng. 12, 29–53 
(2010). 
19. Walton-Geer, P. S. Prevention of pressure ulcers in the surgical patient. AORN J. 89, 538-
48-51 (2009).
20. Campbell, C. & Parish, L. C. The decubitus ulcer: facts and controversies. Clin. Dermatol.
28, 527–32 (2010).
21. Alvarez, O. Pressure ulcers - critical considerations in prevention and management. Clin
Mater 8, 209–222 (1991).
22. Levi, B. & Rees, R. Diagnosis and management of pressure ulcers. Clin Plast Surg 34, 735–
248 (2007).
23. Serpa, L. F., Santos, V. L. C. G., Peres, G. R. P., Cavicchioli, M. G. S. & Hermida, M. M.
Validity of the Braden and Waterlow subscales in predicting pressure ulcer risk in
hospitalized patients. Appl. Nurs. Res. 24, e23-8 (2011).
24. Anthony, D., Papanikolaou, P., Parboteeah, S. & Saleh, M. Do risk assessment scales for
pressure ulcers work? J. Tissue Viability 19, 132–6 (2010).
25. Waterlow. Pressure sores: A risk assessment card. Nurs. Times 81, 49–55 (19865).
26. Braden, B. & Bergstrom, N. A conceptual schema for the study of the etiology of pressure
sores. Rehabil. Nurs. 12, 8–12 (1987).
27. Kottner, J. & Dassen, T. Pressure ulcer risk assessment in critical care: interrater reliability
and validity studies of the Braden and Waterlow scales and subjective ratings in two
intensive care units. Int. J. Nurs. Stud. 47, 671–7 (2010).
28. Mallah, Z., Nassar, N. & Kurdahi Badr, L. The effectiveness of a pressure ulcer intervention
program on the prevalence of hospital acquired pressure ulcers: controlled before and after
study. Appl. Nurs. Res. 28, 106–113 (2014).
29. Pressure ulcers. NHS choices (2012). Available at: http://www.nhs.uk/Conditions/Pressure-
ulcers/Pages/Introduction.aspx.
30. Sugarman, B. et al. Osteomyelitis beneath pressure sores. JAMA 143, 683–688 (1983).
31. Hagisawa, S. & Ferguson-pell, M. Evidence supporting the use of two-hourly turning for
pressure ulcer prevention. J. Tissue Viability 17, 76–81 (2008).
32. Ã, K. V., Grypdonck, M. & Defloor, T. Alternating pressure air mattresses as prevention for
pressure ulcers  : A literature review. 45, 784–801 (2008).
33. Mcinnes, E., Sem, B., Jc, D. & Cullum, N. Support surfaces for pressure ulcer prevention
(Review). Cochrane Libr. 1–130 (2011).
34. Yusuf, S. et al. Microclimate and development of pressure ulcers and superficial skin
changes. Int. Wound J. ISSN 12, 1–7 (2015).
35. Thomas, D. R. Prevention and treatment of pressure ulcers. J. Am. Med. Dir. Assoc. 7, 46–
59 (2006).
36. Whitney, J. et al. Guidelines for the treatment of pressure ulcers. Wound Repair Regen. 14,
663–679 (1999).
37. Kuffler, D. P. Techniques for wound healing with a focus on pressure ulcers elimination.
Open Circ. Vasc. J. 3, 72–84 (2010).
38. Menke, M. N., Menke, N. B., Boardman, C. H. & Diegelmann, R. F. Biologic therapeutics
Bibliography 
- 223 -
and molecular profiling to optimize wound healing. Gynecol. Oncol. 111, S87-91 (2008). 
39. Cornell, R. S., Meyr, A. J., Steinberg, J. S. & Attinger, C. E. Debridement of the noninfected
wound. J. Vasc. Surg. 52, S31–S36 (2010).
40. Sherman, R. . Maggot therapy for foot and leg wounds. Int J Low Extrem Wounds 1, 135–
142 (2002).
41. Thomson, P. D. & Smith, D. J. What is infection? Am. J. Surg. 167, 7–11 (1994).
42. Daltrey, D., Rhodes, B. & Chattwood, J. Investigation into the microbial flora of healing
and non-healing decubitus ulcers. J Clin Pathol 34, 701–705 (1981).
43. Seiler, W., Stahelin, H. & Sonnabend, W. Effect of aerobic and anaerobic germs on the
healing of decubitus ulcers. Schweiz Med Wochenschr 109, 1594–1599 (1979).
44. Black, J. M. et al. Pressure ulcers: avoidable or unavoidable? Results of the National
Pressure Ulcer Panel consensus conference. Ostomy Wound Manag. 57, 24–37 (2011).
45. Lazzara, D. & Buschmann, M. Lazzara DJ, Buschmann MT. Prevention of pressure ulcers
in elderly nursing home residents: Are special support surfaces the answer? Decubitus 4,
42–49 (1991).
46. Whitney, J., Fellows, B. & Larson, E. Do mattresses make a difference? J Gerontol Nurs
10, 2025 (1984).
47. Krouskop, T., Williams, R. & Krebs, M. Effectiveness of mattress over- lays in reducing
interface pressures during recumbency. J Rehabil Res 22, 7–10 (1985).
48. Daechsel, D. & Connine, T. Special mattresses: effectiveness in preventing decubitus ulcers
in chronic neurologic patients. Arch Phys Med Rehabil 66, 246–248 (1985).
49. Bourdel-Marchasson, I Barateau, M. & Sourgen, C. Prospective audits of quality of PEM
recognition and nutritional support in critically ill elderly patients. Clin Nutr 18, 233–240
(1999).
50. Bourdel-Marchasson, I., Barateau, M. & Rondeau, V. A multi-center trial of the effects of
oral nutritional supplementation in critically ill older inpatients. GAGE Group. Groupe
Aquitain Geriatrique d’Evaluation. Nutrition  ; 16:1–5. 16, 1–5 (2000).
51. Tandara, A. a & Mustoe, T. a. Oxygen in wound healing--more than a nutrient. World J.
Surg. 28, 294–300 (2004).
52. Braddock, M., D, P., Campbell, C. J. & Zuder, D. Current therapies for wound healing  :
electrical stimulation , biological therapeutics , and the potential for gene therapy. Int. J.
Dermatol. 38, 808–817 (1999).
53. Chen, S., Ward, S. & Oluyinka, O. Ability of chronic wound fluids to degrade peptide
growth factors is associated with increased levels of elastase activity and diminished levels
of proteinase inhibitors. Wound Repair Regen 30, 23–32 (1997).
54. Gregory, S., Boyle, J., Rennison, T. & Cullen, B. An ORC/ Collagen Matrix containing
silver preserves wound healing growth factors from host and bacterial proteolytic
degradation. Wound Repair Regen. 13, A23-33 (2005).
55. Wlaschek, M., Peus, D. & Achterberg, V. Protease inhibitors protect growth factor activity
in chronic wounds. Br J Dermatol 137, 646–476 (1997).
56. Thomas, D. R. Are all pressure ulcers avoidable? J. Am. Med. Dir. Assoc. 2, 297–301 (2003).
57. Broughton, G., Janis, J. E. & Attinger, C. E. Wound healing: an overview. Plast. Reconstr.
Surg. 117, 1e-S–32e-S (2006).
Bibliography 
- 224 -
58. Stechmiller, J. K. et al. Guidelines for the prevention of pressure ulcers. Wound Repair
Regen. 16, 151–168 (2008).
59. Saito, Y. et al. The loss of MCP-1 attenuates cutaneous ischemia-reperfusion injury in a
mouse model of pressure ulcer. J. Invest. Dermatol. 128, 1838–51 (2008).
60. Ramundo, J. & Gray, M. Collagenase for enzymatic debridement - a systematic review. J.
Wound Ostomy Cont. 36, S4–S11 (2009).
61. Welzel, J., Bruhns, M. & Wolff, H. H. Optical coherence tomography in contact dermatitis
and psoriasis. Arch. Dermatol. Res. 295, 50–5 (2003).
62. Levin, J. & Maibach, H. The correlation between transepidermal water loss and
percutaneous absorption: an overview. J. Control. Release 103, 291–299 (2005).
63. Lai-Cheong, J. E. & McGrath, J. a. Structure and function of skin, hair and nails. Medicine
(Baltimore). 37, 223–226 (2009).
64. Wickett, R. R. & Visscher, M. O. Structure and function of the epidermal barrier. Am. J.
Infect. Control 34, S98–S110 (2006).
65. Salcido, R., Popescu, A. & Ahn, C. Animal models in pressure ulcer research. J Spinal Cord
Med. 30, 107–116 (2007).
66. Bouwstra, J. A. & Ponec, M. The skin barrier in healthy and diseased state. Biochim.
Biophys. Acta 1758 1758, 2080–95 (2006).
67. Gniadecka, M. & Jemec, G. B. Quantitative evaluation of chronological ageing and
photoageing in vivo: studies on skin echogenicity and thickness. Br. J. Dermatol. 139, 815–
21 (1998).
68. Lodish, H., Berk, A. & Zipursky, S. in Molecular Cell Biology. 4th edition. Section 22.3
(W. H. Freeman;, 2000).
69. Liao, F., Burns, S. & Jan, Y.-K. Skin blood flow dynamics and its role in pressure ulcers. J.
Tissue Viability 22, 25–36 (2013).
70. Bierman, W. The temperature of the skin surface. Jour. A. M. A 106, 1158–1162 (1936).
71. JA., K. Barr’s the Human Nervous System: an Anatomical Viewpoint. (Lippincott, Williams
and Wilkins, 2009).
72. Gambichler, T., Matip, R., Moussa, G., Altmeyer, P. & Hoffmann, K. In vivo data of
epidermal thickness evaluated by optical coherence tomography: effects of age, gender, skin
type, and anatomic site. J. Dermatol. Sci. 44, 145–52 (2006).
73. Sandby-Møller, J., Poulsen, T. & Wulf, H. C. Epidermal thickness at different body sites:
relationship to age, gender, pigmentation, blood content, skin type and smoking habits. Acta
Derm. Venereol. 83, 410–3 (2003).
74. Schwindt, D. A., Wilhelm, K. P. & Maibach, H. I. Water diffusion characteristics of human
stratum corneum at different anatomical sites in vivo. J. Invest. Dermatol. 111, 385–9
(1998).
75. Farage, M. A., Miller, K. W., Elsner, P. & Maibach, H. I. Characteristics of the aging skin.
Adv. wound care 2, 5–10 (2013).
76. Bos, J. D. & Meinardi, M. M. The 500 Dalton rule for the skin penetration of chemical
compounds and drugs. Exp. Dermatol. 9, 165–9 (2000).
77. Benson, H. Transdermal drug delivery: penetration enhancement techniques. Curr. Drug
Deliv. 2, 23–33 (2005).
Bibliography 
- 225 -
78. Marwah, H. et al. Permeation enhancer strategies in transdermal drug delivery. Drug Deliv
23, 564–578 (2016).
79. Hadgraft, J. & Pugh, W. J. The selection and design of topical and transdermal agents: a
review. The journal of investigative dermatology 3, 131–135 (1998).
80. De Rie, M., Meinardi, M. & Bos, J. Lack of efficacy of topical cyclosporin A in atopic
dermatitis and allergic contact dermatitis. Acta Derm Venereol. 71, 452–454 (1991).
81. Powles, A. V et al. Intralesional injection of cyclosporin in psoriasis. Lancet 331, 537
(1988).
82. Diegelmann, R. F. & Evans, M. C. Wound healing: an overview of acute, fibrotic and
delayed healing. Front. Biosci. 9, 283–289 (2004).
83. Toriseva, M. & Kähäri, V.-M. Proteinases in cutaneous wound healing. Cell. Mol. Life Sci.
66, 203–24 (2009).
84. Liebl, H. & Kloth, L. C. Skin cell proliferation stimulated by microneedles. J. Am. Coll.
Clin. Wound Spec. 4, 2–6 (2012).
85. Xue, M., Le, N. T. V & Jackson, C. J. Targeting matrix metalloproteases to improve
cutaneous wound healing. Expert Opin. Ther. Targets 10, 143–55 (2006).
86. Dorsett-Martin, W. A. Rat models of skin wound healing: a review. Wound Repair Regen.
12, 591–9 (2004).
87. Mirastschijski, U., Impola, U., Karsdal, M. A., Saarialho-Kere, U. & Agren, M. S. Matrix
metalloproteinase inhibitor BB-3103 unlike the serine proteinase inhibitor aprotinin
abrogates epidermal healing of human skin wounds ex vivo. J. Invest. Dermatol. 118, 55–
64 (2002).
88. Sanders, J. E., Mitchell, S. B., Wang, Y.-N. & Wu, K. An explant model for the investigation
of skin adaptation to mechanical stress. IEEE Trans. Biomed. Eng. 49, 1626–31 (2002).
89. Peirce, S. M., Skalak, T. C. & Rodeheaver, G. T. Ischemia-reperfusion injury in chronic
pressure ulcer formation: a skin model in the rat. Wound Repair Regen. 8, 68–76 (2000).
90. Groot, H. De & Rauen, U. Ischemia-reperfusion injury: in pathogenic networks: a review.
484, 481–484 (2007).
91. Weiskopf, R. B., Collard, C. D., Gelman, S. & Ph, D. Prevention of ischemia-reperfusion
injury. 94, 1133–1138 (2001).
92. Kosiak, M. Etiology and Pathology of ischemic ulcers. Arch. Phys. Med. Rehabil. 40, 19–
29 (1959).
93. Tsuji, S., Ichioka, S., Sekiya, N. & Nakatsuka, T. Analysis of ischemia-reperfusion injury
in a microcirculatory model of pressure ulcers. Wound Repair Regen. 13, 209–215 (2005).
94. Woolfson, R. G., Millar, C. G. & Neild, G. H. Ischaemia and reperfusion injury in the
kidney: current status and future direction. Nephrol. Dial. Transplant 9, 1529–31 (1994).
95. Herrman, E. C., Knapp, C. F., Donofrio, J. C. & Salcido, R. Skin perfusion responses to
surface pressure-induced ischemia: implication for the developing pressure ulcer. J. Rehabil.
Res. Dev. 36, 109–20 (1999).
96. Wang, W. Z., Baynosa, R. C. & Zamboni, W. A. Update on ischemia-reperfusion injury for
the plastic surgeon: 2011. Plast. Reconstr. Surg. 128, 685–92 (2011).
97. Anaya-Prado, R. The molecular events underlying ischemia/reperfusion injiury. Transplant.
Proc. 34, 2518–2519 (2002).
Bibliography 
- 226 -
98. Kalogeris, T., Baines, C. P., Krenz, M. & Korthuis, R. J. Cell Biology of
Ischemia/Reperfusion Injury. International Review Of Cell and Molecular Biology 298,
(Elsevier Inc., 2012).
99. Wassermann, E. et al. A chronic pressure ulcer model in the nude mouse. Wound Repair
Regen. 17, 480–4 (2009).
100. Reid, R. R., Sull, A. C., Mogford, J. E., Roy, N. & Mustoe, T. a. A novel murine model of
cyclical cutaneous ischemia-reperfusion injury. Journal of Surgical Research 116, 172–180
(2004).
101. Pilcher, B. K. et al. Role of matrix metalloproteinases and their inhibition in cutaneous
wound healing and allergic contact hypersensitivity. Ann. N. Y. Acad. Sci. 878, 12–24
(1999).
102. Weckroth, M., Vaheri,  a, Lauharanta, J., Sorsa, T. & Konttinen, Y. T. Matrix
metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. The Journal of
investigative dermatology 106, 1119–24 (1996).
103. Witte, M. B. et al. Metalloproteinase inhibitors and wound healing: a novel enhancer of
wound strength. Surgery 124, 464–70 (1998).
104. Rogers, A. A., Burnett, S., Moore, J. C., Shakespeare, P. G. & Chen, W. Y. Involvement of
proteolytic enzymes--plasminogen activators and matrix metalloproteinases--in the
pathophysiology of pressure ulcers. Wound Repair Regen. 3, 273–83 (1995).
105. Wysoci, A., Stiano-Coico, L. & Grinnell, F. Wound fluid from chronic leg ulcers contain
elevated levels of MMP-2 and MMP-9. J Invest Dermatol 101, 64–68 (1993).
106. Nwomeh, B. C., Liang, H., Cohen, I. K., Yager, D. R. & Ph, D. MMP-8 is predominant
collagenase in healing wound and nonhealing ulcers. J. Surg. Res. 195, 189–195 (1999).
107. Yager, D., Zhang, L., Liang, H.-X., Diegelmann, R. F. & Cohen, I. K. Wound Fluid from
Human Pressure Ulcers Contain Elevated Matrix Metalloproteinase Levels and Activity
Compared to Surgical Wound Fluids. J Invest Dermatol 734–748 (1996).
108. Madlener, M. Differential expression of matrix metalloproteinases and their physiological
inhibitors in acute murine skin wounds. Arch. Dermatol. Res. 290 Suppl, S24-9 (1998).
109. Rayment, E. A. & Upton, Z. Finding the culprit: a review of the influences of proteases on
the chronic wound environment. Int. J. Low. Extrem. Wounds 8, 19–27 (2009).
110. Saarialho-Kere, U. K. Patterns of matrix metalloproteinase and TIMP expression in chronic
ulcers. Arch. Dermatol. Res. 290 Suppl, S47-54 (1998).
111. Moor, A. N., Vachon, D. J. & Gould, L. J. Proteolytic activity in wound fluids and tissues
derived from chronic venous leg ulcers. Wound Repair Regen. 17, 832–9 (2009).
112. Naidoo, C., A, H. G., J, H. P. & Gp, H. C. Matrix metalloproteinase inhibition and antibiotics
in the treatment of chronic wounds. Wound Heal. South. Africa 2, 71–73 (2009).
113. Widgerow, A. D. Chronic wound fluid--thinking outside the box. Wound Repair Regen. 19,
287–91 (2011).
114. Gibson, D., Cullen, B., Legerstee, R., Hardina, K. & Schultz, G. MMPs made easy. Wounds
Int. 1, 1–6 (2009).
115. Mutsaers, S. E., Bishop, J. E., McGrouther, G. & Laurent, G. J. Mechanisms of tissue repair:
from wound healing to fibrosis. Int. J. Biochem. Cell Biol. 29, 5–17 (1997).
116. Stechmiller, J., Cowan, L. & Schultz, G. The role of doxycycline as a matrix
metalloproteinase inhibitor for the treatment of chronic wounds. Biol. Res. Nurs. 11, 336–
Bibliography 
  
 
 - 227 - 
44 (2010). 
117. Trengove, N. J. et al. Analysis of the acute and chronic wound environments  : the role of 
proteases and their inhibitors. Wound Repair Regen 7, 442–452 (1999). 
118. Ladwig, G. P. et al. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of 
matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure 
ulcers. Wound Repair Regen. 10, 26–37 (2002). 
119. Tarnuzzer, R. W. & Schultz, G. S. Biochemical analysis of acute and chronic wound 
environments. Wound Repair Regen. 4, 321–325 (1996). 
120. Reiss, M. J., Han, Y., Garcia, E., Goldberg, M. & Yu, H. Matrix metalloproteinase-9 delays 
wound healing in a murine wound model. Surgery 147, 295–302 (1994). 
121. Frøssing, S., Rønø, B., Hald, A., Rømer, J. & Lund, L. R. Skin wound healing in MMP2-
deficient and MMP2 / plasminogen double-deficient mice. Exp. Dermatol. 19, e234-40 
(2010). 
122. Wysocki, A. B. Evaluating and managing open skin wounds: colonization versus infection. 
AACN Clin. Issues 13, 382–97 (2002). 
123. Machado, L. S. et al. Delayed minocycline inhibits ischemia-activated matrix 
metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 7, 56 (2006). 
124. Gendron, R., Grenier, D., Sorsa, T. & Mayrand, D. Inhibition of the activities of matrix 
metalloproteinases 2, 8, and 9 by chlorhexidine. Clin. Diagn. Lab. Immunol. 6, 437–9 
(1999). 
125. Kiili, M. et al. Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: 
molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival 
tissue. J. Clin. Periodontol. 29, 224–32 (2002). 
126. Ramnath, N. & Creaven, P. J. Matrix metalloproteinase inhibitors. Curr. Oncol. Rep. 6, 96–
102 (2004). 
127. Daniel, R., Priest, D. & DC, W. Etiologic factors in pressure sores: an experimental model. 
Arch. Phys. Med. Rehabil. 62, 492–8 (1981). 
128. Nola, G. & Vistines, L. Differential response of skin and muscle in the experimental 
production of pressure sores. Plast. Reconstr. Surg. 66, 728–33 (1980). 
129. Boyce, S. T. & Warden, G. D. Principles and practices for treatment of cutaneous wounds 
with cultured skin substitutes. Am. J. Surg. 183, 445–56 (2002). 
130. Kirketerp-møller, K., Zulkowski, K. & James, G. in Biofilm Infections (eds. Bjarnsholt, T., 
Jensen, P. Ø., Moser, C. & Høiby, N.) 11–25 (Springer New York, 2011). doi:10.1007/978-
1-4419-6084-9 
131. Sv, M., Min, D. & Dk, Y. Matrix metalloproteinases and their roles in poor wound healing 
in diabetes. Wound Pract. Res. 16, 116–121 (2008). 
132. Cullen, B., Smith, R., McCulloch, E., Silcock, D. & Morrison, L. Mechanism of action of 
Promogran, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound 
Repair Regen. 10, 16–25 (2002). 
133. Vin, F., Teot, L. & Meaume, S. The healing properties of Promogran in venous leg ulcers. 
J. Wound Care 11, 335– 341 (2002). 
134. Vandenbroucke, R. E. & Libert, C. Is there new hope for therapeutic matrix 
metalloproteinase inhibition? Nat. Rev. Drug Discov. 13, 904–927 (2014). 
Bibliography 
- 228 -
135. Scimeca, C. L., Bharara, M., Fisher, T. K., Giovinco, N. & Armstrong, D. G. Novel use of
doxycycline in continuous-instillation negative pressure wound therapy as ‘wound
chemotherapy’. Foot Ankle Spec. 3, 190–193 (2010).
136. Skúlason, S., Ingólfsson, E. & Kristmundsdóttir, T. Development of a simple HPLC method
for separation of doxycycline and its degradation products. J. Pharm. Biomed. Anal. 33,
667–672 (2003).
137. Skulason, S., Holbrook, W. P. & Kristmundsdottir, T. Clinical assessment of the effect of a
matrix metalloproteinase inhibitor on aphthous ulcers. Acta Odontol. Scand. 67, 25–9
(2009).
138. Sloan, B. & Scheinfeld, N. The use and safety of doxycycline hyclate and other second-
generation tetracyclines. Expert Opin. Drug Saf. 7, 571–577 (2008).
139. Giovagnoli, S., Tsai, T. & DeLuca, P. P. Formulation and release behavior of doxycycline-
alginate hydrogel microparticles embedded into pluronic F127 thermogels as a potential new
vehicle for doxycycline intradermal sustained delivery. AAPS PharmSciTech 11, 212–220
(2010).
140. Kogawa, A. C. & Salgado, H. R. N. Doxycycline hyclate: A review of properties,
applications and analytical methods. Int. J. Life Sci. Pharma Res. 2, 11–25 (2012).
141. Manning, M. W., Cassis, L. A. & Daugherty, A. Differential effects of doxycycline, a broad-
spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and
abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 23, 483–8 (2003).
142. Yager, D. R. & Nwomeh, B. C. The proteolytic environment of chronic wounds. Wound
Repair Regen. 7, 433–41 (1999).
143. Doxycycline Hyclate: Product Information. (Sigma-Aldrich, 1993).
144. Peridontics: Trade News Focus - Periostat (doxycycline 20 mg). British Dental Journal 200,
115 (2006).
145. Javali, M. A. & Vandana, K. L. A comparative evaluation of atrigel delivery system (10%
doxycycline hyclate) Atridox with scaling and root planing and combination therapy in
treatment of periodontitis: A clinical study. J. Indian Soc. Periodontol. 16, 43–8 (2012).
146. Trommer, H. & Neubert, R. H. H. Overcoming the stratum corneum: the modulation of skin
penetration. A review. Skin Pharmacol. Physiol. 19, 106–21 (2006).
147. Gill, H. S. & Prausnitz, M. R. Pocketed microneedles for drug delivery to the skin. J. Phys.
Chem. Solids 69, 1537–1541 (2008).
148. Prausnitz, M. R. & Langer, R. Transdermal drug delivery. Nat. Biotechnol. 26, 1261–1268
(2009).
149. Williams, A. C. & Barry, B. W. Penetration enhancers. Adv. Drug Deliv. Rev. 56, 603–618
(2004).
150. Pathan, I. B. & Setty, C. M. Chemical penetration enhancers for transdermal drug delivery
systems. Trop. J. Pharm. Res. 8, 173–179 (2009).
151. Mitragotri, S. Devices for overcoming biological barriers: the use of physical forces to
disrupt the barriers. Adv. Drug Deliv. Rev. 65, 100–3 (2013).
152. Mitragotri, S., Blankschtein, D. & Langer, R. Ultrasound-mediated transdermal protein
delivery. Science 269, 850–853 (1995).
153. Paliwal, S., Menon, G. K. & Mitragotri, S. Low-frequency sonophoresis: ultrastructural
basis for stratum corneum permeability assessed using quantum dots. J. Invest. Dermatol.
Bibliography 
  
 
 - 229 - 
126, 1095–1101 (2006). 
154. Kalia, Y. N., Naik, A., Garrison, J. & Guy, R. H. Iontophoretic drug delivery. Adv. Drug 
Deliv. Rev. 56, 619–658 (2004). 
155. Guy, R. H. et al. Iontophoresis: Electrorepulsion and electroosmosis. J. Control. Release 
64, 129–132 (2000). 
156. Spierings, E. L. H., Brevard, J. A. & Katz, N. P. Two-minute skin anesthesia through 
ultrasound pretreatment and iontophoretic delivery of a topical anesthetic: A feasibility 
study. Pain Med. 9, 55–59 (2008). 
157. Prausnitz, M. R., Bose, V. G., Langer, R. & Weaver, J. C. Electroporation of mammalian 
skin: a mechanism to enhance transdermal drug delivery. Proc. Natl. Acad. Sci. U. S. A. 90, 
10504–10508 (1993). 
158. Heller, L., Ugen, K. & Heller, R. Electroporation for targeted gene transfer. Expert Opin. 
Drug Deliv. 2, 255–68 (2005). 
159. Mitragotri, S. Immunization without needles. Nat. Rev. Immunol. 5, 905–16 (2005). 
160. Nava-Arzaluz, M. G., Calderon-Lojero, I., Quintanar-Guerrero, D., Villalobos-Garcia, R. & 
Ganem-Quintanar,  a. Microneedles as transdermal delivery systems: combination with 
other enhancing strategies. Curr. Drug Deliv. 9, 57–73 (2012). 
161. Henry, S., McAllister, D., Allen, M. & Prausnitz, M. Microfabricated microneedles: A novel 
approach to transdermal drug delivery. J. Pharm. Sci. 88, 948 (1999). 
162. Wu, Y., Qiu, Y., Zhang, S., Qin, G. & Gao, Y. Microneedle-based drug delivery: studies on 
delivery parameters and biocompatibility. Biomed. Microdevices 10, 601–10 (2008). 
163. Davis, S. P., Landis, B. J., Adams, Z. H., Allen, M. G. & Prausnitz, M. R. Insertion of 
microneedles into skin: measurement and prediction of insertion force and needle fracture 
force. J. Biomech. 37, 1155–63 (2004). 
164. Kaushik, S. et al. Lack of pain associated with microfabricated microneedles. Anesth. Analg. 
92, 502–4 (2001). 
165. Gupta, J., Park, S. S., Bondy, B., Felner, E. I. & Prausnitz, M. R. Infusion pressure and pain 
during microneedle injection into skin of human subjects. Biomaterials 32, 6823–31 (2011). 
166. Bal, S. M., Caussin, J., Pavel, S. & Bouwstra, J. A. In vivo assessment of safety of 
microneedle arrays in human skin. Eur. J. Pharm. Sci. 35, 193–202 (2008). 
167. Park, J.-H., Allen, M. G. & Prausnitz, M. R. Polymer microneedles for controlled-release 
drug delivery. Pharm. Res. 23, 1008–1019 (2006). 
168. Kommareddy, S., Baudner, B. C., Oh, S., Kwon, S. & Singh, M. Dissolvable microneedle 
patches for the delivery of cell-culture-derived influenza vaccine antigens. J. Pharm. Sci. 
101, 1021–1027 (2012). 
169. Edens, C., Collins, M. L., Ayers, J., Rota, P. A. & Prausnitz, M. R. Measles vaccination 
using a microneedle patch. Vaccine 31, 3403–3409 (2013). 
170. Jj, N., Na, R., Faster, F. E. I., Brown, R. & Nicholas, A. Faster pharmacokinetics and 
increased patient acceptance of intradermal insulin delivery using a single hollow 
microneedle in children and adolescents with type 1 diabetes. Pediatr. Diabetes 14, 459–
465 (2013). 
171. Gupta, J., Felner, E. I., Prausnitz, M. R. & Ph, D. Minimally invasive insuling delivery in 
subjects with type 1 diabetes using hollow microneedles. Diabetes Technol. Ther. 11, 329–
337 (2009). 
Bibliography 
- 230 -
172. Prausnitz, M. R. Engineering microneedle patches for vaccination and drug delivery to the
skin. Annu. Rev. Chem .Biomol. Eng. 8, 1–24 (2017).
173. van der Maaden, K., Jiskoot, W. & Bouwstra, J. Microneedle technologies for (trans)dermal
drug and vaccine delivery. J. Control. Release 161, 645–55 (2012).
174. Larrañeta, E., McCrudden, M. T. C., Courtenay, A. J. & Donnelly, R. F. Microneedles: A
New Frontier in Nanomedicine Delivery. Pharm. Res. 33, 1055–1073 (2016).
175. Ita, K. Transdermal delivery of drugs with microneedles—potential and challenges.
Pharmaceutics 7, 90–105 (2015).
176. McAllister, D. V et al. Microneedles for transdermal delivery of macromolecules. in
[Engineering in Medicine and Biology, 1999. 21st Annual Conference and the 1999 Annual
Fall Meetring of the Biomedical Engineering Society] BMES/EMBS Conference, 1999.
Proceedings of the First Joint 2, 836 (IEEE, 1999).
177. Liu, R., Zhang, M. & Jin, C. In vivo and in situ imaging of controlled-release dissolving silk
microneedles into the skin by optical coherence tomography. J. Biophotonics 8, 1–8 (2016).
178. Li, G., Badkar, A., Nema, S., Kolli, C. S. & Banga, A. K. In vitro transdermal delivery of
therapeutic antibodies using maltose microneedles. Int. J. Pharm. 368, 109–15 (2009).
179. Liu, S. et al. Transdermal delivery of relatively high molecular weight drugs using novel
self-dissolving microneedle arrays fabricated from hyaluronic acid and their characteristics
and safety after application to the skin. Eur. J. Pharm. Biopharm. 86, 267–276 (2014).
180. Liu, S. et al. The development and characteristics of novel microneedle arrays fabricated
from hyaluronic acid, and their application in the transdermal delivery of insulin. J. Control.
Release 161, 933–941 (2012).
181. Kim, M., Jung, B. & Park, J.-H. Hydrogel swelling as a trigger to release biodegradable
polymer microneedles in skin. Biomaterials 33, 668–78 (2012).
182. Singh, A. & Yadav, S. Microneedling: Advances and widening horizons. Indian Dermatol.
Online J. 7, 244 (2016).
183. Oh, J.-H. et al. Influence of the delivery systems using a microneedle array on the
permeation of a hydrophilic molecule, calcein. Eur. J. Pharm. Biopharm. 69, 1040–5
(2008).
184. Kim, Y.-C., Park, J.-H. & Prausnitz, M. R. Microneedles for drug and vaccine delivery. Adv.
Drug Deliv. Rev. 64, 1547–1568 (2012).
185. Raphael, A. P. et al. Formulations for microprojection / microneedle vaccine delivery  :
Structure , strength and release pro fi les. J. Control. Release 225, 40–52 (2016).
186. Vrdoljak, A. et al. Coated microneedle arrays for transcutaneous delivery of live virus
vaccines. J. Control. Release 159, 34–42 (2012).
187. Davis, S. P., Martanto, W., Allen, M. G., Member, S. & Prausnitz, M. R. Hollow metal
microneedles for insulin delivery to diabetic rats. IEEE Trans. Biomed. Eng. 52, 909–915
(2005).
188. Zhang, W. et al. Penetration and distribution of PLGA nanoparticles in the human skin
treated with microneedles. Int. J. Pharm. 402, 205–12 (2010).
189. Kumar, A. et al. Permeation of antigen protein-conjugated nanoparticles and live bacteria
through microneedle-treated mouse skin. Int. J. Nanomedicine 6, 1253–64 (2011).
190. Kim, C. S. et al. Efficient and facile delivery of gold nanoparticles in vivo using dissolvable
microneedles for contrast-enhanced optical coherence tomography. Biomed. Opt. Express
Bibliography 
- 231 -
1, 106–113 (2010). 
191. Fabbrocini, G., Fardella, N., Monfrecola,  a, Proietti, I. & Innocenzi, D. Acne scarring
treatment using skin needling. Clin. Exp. Dermatol. 34, 874–9 (2009).
192. Bariya, S. H., Gohel, M. C., Mehta, T. a & Sharma, O. P. Microneedles: an emerging
transdermal drug delivery system. J. Pharm. Pharmacol. 64, 11–29 (2012).
193. Chen, B., Wei, J. & Iliescu, C. Sonophoretic enhanced microneedles array (SEMA)-
Improving the efficiency of transdermal drug delivery. Sensors Actuators, B Chem. 145, 54–
60 (2010).
194. Han, T. & Das, D. B. Permeability enhancement for transdermal delivery of large moelcule
using low-frequency sonophoresis combined with microneedles. J. Pharm. Sci. 102, 3614–
22 (2013).
195. Li, C. G., Lee, C. Y., Lee, K. & Jung, H. An optimized hollow microneedle for minimally
invasive blood extraction. Biomed. Microdevices 15, 17–25 (2013).
196. Strambini, L. M. et al. Self-powered microneedle-based biosensors for pain-free high-
accuracy measurement of glycaemia in interstitial fluid. Biosens. Bioelectron. 66, 162–168
(2015).
197. Valdés-Ramírez, G. et al. Microneedle-based self-powered glucose sensor. Electrochem.
commun. 47, 58–62 (2014).
198. Hwa, K. Y., Subramani, B., Chang, P. W., Chien, M. & Huang, J. T. Transdermal
microneedle array-based sensor for real time continuous glucose monitoring. Int. J.
Electrochem. Sci. 10, 2455–2466 (2015).
199. Jina, A. et al. Design, development, and evaluation of a novel microneedle array-based
continuous glucose monitor. J. Diabetes Sci. Technol. 8, 483–7 (2014).
200. Cunningham, J. J., Nikolovski, J., Lindernab, J. J. & Mooney, D. J. Quantification of
fibronectin adsorption to silicone-rubber cell culture substrates. Biotechniques 32, 876–887
(2002).
201. Netzlaff, F., Lehr, C.-M., Wertz, P. W. & Schaefer, U. F. The human epidermis models
EpiSkin, SkinEthic and EpiDerm: an evaluation of morphology and their suitability for
testing phototoxicity, irritancy, corrosivity, and substance transport. Eur. J. Pharm.
Biopharm. 60, 167–78 (2005).
202. Xu, W. et al. Application of a partial-thickness human ex vivo skin culture model in
cutaneous wound healing study. Lab. Invest. 92, 584–99 (2012).
203. Godin, B. & Touitou, E. Transdermal skin delivery: predictions for humans from in vivo,
ex vivo and animal models. Adv. Drug Deliv. Rev. 59, 1152–61 (2007).
204. Wong, V. W., Sorkin, M., Glotzbach, J. P., Longaker, M. T. & Gurtner, G. C. Surgical
approaches to create murine models of human wound healing. J. Biomed. Biotechnol. 1–8
(2011). doi:10.1155/2011/969618
205. Xie, Y. et al. The microvasculature in cutaneous wound healing in the female red Duroc pig
is similar to that in human hypertrophic scars and different from that in the female Yorkshire
pig. J. Burn Care Res. 28, 500–6 (1976).
206. Porter, R. M. Mouse models for human hair loss disorders. J. Anat. 202, 125–31 (2003).
207. Simon, G. a & Maibach, H. I. Relevance of hairless mouse as an experimental model of
percutaneous penetration in man. Skin Pharmacol. Appl. Skin Physiol. 11, 80–6 (1998).
208. Walker, J. M. Mouse models for drug discovery: methods and protocols. (Humana Press,
Bibliography 
- 232 -
2012). 
209. Azzi, L., El-Alfy, M., Martel, C. & Labrie, F. Gender differences in mouse skin morphology
and specific effects of sex steroids and dehydroepiandrosterone. J. Invest. Dermatol. 124,
22–7 (2005).
210. Stekelenburg, A. et al. Role of ischemia and deformation in the onset of compression-
induced deep tissue injury: MRI-based studies in a rat model. J. Appl. Physiol. 102, 2002–
11 (2007).
211. Lanzafame, R. J. et al. Reciprocity of exposure time and irradiance on energy density during
photoradiation on wound healing in a murine pressure ulcer model. Lasers Surg. Med. 542,
534–542 (2007).
212. Stadler, I., Zhang, R.-Y., Oskoui, P., Whittaker, M. S. & Lanzafame, R. J. Development of
a simple, noninvasive, clinically relevant model of pressure ulcers in the mouse. J. Invest.
Surg. 17, 221–7 (2004).
213. Li, H., Ezra, D. G., Burton, M. J. & Bailly, M. Doxycycline prevents matrix remodeling and
contraction by trichiasis-derived conjunctival fibroblasts. Invest. Ophthalmol. Vis. Sci. 54,
4675–82 (2013).
214. Vandervoort, J. & Ludwig, A. Microneedles for transdermal drug delivery: a minireview.
Front. Biosci. a J. virtual Libr. 13, 1711–1715 (2008).
215. Scott, C. a & Kelsell, D. P. Key functions for gap junctions in skin and hearing. Biochem.
J. 438, 245–54 (2011).
216. Scott, C. a, Tattersall, D., O’Toole, E. a & Kelsell, D. P. Connexins in epidermal
homeostasis and skin disease. Biochim. Biophys. Acta 1818, 1952–61 (2012).
217. Dbouk, H. a, Mroue, R. M., El-Sabban, M. E. & Talhouk, R. S. Connexins: a myriad of
functions extending beyond assembly of gap junction channels. Cell Commun. Signal. 7, 4
(2009).
218. Sun, W. et al. Transdermal delivery of functional collagen vial polyvinylpyrrolidone
microneedles. Ann. Biomed. Eng. 43, 2978–2990 (2015).
219. Mohammed, Y. H. et al. Microneedle enhanced delivery of cosmeceutically relevant
peptides in human skin. PLoS One 9, 1–9 (2014).
220. Pudukadan, D. Treatment of acne scars on darker skin types using noninsulated smooth
motion, electronically controlled radiofrequency microneedles treatment system.
Dermatologic Surg. 43, S64–S69 (2017).
221. Wang, R. et al. Oxygen-glucose deprivation induced glial scar-like change in astrocytes.
PLoS One 7, e37574 (2012).
222. Mccrudden, M. T. C. et al. Microneedle applications in improving skin appearance. Exp.
Dermatol. 24, 561–566 (2015).
223. Kim, M., Yang, H., Jung, H. & Jung, H. Novel cosmetic patches for wrinkle improvement:
retinyl retinoate- and ascorbic acid-loaded dissolving microneedles. Int. J. Cosmet. Sci. 36,
207–12 (2014).
224. Lee, C. et al. Evaluation of the anti-wrinkle effect of an ascorbic acid-loaded dissolving
microneedle patch via a double-blind, placebo-controlled clinical study. Int. J. Cosmet. Sci.
38, 375–381 (2016).
225. Badran, M. M., Kuntsche, J. & Fahr, A. Skin penetration enhancement by a microneedle
device (Dermaroller) in vitro: Dependency on needle size and applied formulation. Eur. J.
Pharm. Sci. 36, 511–523 (2009).
Bibliography 
- 233 -
226. Chernokalskaya, E., Vivek, J., Kavonian, M. & Brewster, D. Polymeric membranes with
human skin-like permeabiltiy properties and uses thereof (US 8,765,254 B2). (2014).
227. Balasubramani, M., Kumar, T. R. & Babu, M. Skin substitutes: a review. Burns 27, 534–44
(2001).
228. Selzer, D., Abdel-Mottaleb, M. M. A., Hahn, T., Schaefer, U. F. & Neumann, D. Finite and
infinite dosing: Difficulties in measurements, evaluations and predictions. Adv. Drug Deliv.
Rev. 65, 278–294 (2013).
229. Justin, R. & Chen, B. Strong and conductive chitosan-reduced graphene oxide
nanocomposites for transdermal drug delivery. J. Mater. Chem. B 2, 3759–3770 (2014).
230. Boks, M. A. et al. Controlled release of a model vaccine by nanoporous ceramic microneedle
arrays. Int. J. Pharm. 491, 375–383 (2015).
231. Kalluri, H., Kolli, C. S. & Banga, A. K. Characterization of microchannels created by metal
microneedles: formation and closure. AAPS J. 13, 473–481 (2011).
232. Uchida, T. et al. Prediction of skin permeation by chemical compounds using the artificial
membrane, Strat-M. Eur. J. Pharm. Sci. 67, 113–118 (2015).
233. Karadzovska, D. & Riviere, J. E. Assessing vehicle effects on skin absorption using artificial
membrane assays. Eur. J. Pharm. Sci. 50, 569–76 (2013).
234. Simon, A., Amaro, M. I., Healy, A. M., Cabral, L. M. & de Sousa, V. P. Comparative
evaluation of rivastigmine permeation from a transdermal system in the Franz cell using
synthetic membranes and pig ear skin with in vivo-in vitro correlation. Int. J. Pharm. 512,
234–241 (2016).
235. Park, J., Choi, S., Seo, S., Bin, Y. & Prausnitz, M. R. A microneedle roller for transdermal
drug delivery. Eur. J. Pharm. Biopharm. 76, 282–289 (2010).
236. Kim, H. M., Lim, Y. Y., An, J. H., Kim, M. N. & Kim, B. J. Transdermal drug delivery
using disk microneedle rollers in a hairless rat model. Int. J. Dermatol. 51, 859–863 (2012).
237. Banga, A. K. Microporation applications for enhancing drug delivery. Expert Opin. Drug
Deliv. 6, 343–354 (2009).
238. Birchall, J. et al. Cutaneous DNA delivery and gene expression in ex vivo human skin
explants via wet-etch micro-fabricated micro-needles. J. Drug Target. 13, 415–21 (2005).
239. Ashraf, M. W. et al. Design, fabrication and analysis of silicon hollow microneedles for
transdermal drug delivery system for treatment of hemodynamic dysfunctions. Cardiovasc.
Eng. 10, 91–108 (2010).
240. Arendt-Nielsen, L., Egekvist, H. & Bjerring, P. Pain following controlled cutaneous
insertion of needles with different diameters. Somatosens. Mot. Res. 23, 37–43 (2006).
241. Zhou, C., Liu, Y., Wang, H., Zhang, P. & Zhang, J. Transdermal delivery of insulin using
microneedle rollers in vivo. Int. J. Pharm. 392, 127–133 (2010).
242. You, S.-K. et al. Effect of applying modes of the polymer microneedle-roller on the
permeation of L-ascorbic acid in rats. J. Drug Target. 18, 15–20 (2010).
243. Markov, I. Crystal Growth for Beginners: Fundamentals of Nucleation, Crystal Growth and
Epitaxy. (World Scientific Publishing Co Pte Ltd, 2003).
244. Van Linthout, S., Miteva, K. & Tschope, C. Crosstalk between fibroblasts and inflammatory
cells. Cardiovasc. Res. 102, 258–269 (2014).
245. Ehrlich, H. P. Wound closure: evidence of cooperation between fibroblasts and collagen
Bibliography 
  
 
 - 234 - 
matrix. Eye 2, 149–57 (1988). 
246. Phillips, J. a, Vacanti, C. A. & Bonassar, L. J. Fibroblasts regulate contractile force 
independent of MMP activity in 3D-collagen. Biochem. Biophys. Res. Commun. 312, 725–
732 (2003). 
247. Ehrlich, H. P. & Hunt, T. K. Collagen organization critical role in wound contraction. Adv. 
Wound Care 1, 3–9 (2012). 
248. Dallon, J. C. & Ehrlich, H. P. A review of fibroblast-populated collagen lattices. Wound 
Repair Regen. 16, 472–479 (2008). 
249. Elsdale, T. & Bard, J. Collagen substrata for studies on cell behaviour. J. Cell Biol. 54, 626–
637 (1972). 
250. Bell, E., Ivarsson, B. & Merrill, C. Production of a tissue-like structure by contraction of 
collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc. Natl. 
Acad. Sci. U. S. A. 76, 1274–8 (1979). 
251. Kobayashi, T. et al. Matrix metalloproteinase-9 activates TGF-β and stimulates fibroblast 
contraction of collagen gels. Am. J. Physiol. - Lung Cell. Mol. Physiol. 306, L1006–L1015 
(2014). 
252. Martin-Martin, B., Tovell, V., Dahlmann-Noor, A. H., Khaw, P. T. & Bailly, M. The effect 
of MMP inhibitor GM6001 on early fibroblast-mediated collagen matrix contraction is 
correlated to a decrease in cell protrusive activity. Eur. J. Cell Biol. 90, 26–36 (2011). 
253. Becker, D. L., Thrasivoulou, C. & Phillips, A. R. J. Connexins in wound healing; 
perspectives in diabetic patients. Biochim. Biophys. Acta 1818, 2068–75 (2012). 
254. Wang, N. et al. Selective inhibition of Cx43 hemichannels by Gap19 and its impact on 
myocardial ischemia/reperfusion injury. Basic Res. Cardiol. 108, 309 (2013). 
255. Evans, W. H., De Vuyst, E. & Leybaert, L. The gap junction cellular internet: connexin 
hemichannels enter the signalling limelight. Biochem. J. 397, 1–14 (2006). 
256. Evans, W. H. & Martin, P. E. M. Gap junctions: structure and function (Review). Mol. 
Membr. Biol. 19, 121–36 (2002). 
257. Haq, M. I. et al. Clinical administration of microneedles: skin puncture, pain and sensation. 
Biomed. Microdevices 11, 35–47 (2009). 
258. Li, H., Roos, J. C. P., Rose, G. E., Bailly, M. & Ezra, D. G. Eyelid and sternum fibroblasts 
differ in their contraction potential and responses to inflammatory cytokines. Plast. 
Reconstr. Surg. 3, e448 (2015). 
259. Franco, C. et al. Doxycycline alters vascular smooth muscle cell adhesion, migration and 
reorganization of fibrillar collagen matrices. Am. J. Pathol. 168, 1697–1709 (2006). 
260. Daniels, J. T. et al. Matrix metalloproteinase inhibition modulates fibroblast-mediated 
matrix and collagen production in vitro. Invest. Ophthalmol. Vis. Sci. 44, 1104–1110 (2003). 
261. Bildt, M. M., Bloemen, M., Kuijpers-Jagtman,  a M. & Von den Hoff, J. W. Matrix 
metalloproteinase inhibitors reduce collagen gel contraction and alpha-smooth muscle actin 
expression by periodontal ligament cells. J. Periodontal Res. 44, 266–74 (2009). 
262. Lee, S. J. et al. Use of fractionated microneedle radiofrequency for the treatment of 
inflammatory acne vulgaris in 18 Korean patients. Dermatol. Surg. 38, 400–5 (2012). 
263. Mendoza-Naranjo, A. et al. Targeting Cx43 and N-cadherin, which are abnormally 
upregulated in venous leg ulcers, influences migration, adhesion and activation of Rho 
GTPases. PLoS One 7, e37374 (2012). 
Bibliography 
- 235 -
264. Sáez, J. C. et al. Cell membrane permeabilization via connexin hemichannels in living and
dying cells. Exp. Cell Res. 316, 2377–89 (2010).
265. Liang, C.-C., Park, A. Y. & Guan, J.-L. In vitro scratch assay: a convenient and inexpensive
method for analysis of cell migration in vitro. Nat. Protoc. 2, 329–33 (2007).
266. Yarrow, J. C., Perlman, Z. E., Westwood, N. J. & Mitchison, T. J. A high-throughput cell
migration assay using scratch wound healing, a comparison of image-based readout
methods. BMC Biotechnol. 4, 21 (2004).
267. Cho, S. I. et al. Evaluation of the clinical efficacy of fractional radiofrequency microneedle
treatment in acne scars and large facial pores. Dermatol. Surg. 38, 1017–24 (2012).
268. Ehrlich, H. P. & Moyer, K. E. in Wound Regeneration and Repair: Methods and Protocols,
Methods in Molecular Biology 1037, 45–58 (Springer Science+Business Media New York,
2013).
269. Smith, G. N., Mickler, E. a, Hasty, K. a & Brandt, K. D. Specificity of inhibition of matrix
metalloproteinase activity by doxycycline. Arthritis Rheum. 42, 1140–6 (1999).
270. Pieper, B. in Acute & Chronic Wounds: Current Management Concepts 205–234 (Mosby
Elsevier, 2007).
271. Defloor, T. The effect of position and mattress on interface pressure. Appl. Nurs. Res. 13,
2–11 (2000).
272. Manorama, A., Meyer, R., Wiseman, R. & Bush, T. R. Quantifying the effects of external
shear loads on arterial and venous blood flow: implications for pressure ulcer development.
Clin. Biomech. 28, 574–8 (2013).
273. Li, H. et al. Independent adipogenic and contractile properties of fibroblasts in graves’
orbitopathy: an in vitro model for the evaluation of treatments. PLoS One 9, e95586 (2014).
274. Martin, P. & Leibovich, S. J. Inflammatory cells during wound repair: the good, the bad and
the ugly. Trends Cell Biol. 15, 599–607 (2005).
275. McKleroy, W., Lee, T.-H. & Atabai, K. Always cleave up your mess: targeting collagen
degradation to treat tissue fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 304, L709-21
(2013).
276. Mandal, M., Mandal, A., Das, S., Chakraborti, T. & Sajal, C. Clinical implications of matrix
metalloproteinases. Mol. Cell. Biochem. 252, 305–29 (2003).
277. Cechowska-Pasko, M., Pałka, J. & Bańkowski, E. Glucose-depleted medium reduces the
collagen content of human skin fibroblast cultures. Mol. Cell. Biochem. 305, 79–85 (2007).
278. Cechowska-Pasko, M., Surazyński, A. & Bańkowski, E. The effect of glucose deprivation
on collagen synthesis in fibroblast cultures. Mol. Cell. Biochem. 327, 211–8 (2009).
279. Passmore, J. S., Lukey, P. T. & Ress, S. R. The human macrophage cell line U937 as an in
vitro model for selective evaluation of mycobacterial antigen-specific cytotoxic T-cell
function. Immunology 102, 146–156 (2001).
280. Ishikawa, M. et al. A Novel Assay System for Macrophage-activating Factor Activity Using
a Human U937 Cell Line. 4582, 4577–4581 (2014).
281. Castrillo, A. et al. Protein kinase C is required for macrophage activation and defense
against bacterial infection. J. Exp. Med. 194, 1231–1242 (2001).
282. Tomasek, J. J., Haaksma, C. J., Eddy, R. J. & Vaughan, M. B. Fibroblast contraction occurs
on release of tension in attached collagen lattices: dependency on an organized actin
cytoskeleton and serum. Anat. Rec. 232, 359–368 (1992).
Bibliography 
  
 
 - 236 - 
283. Skold, C. M. et al. Blood monocytes attenuate lung fibroblast contraction of three-
dimensional collagen gels in coculture. Am J Physiol Lung Cell Mol Physiol 279, L667–
L674 (2000). 
284. Zhu, Y. et al. Fibroblasts and monocyte macrophages contract and degrade three-
dimensional collagen gels in extended co-culture. (2001). 
285. Lindner, D. et al. Differential Expression of Matrix Metalloproteases in Human Fibroblasts 
with Different Origins. 2012, (2012). 
286. Choi, W. Combined oxygen and glucose deprivation in cortical cell culture: calcium-
dependent and calcium independent mechanisms of neuronal injury. J. Neurosci. 13 (8), 
3510–3524 (1993). 
287. Wang, X. et al. The role of connexin 43 and hemichannels correlated with the astrocytic 
death following ischemia/reperfusion insult. Cell. Mol. Neurobiol. 33, 401–10 (2013). 
288. Cronin, M., Anderson, P. N., Cook, J. E., Green, C. R. & Becker, D. L. Blocking connexin43 
expression reduces inflammation and improves functional recovery after spinal cord injury. 
Mol. Cell. Neurosci. 39, 152–60 (2008). 
289. Chanson, M. et al. Gap junctional communication in tissue inflammation and repair. 
Biochim. Biophys. Acta 1711, 197–207 (2005). 
290. Gillani, S., Cao, J., Suzuki, T. & Hak, D. J. The effect of ischemia reperfusion injury on 
skeletal muscle. Injury 43, 670–5 (2012). 
291. Jagodzinski, N. A., Weerasinghe, C. & Porter, K. Crush injuries and crush syndrome - a 
review. Part 1: the systemic injury. Trauma 12, 69–88 (2010). 
292. Reid, R. R., Said, H. K., Mogford, J. E. & Mustoe, T. a. The future of wound healing: 
pursuing surgical models in transgenic and knockout mice. J. Am. Coll. Surg. 199, 578–85 
(2004). 
293. Dinsdale, S. Decubitus ulcers: role of pressure and friction in causation. Arch. Phys. Med. 
Rehabil. 55, 147–52 (1974). 
294. Tew, G. A., Klonizakis, M., Crank, H., Briers, J. D. & Hodges, G. J. Comparison of laser 
speckle contrast imaging with laser doppler for assessing microvascular function. 
Microvasc. Res. 82, 326–332 (2011). 
295. Choi, W. J., Wang, H. & Wang, R. K. Optical coherence tomography microangiography for 
monitoring the response of vascular perfusion to external pressure on human skin tissue. J. 
Biomed. Opt. 19, 56003 (2014). 
296. Black, J., Dorner, B. & Ratliff, C. National Pressure Ulcer Advisory Panel’s updated 
pressure ulcer staging system. Adv Ski. Wound Care 20, 269–274 (2007). 
297. Stojadinovic, O. et al. Deep tissue injury in development of pressure ulcers: a decrease of 
inflammasome activation and changes in human skin morphology in response to aging and 
mechanical load. PLoS One 8, e69223 (2013). 
298. Aoi, N. et al. Ultrasound assessment of deep tissue injury in pressure ulcers: possible 
prediction of pressure ulcer progression. Plast. Reconstr. Surg. 124, 540–50 (2009). 
299. Donnelly, J. Should we include deep tissue injury in pressure ulcer staging systems? The 
NPUAP debate. J. Wound Care 14, 207–10 (2005). 
300. Berlowitz, D. R. & Brienza, D. M. Are all pressure ulcers the result of deep tissue injury? 
A review of the literature. Ostomy Wound Manag. 53, 34–8 (2007). 
301. Greaves, N. S. et al. Optical coherence tomography: a reliable alternative to invasive 
Bibliography 
- 237 -
histological assessment of acute wound healing in human skin? Br. J. Dermatol. 170, 840–
850 (2013). 
302. Mogensen, M., Thrane, L., Jørgensen, T. M., Andersen, P. E. & Jemec, G. B. E. OCT
imaging of skin cancer and other dermatological diseases. J. Biophotonics 2, 442–51 (2009).
303. Fujimoto, J. G. Optical coherence tomography for ultrahigh resolution in vivo imaging. Nat.
Biotechnol. 21, 1361–7 (2003).
304. Baris, H. N., Cohen, I. J. & Mistry, P. K. Gaucher disease: The metabolic defect,
pathophysiology, phenotypes and natural history. Pediatr. Endocrinol. Rev. 12, 72–81
(2014).
305. Schmitt, J. M. Optical coherence tomography (OCT): a review. IEEE J. Sel. Top. Quantum
Electron. 5, 1205–1215 (1999).
306. Sainter, A. W., King, T. A. & Dickinson, M. R. Effect of target biological tissue and choice
of light source on penetration depth and resolution in optical coherence tomography. J. Med.
Opt. 9, 193–199 (2004).
307. Gambichler, T. et al. Applications of optical coherence tomography in dermatology. J.
Dermatol. Sci. 40, 85–94 (2005).
308. Gambichler, T., Jaedicke, V. & Terras, S. Optical coherence tomography in dermatology:
technical and clinical aspects. Arch. Dermatol. Res. 303, 457–73 (2011).
309. Adegun, O. K. et al. Quantitative analysis of optical coherence tomography and
histopathology images of normal and dysplastic oral mucosal tissues. Lasers Med. Sci. 27,
795–804 (2012).
310. Branzan, A. L., Landthaler, M. & Szeimies, R.-M. In vivo confocal scanning laser
microscopy in dermatology. Lasers Med. Sci. 22, 73–82 (2007).
311. Neerken, S., Lucassen, G. W., Bisschop, M. a, Lenderink, E. & Nuijs, T. a M.
Characterization of age-related effects in human skin: A comparative study that applies
confocal laser scanning microscopy and optical coherence tomography. J. Biomed. Opt. 9,
274–81 (2004).
312. Gambichler, T. et al. Epidermal thickness assessed by optical coherence tomography and
routine histology: preliminary results of method comparison. J. Eur. Acad. Dermatol.
Venereol. 20, 791–5 (2006).
313. Mogensen, M., Morsy, H. a, Thrane, L. & Jemec, G. B. E. Morphology and epidermal
thickness of normal skin imaged by optical coherence tomography. Dermatology 217, 14–
20 (2008).
314. Weissman, J., Hancewicz, T. & Kaplan, P. Optical coherence tomography of skin for
measurement of epidermal thickness by shapelet-based image analysis. Opt. Express 12,
5760–9 (2004).
315. Stekelenburg, A., Oomens, C. W. J., Strijkers, G. J., Nicolay, K. & Bader, D. L.
Compression-induced deep tissue injury examined with magnetic resonance imaging and
histology. 1946–1954 (2006). doi:10.1152/japplphysiol.00889.2005.
316. Moore, Z., Patton, D., Rhodes, S. L. & O’Connor, T. Subepidermal moisture (SEM) and
bioimpedance: A literature review of a novel method for early detection of pressure-induced
tissue damage (pressure ulcers). Int. Wound J. (2016). doi:10.1111/iwj.12604
317. Clendenin, M., Jaradeh, K., Shamirian, A. & Rhodes, S. L. Inter-operator and inter-device
agreement and reliability of the SEM Scanner. J. Tissue Viability 24, 17–23 (2015).
318. Bates-Jensen, B. M., McCreath, H. E., Kono, A., Apeles, N. C. R. & Alessi, C. Subepidermal
Bibliography 
  
 
 - 238 - 
moisture predicts erythema and Stage 1 pressure ulcers in nursing home residents: A pilot 
study. J. Am. Geriatr. Soc. 55, 1199–1205 (2007). 
319. Bates-Jensen, B. M., McCreath, H. E., Pongquan, V. & Apeles, N. C. R. Subepidermal 
moisture differentiates erythema and stage I pressure ulcers in nursing home residents. 
Wound Repair Regen. 16, 189–197 (2008). 
320. Harrow, J. J. & Mayrovitz, H. N. Subepidermal moisture surrounding pressure ulcers in 
persons with a spinal cord injury: a pilot study. J. Spinal Cord Med. 37, 719–28 (2014). 
321. Guihan, M. et al. Assessing the feasibility of subepidermal moisture to predict erythema and 
stage 1 pressure ulcers in persons with spinal cord injury: a pilot study. J. Spinal Cord Med. 
35, 46–52 (2012). 
322. Ching, C. T.-S. et al. Tissue electrical properties monitoring for the prevention of pressure 
sore. Prosthet. Orthot. Int. 35, 386–94 (2011). 
323. Coulman, S. A. et al. In vivo, in situ imaging of microneedle insertion into the skin of human 
volunteers usint optical coherence tomography. Pharm. Res. 28, 66–81 (2011). 
324. Larrañeta, E. et al. A proposed model membrane and test method for microneedle insertion 
studies. Int. J. Pharm. 472, 65–73 (2014). 
325. Enfield, J., Connell, M. O., Lawlor, K. & Leahy, M. In-vivo dynamic characterization of 
microneedle skin penetration using optical coherence tomography. J. Biomed. Opt. 15, 1–7 
(2013). 
326. Thakur, R. R. S., Fallows, S. J., McMillan, H. L., Donnelly, R. F. & Jones, D. S. 
Microneedle-mediated intrascleral delivery of in situ forming thermoresponsive implants 
for sustained ocular drug delivery. J. Pharm. Pharmacol. 66, 584–585 (2014). 
327. Guo, L. et al. Optical coherence tomography angiography offers comprehensive evaluation 
of skin optical clearing in vivo by quantifying optical properties and blood flow imaging 
simultaneously. J. Biomed. Opt. 21, 81202 (2016). 
328. Brogden, N. K. et al. Diclofenac delays micropore closure following microneedle treatment 
in human subjects. J. Control. Release 163, 220–229 (2012). 
329. Brogden, N. K., Banks, S. L., Crofford, L. J. & Stinchcomb, A. L. Diclofenac Enables 
Unprecedented Week-Long Microneedle- Enhanced Delivery of a Skin Impermeable 
Medication in Humans. 1947–1955 (2013). doi:10.1007/s11095-013-1036-1 
330. Grove, T. Z., Osuji, C. O., Forster, J. D., Dufresne, E. R. & Regan, L. Stimuli-responsive 
smart gels realized via modular protein design. J. Am. Chem. Soc. 132, 14024–6 (2010). 
331. Grove, T. Z., Forster, J., Pimienta, G., Dufresne, E. & Regan, L. A modular approach to the 
design of protein-based smart gels. Biopolymers 97, 508–17 (2012). 
332. Turk, B. E., Huang, L. L., Piro, E. T. & Cantley, L. C. Determination of protease cleavage 
site motifs using mixture-based oriented peptide libraries. Nat. Biotechnol. 19, 661–7 
(2001). 
333. Zhang, M., Desai, T. & Ferrari, M. Proteins and cells on PEG immobilized silicon surfaces. 
Biomaterials 19, 953–60 (1998). 
334. Zakeri, B. & Howarth, M. Spontaneous intermolecular amide bond formation between side 
chails for irreversible peptide targeting. Am. Chem. Soc. 132, 4526–4527 (2010). 
335. Zhang, W.-B., Sun, F., Tirrell, D. a & Arnold, F. H. Controlling macromolecular topology 
with genetically encoded SpyTag-SpyCatcher chemistry. J. Am. Chem. Soc. 135, 13988–97 
(2013). 
Bibliography 
  
 
 - 239 - 
 
 
 
 
 
 
 
 
 
Appendices 
 
  
Appendix A — Development of a single custom-made 
hollow microneedle in combination with a Hamilton 
syringe 
An alternative to solid microneedles for doxycycline delivery is the use of hollow microneedle 
for the infusion of doxycycline solutions or in situ-forming gels. To begin the process of 
developing a bespoke hollow microneedle for intradermal delivery of doxycycline, an existing 
system that could already provide precise delivery in a controlled way was adapted. Hamilton 
needles are needles with a modular design that allows its individual components to be tailored 
by volume and needle gauge to suit particular applications (Figure 8.1 – A). The Hamilton 
syringe used was a Hamilton #702 N 25 µl syringe (Hamilton Company, Nevada, USA). The 
aim was to first create an adaptor upon which microneedles of differing length and geometry 
could be integrated (Figure 8.1 – B).  
The measurements of the annulus and height of the tip of the syringe body were calculated and 
used to produce a design which was brought to fruition by the team at the Joint Department of 
Biomedical Engineering (University of North State University, Georgia, USA) who produced 
the small urethane dimethacrylate (UDMA)-based adaptor (Figure 8.1 – C). The 
measurements of the Hamilton syringe were determined using calipers  and  manufacturer’s 
references. The adaptor module was designed to fit onto the opening of the syringe to be 
as seal-tight as possible. The annulus of the adaptor on the opposite end had to be of a 
greater enough width as to avoid backpressure of liquid when needling. The production of 
the adaptor alone proved successful and thus the single microneedle-adaptor module has 
been designed and is in production. 
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Figure 8.1 — Development of a single microneedle adaptor unit compatible with a 
Hamilton syringe: (A) Modular design of the Hamilton needles and syringes. (B) Schematic 
representation of the UDMA-based adaptor and its measurements for compatibility with the 
Hamilton syringe (left), the proposed adaptor with the single hollow microneedle included 
(right). (C) Photographs of the UDMA-based adapted produced at the Joint Department of 
Biomedical Engineering (University of North State University, Georgia, USA).
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Appendix B — Impregnating various wound dressings 
with doxycycline solution  
A series of experiments were carried out to assess the ability of different adhesive wound 
dressings to become saturated with doxycycline solution. The concept behind this was that 
wound dressings impregnated with doxycycline could be applied to early stage pressure ulcer 
sites that had been permeabilised by microneedle application. Once applied they act as a drug 
reservoir for a more controlled release of the drug rather than an immediate bolus delivery. 
Three commercially available wound dressings were assessed: (i) Elastoplast water resistant 
plaster (Beiersdorf UK, Birmingham, UK) — typically used on small wounds and cuts, (ii) 
Comfeel® wound dressing (Coloplast, Peterborough, UK) — a hydrocolloid dressing for the 
sealing and protection of wounds, and (iii) Cilguard® (SudMed, Glossop, UK) — a 
polyurethane foam dressing with soft silicone adhesion. Each wound dressing was cut to the 
same volume (1 cm x 1 cm x 1 mm). 
The samples were immersed in wells that contained 10 ml of 10 mg/ml doxycycline solution 
(Alfa Aesar, Massachusetts, USA). The volume of doxycycline that was absorbed and retained 
was measured by periodically weighing the dressings. Dressing saturation was indicated when 
the mass plateaued. The dressings were blotted with filter paper before weighing to remove any 
excess moisture. Volume for volume, the Elastoplast dressing became saturated most rapidly 
and the Comfeel® dressing was the most absorbent (Figure 8.2). The next step is to see 
whether the dressings release their absorbed load once saturated, to what extent and over what 
sort of time frame. 
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Figure 8.2 — Absorption and saturation of Comfeel®, Cilguard ® and 
Elastoplast wound dressings by monitoring their mass until it plateaued. 
- 243 -
Appendix C — Development of an MMP-cleavable 
protein-based smart gel
Introduction 
Research project 
During my Ph.D., I undertook an Institute of Biomedical Engineering (IBME)-funded trip to 
Yale University, USA where I worked on a collaborative project as part of the IBME-led Yale-
UCL Medical Technologies Collaborative (MTC) for two months. The general idea behind 
these funded collaborations is to develop innovative technologies to solve medical challenges. 
I was one of two Ph.D. students to be funded under their research theme of ‘Biomaterials and 
Drug Delivery’. I carried out my research at the Department of Molecular Biophysics and 
Biochemistry in collaboration with the principal investigator Professor Lynne Regan whose 
research specialises in the protein chemistry of gels. My main aim was to provide an application 
of their fundamental research on polymeric gels to a real-world medical problem. 
Consequently, I worked on the development of a smart gel for chronic wound healing. The 
entire body of work described here was carried out by myself (unless otherwise credited) under 
the supervision and guidance of Ashley Schloss (Ph.D. student) and Professor Lynne Regan.  
Smart gels for controlled drug delivery in situ 
Hydrogels are a hydrophilic networks of polymer chains that are used in several medical and 
research applications. A relatively new subtype are environmentally-sensitive hydrogels also 
known as smart gels330,331. In recent years, smart gels have become of increasing interest for 
controlled drug release applications. Smart gels have the ability to “sense” changes in their 
environment, such as changes in metabolite concentration, and can release an encapsulated load 
as result of this detected change. In this project, the smart gel’s environmental cue would be an 
increase in matrix metalloproteinase (MMP) levels which would be responsible for cleaving a 
structural component of the gel. This then results in the release of trapped drugs, potentially 
MMP inhibitors such as doxycycline, from within the gel network. The drug can then act at the 
site of chronic wound: (i) to regulate MMP activity, (ii) to curb pressure ulcer development and 
(iii) to facilitate the wound healing process. For wounds where the skin has not yet been
exposed, it is possible that individual gel components could be delivered separately via
microneedles and will only form the gel once delivered and combined in situ.
The MMP recognition site (MMPRS) 
The MMP recognition site, or the MMPRS, is the novel component of the proposed smart gel. 
It is a consensus sequence of eight amino acids, VPMSMRGG, cleavable (or with close to 
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optimal cleavage) by human MMPs 1 and 9, which have been shown to be aberrantly up-
regulated in human chronic wounds through clinical investigations of wound fluid and 
exudate105,114. This sequence was investigated by Ashley Schloss and chosen from a library of 
MMP cleavage site consensus sequences332. The MMP 1 consensus sequence was chosen as it 
had relatively low MMP 7 activity, an MMP for which literature evidence for its presence in 
chronic wound was not found. The MMPRS can be targeted by MMPs for cleavage and thus 
provides the degradable component of the gel. For interactions with itself or other proteins and 
peptides, the MMPRS peptide can be terminally functionalised with amino acids such as 
cysteine to allow for covalent di-sulphide bond formation.  
Approaches to MMP-degradable smart gels 
There were three possible approaches to producing MMP-degradable smart gels, all using 
covalent bonds between peptide-protein or peptide-peptide components and all containing the 
MMP-cleavable peptide sequence, MMPRS. These were: (i) multi-arm polyethylene glycol and 
MMPRS peptide gels, (ii) MMPRS concatenated polypeptide gels and (iii) SpyTag-SpyCatcher 
gels. The unifying feature of these gels is that the protein-peptide/peptide-peptide components 
are covalently bonded and this union is only broken through cleavage of the MMPRS. Each 
approach presents potential advantages and disadvantages. 
(i) Multi-arm polyethylene glycol and MMPRS peptide gel
Polyethylene glycol, or PEG, is an FDA-approved synthetic polymer used in many biomedical 
applications including drug delivery330,331,333. It comes in a range of molecular weights which 
can be selected to best suit a specific application.  A multi-arm PEG unit can be used as a 
branching scaffold to build individual units of peptides onto to create a gel network. To 
covalently bond PEG to the MMPRS peptide for gel formation, both components need to be 
terminally functionalised. In this approach, the MMPRS is functionalised with two terminal 
cysteine residues, while a four-arm PEG molecule is functionalised with vinyl sulfone 
(Figure 8.3 – A). Under oxidising conditions, these functional groups can form covalent 
bonds. The MMPRS peptide can be further modified to increase the reactivity of the 
cysteines through the addition of two lysine residues which reduces the pKa of the disulphide 
bond formation. The non-lysine modified peptide is referred to as the ‘nK’ MMPRS 
subtype, whilst the lysine-modified peptide is referred to as the ‘K’ MMPRS subtype (Table 
9). 
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Table 9 — Amino acid sequences of MMPRS peptide subtypes. The nK peptide sequence 
is flanked on its N-terminal and C-terminal with CYGG and GGC residues, respectively, 
while the K peptide sequence is flanked on its N-terminal and C-terminal with CKYGG 
and GGKC residues, respectively. 
(ii) MMPRS concatenated polypeptide gel
Since the MMPRS peptide is functionalised with cysteine residues at either end it can form 
cysteine-cysteine disulphide bonds with itself under oxidising conditions thus creating 
a concatenated polypeptide (Figure 8.3 – B). This removes the need for an intermediate 
protein scaffold like PEG. However, because of the linearity of the polypeptides formed, gel 
formation may not be optimal due to a lack of branching which is otherwise exhibited when 
using a PEG scaffold. Nonetheless, it is possible that chain folding could result in a gel-like 
substance. 
(iii) SpyTag-SpyCatcher gel
SpyTag-SpyCatcher is a highly-reactive, genetically encoded protein-peptide pair developed 
by Howarth et al. (2010)334 and structurally investigated by Arnold and colleagues (2013)335. 
SpyCatcher is a 12 kDa peptide with a reactive 255 lysine residue that can covalently bond to 
the reactive 20th aspartic acid residue of the 1.1 kDa SpyTag peptide. In their paper, Arnold et 
al. (2013) investigated different protein structures that could be made with this interactive 
pair335. Their work inspired the idea of SpyTag-SpyCatcher based MMP-degradable smart 
gels. The idea behind this gel is to have a terminally functionalised MMPRS peptide with 
SpyTag on either end and a concatenated SpyCatcher arranged as a four-unit protein. These 
two separate components can then interact to create the gel network (Figure 8.3 – C). Note 
how the cleavable element of the gel, the MMPRS, is flanked by SpyTag.  
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Peptide subtype Additional amino acids Amino acid sequence 
MMPRS peptide None VPMSMRGG 
nK MMPRS peptide 2x cysteine CYGGVPMSMRGGC 
K MMPRS peptide 2x cysteine, 2 x lysine CKYGGVPMSMRGGKC 
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Figure 8.3 — Schematic representation of the three approaches towards MMP-
cleavable smart gels: (A) The MMPRS peptide-PEG reaction resulting in a hypothetical 
MMP-degradable hydrogel scaffold with chemically cross-linked PEG and MMPRS 
units. (B) MMPRS peptide concatenation reaction. Individual MMPRS peptide units can 
be concatenated under oxidising conditions such as basic pH and aeration to form a linear 
polypeptide chain that should demonstrate different physiochemical properties. (C) 
Hypothetical SpyTag-SpyCatcher smart gel using homotelechelically-modified SpyTag 
and SpyCatcher proteins. 
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Research outline 
The body of work presented here aimed to investigate whether MMP-degradable protein-
peptide based smart gels could be used to encapsulate and release drugs in a controlled manner 
for the treatment of chronic wounds. The major aims were: (i) express, purify and characterise 
the two subtypes of MMPRS peptide (nK and K), (ii) to concatenate purified MMPRS peptides 
to form a polypeptide and (iii) to clone SpyCatcher and SpyTag into competent bacteria. 
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Methods and materials 
Table 10 — Recipes for reagents and buffers used in protein synthesis and purification. 
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Approach 1 — Multi-arm PEG and MMPRS peptide gel 
Cloning and Molecular Biology 
Cloning of the MMPRS peptides into BL21 E. Coli was carried out prior to this study by Ashley 
Schloss.  
Protein synthesis 
Colonies were selected from K and nK MMPRS peptide plates and transferred to culture tubes. 
5 mL of L-Broth and 5 µl of ampicillin were added to the colonies. Colonies were placed on a 
shaker for s 5h at 37oC. Each resulting culture was transferred to a flask of 500 ml Autoclaved 
Broth & Nutrient Mixture (Table 10) and 1 ml ampicillin (Sigma-Aldrich). Flasks were shaken 
overnight at 37oC. Cultures were transferred to 500 ml centrifuge tubes and centrifuged at 6000 
rpm at 4oC. The supernatant was decanted and cell pellets re-suspended in 20 ml Resuspension 
Solution (Table 10) then transferred to 50 ml Falcon tubes and incubated on ice for 30 minutes. 
Solutions were sonicated on ice for 15 runs of 10 seconds on and 20 seconds off. This was 
repeated twice for each sample until the solutions cleared. Samples were transferred to 500 µl 
centrifuge containers and the re-suspended solutions centrifuged for 1 hour at 17 000 rpm and 
4oC. The supernatant containing the protein was collected for purification and the pellet 
containing dead cells and waste removed. 
Protein purification 
Nickel affinity chromatography purification 
Five ml of nickel resin (HisPur Ni-NTA Resin; Thermo Fisher Scientific, Massachusetts, USA) 
was added to chromatography columns and the storage ethanol drained. Columns were washed 
twice with Ultrapure water and 20 mL of Buffer A + 20 mM imidazole (Table 10). The resin 
was then equilibrated with the samples through repeated inversions for 1 hour. For initial 
purification from contaminants, the MBP-MMPRS protein was washed through with 20 ml of 
buffer A + 20 mM imidazole and five times with 20 ml Buffer B (Table 10). The protein was 
eluted with buffer B + 250 mM imidazole (Table 10). Elution solution was dialysed in 5 mM 
Tris and 30 mM NaCl using dialysis tubing. The dialysis tubing was stirred at 4oC overnight.  
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TEV cleavage reaction 
Samples were transferred from the dialysis tubing to 50 ml Falcon tubes. 1 ml of Tobacco Etch 
virus (TEV) enzyme was added per 20 ml of dialysed sample and shaken overnight for the TEV 
cleavage reaction to occur. 
Nickel affinity chromatography and purification of the MMPRS peptide 
The solution from the TEV reaction underwent a second nickel affinity chromatography step 
to separate the MMPRS peptide from the MBP fusion tag. Nickel resin (10-20 ml) was added 
to chromatography columns and the storage ethanol drained. Columns were washed once with 
A 
B 
Figure 8.4 — Schematic representations of peptides cloned into the E. Coli: (A) 
The MMPRS (Matrix metalloproteinase recognistion site) peptide is cleavable by 
certain MMPs. It is coded with a His-Tag, TEV (Tobacco Etch virus) enzyme 
cleavable peptide and MBP (maltose-binding protein] fusion tag). His-Tag is a six 
histidine-long tag which allows for protein purification by nickel affinity 
chromatography. The histidine is out-competed by imidazole during elution steps. The 
MBP acts as a fusion tag for expressing the MMPRS peptide which enhances solubility, 
increases protein expression in E. Coli and increases the yield of desired product. The 
TEV enzyme-cleavable peptide has an amino acid sequence of ‘ENLYFQC’ and is 
cleaved at the ‘QC’ by the TEV enzyme to separate the MBP protein from the 
MMPRS peptide. (B) In the SpyTag-SpyCatcher approach to gel formation, the 
MMPRS peptide is coded with SpyTag and an amino acid linker. The SpyTag flags 
the MMPRS sequence forming a homotelechelic terminally functionalised peptide. 6 
G/P (6 glycine or proline) refers to the six amino acid-long linker which comes in two 
subtypes, glycine and proline.  
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Ultrapure water followed by 20 ml of buffer A. The resin was then equilibrated with the samples 
through repeated inversions for 1 hour. To separate the MMPRS peptide from the MBP fusion 
tag, the solution was first passed through the column and the flow-through collected as the 
MMPRS peptide. To elute the MBP protein, 20 ml of buffer B + 250 mM imidazole (Table 10) 
was passed through the column and the elution collected for characterisation. 
Protein characterisation 
SDS-PAGE protein characterisation 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
determine the success of each nickel affinity chromatography step. Twenty ml of each solution 
to be characterised was added to 5 ml of dye and pipetted into a 15% SDS gel. A standard 
protein ladder (SDS-PAGE polypeptide standards, BioRad) was run alongside the samples. The 
gels were run at 160 V until the indicator dye reached the bottom of the gel.  This took 
approximately 1 to 1.5 hours. The gels were removed and stained with Coomassie Blue stain 
and de-stained with Destain Solution (10% (v/v) acetic acid, 50% (v/v) methanol and 40% (v/v) 
water). Gels were imaged using a shielded light box and a camera. Any gels that had extra 
bands indicating contamination with a product other than the desired peptide were re-run 
through the corresponding purification step. Any samples that did not show the peptide of 
interest were discarded. 
Sep-Pak Solid Phase Extraction (SPE) 
Solid phase extraction (SPE) using Sep-Pak Cartridges (Waters, Massachusetts, USA) was used 
to separate the remaining components of the flow-through collected from the second nickel 
affinity chromatography step based on their chemical properties. The desired MMPRS peptide 
was retained on the stationary phase during the runs and could then be eluted. To condition the 
SPE cartridge, 3 ml of Conditioning Solution was passed through the packing bed without air 
entering the cartridge material. The SPE cartridge was equilibrated by passing 2 ml of 
Equilibration/ Load Solution through the packing bed. The sample was slowly passed through 
the cartridge (no faster than 1 drop per second) and this was repeated seven times in total. 500 
µl of the sample could be taken between each run for further analyses. To desalt the sample, 1 
ml Desalting Solution was passed through the cartridge. To elute the sample, 1 ml of Elution 
Solution was passed slowly through the cartridge and the eluent collected in a 1.5 ml Eppendorf 
which had been previously weighed. 
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Freeze drying and lyophilisation 
In preparation for lyophilisation, the sample was freeze dried. The lid of the Eppendorf was 
pierced prior to allow the solvent to evaporate. The sample was then rapidly cooled in a liquid 
nitrogen bath. Samples were lyophilised overnight.  
Analytical High-Performance Liquid Chromatography (HPLC) 
Analytical HPLC is a sampling technique used to separate components of solutions based on 
their chemical properties. Samples were loaded into a modular HPLC system using a 20–80 % 
gradient over 30 minutes. Insulin was used as a standard that has a characteristic 
chromatographic peak at 21 minutes. 
HPLC fraction collection 
1 ml fractions were collected from HPLC at selected chromatographic peaks believed to 
correspond with the analyte of interest and stored at 4oC.   
Matrix-assisted laser ionization-time of flight (MALDI-TOF) mass spectrometry 
MALDI-TOF mass spectrometry was used to confirm the presence of the MMPRS peptides 
based on their expected molecular weights. These were calculated from their amino acid 
sequences. During sample preparation, equal volumes of ACCA solution (50% α-cyano-4-
hydroxy-3-methoxycinnamic acid, 25% TFA and 25% Ultrapure water by weight) and the 
sample were mixed, vortexed and spotted as 1 µL droplet onto a MALDI-TOF plate.  ‘ACCA 
solution only’ and ‘ACCA solution + a non-analyte fraction’ acted as negative controls and 
‘ACCA solution + insulin’ acted as a standard of known molecular weight. 
Approach 2 — MMPRS peptide concatenation 
Disulphide bond induction 
MMPRS peptides can be covalently bonded via their terminal cysteine residues by inducing 
disulphide bond formation. This reaction forms a concatenated polypeptide built from the 
individual MMPRS units. Not only can disulphide bond induction be used to initiate gel 
formation, it can also be used to confirm the presence of MMPRS peptides in samples. A 
concatenated polypeptide will show different physiochemical properties compared with 
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individual peptides and the corresponding changes in hydrophobicity and molecular mass will 
be detectable by analytical HPLC and mass spectrometry respectively. To induce disulphide 
bond formation, oxidising conditions are required and can be provided using a basic pH and 
aerating the sample. After lyophilisation, the purified samples were reconstituted with sterilised 
water. Equal volumes of 2M Tris buffer (pH 10.2) and the reconstituted sample were added 
together in an Eppendorf. Samples were placed on a shaker overnight to allow them to aerate. 
Samples were then run under analytical HPLC and MALDI-TOF mass spectrometry. 
Approach 3 — MMPRS peptide concatenation 
Cloning and molecular biology 
The SpyTag gene was ordered from GeneScript. Plasmids were transformed into a competent 
Escherichia coli strain, DH10β, using electroporation. 20 µL of sterilised water was used to 
dissolve the lyophilised DNA. 1 µL of DNA was transferred to 50 µL of DH10β cells and 
transferred to an electroporation cuvette. The cuvette was pulsed at 2.5 µL (MicroPulser, 
BioRad), 500 µL of L-Broth immediately to the cells. Cells were shaken for several hours at 
37oC. 1 µL of cells were plated on agar plates and incubated overnight at 37oC.  
Results 
Multi-arm PEG and MMPRS peptide gel 
Protein purification and expression 
For both subtypes the MBP-MMPRS protein was successfully eluted from the nickel column 
indicated by ‘Elut.’ (Figure 8.5 – A). The elution was dialysed and the TEV enzyme added 
for to the TEV cleavage reaction. The TEV reaction was used to cleave the MMPRS peptide 
from its MBP fusion tag. The gels show that MBP is present both before (‘Elut.’) and after 
(‘TEV’) the TEV reaction (Figure 8.5 – B). The MMPRS peptide is not observed as it is of 
very low molecular weight (~1.5 kDa). After the MMPRS peptide had been cleaved from 
the MBP protein, it no longer bound to the nickel. Thus, when the sample was passed 
through the column it could be collected as flow-through (‘FT’) (Figure 8.5 – C). To elute 
the MBP protein, an imidazole-containing buffer was used (‘Wash B’). Presence of MBP 
in the flow-through suggested not enough nickel had been used in the column so these 
samples were re-run using 10-20 mL nickel/run until MBP could no longer be detected.
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Figure 8.5 — (A) SDS-PAGE gel of nickel purification step one: separating the 
MMPRS-MBP protein from contaminants. (B) SDS-PAGE gel of TEV reaction 
compared with the elution. (C) SDS-PAGE gel of the second nickel purification step 
— separation of the MMPRs peptide from the MBP fusion tags. 
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Figure 8.6 — Analytical HPLC traces of MMPRS peptide samples: (A) Analytical 
HPLC trace of 200mg human insulin gives a characteristic, strong monodisperse peak at 
21 minutes. (B) Analytical HPLC trace of the nK MMPRS peptide gives a strong peak at 
15 minutes. (C) Analytical HPLC trace of K MMPRS peptide gives a relatively weaker 
peak at 27 minutes.   
insulin 
nK peptide 
K peptide 
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Figure 8.7 — MALDI-TOF mass spectrometry graphs for: (A) Human insulin. 
(B) nK MMPRS peptide subtype. (C) K MMPRS peptide subtype.   
insulin 
nK peptide 
K peptide 
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Figure 8.8 -—Analytical HPLC traces of oxidised MMPRS peptide samples: (A) 
nK MMPRS peptide subtype. (B) K MMPRS peptide subtype. 
nK peptide 
K peptide 
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 Table 11 — Expected and observed peptide masses based on amino acid sequences. 
Discussion 
The MMPRS peptide was successfully cleaved and purified from its MBP fusion tag 
The TEV reaction was responsible for cleaving the MBP fusion tag from the MMPRS peptide. 
During the second nickel affinity chromatography step, the His-Tag binds the MBP to the 
column while MMPRS is collected in the flow-through. The results show that when sufficient 
nickel is used in the column, there are no bands on the SDS-PAGE gel to indicate MBP is 
present in the flow-through (the MMPRS peptide is itself too small to show up on the SDS-
PAGE gel) (Figure 8.5 – C). To confirm the presence of the MBP protein, the column 
contents were eluted using imidazole. The results show that the MBP protein was indeed 
present and this is indicated by a thick band in the SDS-PAGE gel (Figure 8.5 – C). For 
gels which indicated that MBP was present in the MMPRS flow-through, the flow-through 
was re-run through the nickel column until the MBP could no longer be detected. Each re-run 
used between 10–20 mL of nickel resin.  
Analytical HPLC on the samples suggested the presence of the two different MMPRS 
subtypes 
Analytical HPLC was used to determine: (i) the chromatographic peak corresponding to each 
of the MMPRS peptides, (ii) the relative amount of the sample and, (iii) the purity of the sample. 
The protein standard, human insulin, produced a strong and monodisperse peak at 21 minutes. 
The trace for nK peptide was not monodisperse but there was a strong peak between 200 
- 500mV at 14 minutes (Figure 8.6 – B). The trace for K peptide was also not monodisperse 
and the peak of interest was not as strong at nK, with a measurement of around 75mV at 26 
minutes (Figure 8.6 – C). Positive indication of the presence of the MMPRS peptides in the 
samples is the two different peaks. This suggests that two different molecules are present. This 
is expected as HPLC separates molecules based on their polarity and the nK peptide and K 
peptides differ by two lysine residues in their amino acid sequences which change the polarity 
of the K peptide: at pH 7, lysine residues are positively charged. A more hydrophobic 
peptide is expected to produce a peak later, explaining the nK peptides later time-point.  
Furthermore, the results 
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Protein sample Observed  Mass (Da) Expected mass (Da) 
nK peptide 1316 (and 1591) 1317 
K peptide 1847 1573 
Human insulin standard 5802 5808 
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suggest that there was a lower concentration of K than nK in the purified samples and 
contaminants peaks on the trace could be from salts which were used during the purification 
steps. 
MALDI-TOF mass spectrometry confirmed the presence of the nK MMPRS peptide and 
suggested the presence of a modified K MMPRS peptide 
Both nK and K peptide samples were flown under mass spectrometry to determine the 
molecular weights of proteins in the sample. These values were compared with the expected 
molecular weights of the peptides, which are 1317 and 1573, for nK and K 
respectively. Interestingly, nK samples consistently produced a dual peak (Figure 8.7 – B), 
one at 1316 which is the expected molecular weight and another at 1591, 274 Da greater 
than the expected molecular weight. The K sample produced a monodisperse peak at 1847 
(Figure 8.7 – C), which is 275 Da greater than the expected molecular weight. The fact that 
peaks of different values were consistently obtained for the two different subtypes ruled out 
contaminants being responsible for the results and heavily suggested the presence of the 
peptides. However, the dual peak obtained for nK raised the question of potential 
modifications to the peptides, especially seeing as the difference between expected and 
observed were comparable, at around 274 Da. Suggestions for the discrepancies include 
post-translational modifications by the bacteria or some form of oxidation reaction 
occurring at the cysteine residues. The dual peaks for nK and the single peak for K indicate 
that there are two species of nK in the samples and a single species of K. This could be 
explained by the fact that the K peptide is more reactive due to its two additional lysine 
residues. Thus any modification reactions causing the shift in weight are more likely to go to 
completion for the more reactive peptide, K. At present, the chemical modification has not 
been attributed to any reaction. 
MMPRS concatenation results are currently inconclusive but could be used to 
identify presence of MMPRS peptides 
The unexpected peaks from the initial mass spec. analyses, with 274Da greater mass 
than expected, led to the uncertainty of the presence of the MMPRS peptides in the 
samples. An MMPRS concatenation reaction was thus used to confirm the presence of the 
peptides, as under oxidising conditions individual peptide units would covalently bond 
to form a linear polypeptide chain that had different physiochemical properties. However, a 
major limitation of the oxidisation reaction was the addition of Tris buffer. This caused a rise 
in pH of the solution interfering with the ACCA matrix and rendering the spotted sample 
unanalysable by mass spectrometry. To overcome this, for future experiments, the 
solution can be neutralised carefully with hydrochloric acid after the concatenation 
reaction which should not interfere 
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with the disulphide bonds. The oxidised samples were also run under HPLC. For both the K 
and nK samples, there were peaks at 15 minutes (Figure 8.8 – A and B). Neither of the peaks 
overlapped with the unoxidised samples suggesting a different species in the oxidised sample 
compared with the unoxidised sample.  However, these results were not reproducible. Thus, at 
present, the analytical HPLC traces for the MMPRS concatenation suggest the presence of 
polypeptide chains but are not conclusive. 
SpyTag-SpyCatcher presents a promising approach to MMP-cleavable protein-based gel 
formation 
The SpyTag and SpyCatcher elements are in the process of being expressed and purified. 
Concatenation of the SpyCatcher is currently being carried out by Ashley Schloss. 
Future work 
The work carried out in this research collaboration shows promising results in working towards 
the development of an MMP-cleavable protein-peptide smart gel but requires further work to 
see it to completion. This includes: (i) the continued characterisation of the MMPRS peptide, 
(ii) gel formation using functionalised PEG and purified MMPRS peptide and (iii) expression,
purification and characterisation of the MMPRS-modified SpyTag peptide and concatenated
SpyCatcher protein.
Conclusion 
MMP-degradable protein-peptide based smart gels present an interesting and innovative 
method for delivering drugs in a controlled manner. In chronic wounds, these gels could be 
used to deliver therapeutics that inhibit the MMPs responsible for preventing the wound from 
healing properly.  There are multiple approaches to gel formation, each with their own 
advantages and limitations. The unifying features amongst these approaches are that they 
involve covalently bonded protein-peptide units and an MMP-cleavable component. This MMP 
cleavable component, known as the MMPRS, has been designed based upon a consensus amino 
acid sequence that is a natural enzymatic target of the MMPs believed to be upregulated in the 
chronic wound environment. The MMPRS peptide-PEG gel approach has shown promising 
results in the production of the individual gel components; however, it appears that the SpyTag-
SpyCatcher will be the more successful avenue. In all, this international collaboration has 
brought together approaches from two different disciplines to address an important clinical 
problem in an innovative way.  
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Appendix D — MMP zymography of FPCL supernatant
Introduction 
As previously outlined in the main body of the thesis, an up-regulation in MMP activity and/or 
expression is believed to be responsible for the ECM degradation seen in IR injury tissue. One 
method for assessing the effect of MMP on the ECM at an injury site is zymography, which is 
used for the detection of enzyme activity alongside the MMP activity assay. In fact, 
zymography uses MMP activity to help detect MMP expression. Excised tissue that has 
undergone IR injury can be liquefied and homogenised and the supernatant used to determine 
levels of MMPs present in the tissue. Data from these analyses could be used to determine how 
the activity and/or expression of MMPs correlates with ECM degradation. 
Methods and materials 
Zymography assay function 
Zymography is a technique that uses the intrinsic function of an enzyme to digest molecules to 
monitor its expression, activation and activity within a solution. Solutions containing the MMP 
are supplemented with a loading buffer, free of reducing agent, that has several functions which 
include providing a tracking dye and denaturing the proteins to linearise them. The buffer is 
loaded into a zymographic gel that contains an MMP substrate such as gelatin. An electric 
current is passed across the gel which has been immersed in running buffer that is designed to 
provide a constant migration rate. The current causes proteins to migrate, with the distance of 
migration being inversely correlated to the protein’s molecular weight (that is, smaller proteins 
will migrate further than larger ones in a given time).  
After migration, the gel is bathed in renaturing buffer which allows the proteins to regain their 
tertiary structure required for enzymatic activity and is then bathed in denaturing buffer which 
is designed to allow the proteases to digest their substrates. A dye is then applied to the gel is 
to stain the MMP substrate and the gel is then washed to remove any excess dye. Areas of 
digestion appear as clear bands in the gel and the clearer the band the more concentrated the 
protease. Band staining intensity can be determined by a technique known as densitometry 
which can be carried out using the imaging software, ImageJ® (National Institutes of Health 
[NIH], Maryland, USA). Once normalised to controls the results can provide information on 
the expression of MMPs and their pro-MMPs in a solution over a specified period of time. 
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Sample collection 
Supernatant samples (75 µl) were collected from FPCL culture medium on days 0, 3 and 7 and 
stored at 20oC. 
Zymogram gel electrophoresis 
Samples were analysed using the NovexTM 10% Zymogram (Gelatin) Gel with the 
manufacturer’s recommended buffers. The manufacturer’s claim the gel has a sensitive level of 
5 x 10-6 units of collagenase. Triplicate samples were combined into a single 1.5 ml Eppendorf. 
Combined samples (15 µl) and 15 µl of 2x sample Tris-Glycine SDS buffer were added together 
in a separate 1.5 ml Eppendorf. The gels (10% Zymogram Gelatin Protein Gels, 1.0 mm, 10 
well) were rinsed under water, added to the gel box and supplemented with 500 ml of Tris-
Glycine SDS running buffer. Individual wells of the gel were cleaned using a 1 ml Pasteur 
pipette to remove residue. The standard protein ladder was centrifuged and 5 µl loaded into the 
first well of each gel. Each sample (28 µl) was then loaded into an individual well. The gels 
were run at 125 V for 90 minutes. 
Renaturing and developing zymogram gels 
Gels were carefully removed from the gel box and placed into individual washing containers. 
Fifty ml of 1x zymogram renaturing buffer was added to each gel. The gels were agitated for 
30 minutes at room temperature on a plate shaker and the renaturing buffer decanted off. 
Zymogram 1x Developing Buffer (50 ml) was then added to the gels which were agitated for a 
further 30 minutes. The developing buffer was decanted replaced with fresh developing buffer 
and the gels were incubated overnight at 37oC. After 16 hours the developing buffer was drained 
off and 50 ml of de-iodinated water was added to gels. Gels were agitated for 10 minutes and 
the water decanted. This step was repeated twice more. The SimplyBlueTM SafeBlue stain (Life 
Technologies, Paisley, UK) was added directly to the gels (~50 ml per gel) and incubated for 
an hour with gentle agitation. The stain was drained off and the gels washed with deiodinated 
water. The gels were imaged under UV light and images were saved electronically for 
densitometric analysis. 
Analysis of zymograms by densitometry 
Clear bands appeared on the gels at areas of protease digestion. A protein ladder had been run 
on the gel so that these bands could be matched to the MMP standard and be identified. To 
determine the respective concentration of MMP in each band, the band density needed to be 
determined. This was achieved through densitometry using ImageJ® software. Firstly, the 
images were converted to 8-bit grey scale files. The ‘rectangular selection tool’ was used to 
outline the first band. The band was then numbered and using its outline was moved to the next 
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band. This was repeated until all the bands were selected.  A profile plot of band intensity was 
generated for each band The ‘straight line selection’ tool was used to delineate the peaks of 
interest within separately enclosed areas. The ‘wand tool’, when clicked inside each peak, 
selected that peak and gave the corresponding intensity value. Zymographic bands from control 
and doxycycline-treated FPCLs were normalised to media controls which were complete 
DMEM only and 416 µM doxycycline (in DMEM), respectively. The normalisation removed 
the basal MMP expression levels and allowed statistical significance of results to be determined 
when pooling values from replicate gels. 
Results 
MMP 2 expression was reduced in doxycycline treated FPCLs. 
Doxycycline treatment (416 µM) caused a significant reduction in MMP 2 expression and/or 
activity by day 7 in the FPCL supernatant. The zymograms of the supernatant collected from 
the FPCLs yielded four major bands, MMP 2 (63 kDa) and MMP 9 (82 kDa) and their 
respective zymogens, pro-MMP 2 (72 kDa) and pro-MMP 9 (92 kDa) (Figure 8.9). Despite 
inconclusive results for days 0 and 3, it was evident from triplicate experiments that either the 
activity, expression or both of MMP 2 was significantly attenuated by day 7 when FPCLs 
were treated with 416 µM doxycycline (Figure 8.10). 
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Figure 8.10 — MMP 2 levels were significantly reduced by doxycycline treatment 
by day 7 (n=3). The bar graph plots the pooled relative band intensities of untreated and 
FPCLs treated with 416 µM of doxycycline, normalised to media controls. Statisical 
analysis was carried out using a two-paired parametric t-test. Levels of MMP 2 were 
significantly reduced in FPCL supernatant treated with 416 µM doxycycline by day 7 (p 
< 0.001). Error bars indicate the standard error of the mean.  
Figure 8.9 — Zymograms showing the band intensity of the gel media at three 
different time points (days 0, 3 and 7). Pro-MMP 9, MMP 9, pro-MMP 2 and MMP 2 
can be detected as determined by the standard protein ladder. 
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Appendix E — OCT images of drug delivery through a 
hollow microneedle array 
In a preliminary investigation, the insertion of hollow microneedle array into excised murine 
tissue and its ability to delivery fluids were assessed using OCT. The 4 mm x 5 mm 16 
microneedle array (Figure 8.11) was synthesised from urethane dimethacrylate (UDMA) and 
produced by the research group headed by Dr Roger Narayan (Joint Department of Biomedical 
Engineering, University of North State University, Georgia, USA). The microneedle array was 
applied by hand onto the apical surface of excised murine dorsum and imaged before, during 
and after application (Figure 8.12). Fluid delivery through the microneedle annuli 
was visualised using titanium dioxide nanoparticles (5-20 nm) suspended in PBS to provide 
contrast enhancement in OCT imaging (Figure 8.13). From the images obtained it is feasible 
that OCT could be used to monitor microneedle insertion into the skin and to visualise 
fluid delivery through the hollow microneedles. OCT, as previously observed with magnetic 
compression, is also able to detect changes caused by stress and strains to the skin layers. 
Figure 8.11 — UDMA-based hollow microneedle array: (A) Photograph of the base 
of the 4 mm x 5 mm array containing 16 microneedles. (B) Top-down 
scannining electron micrograph showing the array’s microneedle and their annuli. (C) 
OCT cross-section through the microneedle array. 
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Figure 8.12 — Application of the hollow microneedle array onto excised murine 
dorsum as visualised by OCT: (A) Skin before array application. (B) The microneedle 
array was applied by hand onto the apical surface of skin. (C) At the site of microneedle 
application, compression of the skin’s striations was observed. 
Appendix E — OCT images of drug delivery through a hollow microneedle array 
- 267 -
Figure 8.13 — Delivery of titanium dioxide nanoparticles suspended in PBS 
through hollow microneedles as visualised by OCT.
